

C H I C A G O 2 0 1 0

INTERNATIONAL SOCIETY FOR HEART
AND LUNG TRANSPLANTATION
30TH ANNIVERSARY MEETING
& SCIENTIFIC SESSIONS



FINAL PROGRAM



APRIL 21-24, 2010



HILTON CHICAGO



INTERNATIONAL SOCIETY FOR
HEART AND LUNG TRANSPLANTATION

Welcome!



Thirty Year Anniversary

Thank you for joining
us in Chicago
as we celebrate the
Thirty Year Anniversary
Meeting of the society!

INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION
30th Anniversary Meeting and Scientific Sessions

BOARD OF DIRECTORS

PRESIDENT

James K. Kirklin, MD, Birmingham, AL

PRESIDENT-ELECT

John Dark, MB, FRCS, Newcastle Upon Tyne, United Kingdom

PAST PRESIDENT

Mandeep R. Mehra, MD, Baltimore, MD
Editor-in-Chief, *Journal of Heart and Lung Transplantation*

SECRETARY-TREASURER

Heather J. Ross, MD, FRCPC, Toronto, ON, Canada

DIRECTORS

Susan M. Chernenko, RN, MN, NP, Toronto, ON, Canada

Duane Davis, MD, Durham, NC

Roger W. Evans, PhD, Rochester, MN

Allan R. Glanville, MD, FRACP, Sydney, Australia

Takeshi Nakatani, MD, PhD, Osaka, Japan

Jayan Parameshwar, FRCP, Cambridge, United Kingdom

Stuart C. Sweet, MD, PhD, St. Louis, MO

J. David Vega, MD, Atlanta, GA

Florian M. Wagner, MD, Hamburg, Germany

Lori J. West, MD, D.Phil, Edmonton, AB, Canada

Andreas O. Zuckermann, MD, Vienna, Austria

EX-OFFICIO BOARD MEMBERS

TRANSPLANT REGISTRY MEDICAL DIRECTOR

Marshall I. Hertz, MD, Minneapolis, MN

2010 SCIENTIFIC PROGRAM CHAIR

Hermann Reichenspurner, MD, PhD, Hamburg, Germany

STAFF

Amanda W. Rowe, Executive Director

Phyllis Glenn, Director of Membership Services

Lisa A. Edwards, Director of Meetings

Lee Ann Mills, Director of Operations

Susie Newton, Administrative Assistant/Web Master

14673 Midway Road, Suite 200
Addison, Texas 75001
PHONE: 972-490-9495 FAX: 972-490-9499
www.ishlt.org ishlt@ishlt.org



ABOUT ISHLT

The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 2500 members from over 45 countries, representing over 10 different disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include basic scientists, anesthesiologists, cardiologists, cardiothoracic surgeons, immunologists, ethicists, nurses, pharmacists, pathologists, perfusionists, pulmonologists, transplant coordinators and tissue engineers. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.



THE PURPOSES OF THE SOCIETY ARE:

To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease and related sciences.

To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.

To hold scientific meetings featuring presentations and discussions relevant to these disciplines.

To sponsor a scientific journal for the publication of manuscripts related to these disciplines.

To establish and maintain an international registry for heart and lung transplantation.

To award research grants and establish endowments for the study of these disciplines.

Dearborn Street Station · Chicago Temple · Chicago River · Alfred Caldwell Garden · Taste of Chicago · Michigan · Mile



SCIENTIFIC PROGRAM COMMITTEE

PROGRAM CHAIR: Hermann Reichenspurner, MD, PhD,
University Heart Center Hamburg, Germany,

PRESIDENT: James K. Kirklin, MD, ISHLT President,
University of Alabama at Birmingham, AL,

Allen S. Anderson, MD, University of Chicago Medical Center,
Chicago, IL

Sharon A. Beer, RN, MSc, Queen Elizabeth Hospital,
Birmingham, United Kingdom

Tuvia Ben Gal, MD, Rabin Medical Center, Petah Tikva, Israel

Gerald J. Berry, MD, Stanford University, Stanford, CA

Roberta C. Bogaev, MD, FACC, Texas Heart Institute, Houston, TX

John V. Conte, MD, Johns Hopkins Hospital, Baltimore, MD

John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne,
United Kingdom

Duane Davis, MD, Duke University Medical Center, Durham, NC

Daniel F. Dilling, MD, Loyola University Medical Center,
Maywood, IL

Giuseppe G. Faggian, MD, University of Verona Medical School,
Verona, Italy

Paul W. M. Fedak, MD, PhD, FRCSC, Foothills Medical Center,
Calgary, Alberta, Canada

Andrew J. Fisher, FRCP, PhD, Institute of Cellular Medicine,
Newcastle Upon Tyne, United Kingdom

Kimberly L. Gandy, MD, PhD, Children's Hospital of Wisconsin,
Milwaukee, WI

Allan R. Glanville, MD, FRACP, St. Vincent's Hospital,
Darlinghurst, NSW, Australia

Jan F. Gummert, MD, PhD, Herz- und Diabeteszentrum NRW,
Bad Oeynhausen, Germany

Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

Daphne T. Hsu, MD, Children's Hospital at Montefiore, Bronx, NY

Mandeep R. Mehra, MD, JHLT Editor, University of Maryland
School of Medicine, Baltimore, MD

Bruno M. Meiser, MD, Herzchirurgische Klinik und Poliklinik,
Munchen, Germany

Omar A. Minai, MD, Cleveland Clinic Foundation, Cleveland, OH

Martha L. Mooney, MD, Sentara Norfolk Transplant Center/
EVMS, Norfolk, VA

Michael G. Petty, PhD(c), RN, CCNS, CNS, University of
Minnesota Medical Center, Minneapolis, MN

Richard N. Pierson, III, MD, University of Maryland, Baltimore, MD

Heather J. Ross, MD, MHSc, FRCP(c), Toronto General Hospital,
Toronto, Ontario, Canada

Sonja Schrepfer, MD, PhD, University Heart Center Hamburg,
Hamburg, Germany

Randall C. Starling, MD, MPH, The Cleveland Clinic Foundation,
Cleveland, OH

Marc A. Stern, MD, Hopital Foch, Suresnes Cedex, France

David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH

Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg,
Leuven, Belgium

Florian M. Wagner, MD, University Hospital Eppendorf,
Hamburg, Germany

Marian Zembala, MD, PhD, FESC, Silesian Medical School,
Zabrze, Poland

ABSTRACT REVIEWERS

Dan Admon, MD, Hadassah University Hospital, Jerusalem, Israel
Annalisa Angelini, MD, Universita Di Padova, Italy
Selim M. Arcasoy, MD, Columbia University, New York, NY
Abbas Ardehali, UCLA School of Medicine, Los Angeles, CA
James B. Atkinson, MD, PhD, Vanderbilt University Medical Center, Nashville, TN
Carla C. Baan, PhD, Erasmus MC, Rotterdam, The Netherlands
David A. Baran, MD, Newark Beth Israel Medical Center, Newark, NJ
Juergen Behr, MD, University of Munich, Germany
Christian Benden, MD, University Hospital Zurich, Switzerland
Alexandria Berg, RN, Children's Healthcare of Atlanta, GA
Sangeeta M. Bhorade, MD, University of Chicago, IL
Emma Birks, MRCP, Harefield Hospital, Harefield, Middlesex, United Kingdom
Annette Boehler, MD, University Hospital Zurich, Switzerland
Michael Burch, MD, Great Ormond Street Hospital, London, United Kingdom
Allen P. Burke, MD, University of Maryland Medical Center, Baltimore, MD
Jason D. Christie, MD, University of Pennsylvania, Philadelphia, PA
Paul Corris, MB FRCP, Freeman Hospital, Newcastle, United Kingdom
Maria Rosa Costanzo, MD, FACC, FAHA, Midwest Heart Specialists, Naperville, IL
Angelika Costard-Jaeckle, MD, University Heart Center Hamburg, Hamburg, Germany
William G. Cotts, MD, Bluhm Cardiovascular Institute, Northwestern University, Chicago, IL
Maria G. Crespo Leiro, MD, Unidad de Insuficiencia Cardiaca y Trasplante Cardiaco, La Coruna, Spain
Lara Danziger-Isakov, MD, MPH, The Cleveland Clinic Foundation, Cleveland, OH
Tobias Deuse, MD, PhD, University Heart Center Hamburg, Germany
Annette DeVito Dabbs, RN, PhD, University of Pittsburgh School of Nursing, Pittsburgh, PA
Fabienne Dobbels, MSc, PhD, University Hospital Leuven, Belgium
Brooks S. Edwards, MD, Mayo Clinic, Rochester, MN
Thomas M. Egan, MD, MSC, University of North Carolina School of Medicine, Chapel Hill, NC
Howard Eisen, MD, Drexel University College of Medicine, Philadelphia, PA
Aly El Banayosy, MD, Penn State Hershey Medical Center, Hershey, PA
Okan Elidemir, MD, Texas Children's Hospital, Houston, TX
Stephan Enslinger, MD, PhD, University of Erlangen-Nurnberg, Erlangen, Germany

Michiel E. Erasmus, MD, PhD, University Medical Center Groningen, The Netherlands
Roberto Fiocchi, MD, PhD, Ospedali Riuniti di Bergamo, Italy
Michael C. Fishbein, MD, UCLA School of Medicine, Los Angeles, CA
Juliet E. Foweraker, MD, PhD, Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom
Robert Frantz, MD, Mayo Clinic, Rochester, MN
Darren H. Freed, MD, PhD, FRCSC, St. Boniface General Hospital, Winnipeg, Manitoba, Canada
James P. Gagermeier, MD, Loyola University Medical Center, Chicago, IL
Edward Garrity, Jr., MD, University of Chicago Medical Center, Chicago, IL
James F. George, PhD, University of Alabama at Birmingham, AL
Reda Girgis, MB BCh, Johns Hopkins University, Baltimore, MD
Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY
Gonzalo V. Gonzalez-Stawinski, MD, The Cleveland Clinic Foundation, Cleveland, OH
Kate Gould, FRCPath, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Cynthia Gries, MD, MSc, University of Washington, Seattle, WA
Finn Gustafsson, MD, PhD, Rigshospitalet, Copenhagen, Denmark
Elizabeth Hammond, MD, LDS Hospital, Salt Lake City, UT
Ari L. J. Harjula, MD, Helsinki University Central Hospital, Helsinki, Finland
Ray E. Hershberger, MD, University of Miami Miller School of Medicine, Miami, FL
Peter M. Hopkins, FRACP, The Prince Charles Hospital, Brisbane, Australia
Evelyn Horn, MD, Well Cornell Medical Center, New York, NY
Shahid Husain, MD, MS, Toronto General Hospital, Ontario, Canada
Martin Iversen, MD, PhD, Rigshospitalet, Copenhagen, Denmark
Peter Jaksch, MD, General Hospital Vienna, Austria
Robert Jaquiss, MD, Arkansas Children's Hospital, Little Rock, AR
Valluvan Jeevanandam, MD, University of Chicago Hospitals, Chicago, IL
Annemarie Kaan, MCN, RN, St. Paul's Hospital, Vancouver, British Columbia, Canada
Walter G. Kao, MD, FACC, University of Wisconsin School of Medicine, Madison, WI
Anne Keogh, MBBS, MD, St. Vincent's Hospital, Sydney, Australia
Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Ontario, Canada
James K. Kirklin, MD, University of Alabama at Birmingham, AL
Walter Klepetko, MD, University of Vienna, Austria
Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA
Christiane Kugler, PhD, Hannover Medical School, Hannover, Germany
Sudhir S. Kushwaha, MD, Mayo Clinic, Rochester, MN
Hans B. Lehmkuhl, MD, Deutsches Herzzentrum Berlin, Germany

Pascal Leprince, MD, PhD, Hospital Pitie-Salpetriere
Deborah J. Levine, MD, University of Texas Health Science Center,
San Antonio, TX
Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Alfred Hospital,
Melbourne, Australia
Katherine Lietz, MD, PhD, Yale University School of Medicine,
New Haven, CT
Jane MacIver, RN, MSc, Toronto General Hospital, Toronto,
Ontario, Canada
Donna M. Mancini, MD, New York Presbyterian Hospital,
New York, NY
Charles C. Marboe, MD, College of Physicians & Surgeons,
New York, NY
Sandra Martin, RN, MSN, University Hospital Leuven, Belgium
Stanley I. Martin, MD, Ohio State University Medical Center,
Columbus, OH
Frauke Mattner, MD, Hannover Medical Center, Hannover,
Germany
Kenneth McCurry, MD, Cleveland Clinic Foundation, Cleveland, OH
Keith McNeil, FRACP, Metro North Health Service District,
Herston, Queensland, Australia
Federica Meloni, MD, PhD, University of Pavia, Italy
Carmelo Milano, MD, Duke University Medical Center,
Durham, NC
Henrik Miltung, PhD, Erich & Hanna Klessmann Institute,
Bad Oeynhausen, Germany
Paul J. Mohacsi, MD, University Hospital, Berne, Switzerland
Jean-Francois Mornex, MD, Hopital Louis Pradel, Lyon, France
Michiel Morshuis, MD, Heart Center NRW, Bad Oeynhausen,
Germany
Jonathan B. Orens, MD, Johns Hopkins University, Baltimore, MD
Robert F. Padera, MD, PhD, Brigham & Women's Hospital,
Boston, MA
Elfriede Pahl Schuette, MD, Children's Memorial Hospital,
Chicago, IL
Scott M. Palmer, MD, MHS, Duke University, Durham, NC
Myung H. Park, MD, University of Maryland School of Medicine,
Baltimore, MD
Si M. Pham, MD, University of Miami/Jackson Memorial Hospital,
Miami, FL
Sean P. Pinney, MD, Mount Sinai Medical Center, New York, NY
Christophe Pison, MSc, MD, PHD, CHU de Grenoble, France
Jeffrey L. Platt, MD, University of Michigan, Ann Arbor, MI
J. Eduardo Rame, MD, Penn Heart and Vascular Center,
Philadelphia, PA
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto,
Ontario, Canada
Olaf Reinhartz, MD, Stanford University, Stanford, CA
Mauro Rinaldi, MD, IRCCS Policlinico San Matteo, Torino, Italy
Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom

Stuart Russell, MD, Johns Hopkins Hospital, Baltimore, MD
Robert J. Schilz, MD, Case Western Reserve University, Cleveland, OH
Fernanda P. Silveira, MD, University of Pittsburgh Medical Center,
Pittsburgh, PA
Lianne G. Singer, MD, FRCPC, Toronto General Hospital,
Ontario, Canada
Gregory I. Snell, FRACP, MBB, Alfred Hospital, Melbourne,
Australia
Stuart C. Sweet, MD, PhD, St. Louis Children's Hospital,
St. Louis, MO
Gabor B. Szabo, MD, PhD, University of Heidelberg, Germany
Jose Tallaj, MD, University of Alabama at Birmingham, AL
Henry D. Tazelaar, MD, Mayo Clinic, Scottsdale, AZ
Jeffrey J. Teuteberg, MD, University of Pittsburgh/Presbyterian,
Pittsburgh, PA
Hendrik Treede, MD, University Heart Center Hamburg, Germany
Vincent G. Valentine, MD, University of Texas Medical Branch,
Galveston, TX
Dirk Van Raemdonck, MD, PhD, University Hospital
Gasthuisberg, Leuven, Belgium
Johan Vanhaecke, MD, University Hospital Gasthuisberg,
Leuven, Belgium
Erik A. M. Verschuuren, MD, PhD, University Medical Centre,
Groningen, The Netherlands
Robert G. Weintraub, MB BS FRAC, Royal Children's Hospital,
Parkville, Victoria, Australia
Richard D. Weisel, MD, Toronto General Hospital, Toronto,
Ontario, Canada
Lori J. West, MD, DPhil, University of Alberta, Edmonton, Canada
Glen P. Westall, FRACP, PhD, Melbourne, Australia
Connie White-Williams, PhD, University of Alabama at
Birmingham, AL
Gayle L. Winters, MD, Brigham & Women's Hospital, Boston, MA
Thorsten Wittwer, MD, PhD, MA, University Hospital of Cologne,
Germany
Joseph Woo, MD, University of Pennsylvania Health System,
Philadelphia, PA
Roger Yusen, MD, MPH, Washington University School of
Medicine, St. Louis, MO
Michael Zakliczynski, MD, Silesian Centre for Heart Disease,
Gliwice, Poland
Andreas O. Zuckermann, MD, University of Vienna, Austria

SCIENTIFIC COUNCIL OPERATING BOARDS

HEART FAILURE AND TRANSPLANT MEDICINE

Maria G. Crespo-Leiro, MD, Chair
Allen Anderson, MD, FACC, Vice-Chair
Maria Rosa Costanzo, MD, Past-Chair
Nicholas R. Banner, FRCP, Standards and
Guidelines Workforce Leader

Allen S. Anderson, MD, Education Workforce Leader
Mariano Feccia, MD, Registries and Databases Workforce Leader
David P. Nelson, MD, Communications Workforce Leader
Robert C. Bourge, MD, Development Liaison

MECHANICAL CIRCULATORY SUPPORT

Emma Birks, MRCP, PhD, Chair
Francis D. Pagani, MD, PhD, Vice-Chair
Stephanie A. Moore, MD, Standards and Guidelines
Workforce Leader

Roberta C. Bogaev, MD, FACC, Education Workforce Leader
Jaap Lahpor, MD, PhD, Registries and Databases Workforce Leader
Evgenij V. Potapov, MD, Communications Workforce Leader
Mario C. Deng, MD, Development Liaison

INFECTIOUS DISEASES

Margaret M. Hannan, MD, Chair
Martha L. Mooney, MD, Vice-Chair
Shahid Husain, MD, MS, Past-Chair
Lara Danziger-Isakov, MD, MPH, Standards and Guidelines
Workforce Leader

Martha L. Mooney, MD, Education Workforce Leader
Frauke Mattner, MD, Registries and Databases Workforce Leader
Vincent G. Valentine, MD, Communications Workforce Leader
Eric A. M. Verschuuren, MD, PhD, Development Liaison

NURSING, HEALTH SCIENCE AND ALLIED HEALTH

Connie White-Williams, MSN, Chair
Bernice L. Coleman, RN, PhD, Vice-Chair
Annette J. Devito Dabbs, RN, PhD, Past Chair
Michael G. Petty, PhD(c), RN, CCNS, CNS, Standards and
Guidelines Workforce Leader
Sharon A. Beer, RN, MSn, Education Workforce Leader
Fabienne Dobbels, PhD, Registries and Databases Workforce Leader
Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Communications
Workforce Leader
Judy A. Currey, PhD, Grants and Awards Workforce Leader
Kevin Carney, RN, CCTC, Development Liaison

PATHOLOGY AND BASIC SCIENCE

Stephan M. Ensminger, MD, PhD, Chair
Annalisa Angelini, MD, Vice Chair
E. Rene Rodriguez, MD, Past Chair
Carmela D. Tan, MD, Standards and Guidelines Workforce Leader
E. Rene Rodriguez, MD, Education Workforce Leader
Robert F. Padera, MD, PhD, Registries and Databases
Workforce Leader
James B. Atkinson, MD, PhD, Communications Workforce Leader

PEDIATRIC TRANSPLANTATION

Christian Benden, MD, Chair
Elfriede Pahl Schuette, MD, Vice-Chair
Michael Burch, MD, Past Chair
Okan Elidemir, MD, Standards and Guidelines Workforce Leader
Daphne Hsu, MD, Education Workforce Leader
Richard E. Chinnock, MD, Registries and Databases
Workforce Leader
Anne L. Dipchand, MD, Communications Workforce Leader

PULMONARY ARTERIAL HYPERTENSION

Raymond L. Benza, MD, Chair
Myung Park, MD, Vice-Chair
John P. Scott, MD, Past-Chair
Evelyn Horn, MD, Standards and Guidelines Workforce Leader
Omar A. Minai, MD, Education Workforce Leader
Adaani Frost, MD, Registries and Databases Workforce Leader
Deborah J. Levine, MD, Communications Workforce Leader
Srinivas Murali, MD, Development Liaison

PULMONARY TRANSPLANTATION

Geert M. Verleden, MD, PhD, Chair
Lianne G. Singer, MD, FRCPC, Vice Chair
David Weill, MD, Vice Chair-Elect/Secretary
Martin R. Zamora, MD, Past Chair
David Weill, MD, Standards and Guidelines Workforce Leader
Christopher H. Wigfield, MD, FRCS, Education
Workforce Leader
Shaf Keshavjee, MD, Registries and Databases Workforce Leader
Christine L. Lau, MD, Communications Workforce Leader
Roger D. Yusen, MD, MPH, Quality of Life Workforce Leader
Patrick Evrard, MD, Development Liaison Officer

JUNIOR FACULTY AND TRAINEE COUNCIL

Lorriana E. Leard, MD, Chair
David W. Markham, MD, Vice Chair
Cynthia J. Gries, MD, Past Chair
Susan D. Moffatt-Bruce, MD, PhD, Standards and
Guidelines Workforce Leader
Daniel F. Dilling, MD, Education Workforce Leader
Jennifer C. Matthews, MD, Registries and Databases
Workforce Leader
Pali D. Shah, MD, Communications Workforce Leader
Arezu, Z. Aliabadi, MD, Development Liaison

ISHLT COMMITTEES

EDUCATION COMMITTEE

Andrew Fisher, FRCP, PhD, Chair

Daniel F. Dilling, MD, Junior Faculty and
Trainee Council Workforce Leader

Allen S. Anderson, MD, FACC, Heart Failure
Council Workforce Leader

Sharon A. Beer, RN, MSc, Nursing, Health Science
and Allied Health Council Workforce Leader

Martha L. Mooney, MD, Infectious Diseases Council
Workforce Leader

Christopher H. Wigfield, MD, FRCS, Pulmonary
Transplantation Council Workforce Leader

Daphne Hsu, MD, Pediatric Council Workforce Leader

Omar A. Minai, MD, Pulmonary Hypertension
Council Workforce Leader

Roberta C. Bogaev, MD, FACC, Mechanical
Circulatory Support Council Workforce Leader

E. Rene Rodriguez, MD, Pathology and Basic Science
Council Workforce Leader

Keith McNeil, FRACP, At Large Member

Andreas O. Zuckermann, MD, At Large Member

Beatriz Diaz Molina, MD, At Large Member

COMMUNICATIONS COMMITTEE

Maryl R. Johnson, MD, Chair

Pali D. Shah, MD, Junior Faculty and Trainee
Council Workforce Leader

David P. Nelson, MD, Heart Failure Council Workforce Leader

Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Nursing,
Health Science and Allied Health Council Workforce Leader

Vincent G. Valentine, MD, Infectious Diseases
Council Workforce Leader

Christine L. Lau, MD, Pulmonary Transplant
Council Workforce Leader

Anne I. Dipchand, MD, Pediatric Council Workforce Leader

Deborah J. Levine, MD, Pulmonary Hypertension
Council Workforce Leader

Evgenij V. Potapov, MD, Mechanical Circulatory
Support Council Workforce Leader

James B. Atkinson, MD, PhD, Pathology and Basic
Science Council Workforce Leader

Nicholas R. Banner, FRCP, Education Committee Representative

David Weill, MD, Standards and Guidelines
Committee Representative

David S. Feldman, MD, ISHLT Links Newsletter Editor

Mandeep R. Mehra, MD, Editor, Journal of Heart and
Lung Transplantation

Cynthia S. Herrington, MD, At Large Member

Cedric D. Sheffield, MD, At Large Member

Cynthia J. Gries, MD, MSc, At Large Member

GRANTS AND AWARDS COMMITTEE

Duane Davis, MD, Chair

Mark Barr, MD, Past Chair

Lori J. West, MD, DPhil

Carla C. Baan, PhD

Marshall I. Hertz, MD, Reviewer

Bernice L. Coleman, RN, PhD, Reviewer

JHLT EDITORIAL BOARD

Mandeep Mehra, MBBS, FACC, FACP, Editor-in-Chief

Patricia Uber, PharmD, Scientific Managing Editor

Maria Rosa Costanzo, MD, Editor Emeritus 1995-1999

James K. Kirklin, MD, Editor Emeritus 2000-2009

EDITORIAL OFFICE CONSULTANTS:

Jonathan B. Orens, MD

Jayan Parameshwar, FRCP

Richard N. Pierson III, MD

EDITORIAL BOARD CONSULTANTS:

Claus B. Andersen, MD, D.M.Sc

Marcelo Cantarovich, MD

Charles E. Canter, MD

Pablo F. Castro, MD

Richard E. Chinnock, MD

John V. Conte, MD

Paul A. Corris, MB FRCP

Duane Davis, MD

Fabienne Dobbels, MSc, PhD

Howard J. Eisen, MD

Roger W. Evans, PhD

Michael C. Fishbein, MD

Edward R. Garrity, Jr., MD

James F. George, PhD

Alan R. Glanville, MD, FRACP

Kate Gould, FRCPath

Kathleen L. Grady, PhD, APN, FAAN

Shahid Husain, MD, MS

Maryl R. Johnson, MD

Shaf Keshavjee, MD, FRCSC

Jon Kobashigawa, MD

Willem Kop

Bruce McManus, MD, PhD

Bruno M. Meiser, MD

Alan H. Menkis, MD, FRCS(C)

Leslie W. Miller, MD

Francesco Parisi, MD
Myung H. Park, MD
Soon J. Park, MD
Heather J. Ross, MD, MHSc, FRCP(c)
Lewis J. Rubin, MD
Stephan Schueler, MD, PhD
Randall C. Starling, MD, MPH
Stuart C. Sweet, MD, PhD
Hector Ventura, MD
Steve A. Webber, MB ChB, MRCP
Lori J. West, MD, DPhil
Andreas O. Zuckermann, MD

PROFESSIONAL STANDARDS AND GUIDELINES COMMITTEE

Maria Rosa Costanzo, MD, Chair
Susan D. Moffatt-Bruce, MD, PhD, Junior Faculty and
Trainee Council Workforce Leader
Nicholas R. Banner, FRCP, Heart Failure Council Workforce Leader
Michael G. Petty, PhD(c), RN, CCNS, CNS, Nursing,
Health Science and Allied Health Council Workforce Leader
Lara Danziger-Isakov, MD, MPH, Infectious Diseases
Council Workforce Leader
David Weill, MD, Pulmonary Transplantation
Council Workforce Leader
Okan Elidemir, MD, Pediatric Council Workforce Leader
Evelyn Horn, MD, Pulmonary Hypertension
Council Workforce Leader
Stephanie A. Moore, MD, Mechanical Circulatory
Support Council Workforce Leader
Carmela D. Tan, MD, Pathology and Basic Science
Council Workforce Leader
Diego H. Delgado, MD, At Large Member
Maria G. Crespo-Leiro, MD, At Large Member
Daniela Pini, MD, At Large Member

REGISTRIES AND DATABASES COMMITTEE

Marshall I. Hertz, MD, Chair
Jennifer C. Matthews, MD, Junior Faculty and
Trainee Council Workforce Leader
Mariano Feccia, MD, Heart Failure Council Workforce Leader
Fabienne Dobbels, PhD, Nursing, Health Science and
Allied Health Council Workforce Leader
Frauke Mattner, MD, Infectious Diseases Council Workforce Leader
Shaf Keshavjee, MD, Pulmonary Transplantation Workforce Leader
Richard E. Chinnock, MD, Pediatric Council Workforce Leader
Adaani Frost, MD, Pulmonary Hypertension Council
Workforce Leader
Jaap Lahpor, MD, PhD, Mechanical Circulatory Support
Council Workforce Leader

Robert F. Padera, MD, PhD, Pathology and
Basic Science Council Workforce Leader
Roger D. Yusen, MD, MPH, Outcomes Specialist
Maria G. Crespo-Leiro, MD, Outcomes Specialist
Leah Edwards, PhD, Thoracic Registry Biostatistician

THORACIC REGISTRY STEERING COMMITTEE

Marshall I. Hertz, MD, Medical Director
Josef Stehlik, MD, MPH, Associate Medical Director, Heart
Jason D. Christie, MD, Associate Medical Director,
Lung/Heart-Lung
Richard Kirk, MA, FRCP, FRCPC, H,
Associate Medical Director, Pediatric Heart
Paul Aurora, MRCP, PhD, Associate Medical Director,
Pediatric Lung/Heart-Lung
Fabienne Dobbels, PhD, Associate Medical Director, Outcomes
Axel Rahmel, MD, Associate Medical Director, OEO Relations
Leah Edwards, PhD, Associate Medical Director, Biostatistics
Jaime Williamson, SAS Analyst
Kathryn A. Philibin, RN, TII Liaison
Anna Kucheryavaya, Assistant Biostatistician



PAST EDITORS

Journal Of Heart And Lung Transplantation

2000-2009	James K. Kirklin, MD
1995-1999	Maria Rosa Costanzo, MD
1986-1994	Michael P. Kaye, MD
1981-1985	Jacques G. Losman, MD

MEDICAL DIRECTORS, THORACIC ORGAN TRANSPLANT REGISTRY

2001-Present	Marshall I. Hertz, MD
1993-2001	Jeffrey D. Hosenpud, MD
1987-1993	Michael P. Kaye, MD

PAST PRESIDENTS

2008-2009	Mandeep R. Mehra, MD
2007-2008	Paul A. Corris, MB FRCP
2006-2007	Robert C. Robbins, MD
2005-2006	Mark L. Barr, MD
2004-2005	Alec Patterson, MD
2003-2004	Jon Kobashigawa, MD
2002-2003	Stephan Schueler, MD
2001-2002	James B. Young, MD
2000-2001	Anne Keogh, MBBS, MD
1999-2000	Robert L. Kormos, MD
1998-1999	Alan Menkis, MD, FRCS(C)
1997-1998	Leslie Miller, MD
1996-1997	William Baumgartner, MD
1995-1996	Sharon Hunt, MD
1994-1995	John Wallwork, FRCS
1993-1994	Eric Rose, MD
1992-1993	John O'Connell, MD
1991-1992	Christian Cabrol, MD
1990-1991	Margaret Billingham, MD
1988-1990	Bruno Reichart, MD
1986-1988	Stuart Jamieson, MD
1984-1986	Terence English, FRCS
1982-1984	Jack Copeland, MD
1981-1982	Michael Hess, MD

PAST SCIENTIFIC PROGRAM CHAIRS

2009	Paris, France	Randall C. Starling, MD, MPH
2008	Boston, MA	Lori J. West, MD, DPhil
2007	San Francisco, CA	Duane Davis, MD
2006	Madrid, Spain	John Dark, MB, FRCS
2005	Philadelphia, PA	Shaf Keshavjee, MD
2004	San Francisco, CA	Mandeep R. Mehra, MD
2003	Vienna, Austria	Bruce R. Rosengard, MD
2002	Washington, DC	Robert C. Robbins, MD
2001	Vancouver, Canada	David O. Taylor, MD
2000	Osaka, Japan	Jon Kobashigawa, MD
1999	San Francisco, CA	Mark L. Barr, MD
1998	Chicago, IL	James B. Young, MD
1997	London, England	Stephan Schueler, MD
1996	New York, NY	William A. Baumgartner, MD
1995	San Francisco, CA	Leslie W. Miller, MD
1994	Venice, Italy	John Wallwork, MBChB, FRCS
1993	Boca Raton, FL	Maria Rosa Costanzo, MD
1992	San Diego, CA	Eric A. Rose, MD
1991	Paris, France	John B. O'Connell, MD
1990	San Diego, CA	D. Glenn Pennington, MD
1989	Munich, Germany	Bruno Reichart, MD
1988	Los Angeles, CA	John C. Baldwin, MD
1987	New Orleans, LA	
1986	New York, NY	
1985	Anaheim, CA	Terence A. H. English, FRCS and Hillel Laks, MD
1984	New York, NY	Randall B. Griep, MD
1983	New Orleans, LA	Stuart W. Jamieson, MD and Mark E. Thompson, MD
1982	Phoenix, AZ	Michael Kaye, MD and Bernard Gersh, MD
1981	San Francisco, CA	Edward B. Stinson, MD and Michael L. Hess, MD

ISHLT AWARD RECIPIENTS

LIFETIME ACHIEVEMENT AWARD

2004	Sir Magdi Yacoub, MD
1999	Keith Reemtsma, MD
1996	Norman Shumway, MD

LIFETIME SERVICE AWARD

1997	Jacques G. Losman, MD
1996	Michael P. Kaye, MD

PIONEERS IN TRANSPLANTATION LECTURE

2009	Christian E. A. Cabrol, MD
2008	Richard E. Lower, MD
2006	Leonard L. Bailey, MD
2002	Michael DeBakey, MD Bruce A. Reitz, MD
2000	Christiaan Barnard, MD Joel D. Cooper, MD Norman E. Shumway, MD

NORMAN E. SHUMWAY ISHLT CAREER DEVELOPMENT AWARD

2008	Glen Westall, MD, PhD <i>(supported by Roche)</i>
2006	Dennis W. Wigle, MD, PhD <i>(supported by Astellas Pharma)</i>
2004	Allan M. Ramirez, MD <i>(supported by Novartis Pharma)</i>
2002	Anthony Azakie, MD <i>(supported by Roche)</i>
2000	Gordon D. Wu, MD <i>(supported by Roche)</i>

ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANTS

2009	Hua Shen, MD, PhD <i>(supported by Astellas)</i> Tobias Deuse, MD, PhD <i>(supported by Novartis)</i> Masahiro Miyajima, MD, PhD <i>(supported by XDx)</i> Shin Hirayama, MD, PhD <i>(supported by Gilead)</i>
2008	Jonathan Choy, PhD <i>(supported by XDx)</i> Satoshi Itoh, MD <i>(supported by Transmedics)</i> Tereza Martinu, MD <i>(supported by Novartis)</i> Deepti Saini, PhD <i>(supported by Gilead)</i> Atsushi Shiozaki, MD, PhD <i>(supported by Astellas)</i> Seiichiro Sugimoto, MD, PhD <i>(supported by Roche)</i>
2007	J. Raymond Fitzpatrick, III, MD <i>(supported by Encysive)</i> Howard J. Huang, MD <i>(supported by Transmedics)</i> Mylvganam Jeyakanthan, MD <i>(supported by XDx)</i> Timothy M. Millington, MD <i>(supported by Novartis)</i> Satish N. Nadig, MD <i>(supported by Roche)</i> Takeshi Oyaizu, MD, PhD <i>(supported by Actelion)</i> Sonja Schrepfer, MD <i>(supported by Astellas)</i>
2006	Rachel L. Anderson, MBBS <i>(supported by Roche)</i> Zhaohui Li, PhD <i>(supported by Transmedics)</i> Heather E. Merry, MD <i>(supported by Encysive)</i> Edward N. Seung, PhD <i>(supported by XDx)</i> Matthew J. Weiss, MD <i>(supported by Novartis)</i>

- 2005 Ryan C. Fields, MD (supported by Chiron)
Arne Neyrinck, MD (supported by Astellas)
Ahmad Saad, MD (supported by Roche)
- 2004 Christian A. Gleissner, MD (supported by Astellas)
Tsuyoshi Shoji, MD, PhD (supported by Actelion)
Kendra N. Taylor, PhD (supported by Roche)
Monica Zwierzchonieuska, MD (supported by XDx)
- 2003 Ewout J. van den Bos, MD (supported by Astellas)
Felix Fernandez, MD (supported by Roche)
- 2002 Ruediger Hoebelt, MD (supported by Roche)
- 2001 Arnar Geirsson, MD (supported by Roche)
Matteo Vatta, PhD (supported by Roche)
- 2000 Richard S. Lee, MD (supported by Novartis)
Christopher H. Wigfield, FRCS (supported by Roche)
- 1999 George Juang, MD (supported by Novartis)
Sivasai Krovvidi, PhD (supported by Roche)
Satoshi Saito, MD (supported by Novartis)
Donald Wong, PhD (supported by Roche)
- 1998 Kelly S.A. Blair, MD (supported by Roche)
A.M. El Gamel, MD (supported by Roche)
Christine L. Lau, MD (supported by Wyeth-Ayerst)
Scott D. Ross, MD
Margaret L. Schwarze, MD (supported by Novartis)
- 1997 Jonathan Chen, MD (supported by Roche)
Alyssa M. Krasinskas, MD (supported by Astellas)
Owen T. Lawrence, MD (supported by Ortho-Biotech)
Anne K. Raisanen-Sokolowski, MD (supported by Roche)
- 1996 Tuija S. Ikonen, MD (supported by Roche)
Andrew F. Pierre, MD (supported by Ortho-Biotech)
- 1995 Frances L. Johnson, MD (supported by Ortho-Biotech)

ISHLT TRANSPLANT REGISTRY JUNIOR FACULTY AWARD

- 2008 Cynthia Gries, MD, MSc
Scott Halpern, MD, PhD
Josef Stehlik, MD, MPH
- 2007 Beth D. Kaufman, MD

ISHLT NURSING AND SOCIAL SCIENCES RESEARCH GRANT

- 2009 Jane MacIver, RN, MSc
- 2008 Stacey M. Pollock-BarZiv, PhD
- 2007 Mi-Kyung Song, PhD
- 2006 Thierry Troosters, PhD
- 2005 Annemarie F. Kaan, MCN
- 2004 Deidre E. Logan, PhD
- 2003 Diane H. Leloudis, RN, MSN
Janet E. Madill, PhD
- 2002 Annette J. De Vito Dabbs, RN, MN, PhD
- 2001 Lynn Doering, RN, DNSc
- 2000 Nancy M. Albert, MSN, RN
- 1999 Jeanne Salyer, PhD
- 1998 Katherine St. Clair, RN, MSN
- 1997 Eileen Collins, RN, PhD



19 20

PHILIP K. CAVES AWARD

- 2009 Howard Huang, MD
- 2008 Satish N. Nadig, MD
- 2007 Heather E. Merry, MD
- 2006 Gregor Warnecke, MD
- 2005 Sigrid Sandner, MD
Frank D'Ovidio, MD
- 2004 M.D. Peterson, MD
- 2003 Sigrid Sandner, MD
- 2002 Peter Blaha, MD
- 2001 Alexander S. Krupnick, MD
- 2000 Michael P. Fischbein, MD
- 1999 Joerg Koglin, MD
- 1998 Carla C. Baan, MD
- 1997 Simon D. Eiref, MD
- 1996 Moninder S. Bhabra, MD
- 1995 Elizabeth A. Davis, MD
- 1994 Jobst Winter, MD
Alain Chapelier, MD
- 1993 David Marshman, MD
- 1992 David P. Kapelanski, MD
- 1991 A. Jiminez, MD
- 1990 Andres J. Duncan, MD
- 1989 A.M. Wood, MD
- 1988 Charles D. Fraser, Jr., MD
- 1987 Wim Van Der Bij, MD
- 1986 Stuart J. Knechtel, MD
- 1985 Michael A. Breda, MD
- 1984 Hermann Reichenspurner, MD
- 1983 Robbin G. Cohen, MD

NURSING AND SOCIAL SCIENCES EXCELLENCE IN RESEARCH AWARD

- 2009 Connie White-Williams, MSN
- 2008 Annette DeVito Dabbs, RN, PhD
- 2007 Christianne Kugler, PhD
- 2006 Kathleen L. Grady, PhD, RN
- 2005 Mary Amanda Dew, PhD

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL BEST MCSD PAPER AWARD

- 2009 Nishant Shah, MD (supported by Thoratec)

ISHLT BRANISLAV RADOVANCEVIC MEMORIAL FELLOWSHIP GRANT

- 2009 Sasa D. Borovic, MD (supported by Thoratec)

HIGHLIGHTS OF THE SCIENTIFIC PROGRAM

MECHANICAL CIRCULATORY SUPPORT

The 30th Anniversary Meeting and Scientific Sessions of ISHLT will have a record number of presentations addressing the challenges of patient selection for mechanical circulatory support (MCS), clinical management of the MCS patient and recommendations to reduce adverse events associated with device support. Your colleagues share their experience with some of the most dreaded complications of MCS in a Sunrise Symposium, **“VADs Gone Bad Case Presentations,”** on Wednesday morning.

The first satellite session on Wednesday morning, **“The Ultimate VAD Symposium,”** will provide participants with a comprehensive overview of MCS – from patient and device selection to outpatient management. Immediately thereafter, a satellite symposium, **“Who Plays God? Ethics in Transplantation and MCS Devices,”** will address the ethical issues teams face when patients require transitioning to palliative care. During the Opening Plenary Session on Wednesday afternoon, Dr. James Kirklin will give attendees the most recent update from the INTERMACS registry.

Gender differences in device outcomes and adverse events will be discussed on Thursday morning in the **“Battle of the Sexes.”** Thursday afternoon’s concurrent session, **“Device Disasters: Can We Avoid Them?”** will review strategies to address adverse events in LVAD patients. In **“Getting Back to the Basics: MCS Devices and the Myocyte,”** which will be held on Thursday afternoon, insights can be gleaned regarding the molecular and cellular mechanisms behind patients’ clinical responses to MCS.

Friday morning, the concurrent session, **“Cost Effectiveness and Long-Term Outcomes,”** addresses the financial impact of advanced technology. Friday afternoon there will be two sentinel concurrent sessions: **“The Menu: Which Device When?”** and **“Expert Consensus Definitions in Cardiothoracic Transplantation and MCS Infections.”**

21 22

Saturday morning's plenary session will conclude with an unprecedented debate by Dr. O.H. Frazier and Dr. Mandeep Mehra: **"MCS is IN, Heart Transplantation is OUT."** Whether you are new to the field of MCS or a seasoned VAD clinician, at this year's ISHLT meeting you will find stimulating and provocative presentations that will help you enhance the care of patients requiring MCS.

PULMONARY HYPERTENSION

This year, the PH members of the Program Committee have put together a stellar series of seminars that highlight management of advanced PH. On Wednesday April 21 the 7:00 AM Sunrise Symposium, **"Clinical Challenges in the Management of Right Ventricular Failure,"** will focus on RV failure management, especially in patients waiting for thoracic transplants. That will be followed with an 8:15 Wednesday Satellite Symposium called **"Innovations in Pulmonary Hypertension: Advances in Medical and Surgical Therapies"** where the new guidelines including use of combination therapies will be presented. On Thursday April 22 at 10:45 a Concurrent Session titled, **"Novel Genomic, Proteomic, and Clinical Risk Markers in Pulmonary Arterial Hypertension"** is scheduled. One of the main themes throughout these sessions will be a focus on right ventricular (dys)function, its imaging, its assessment and its management, with presentations from some of the leading authorities in the world. On the whole, this year's meeting offers a great opportunity to learn more about PH and its management.

INFECTIOUS DISEASE

This year's Annual Meeting is laced with venues presenting cutting edge developments in transplant and mechanical circulatory system (MCS) related infectious diseases. On Wednesday, Satellite Symposium 6 unfolds the impact of emerging pathogens on the cardiothoracic transplantation center's every day business by the experts in the field. The Australian experience of the novel 2009 influenza H1 N1 pandemic will be described; with a six month head start before the Northern Hemisphere's tangle

with the pandemic influenza virus, they have a lot to tell that we can all learn from.

Management of this and other donor derived infections will be investigated from donor evaluation at the time of transplantation through inadvertent donor transmitted infections in the cardiothoracic transplant recipient. Timely laboratory diagnostics will be examined for donor selection and resources explored that are available to assist in post transplant evaluation of a donor-derived infection. The post transplant presentation, diagnosis and management of geographically restricted infectious diseases will also be explored.

On Thursday, Concurrent Session 21 contains molecular and clinical studies furthering our understanding of the interrelationship between transplant immunology and pathogen and several relevant talks concerning clinical management of transplant and MCS related infections.

Friday's Concurrent Session 40 should not be missed by anyone involved in clinical research. This session will premier the summary of the **"ISHLT Expert Consensus Definitions of Infections in Cardiothoracic Transplantation and Mechanical Circulatory Support Patients."** A panel of workforce members will lead the panel discussion at the end of the presentations for further clarification of these definitions.

On Saturday morning, Sunrise Symposium 7 **"Crossing the Lines"** puts the definitions of mechanical circulatory support related infectious diseases into the clinical application – learning from the past and going into the future with a unified set of definitions for these infections. **"The Expert Consensus Definitions of Infections in Cardiothoracic Transplantation and Mechanical Circulatory Support Patients"** will be available for use in future studies to accurately capture the true incidence of infectious diseases in these patients.

PEDIATRIC TRANSPLANTATION

There are several programs of particular interest to the pediatric transplant community. At 7:00 am on Wednesday, April 21, there will be a Sunrise Symposium on **"Technical Issues in Mechanical Support in the Pediatric Patient"** followed by two Satellite Symposia with a pediatric focus: **"Coronary Vasculopathy from Bench to Bedside"** and **"Management of the Sensitized Patient."**

On Saturday, April 24, there will be a Sunrise Symposium with case presentations on **"Tough Cases in the Management of the Sensitized Patient"** and a symposium on **"Transplantation in the Pediatric Patient with Cardiomyopathy."** There will be three outstanding oral presentation sessions, a moderated poster session and a general poster session dedicated to pediatric transplantation.

BASIC SCIENCE

One of the most important events of the meeting is the **Caves Award** session, during which young academic scientists present their "hottest" experimental and clinical research. Another session not to be missed is **"Stem Cell Research and Tissue Engineering,"** especially the invited presentation by Professor Eschenhagen.

PULMONARY TRANSPLANTATION

The following programs are of interest related to pulmonary transplantation. Satellite Symposium 9 will cover the significance of airways inflammation in lung allograft dysfunction. This symposium discusses the current understanding of airways inflammation and its potential role in the evolution of chronic rejection, but will also highlight new insights and different treatment modalities. Satellite Symposia 4 and 10, which deal with the diagnosis and the management of sensitized patients, will further give the recent evolution in the role of antibody-mediated rejection. This is only a very small part of the program, but cannot be missed by the attendees who still have questions on these topics.

NURSING, HEALTH SCIENCE AND ALLIED HEALTH

Our 2010 Annual Meeting program has been constructed and designed based on feedback and evaluations from our nursing science, social science and allied health colleagues. We are delighted to report that the nursing and social science content of this year's meeting is focused on presentations and discussions, balanced between clinical research, outcomes in practice and for the first time, participants will be afforded the opportunity to discuss in case study methodology format, specific care challenges in the heart and lung recipient population.

Please put the following sessions on your calendars as "Not to be Missed!"

Wednesday, April 21st, 7:00-8:00 AM, Sunrise Symposium 5: Clinical Challenges for Nursing and Allied Health: What Would You Do? Case Presentations.

This interactive session is designed to give you a valuable opportunity to interact with other nursing and allied health professionals as we discuss common clinical challenges. Bring your perspective and your questions to this interesting dialogue.

Wednesday, April 21st, 10:30 AM-12:30 PM, Satellite Symposium 12: Transforming Transplant Care Through Evidence Based Practice

In a series of invited presentations, experts in nursing and other allied health fields explore what we know – and what we don't know – about evidence related to outcomes of our care delivery to transplant and mechanical circulatory support patients. Hear the latest in evidence and join others in considering future directions for research into the care of these unique populations.

**Wednesday, April 21st, 5:15-6:45 PM,
Concurrent Session 4: Nursing Science: And Then We Were Done: Patient Experience Following Surgical Interventions for Heart and Lung Failure**

A series of outstanding abstract presenters work to fill in some of the gaps in knowledge we face in the post-operative management of thoracic transplant recipients. You won't want to miss these highly rated summaries of important current research.

**Thursday, April 22nd, 2:30-4:30 PM,
Concurrent Session 17: Quality of Life and Social Sciences: Have We Done the Right Thing? Assessing Quality of Life Following Cardiothoracic Transplantation**

We often wonder if, in hindsight, we have done the right thing by our patients. Six researchers will shed light on that question through a series of intriguing explorations of activities that are associated with improved quality of life. Come think with us.

PATHOLOGY

This year's Annual Meeting features several landmark and cutting edge developments in the field of pathology as it relates to heart and lung transplantation. Antibody mediated rejection (AMR) (abstracts 92, 94, 95, 97, 111, 179, 220, 317, 319,) and the significance of donor specific antibody and B-cells (13, 39, 70, 100, 148, 152, 248, 251, 315, 320, 322, 342, 454, 458, 459, 464,) are a major focus this year. Significant advances are also presented in molecular assessments of rejection (32, 43, 98, 120, 174, 178, 245, 449, 452, 453, 481, 483), cellular mechanisms of "chronic" rejection and predictors of survival (21, 25, 37, 96, 339, 340, 451), allograft coronary vasculopathy (38, 51, 93, 149, 213, 247, 450, 488) and PTLD and other malignancies complicating transplantation (44, 199, 362, 363, 368, 400, 401, 523). Lung transplantation pathology is also highlighted (150, 151, 298, 299, 300, 301) with particular focus on bronchiolitis obliterative syndrome (99, 154, 302, 316, 324, 341, 342).

Satellite Symposium 4 will focus on the relationship of rejection episodes to the development of heart allograft vasculopathy, BOS and graft survival. The pathobiology of AMR, pre and post transplant AMR surveillance, as well as monitoring and diagnosis of AMR will all be discussed. Satellite Symposium 5 will examine cardiac allograft vasculopathy from bench to bedside, exploring the role of innate and adaptive immunity in the pathogenesis of allograft vasculopathy, prevalence, detection and prognosis of allograft vasculopathy in children.

Satellite Symposium 9 will focus on the role of lymphocytic bronchiolitis and airway inflammation in transplanted lungs, as well as the association with rejection and BOS. Satellite Symposium 10 will discuss several aspects of the management of highly sensitized patients, including the ISHLT Consensus Discussion on AMR in heart transplantation, where a summary of results will be presented.

Concurrent Session 6 "AMR Story Continues" will focus in the use of C4d and other new markers for diagnosis of AMR in heart biopsies. The Thursday plenary ses-

sion will present comparison of gene expression profile and endomyocardial biopsy for surveillance of acute rejection. Concurrent Session 1 will deal with the role of stem cells in basic and translational approaches. Concurrent Session 16 highlights molecular and clinical studies furthering our understanding of the interrelationship between the transplanted or failing heart and gene expression profile markers. Concurrent Session 32 will discuss the mechanisms of inflammation and repair in the lung allograft airway. Concurrent Session 35 will focus on new approaches to the evaluation and treatment of acute rejection, discussing a new C1q assay for prediction of AMR. Concurrent Session 39 will also discuss the molecular mechanisms of organ rejection.

JUNIOR FACULTY & TRAINEES

We are excited to have two new and very special offerings at this year's Annual Meeting. On Thursday April 22 join us at 12:15 PM for the "**International Networking Lunch**," where junior faculty and trainees can be mentored on "**Getting Your Next Job**," "**Balancing Work and Family**," or other topics (pre-registration is required and limited). On Friday, April 23 at 10:45 AM we are excited to see presentations from winners of an abstract competition called "**Clinical Case Dilemmas in Thoracic Transplantation**" – with tough cases presented to expert discussants. All are welcome to observe or to join in the discussion.

HEART FAILURE AND TRANSPLANT MEDICINE

The following sessions should prove to be of particular interest to those engaged in the fields of heart failure and transplant medicine:

- Satellite Symposium 7 (Wednesday, April 21, 10:30-12:30) will be devoted to the ethics of thoracic transplantation.
- Results of several potentially significant clinical trials will be reported at this year's meeting. In the Plenary Session (Thursday, April 22, 8:30-10:15 AM): the IMAGE trial compares the standard biopsy guided surveillance strategy with a noninvasive approach using gene expression profiling in cardiac transplantation. In Concurrent Session 12 (Thursday, April 22, 10:45-12:15): the TICTAC trial, which compared a tacrolimus alone vs a tacrolimus and MMF regimen for routine immunosuppression in cardiac transplantation, will be presented.
- During the Thursday Plenary Session, a summary of the first ISHLT guidelines for the management of the post transplant patient will be presented.
- There will be a series of sessions on mechanical circulatory support which will provide a comprehensive overview of this rapidly evolving field.



- The first ever ISHLT Academy course (Saturday, April 24 – Sunday, April 25) will follow the conclusion of the Scientific Sessions. This separate registration program is designed to be a comprehensive overview of advanced heart failure and cardiac transplantation for practitioners and trainees alike.

ISHLT Wednesday

TIME	INTERNATIONAL BALLROOM	CONTINENTAL A/B	BOULEVARD ROOM	CONTINENTAL C	WALDORF ROOM
7:00 AM	SUNRISE 1 VADs Gone Bad	SUNRISE 2 Mgmt of RVF	SUNRISE 3 Surg Lung Tx	SUNRISE 4 MCS in PED Pts	SUNRISE 5 NNSAH Cases
8:00 AM					
8:15 AM	SATELLITE 1 Ultimate VADs	SATELLITE 2 Innovations in PH	SATELLITE 3 Lung Donors	SATELLITE 4 AMR Part 1	SATELLITE 5 CAV
10:00 AM					
10:15 AM	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK
10:30 AM	SATELLITE 7 Ethics in Tx & MCS	SATELLITE 8 Tackling PVD	SATELLITE 9 Lung Allograft Disf	SATELLITE 10 AMR Part 2	SATELLITE 11 ISHLT Guidelines
12:30 PM					
1:00 PM			MINI ORAL SESSION 1	MINI ORAL SESSION 2	MINI ORAL SESSION 3
2:00 PM					
2:30 PM	OPENING PLENARY SESSION				
4:45 PM	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK
5:15 PM	CONCURRENT SESSION 1	CONCURRENT SESSION 2	CONCURRENT SESSION 3	CONCURRENT SESSION 4	CONCURRENT SESSION 5
5:30 PM	Patients, Pumps and Outcomes	Heart Tx Outcome	Candidate Selection for Lung Tx	Nursing: Patient Experience	Donor & Recipient Sel in Ped Tx
6:30 PM					
6:45 PM					
7:45 PM					
8:00 PM					

MARQUETTE ROOM	JOLIET ROOM	PDR 2	PDR 4	SE/SW EXHIBIT HALL	TIME
		CORPORATE COUNCIL BREAKFAST			7:00 AM
					8:00 AM
SATELLITE 6 Emerging IDs					8:15 AM
					10:00 AM
COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	10:15 AM
SATELLITE 12 Evidence				EXHIBIT AND POSTER HALLS OPEN 10 AM – 7:45 PM	10:30 AM
	REG & DATABASES COMMITTEE MEETING				12:30 PM
MINI ORAL SESSION 4		MINI ORAL SESSION 5			1:00 PM
					2:00 PM
					2:30 PM
COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	4:45 PM
CONCURRENT SESSION 6 AMR Story Continues	COUNCIL MEETING PAST PRESIDENTS				5:15 PM
					5:30 PM
					6:30 PM
				EXHIBIT HALL RECEPTION	6:45 PM
					7:45 PM
					8:00 PM

ISHLT Thursday

TIME	INTERNATIONAL BALLROOM	CONTINENTAL A/B	BOULEVARD ROOM	CONTINENTAL C	WALDORF ROOM
7:00 AM					COUNCIL MEETING ID
8:00 AM	PLENARY SESSION				
8:30 AM					
10:00 AM					
10:15 AM	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK
10:45 AM	CONCURRENT SESSION 7 Battle of the Sexes – Pt Section	CONCURRENT SESSION 8 Heart Tx Outcome	CONCURRENT SESSION 9 Donor Influences After Lung Tx	CONCURRENT SESSION 10 Novel Markers in PAH	CONCURRENT SESSION 11 Stem Cells
12:15 PM					
12:30 PM					
2:00 PM					
2:15 PM					
2:30 PM	CONCURRENT SESSION 13 Device Disasters	CONCURRENT SESSION 14 Heart Tx Post Op	CONCURRENT SESSION 15 Rejection after Lung Tx	CONCURRENT SESSION 16 Every Breath I Take is Better	CONCURRENT SESSION 17 QOL and Social Sciences
4:00 PM	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK
4:30 PM	CONCURRENT SESSION 19 Heart Tx and Immunobiology	CONCURRENT SESSION 20 MCS and the Myocyte	CONCURRENT SESSION 21 Update in Tx Infections	CONCURRENT SESSION 22 Immunosuppression after Lung Tx	CONCURRENT SESSION 23 Ped Tx in Unique Patient Populations
6:00 PM			MINI ORAL SESSION 6	MINI ORAL SESSION 7	MINI ORAL SESSION 8
7:00 PM					
8:00 PM					

MARQUETTE ROOM	JOLIET ROOM	PDR 2	PDR 4	SE/SW EXHIBIT HALL	TIME
COUNCIL MEETING MCS	COUNCIL MEETING PH	COUNCIL MEETING PTH			7:00 AM
					8:00 AM
					8:30 AM
					10:00 AM
COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	10:15 AM
CONCURRENT SESSION 12 Immunosuppression after Heart Tx				EXHIBIT AND POSTER HALLS OPEN 10 AM – 4:30 PM	10:45 AM
		JUNIOR FACULTY & TRAINEE MENTOR LUNCH			12:15 PM
	IPLTC MEETING				12:30 PM
					2:00 PM
CONCURRENT SESSION 18 Tissue Gene Regulation					2:15 PM
					2:30 PM
COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	4:00 PM
CONCURRENT SESSION 24 Heart Failure Outcomes					4:30 PM
MINI ORAL SESSION 9	LTX QOL MEETING	COUNCIL MEETING JR FAC & TRAINEE			6:00 PM
					7:00 PM
					8:00 PM

ISHLT Friday

TIME	INTERNATIONAL BALLROOM	CONTINENTAL A/B	BOULEVARD ROOM	CONTINENTAL C	WALDORF ROOM
7:00 AM					COUNCIL MEETING PULM Tx
8:00 AM	PLENARY SESSION				
8:15 AM					
10:00 AM					
10:15 AM	BUSINESS MEETING	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK
10:45 AM	CONCURRENT SESSION 25 Cost Effectiveness & Outcome	CONCURRENT SESSION 26 Risk of Heart Transplantation	CONCURRENT SESSION 27 BOS Risk Factors and Prevention	CONCURRENT SESSION 28 Making a Better Breath	CONCURRENT SESSION 29 PH: Innovative Therapy
12:15 PM					
12:30 PM					
2:00 PM					
2:15 PM					
2:30 PM		CONCURRENT SESSION 31 The Menu: Which Device When?	CONCURRENT SESSION 32 Inflammation & Repair in Lung	CONCURRENT SESSION 33 Heart Tx: Immunosuppression	CONCURRENT SESSION 34 Healing My Broken Heart
4:00 PM		COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK
4:30 PM		CONCURRENT SESSION 37 Heart Tx Clinical Challenges	CONCURRENT SESSION 38 Lung Tx for Interstitial Lung Dis	CONCURRENT SESSION 39 Molecular Mech of Organ Rejection	CONCURRENT SESSION 40 Expert Defs in CT Tx and MCS Inf
6:00 PM					
7:00 PM					
8:00 PM	PRESIDENT'S GALA RECEPTION - GRAND BALLROOM				
10:00 PM					

TIME	LAKE ERIE ROOM
1:15 PM	2011 PROGRAM COMMITTEE MEETING
2:15 PM	

MARQUETTE ROOM	JOLIET ROOM	PDR 2	PDR 4	SE/SW EXHIBIT HALL	TIME
COUNCIL MEETING HF	COUNCIL MEETING PED	COUNCIL MEETING NNSAH	COUNCIL MEETING BASIC SCIENCE		7:00 AM
					8:00 AM
					8:30 AM
					10:00 AM
COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	10:15 AM
CONCURRENT SESSION 30 Clinical Cases in Thoracic Tx				EXHIBIT AND POSTER HALLS OPEN 10 AM - 4:30 PM	10:45 AM
	JHLT EDITORIAL BOARD OF DIRECTORS LUNCHEON		SCIENTIFIC COUNCIL CHAIRS LUNCHEON		12:15 PM
					12:30 PM
CONCURRENT SESSION 35 Rejection in PED Tx		CONCURRENT SESSION 36 Autoimmunity, Tolerance & Inflammation			2:00 PM
COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	2:15 PM
CONCURRENT SESSION 41 Caves Award Candidates					2:30 PM
					4:00 PM
					4:30 PM
					6:00 PM
			NEW BOARD ORIENTATION MTG		7:00 PM
					8:00 PM
PRESIDENT'S GALA RECEPTION - GRAND BALLROOM					
					10:00 PM

ISHLT Saturday

TIME	INTERNATIONAL BALLROOM	CONTINENTAL A/B	BOULEVARD ROOM	CONTINENTAL C	WALDORF ROOM
7:00 AM			SUNRISE 6 QOL after Lung Tx	SUNRISE 7 Crossing the Lines	SUNRISE 8 Lung Tx Disasters
8:00 AM		PLENARY SESSION			
8:15 AM					
10:15 AM		COFFEE BREAK	COFFEE BREAK	COFFEE BREAK	COFFEE BREAK
10:30 AM		CONCURRENT SESSION 42 Blood, Clots & Antibodies	CONCURRENT SESSION 43 Lung Tx Complications	CONCURRENT SESSION 44 Late Complications Post Heart Tx	CONCURRENT SESSION 45 Tx for PED Cardiomyopathies
NOON				COUNCIL REPORTS TO BOARD	
12:15 PM					
1:00 PM					MASTERS ACADEMY REGISTRATION
1:15 PM					
1:30 PM					
2:30 PM					
					MASTERS ACADEMY SATURDAY SESSION 1 – 3 2 – 9 PM
					SUNDAY SESSION 4 – 5 7 AM – NOON
5:30 PM					
9:00 PM					

MARQUETTE ROOM	JOLIET ROOM	PDR 2	LAKE ERIE ROOM	SE/SW EXHIBIT HALL	TIME
	SUNRISE 9 Sensitized Pt Mgmt				7:00 AM
					8:00 AM
					8:15 AM
COFFEE BREAK	COFFEE BREAK		COFFEE BREAK		10:15 AM
	CONCURRENT SESSION 46 What's Hot! Best Abstracts				10:30 AM
					NOON
					12:15 PM
					1:00 PM
					1:15 PM
			ISHLT BOARD OF DIRECTORS MEETING		1:30 PM
					5:30 PM
					9:00 PM



PRESIDENT'S GALA RECEPTION

THE PRESIDENT'S GALA RECEPTION will be held Friday, April 23rd from 8:00 pm – 10:00 pm inside the beautiful Grand Ballroom of the Chicago Hilton, known to many of us from the famous movie "The Fugitive." The talented Marginal Donors, starring our own Heather Ross, MD, will be performing for the crowd. Please be sure to join us for this wonderful event celebrating the Society's 30 years. One ticket to the Gala Reception is included with each paid registration. Additional tickets may be purchased for \$75 each.



CONTINUING MEDICAL EDUCATION INFORMATION

31

32

ACCREDITATION

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 28 hours in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

EDUCATIONAL OBJECTIVES

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their needs.

33

GOALS

To enable participants to learn about current practices, emerging technologies and medical advances related to heart and lung transplantation and end-stage heart and lung disease: and to provide a forum for participants to engage in discussion, debate and examination regarding the efficacy and applicability of these current practices, emerging technologies and medical advances.

TARGET AUDIENCE

The audience for this program includes physicians, surgeons, scientists, nurses and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields or specialties which cause them to become involved in the treatment of transplant recipients or patients with end-stage heart or lung disease.


LEARNING OBJECTIVES

Please refer to the disclosure documents distributed at the registration desk for the learning objectives for this educational activity.


MEETING ROOM FLOORPLANS

8TH FLOOR

LOWER FLOOR




2ND FLOOR



LOBBY



3RD FLOOR



DISCLOSURE

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner/Presenter.

These disclosures have been distributed from the registration desk to all delegates.

Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational. ISHLT will ensure that all conflicts of interest have been resolved in accordance with ACCME requirements for the purpose of eliminating bias in the presentation of educational and scientific content.

SCHEDULE AT A GLANCE

Tuesday, April 20, 2010

8:00 AM – 8:00 PM

Exhibit Booth Installation/Set-up (Southeast Exhibit Hall)

7:00 AM – 1:00 PM

ISHLT BOARD OF DIRECTORS MEETING
(Lake Erie Room)

NOON – 8:00 PM

Poster Mounting (Southwest Exhibit Hall)

2:00 PM – 4:00 PM

EDUCATION COMMITTEE MEETING (PDR-4)

2:00 PM – 6:00 PM

ISHLT/ERS/ATS CLAD MEETING (Joliet)

4:00 PM – 6:00 PM

THORACIC REGISTRY STEERING COMMITTEE
MEETING (Continental Foyer Office 2)

4:30 PM – 6:30 PM

COMMUNICATIONS COMMITTEE MEETING (PDR-2)
STANDARDS AND GUIDELINES COMMITTEE MEETING
(PDR-4)

5:00 PM – 8:00 PM

Registration Desk Open (8th Street Registration)

5:00 PM – 8:00 PM

Slide Ready Room Open (Grand Tradition)

Wednesday, April 21, 2010

6:00 AM – 7:00 PM

Registration Desk Open (8th Street Registration)

6:00 AM – 7:00 PM

Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM

CORPORATE COUNCIL BREAKFAST MEETING (PDR-2)

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 1:

VADs Gone Bad Case Presentations (International Ballroom)

SUNRISE SYMPOSIUM 2:

Clinical Challenges in the Management of Right Ventricular Failure (Continental A/B)

SUNRISE SYMPOSIUM 3:

Surgical Approaches for Lung Transplantation – Is There Still a Debate? (Boulevard)

SUNRISE SYMPOSIUM 4:

Technical Issues in Mechanical Support in the Pediatric Patient Case Presentations (Continental C)

SUNRISE SYMPOSIUM 5

Clinical Challenges for Nursing and Allied Health: What Would You Do? Case Presentations (Waldorf)

8:00 AM – 10:00 AM

Exhibit Booth Set-up (Southeast Exhibit Hall)

Poster Mounting (Southwest Exhibit Hall)

8:15 AM – 10:15 AM

SATELLITE SYMPOSIUM 1:

The Ultimate VAD Symposium (International Ballroom)

SATELLITE SYMPOSIUM 2:

Innovations in Pulmonary Hypertension: Advances in Medical and Surgical Therapies (Continental A/B)

SATELLITE SYMPOSIUM 3:

Getting to Yes – Increasing Lung Donors (Boulevard)

SATELLITE SYMPOSIUM 4:

Management of the Sensitized Patient and Antibody Mediated Rejection: Part 1 (Continental C)

SATELLITE SYMPOSIUM 5:

Cardiac Allograft Vasculopathy: From Bench to Bedside (Waldorf)

SATELLITE SYMPOSIUM 6:

Emerging Infectious Diseases: Donor Management Issues and Recipient Sequelae (Marquette)

9:00 AM – 5:00 PM

Press Office Open (Continental Office Foyer 1)

10:00 AM – 7:45 PM

Exhibit Hall Open (Southeast Exhibit Hall)

Internet Café Open (Southeast Exhibit Hall)

Poster Viewing (Southwest Exhibit Hall)

10:15 AM – 10:30 AM

Coffee Break (Southeast Exhibit Hall)

10:30 AM – 12:30 PM

SATELLITE SYMPOSIUM 7:

Who Plays God? Ethics in Transplantation and Mechanical Circulatory Support Devices (International Ballroom)

SATELLITE SYMPOSIUM 8:

Universal Issues in Tackling Pulmonary Vascular Disease – Where Do We Stand? (Continental A/B)

SATELLITE SYMPOSIUM 9:

The Significance of Airways Inflammation in Lung Allograft Dysfunction (Boulevard)

SATELLITE SYMPOSIUM 10:

Management of the Sensitized Patient and Antibody Mediated Rejection: Part 2 (Continental C)

SATELLITE SYMPOSIUM 11:

The ISHLT Guidelines for Heart Transplant Recipients: Towards an International Consensus (Waldorf)

SATELLITE SYMPOSIUM 12:

Transforming Transplant Care Through Evidence-Based Practice (Marquette)

12:30 PM – 2:30 PM

Lunch Break

12:30 PM – 1:30 PM

REGISTRIES AND DATABASES COMMITTEE MEETING (Joliet)

1:00 PM – 2:00 PM

MINI ORAL SESSION 1 (Boulevard)

MINI ORAL SESSION 2 (Continental C)

MINI ORAL SESSION 3 (Waldorf)

MINI ORAL SESSION 4 (Marquette)

MINI ORAL SESSION 5 (PDR-2)

2:30 PM – 4:45 PM

OPENING PLENARY SESSION

(International Ballroom)

4:45 PM – 5:15 PM

Coffee Break (Southeast Exhibit Hall)

5:15 PM – 6:45 PM

CONCURRENT SESSION 1:

Patients, Pumps and Outcomes (International Ballroom)

CONCURRENT SESSION 2:

Heart Transplant Outcome; Does the Donor Matter?
(Continental A/B)

CONCURRENT SESSION 3:

Observations on Candidate Selection for Lung Transplant
(Boulevard Room)

CONCURRENT SESSION 4:

Nursing Science: And Then We Were Done: Patient Experience Following Surgical Interventions for Heart and Lung Failure
(Continental C)

CONCURRENT SESSION 5:

Improving Donor and Recipient Selection in Pediatric Transplantation (Waldorf)

CONCURRENT SESSION 6:

The AMR Story Continues (Marquette)

5:30 PM – 6:30 PM

PAST PRESIDENT'S COUNCIL MEETING (Joliet)

6:45 PM – 7:45 PM

Exhibit Hall Opening Reception (Southeast Exhibit Hall)

View Posters (Southwest Exhibit Hall)

**Thursday,
April 22, 2010**

7:00 AM – 6:00 PM

Registration Desk Open (8th Street Registration)

7:00 AM – 7:00 PM

Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM

MECHANICAL CIRCULATORY SUPPORT SCIENTIFIC COUNCIL MEETING (Marquette)

PULMONARY ARTERIAL HYPERTENSION SCIENTIFIC COUNCIL MEETING (Joliet)

PATHOLOGY AND BASIC SCIENCE SCIENTIFIC COUNCIL MEETING (PDR-2)

INFECTIOUS DISEASE SCIENTIFIC COUNCIL MEETING (Waldorf)

8:30 AM – 10:15 AM

PLENARY SESSION
(International Ballroom)

9:00 AM – 5:00 PM

Press Office Open (Continental Office Foyer 1)

10:00 AM – 4:30 PM

Exhibit Hall Open (Southeast Exhibit Hall)

Internet Café Open (Southeast Exhibit Hall)

Poster Viewing (Southwest Exhibit Hall)

10:15 AM – 10:45 AM

Coffee Break (Southeast Exhibit Hall)

10:45 AM – 12:15 PM

CONCURRENT SESSION 7:

Battle of the Sexes - PT Selection (International Ballroom)

CONCURRENT SESSION 8:

Heart Transplantation Outcome (Continental A/B)

CONCURRENT SESSION 9:

Donor Influences on Outcomes After Lung Transplant
(Boulevard)

CONCURRENT SESSION 10:

Novel Genomic, Proteomic & Clinical Risk Markers in PAH
(Continental C)

CONCURRENT SESSION 11:

Stem Cells: Basic and Translational Approaches (Waldorf)

CONCURRENT SESSION 12:

Immunosuppression After Heart Transplantation: Is Less More?
(Marquette)

12:15 PM – 2:15 PM

Lunch Break

12:15 PM – 2:15 PM

JUNIOR FACULTY AND TRAINEE COUNCIL MENTOR LUNCH (PDR-2) (advance ticket purchase required)

12:30 PM – 2:00 PM

INTERNATIONAL PEDIATRIC LUNG TRANSPLANT COLLABORATIVE MEETING (Joliet)

2:30 PM – 4:00 PM

CONCURRENT SESSION 13:

Device Disasters: Can We Avoid Them? (International Ballroom)

CONCURRENT SESSION 14:

Heart Transplantation Post Op Dilemma (Continental A/B)

CONCURRENT SESSION 15:

Clinical Investigation in Acute and Chronic Rejection After Lung Transplantation (Boulevard)

CONCURRENT SESSION 16:

Every Breath I Take is Now Better (Continental C)

CONCURRENT SESSION 17:

Quality of Life and Social Sciences: Have We Done the Right Thing?: Assessing Quality of Life Following Cardiothoracic Transplantation (Waldorf)

CONCURRENT SESSION 18:

Tissue Gene Regulation and Protection From Injury (Marquette)

4:00 PM – 4:30 PM

Coffee Break (Southeast Exhibit Hall)

4:30 PM – 6:00 PM

CONCURRENT SESSION 19:

Clinical Heart Transplantation and Immunology

(International Ballroom)

CONCURRENT SESSION 20:

Getting Back to the Basics: MCSD and the Myocyte

(Continental A/B)

CONCURRENT SESSION 21:

From Bench to Bedside Update in Transplant Infections

(Boulevard)

CONCURRENT SESSION 22:

Immunosuppression After Lung Transplantation: From Mouse to Man (Continental C)

CONCURRENT SESSION 23:

Pediatric Transplantation in Unique Patient Populations

(Waldorf)

CONCURRENT SESSION 24:

Heart Failure: Prognostication and Outcomes (Marquette)

6:00 PM – 7:00 PM

PULMONARY TRANSPLANTATION COUNCIL QUALITY OF LIFE WORKFORCE MEETING (Joliet)

JUNIOR FACULTY AND TRAINEE COUNCIL MEETING

(PDR-2)

6:00 PM – 7:00 PM

MINI ORAL SESSION 6 (Boulevard)

MINI ORAL SESSION 7 (Continental C)

MINI ORAL SESSION 8 (Waldorf)

MINI ORAL SESSION 9 (Marquette)

**Friday,
April 23, 2010**

7:00 AM – 6:00 PM

Registration Desk Open (8th Street Registration)

7:00 AM – 6:00 PM

Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM

PULMONARY TRANSPLANTATION SCIENTIFIC COUNCIL MEETING (Waldorf)

HEART FAILURE AND TRANSPLANT MEDICINE

SCIENTIFIC COUNCIL MEETING (Marquette)

PEDIATRIC TRANSPLANTATION SCIENTIFIC COUNCIL

MEETING (Joliet)

NURSING, HEALTH SCIENCE, AND ALLIED HEALTH

SCIENTIFIC COUNCIL MEETING (PDR-2)

BASIC SCIENCE SCIENTIFIC COUNCIL MEETING

(tentative) (PDR-4)

8:15 AM – 10:15 AM

PLENARY SESSION

(International Ballroom)

9:00 AM – 5:00 PM

Press Office Open (Continental Office Foyer 1)

10:00 AM – 4:30 PM

Exhibit Hall Open (Southeast Exhibit Hall)

Internet Café Open (Southeast Exhibit Hall)

Poster Viewing (Southwest Exhibit Hall)

10:15 AM – 10:45 AM

ANNUAL BUSINESS MEETING (International Ballroom)

ISHLT Members Only

10:15 AM – 10:45 AM

Coffee Break (Southeast Exhibit Hall)

10:45 AM – 12:15 PM

CONCURRENT SESSION 25:

Cost Effectiveness and Long-Term Outcomes

(International Ballroom)

CONCURRENT SESSION 26:

Assessing the Risk of Heart Transplantation (Continental A/B)

CONCURRENT SESSION 27:

Bronchiolitis Obliterans Syndrome (BOS): Risk Factors

and Prevention (Boulevard)

CONCURRENT SESSION 28:

Making a Better Breath (Continental C)

CONCURRENT SESSION 29:

Pulmonary Hypertension; Innovative Therapy (Waldorf)

CONCURRENT SESSION 30:

Clinical Case Dilemmas in Thoracic Transplantation

(Marquette)

12:15 PM – 2:15 PM

Lunch Break

12:30 PM – 2:00 PM

JHLT EDITORIAL BOARD LUNCHEON MEETING

(Joliet Room)

SCIENTIFIC COUNCIL CHAIRS LUNCHEON MEETING
(PDR-4)

1:15 PM – 2:15 PM

2011 PROGRAM COMMITTEE MEETING
(Lake Erie Room)

2:30 PM – 4:00 PM

CONCURRENT SESSION 31:

The Menu: Which Device When? (Continental A/B)

CONCURRENT SESSION 32:

Mechanisms of Inflammation and Repair in the Lung Allograft Airway (Boulevard)

CONCURRENT SESSION 33:

Heart Transplantation; Immunosuppression Controversies
(Continental C)

CONCURRENT SESSION 34:

Healing My Broken Heart (Waldorf)

CONCURRENT SESSION 35:

New Approaches to the Evaluation and Treatment of Rejection in the Pediatric Transplant (Marquette)

CONCURRENT SESSION 36:

Autoimmunity, Tolerance and Inflammation (PDR-2)

4:00 PM – 4:30 PM

Coffee Break (Southeast Exhibit Hall)

4:30 PM – 11:59 PM

Exhibit Hall/Poster Hall Strike
(Southeast/Southwest Exhibit Halls)

4:30 PM – 6:00 PM

CONCURRENT SESSION 37:

Heart Transplantation Clinical Challenges (Continental A/B)

CONCURRENT SESSION 38:

Lung Transplant for Interstitial Lung Disease (Boulevard)

CONCURRENT SESSION 39:

Molecular Mechanisms of Organ Rejection (Continental C)

CONCURRENT SESSION 40:

Expert Consensus Definitions in Cardiothoracic Transplantation and Mechanical Circulatory Support Infections (Waldorf)

CONCURRENT SESSION 41:

Philip K. Caves Award Candidate Presentations (Marquette)

6:00 PM – 7:00 PM

NEW ISHLT BOARD MEMBER ORIENTATION
MEETING (PDR-4)

8:00 PM – 10:00 PM

GALA ANNIVERSARY RECEPTION (Grand Ballroom)

**Saturday,
April 24, 2010**

7:00 AM – 10:30 AM

Registration Desk Open (8th Street Registration)

7:00 AM – 9:00 PM

Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 6:

Linking Outcomes and Quality of Life After Lung Transplant (Boulevard)

SUNRISE SYMPOSIUM 7:

Crossing the Lines (Continental C)

SUNRISE SYMPOSIUM 8:

Disasters Early After Lung Transplant (Waldorf)

SUNRISE SYMPOSIUM 9:

Tough Cases in the Management of the Sensitized Patient Case Presentations (Marquette)

8:00 AM – 10:15 AM

PLENARY SESSION/AWARDS PRESENTATIONS

(Continental A/B)

9:00 AM – 12:00 Noon

Press Office Open (Continental Office Foyer 1)

10:15 AM – 10:30 AM

Coffee Break (Registration Area)

10:30 AM – 12:00 Noon

CONCURRENT SESSION 42:

Blood, Clots and Antibodies (Continental A/B)

CONCURRENT SESSION 43:

Lung Transplantation Complications (Boulevard Room)

CONCURRENT SESSION 44:

Late Complications Post Heart Transplantation
(Continental C)

CONCURRENT SESSION 45:

Transplantation for Pediatric Cardiomyopathies (Waldorf)

CONCURRENT SESSION 46:

What's Hot! Best Abstracts from Mechanical Circulatory Support, Heart Transplantation, Lung Transplantation
(Marquette)

12:15 PM – 1:15 PM

COUNCIL REPORTS TO THE MEMBERSHIP AND
BOARD (Continental C)

1:30 PM – 5:30 PM

ISHLT BOARD OF DIRECTORS MEETING (Lake Erie Room)



The International Society for Heart
and Lung Transplantation
is Most Grateful for the Educational
Grants and Support of:

GOLD LEVEL PARTNER

ASTELLAS

SILVER LEVEL PARTNERS

GILEAD

GENENTECH

NOVARTIS

XDX

BRONZE LEVEL PARTNER

UNITED

THERAPEUTICS

CORPORATE LEVEL PARTNER

GENZYME

Toward this 30th Anniversary Meeting
and Scientific Sessions.

SCIENTIFIC PROGRAM

All meetings and activities will take place at the Hilton Chicago unless otherwise specified. All papers will be presented in English.

Tuesday, April 20, 2010

8:00 AM – 8:00 PM

Exhibit Booth Installation/Set-up (Southeast Exhibit Hall)

7:00 AM – 1:00 PM

ISHLT BOARD OF DIRECTORS MEETING
(Lake Erie Room)

NOON – 8:00 PM

Poster Mounting (Southwest Exhibit Hall)

2:00 PM – 4:00 PM

EDUCATION COMMITTEE MEETING (PDR-4)

2:00 PM – 6:00 PM

ISHLT/ERS/ATS CLAD MEETING (Joliet)

4:00 PM – 6:00 PM

THORACIC REGISTRY STEERING COMMITTEE
MEETING (Continental Foyer Office 2)

4:30 PM – 6:30 PM

COMMUNICATIONS COMMITTEE MEETING (PDR-2)
STANDARDS AND GUIDELINES COMMITTEE MEETING
(PDR-4)

5:00 PM – 8:00 PM

Registration Desk Open (8th Street Registration)

5:00 PM – 8:00 PM

Slide Ready Room Open (Grand Tradition)

Wednesday, April 21, 2010

6:00 AM – 7:00 PM

Registration Desk Open (8th Street Registration)

6:00 AM – 7:00 PM

Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM

CORPORATE COUNCIL BREAKFAST MEETING (PDR-2)

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 1:

VADs Gone Bad Case Presentations (International Ballroom)

CHAIRS: O. HOWARD FRAZIER, MD AND
JOSEPH G. ROGERS, MD

7:00 AM *Suicide Case*, Nicholas G. Smedira, MD, Cleveland
Clinic Foundation, Cleveland, OH

7:15 AM *RV Failure Case*, Renzo Cecere, MD, Royal Victoria
Hospital, Montreal, Quebec, Canada

7:30 AM *Stroke Case*, Stuart D. Russell, MD, Johns Hopkins
Hospital, Baltimore, MD

7:45 AM *Infection Case*, Martin Strueber, MD, Hannover
Medical School, Hannover, Germany

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 2:

*Clinical Challenges in the Management of Right Ventricular
Failure* (Continental A/B)

CHAIRS: EVELYN HORN, MD AND SRINIVAS MURALI, MD

This session will cover the clinical challenges associated with right ventricular failure from pathophysiology, diagnosis, and treatment considerations in RV failure associated with secondary PH in patients with pulmonary and cardiac disorders. Specific focus will be placed on management of RV dysfunction in lung transplant and heart transplant candidates.

7:00 AM *Assessment of RV Function: Why is it Important and How Do You Do It?*, Mardi Gomberg Maitland, MD, MSc, University of Chicago, Chicago, IL

7:20 AM *Optimal Timing for Lung Transplant and the Implications of LAS in Pulmonary Arterial Hypertension – Is It Ever Too Late?* Adaani Frost, MD, Baylor University, Houston, TX

7:40 AM *Pulmonary Hypertension Therapies and VAD Support: Do They Improve Candidacy for Heart Transplant Candidates?*, Teresa De Marco, MD, FACC, University of California, San Francisco, CA

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 3:

Surgical Approaches for Lung Transplantation – Is There Still a Debate? (Boulevard)

CHAIRS: THOMAS K. WADDELL, MD, PHD AND
REHDA SOUILAMAS, MD, PHD

7:00 AM ***Clamshell With Tricks***, Duane Davis, MD, Duke University, Durham, NC

7:16 AM ***Sternal Sparing Clamshell***, Bryan F. Meyers, MD, Washington University School of Medicine, St. Louis, MO

7:32 AM ***Sternotomy With Tricks***, John Dark, MD, FRCS, Freeman Hospital, Newcastle, United Kingdom

7:42 AM ***Antero-Axillary Approach***, Yoshiya Toyoda, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 4:

Technical Issues in Mechanical Support in the Pediatric Patient Case Presentations (Continental C)

CHAIRS: DAVID MORALES, MD AND VICTOR O. MORELL, MD

7:00 AM ***MCS in the Pediatric Patient with Aortic Insufficiency***, Kimberly L. Gandy, MD, PhD, Children's Hospital of Wisconsin, Milwaukee, WI

7:12 AM ***Destination Therapy in a Patient with Potential Persistent Tumor Burden***, Kirk R. Kanter, MD, Emory University, Atlanta, GA

7:24 AM ***MCS of the Single Ventricle Population***, Bennett Pearce, MD, University of Alabama at Birmingham, AL

7:36 AM ***MCS in the Failing Fontan***, Kristine Guleserian, MD, Children's Medical Center, Dallas, TX

7:48 AM ***MCS in the Single Ventricle Patient after Bidirectional Glen***, Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 5:

Clinical Challenges for Nursing and Allied Health: What Would You Do? Case Presentations (Waldorf)

CHAIRS: ANNEMARIE KAAAN, MCN, RN AND
MICHAEL G. PETTY, PHD(C), RN, CCNS, CNS

Health care practitioners consistently report in our educational survey difficulty translating clinical research outcomes into practice. In this session, through a case-study methodology, participants will be offered the opportunity to discuss with experienced healthcare professionals the application of such learning to specific care challenges.

7:00 AM ***VAD Candidate with Psychosocial Warning Signs that Coping with a VAD May be a Challenge: Lack of Caregiver, Lack of Resources, Non-adherence, Accepted as a Device Candidate as a Bridge to Decision***, Daniela Roefe, RN, Heart Center NW, Bad Oeynhausen, Germany,

7:20 AM ***Pediatric Patient Whose Parents have been Non-adherent Presents as an Adult for Re-transplant***, Corby D'Amico, RN, MN, Emory University Hospital, Atlanta, GA,

7:40 AM ***Patients Revisiting the Dark Side: Resumption of Drug, Alcohol, Tobacco Abuse after Transplant: How Does the Caregiving Nurse Cope?*** Christine Hartley, MS, NP, Stanford University Medical Center, Palo Alto, CA,

8:00 AM – 10:00 AM

Exhibit Booth Set-up (Southeast Exhibit Hall)

Poster Mounting (Southwest Exhibit Hall)

8:15 AM – 10:15 AM

SATELLITE SYMPOSIUM 1:

The Ultimate VAD Symposium (International Ballroom)

CHAIRS: JAMES W. LONG, MD, PHD AND
GEORGE M. WIESELTHALER, MD

This session will provide the participant with an overview of mechanical circulatory support from patient and device selection, RV function assessment and management, bridge to recovery – role of clenbuterol, bridge to candidacy in the morbidly obese, destination therapy in the elderly, and management of the VAD recipient with hypertension.

8:15 AM ***Which Device for Which Patient***, Michiel Morshuis, MD, Heart Center NRW, Bad Oeynhausen, Germany

8:35 AM ***RV Failure: Prediction, Prevention and Treatment***, Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Ontario, Canada

8:55 AM ***Clenbuterol: Myth or Magic?***, Francis D. Pagani, MD, PhD, University of Michigan Hospital, Ann Arbor, MI

9:10 AM ***VADs: Are They the Ultimate Weight Loss Machines?*** Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

9:25 AM ***VAD: Are You Ever Too Old?***, Thomas Krabatsch, MD, PhD, German Heart Institute, Berlin, Germany

9:40 AM ***Continuous Flow Devices: What Is Hypertension?*** Randall C. Starling, MD, MPH, Cleveland Clinic Foundation, Cleveland, OH

9:55 AM ***Panel Discussion***

8:15 AM – 10:15 AM

SATELLITE SYMPOSIUM 2:

Innovations in Pulmonary Hypertension: Advances in Medical and Surgical Therapies (Continental A/B)

CHAIRS: MYUNG H. PARK, MD AND OMAR MINAI, MD

This session will focus on the most current up-to-date innovations in diagnosis, management, and research in pulmonary arterial hypertension (PAH). In 2009, the ACCF/AHA Executive Summary and reports from the 4th World Symposium were published. This session will feature highlights from those meetings and present updates on the current guidelines in combination therapy, surgical therapy and upcoming new treatments in PAH.

8:15 AM ***New Mandates From The ACCF/AHA Expert Consensus and 4th World Symposium On Pulmonary Hypertension***, Vallerie McLaughlin, MD, University of Michigan, Ann Arbor, MI

8:30 AM ***Combination Therapy in Pulmonary Hypertension: Do We Have the Evidence for it and Is it the Best Approach?*** Jean-Luc Vachieri, MD, Erasme University Hospital-ULB, Brussels, Belgium

8:45 AM ***Risk Modeling in Pulmonary Arterial Hypertension – Are the Current Approaches Adequate?*** Robert P. Frantz, MD, Mayo Clinic, Rochester, MN

9:00 AM ***New Therapies on the Horizon in Pulmonary Arterial Hypertension – Going Beyond the Three Pathways***, Paul A. Corris, MB FRCP, Freeman Hospital, Newcastle, United Kingdom

9:15 AM ***Beyond Medical Therapy – Surgical and Cellular Options for Pulmonary Hypertension***, Robert J. Schilz, MD, Case Western Reserve University, Cleveland, OH

8:15 AM – 10:15 AM

SATELLITE SYMPOSIUM 3:

Getting to Yes – Increasing Lung Donors (Boulevard)

CHAIRS: DIRK VAN RAEMDONCK, MD, PHD AND BARTLEY P. GRIFFITH, MD

Donor lung utilization is still unacceptably low and varies enormously between regions. Current donor utilization is only 15-20% of existing donors. This session will examine possible approaches (clinical as well as investigational) to improve organ availability.

8:15 AM ***Introduction - What are the Barriers? Where are the Opportunities?*** Duane Davis, MD, Duke University, Durham, NC

8:20 AM ***How To Optimize Donor Lung Procurement***, Charles W. Hoopes, MD, University of California San Francisco, CA

8:40 AM ***Transplant Program Donor Management – Increasing the Donor Pool***, Gregory I. Snell, FRACP, MBB, Alfred Hospital, Melbourne, Australia

9:00 AM ***DCD Donors***, Robert B. Love, MD, Loyola University Medical Center, Maywood, IL

9:20 AM ***State of the Art Ex Vivo Lung Perfusion***, Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Ontario, Canada

9:40 AM ***Resuscitation of the Donor Lung***, Florian M. Wagner, MD, University Heart Center Hamburg Eppendorf, Hamburg, Germany

8:15 AM – 10:15 AM

SATELLITE SYMPOSIUM 4:

Management of the Sensitized Patient and Antibody Mediated Rejection: Part 1 (Continental C)

CHAIRS: NANCY L. REINSMOEN, PHD AND STEVEN D. ZANGWILL, MD

Several reports have demonstrated that pre-transplant sensitization to HLA antigens leads to a decrease in graft survival, an increase in rejection episodes, and the development of cardiac allograft vasculopathy (CAV) after heart transplantation and bronchiolitis obliterative syndrome (BOS) after lung transplantation. Further, the percentage of sensitized thoracic organ candidates receiving transplants is far less than nonsensitized patients leading to increased time on the waitlists and increased death on the waitlists. This session is designed to address the assessment and impact of HLA specific antibodies in thoracic organ transplantation. New cutting edge technologies allow for the identification of donor antigens to be avoided to increase the donor pool for these sensitized patients. UNOS is implementing a calculated PRA to screen donors with unacceptable antigens and to indicate what percentage of the donor pool would be expected to be incompatible for a given patient. Other desensitization therapies are being used to decrease the strength and breadth of the antibody load again to increase the donor pool. Post-transplant monitoring strategies are being utilized to identify patients at risk for immune complications and allow for therapeutic intervention. Several investigators are studying the pathology and clinical implication of donor HLA specific antibodies and efficacy of treatment. This program will attempt to address these issues relevant to thoracic transplantation.

8:15 AM ***Biology of Antibody Mediated Rejection***, Elaine F. Reed, PhD, UCLA Immunogenetics Center, Los Angeles, CA

8:35 AM ***Techniques for Pre- and Post-Transplant Antibody Surveillance***, Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

9:05 AM ***The Crossmatch: How to do it and how to Interpret it***, Josef Stehlik, MD, MPH, University of Utah, Salt Lake City, UT

9:25 AM ***Post-Op Monitoring and Diagnosis of Antibody Mediated Rejection***, Margaret M. Burke, FRCPath, Harefield Hospital, Harefield, Middlesex, United Kingdom

9:45 AM ***Access for Sensitized Patients – A National Algorithm***, Lori J. West, MD, DPhil, University of Alberta, Edmonton, Canada

10:05 AM ***Panel Discussion***

8:15 AM – 10:15 AM

SATELLITE SYMPOSIUM 5:

Cardiac Allograft Vasculopathy: From Bench to Bedside

(Waldorf)

CHAIRS: JEFFREY L. PLATT, MD AND
HANNAH A. VALANTINE, MD

Despite the availability of new immunosuppressive therapies, graft vasculopathy remains a leading cause of graft loss following cardiac transplantation. This symposium is designed to bring together researchers from all perspectives to develop new approaches to the treatment of this problem. This session will educate the basic scientist, translational researcher and clinician about the pathophysiology, clinical manifestations, treatment and outcomes of graft vasculopathy in the heart transplant recipient.

8:15 AM *The Role of Innate Immunity in the Development of Allograft Vasculopathy*, Timothy D. Lee, PhD, Dalhousie University Halifax, Nova Scotia

8:30 AM *Adaptive Immunity in Allograft Vasculopathy*, Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom

8:45 AM *Prevalence, Detection, and Prognosis of Graft Vasculopathy in Children*, Elfriede Pahl Schuette, MD, Children's Memorial Hospital, Chicago, IL

9:00 AM *Non-Angiographic Imaging Modalities for the Diagnosis of Graft Vasculopathy*, Jignesh Patel, MD, PhD, Cedars-Sinai Heart Institute, Beverly Hills, CA

9:15 AM *How to Treat Graft Vasculopathy: Medical and Catheter Based Therapies*, Howard J. Eisen, MD, Drexel University College of Medicine, Philadelphia, PA

9:30 AM *Retransplantation: The Ultimate Treatment*, Clifford Chin, MD, Stanford University, Palo Alto, CA

9:45 AM *Panel Discussion*

8:15 AM – 10:15 AM

SATELLITE SYMPOSIUM 6:

Emerging Infectious Diseases: Donor Management Issues and Recipient Sequelae (Marquette)

CHAIRS: KATE GOULD, FRCPATH AND
STANLEY I. MARTIN, MD

The recent pandemic influenza and the SARS outbreak experience provide a natural "springboard" to discuss 1) the unfolding of an emerging pathogen threatening cardiothoracic transplant activities concerning donor, recipient, transplant teams and community; 2) donor management issues to identify the risks/testing- and its limitations; 3) resources available, should donor transmitted infection be suspected: UNOS/CDC-donor derived infection advisory board, etc.; 4) how a donor-derived infection presents post transplantation and how to diagnose and manage the recipient.

8:15 AM *Novel 2009 Influenza H1N1 Influenza Pandemic as a Model for an Emerging Infection's Impact on Cardiothoracic Transplant Centers: The Australian Experience*, Glen P. Westall, FRACP, PhD, Alfred Hospital, Melbourne, Australia

8:35 AM *Donor Derived Infections: Clinical Relevance and How to Avoid It – Evaluation and Management at Time of Donation. The SARS Experience*, Atul Humar, MD, University of Alberta, Edmonton, Canada

8:55 AM *Donor Derived Infections: Resources to Sort Out the Answers*, Michael G. Ison, MD, MS, UNOS, DTAC, Northwestern University, Chicago, IL

9:15 AM *Donor Infections: Diagnostic Testing and Management to Minimize Risk*, Paolo A. Grossi, MD, PhD, University of Insubria, Varese, Italy

9:40 AM *Transmission of Tropical or Geographically Restricted Infections During Solid Organ Transplantation: Clinical Presentation, Diagnostic Testing, and Outcome*, Patricia Munoz, MD, Hospital General Universitario Gregorio Marañón, Madrid, Spain

10:00 AM *Panel Discussion*

9:00 AM – 5:00 PM

Press Office Open (Continental Foyer Office 1)

10:00 AM – 7:45 PM

Exhibit Hall Open (Southeast Exhibit Hall)

Internet Café Open (Southeast Exhibit Hall)

Poster Viewing (Southwest Exhibit Hall)

10:15 AM – 10:30 AM

Coffee Break (Southeast Exhibit Hall)

10:30 AM – 12:30 PM

SATELLITE SYMPOSIUM 7:

Who Plays God? Ethics in Transplantation and Mechanical Circulatory Support Devices (International Ballroom)

CHAIRS: HEATHER J. ROSS, MD, MHSC, FRCP(C) AND
HANS B. LEHMKUHL, MD

This session will provide an overview of the major ethical issues that come into daily practice.

10:30 AM *Re-Transplantation*, Maryl R. Johnson, MD, University of Wisconsin, Madison, WI

10:45 AM *Multiorgan Transplant - One for You, Two or Three for Me*, Mark Siegler, MD, University of Chicago, IL

11:00 AM *End of Life/ Palliative Care After Organ Transplantation*, Savitri E. Fedson, MD, University of Chicago Hospitals, Chicago, IL

11:15 AM *When Do I Turn the VAD Off?*, Jane MacIver, RN, MSc, Toronto General Hospital, Toronto, Ontario, Canada

- 11:30 AM** *When to Say No – Does It Keep You up at Night?*, Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA
- 11:45 AM** *Mechanical Circulatory Support Devices +/- Transplant in Congenital Heart Patients - Yes Or No?*, Beth D. Kaufman, MD, Children's Hospital of Philadelphia, PA

12:00 PM *Panel Discussion*

10:30 AM – 12:30 PM

SATELLITE SYMPOSIUM 8:

Universal Issues in Tackling Pulmonary Vascular Disease – Where Do We Stand? (Continental A/B)

CHAIRS: RAYMOND L. BENZA, MD AND
DEBORAH J. LEVINE, MD

This session will cover key topics discussing diagnosis and management of a secondary PH commonly seen in clinical practice such as PH associated with lung disease, chronic thromboembolic disease and congenital heart disease, as well as the current “hot” topic of exercise and PH.

- 10:30 AM** *Report From the REVEAL Registry – What Constitutes the “Real” World Pulmonary Hypertension Patient Population?* Harrison W. Farber, MD, Boston University School of Medicine, Boston, MA
- 10:50 AM** *Significance of Pulmonary Hypertension in Parenchymal Lung Disease – Implications and Treatment*, Reda Girgis, MB BCh, Johns Hopkins University, Baltimore, MD
- 11:10 AM** *Chronic Thromboembolic Pulmonary Hypertension – When Does Medical Therapy Have a Place?*, Marion Delcroix, MD, University Hospital Leuven, Belgium
- 11:30 AM** *Congenital Heart Disease and Pulmonary Hypertension*, Curt J. Daniels, MD, Ohio State University, Columbus, OH
- 11:50 AM** *Exercise and Pulmonary Hypertension – How Far Can We Push Our Patients?*, Ronald J. Oudiz, MD, LA Biomedical Research Institute, Torrance, CA

10:30 AM – 12:30 PM

SATELLITE SYMPOSIUM 9:

The Significance of Airways Inflammation in Lung Allograft Dysfunction (Boulevard)

CHAIRS: ANDREW J. FISHER, FRCP, PHD AND
SANGEETA M. BHORADE, MD

Airway inflammation is widely recognized in patients developing lung allograft dysfunction, however the role this plays in the pathogenesis of Bronchiolitis Obliterans Syndrome and the best approach to its management remains unclear. Better understanding of lymphocytic bron-

chiolitis has been identified by the ISHLT pulmonary council educational survey as a key area for improved understanding. This session will explore the pathology of airway inflammation in the transplanted lung, examine any association between airway inflammation and acute and chronic rejection and discuss the evidence to support approaches to management.

10:30 AM *The Pathology of Airways Inflammation in the Transplanted Lung*, Susan Stewart, FRCPATH, Papworth Hospital, Cambridge, United Kingdom

10:55 AM *Is Airways Inflammation a Form of Acute Rejection*, Martin P. Iversen, MD, PhD, Rigshospitalet, Copenhagen, Denmark

11:15 AM *Airways Inflammation as a Risk Factor for Bronchiolitis Obliterans Syndrome (BOS)*, Allan R. Glanville, MD, FRACP, Sydney, Australia

11:35 AM *Treating Airways Inflammation in the Lung Allograft*, Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

11:55 AM *Panel Discussion*

10:30 AM – 12:30 PM

SATELLITE SYMPOSIUM 10:

Management of the Sensitized Patient and Antibody Mediated Rejection: Part 2 (Continental C)

CHAIRS: J. DAVID VEGA, MD AND UWE SCHULZ, MD

Several reports have demonstrated that pre-transplant sensitization to HLA antigens leads to decreased graft survival, an increase in rejection episodes, and the development of cardiac allograft vasculopathy (CAV) after heart transplantation and bronchiolitis obliterans syndrome (BOS) after lung transplantation. Further, the percentage of sensitized thoracic organ candidates receiving transplants is far less than nonsensitized patients leading to increased time on the waitlists and increased death on the waitlists. This proposed session is designed to address the assessment and impact of HLA specific antibodies in thoracic organ transplantation. New cutting edge technologies allow for the identification of donor antigens to be avoided to increase the donor pool for these sensitized patients. UNOS is implementing a calculated PRA to screen donors with unacceptable antigens and to indicate what percentage of the donor pool would be expected to be incompatible for a given patient. Other desensitization therapies are being used to decrease the strength and breadth of the antibody load again to increase the donor pool. Post-transplant monitoring strategies are being utilized to identify patients at risk for immune complications and allow for therapeutic intervention. Several investigators are studying the pathology and clinical implication of donor HLA specific antibodies and efficacy of treatment. This program will address these issues relevant to thoracic transplantation.

10:30 AM *Management of the Sensitized Adult Heart Candidate*, Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, MD

10:50 AM *Management of the Sensitized Pediatric Heart Candidate*, Steven A. Webber, MB ChB, Children's Hospital, Pittsburgh, PA

11:10 AM *Managing the Sensitized Lung Candidate*, Kenneth R. McCurry, MD, Cleveland Clinic Foundation, Cleveland, OH

11:30 AM *Clinical Perspective of Antibody Mediated Rejection*, A.G. Kfoury, MD, FACC, Intermountain Medical Center, Murray, UT

11:50 AM *Results of the ISHLT Consensus Discussion Regarding AMR in Heart Transplantation: Implications for Treatment*, Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA

12:10 PM *Panel Discussion*

10:30 AM – 12:30 PM

SATELLITE SYMPOSIUM 11:

The ISHLT Guidelines for Heart Transplant Recipients: Towards an International Consensus (Waldorf)

CHAIRS: JAMES K. KIRKLIN, MD AND
MANDEEP R. MEHRA, MD

Currently there are no published consensus practice guidelines addressing the care of heart transplant recipients. ISHLT has just completed development of such a set of guidelines. This session is intended to share with the ISHLT membership the key consensus recommendations for the care of heart transplant recipients, including early post-operative care, Immunosuppression and long term care.

10:30 AM *Introduction and Overview of the Process*, Maria Rosa Costanzo, MD, FACC, FAHA, Midwest Heart Specialists, Naperville, IL

10:40 AM *Perioperative Care of Heart Transplant Recipients: Report From Task Force 1*, Anne I. Dipchand, MD, Hospital for Sick Children, Toronto, Ontario, Canada

11:00 AM *Immunosuppression: Report From Task Force 2*, David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH

11:20 AM *Long Term Care fo Transplant Recipients: Report From Task Force 3*, Sharon A. Hunt, MD, Stanford University Medical Center, Palo Alto, CA

11:40 AM *Closing Remarks from Panel*

11:45 AM *Moderated Panel Discussion*

10:30 AM – 12:30 PM

SATELLITE SYMPOSIUM 12:

Transforming Transplant Care Through Evidence-Based Practice (Marquette)

CHAIRS: LINDA OHLER, MSN, FAAN AND
DANIELA ROEFE, RN

There is little information addressing evidence-based nursing and allied health care in MCSD and transplant patients. A gap exists between the evidence that supports transplant nursing and allied health care and daily care of the transplant patient. This symposium will present definitions, the gaps in the literature, and current evidence-based nursing and allied health practice in transplantation. It will also foster audience dialogue on these topics.

10:30 AM *Best Practice in Transplant Care: A Road More or Less Traveled*, Connie White-Williams, PhD, University of Alabama at Birmingham, AL

10:40 AM *Lung Transplantation: Evidence Based Nursing Practice: Are We There Yet?* Susan M. Chernenko, RN, MN, NP, Toronto General Hospital, Toronto, Ontario, Canada

10:55 AM *Care Management in the Pediatric Transplant Patient: Where is the Evidence?*, Karen C. Uzark, PhD, Children's Hospital Heart Center, Cincinnati, OH

11:10 AM *Evidence Based Practice of Self-Care Management in the Adult Mechanical Circulatory Support and Transplant Patient: Is Your Transplant Program Evidence Based?*, Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL

11:25 AM *Mechanical Circulatory Support Infection Control Guidelines: The Disconnect of Science and Practice*, Anne E. Dierlam, RN, Berlin Heart GmbH, Berlin, Germany

11:40 AM *Transitioning the VAD Patient to Independence: Concept vs. Reality*, Annemarie Kaan, MCN, RN, St. Paul's Hospital, Vancouver, British Columbia, Canada

11:55 AM *Professional Development and Contributions of the VAD Coordinator*, Michael A. Sobieski, II, RN, CCP, University Cardiothoracic Surgical Associates, Louisville, KY

12:10 AM *Panel Discussion*

12:30 PM – 2:30 PM

Lunch Break

12:30 PM – 1:30 PM

REGISTRIES AND DATABASES COMMITTEE MEETING (Joliet)

1:00 PM – 2:00 PM

MINI ORAL SESSION 1 (Boulevard)

CHAIRS: ROBERT L. KORMOS, MD AND
LESLIE W. MILLER, MD

1:00 PM (1) *Battling the Achilles' Heel of Left Ventricular Assist Devices: A Novel Technique To Reduce Drive Line Infections*; G.B. Pelz,¹ Z.A. Hashmi,¹ R.J. Moraca,¹ S. Murali,² R.L. Benza,² G.G. Sokos,² G.J. Magovern, Jr.,¹ S.L. Stutz,¹ S.H. Bailey,¹ D.A. Dean.¹ ¹Allegheny General Hospital, Pittsburgh, PA; ²Allegheny General Hospital, Pittsburgh, PA.

1:05 PM (2) *Echocardiographic and Hemodynamic Changes during Interruption of Left Ventricular Assist Device May Predict Outcomes after Weaning from the Device*; S. Saito,¹ G. Matsumiya,¹ Y. Sakata,² T. Sakaguchi,¹ S. Miyagawa,¹ Y. Yoshikawa,¹ T. Yamauchi,¹ T. Kuratani,¹ Y. Sawa.¹¹Osaka University Graduate School of Medicine, Suita, Osaka, Japan; ²Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

1:10 PM (3) *Tricuspid Valve Repair at the Time of Left Ventricular Assist Device Implantation: Is It Warranted?*; D. Saeed,¹ S. Shalli,¹ T. Kidambi,¹ I. Mikati,² C. Malaisrie,¹ R. Lee,¹ W.G. Cotts,³ P.M. McCarthy,¹ E.C. McGee.¹¹Northwestern Memorial Hospital, Chicago; ²Northwestern Memorial Hospital, Chicago; ³Northwestern Memorial Hospital, Chicago.

1:15 PM (4) *Less Frequency of Aortic Valve Opening and Continuous Flow Device Are Risk Factors for Late Onset of Aortic Regurgitation in Patients with Left Ventricular Assist Device*; M. Hatano,¹ K. Kinugawa,¹ T. Shiga,¹ A. Yao,¹ Y. Hirata,¹ T. Nishimura,² S. Kyo,² M. Ono,³ R. Nagai.¹¹The University of Tokyo, Tokyo, Japan; ²The University of Tokyo, Tokyo, Japan; ³The University of Tokyo, Tokyo, Japan.

1:20 PM (5) *Gastrointestinal Bleeding Complications in Continuous Flow LVAD Patients – Is It Device Specific?*; L.-W. Wang,¹ T. Guthrie,¹ G.A. Ewald,² E.M. Geltman,² S. Joseph,² N. Moazami.¹¹Washington University School of Medicine, Saint Louis, MO; ²Washington University School of Medicine, Saint Louis, MO.

1:25 PM (6) *Neurological Adverse Events (NAEs) and Proposed Mechanisms in a Single Center Experience with Continuous-Flow Left Ventricular Assist Devices (LVADs)*; C.M. Halley,¹ G.V. Gonzalez-Stawinski,² E.C. Chu,¹ P.M. Eckman,¹ N.S. Smedira,² R.C. Starling,¹ M.M. Mountis.¹¹Cleveland Clinic Foundation, Cleveland, OH; ²Cleveland Clinic Foundation, Cleveland, OH.

1:30 PM (7) *The Columbia Experience with the Levitronix CentriMag as a Rescue Device in High Risk Patients*; B. Worku,¹ H. Takayama,¹ D. Van Patten,¹ P. Pak,¹ Y. Naka.¹ Columbia University, New York, NY.

1:35 PM (8) *Development of Aortic Insufficiency in Patients Supported with a HeartMate II Left Ventricular Assist Device (LVAD)*; S.-W. Pak,² N. Uriel,¹ H. Takayama,² B. Kachniar,² L.K. Murray,² D. Mancini,¹ Y. Naka,² U.P. Jorde.¹¹Columbia University, New York, NY; ²Columbia University, New York, NY.

1:40 PM (9) *Use of Mechanical Support Devices in Patients with Mechanical Mitral Valve Prosthesis*; A. Goda,¹ H. Takayama,² S.-W. Pak,² J. Ulrich,¹ D. Mancini,¹ Y. Naka.²¹Columbia University, New York, NY; ²Columbia University, New York, NY.

1:45 PM (10) *Dynamic Occlusion of the Inflow Cannula by Multimodality Cardiac Imaging Heralds Serious Adverse Events in Patients with a Continuous Flow Left Ventricular Assist Device*; J. Goerbig-Campbell,¹ R.M. Weiss,¹ A. Guha,¹ F.L. Johnson.¹ University of Iowa, Iowa City.

1:50 PM (11) *Quality of Life in HeartMate II LVAD Patients; Destination Therapy Compared to Post Transplant Bridge to Transplant Therapy at 1 Year*; J.M. Aho,³ E.A. Ziemba,⁴ M.J. Schnaus,⁵ K. Liao,¹ M.R. Pritzker,² M.M. Colvin-Adams,² R. John.¹¹University of Minnesota, Minneapolis, MN; ²University of Minnesota, Minneapolis, MN; ³Chicago Medical School, Chicago, IL; ⁴University of Minnesota, Minneapolis, MN; ⁵University of Minnesota, Minneapolis, MN.

1:55 PM (12) *Delayed Sternal Closure Following LVAD Implantation Is a Safe Alternative to Primary Sternal Closure*; L.-W. Wang,¹ T. Guthrie,¹ G.A. Ewald,² E.M. Geltman,² S. Joseph,² N. Moazami.¹¹Washington University School of Medicine, Saint Louis, MO; ²Washington University School of Medicine, Saint Louis, MO.

1:00 PM – 2:00 PM

MINI ORAL SESSION 2 (Continental C)

CHAIRS: UGOLINO LIVI, MD AND THORSTEN WAHLERS, MD

1:00 PM (13) *Computational Analysis of the Single Antigen Beads Used in Solid Phase Assays for the Detection of Anti-HLA Antibodies*; O.E. Pajaro,¹ J.K. Kirklin,¹ J.F. George.¹ University of Alabama at Birmingham, Birmingham, AL.

1:05 PM (14) *PVRI <9 W.U. x m2 Does Not Predict Early Postoperative Mortality in Pediatric Cardiac Transplantation for Cardiomyopathy*; P. Chiu,¹ M.J. Russo,¹ R.R. Davies,¹ L.J. Addonizio,¹ M.E. Richmond,¹ J.M. Chen.²¹Columbia University, College of Physicians and Surgeons, New York, NY; ²Weill Medical College of Cornell University, New York, NY.

1:10 PM (15) *Predictive Value of Bedside-Tests in the Assessment of Potential Donor Hearts*; R. Yeter,¹ I. Grunwald,¹ G. Hay,¹ H.B. Lehmkuhl,¹ R. Hetzer,¹ C. Knosalla.¹ Deutsches Herzzentrum Berlin, Berlin, Germany.

1:15 PM (16) *Dynamics in Lipid Profile Subfractions in Patients Undergoing Cardiac Transplantation*; F.H. Cheema,² T. Khawaja,² K.J. Schaeffle,² V.K. Topkara,² S. Yaman,² A. Chokshi,¹ G. Magda,² M. Argenziano,² Y. Naka,² P.C. Schulze.¹¹Columbia University Medical Center, New York, NY; ²Columbia University Medical Center, New York, NY.

1:20 PM (17) *The Treatment of Postpartum Cardiomyopathy with the Use of Mechanical Assist Devices and Cardiac Transplantation*; H. Zimmerman,¹ R. Bose,¹ R.G. Smith,¹ J.G. Copeland.¹ University of Arizona, Tucson, AZ.

- 1:25 PM (18) Efficacy Outcome in De-Novo HTxR: Comparison of 6 Immunosuppressive (IS) Regimens (ISR);** H.J. Eisen,¹ J.F. Delgado,² G. Junge,³ A. Karpov,³ H. Lehmkuhl,⁴ C. Pellegrini,⁵ J. Kobashigawa,⁶ H. Schwende,³ A. Zuckermann,⁷ ¹Drexel University College of Medicine, Philadelphia; ²Madrid Hospital, Madrid, Spain; ³Novartis Pharma, Basel, Switzerland; ⁴Deutsches Herzzentrum Berlin, Berlin, Germany; ⁵Policlinico S. Matteo-IRCCS Università degli Studi di Pavia, Pavia, Italy; ⁶Cedars-Sinai Heart Institute, Los Angeles, CA; ⁷Medical University of Vienna, Vienna, Austria.
- 1:30 PM (19) Use of Sildenafil for Prevention of Right Heart Failure in Heart Transplant Recipients with Pulmonary Hypertension;** H. Bedanova,¹ M. Orban,¹ J. Ondrasek,¹ E.D. Petrikovits,² L. Spinarova,³ P. Nemeč.¹ ¹Center of Cardiovascular and Transplant Surgery, Brno, Czech Republic; ²Cardiocenter Vysocina, Jihlava, Czech Republic; ³1st Department of Internal Medicine-Cardioangiology, Brno, Czech Republic.
- 1:35 PM (20) Heart Transplant Survival at Age 70 and Older Similar to Younger Patients;** D. Daneshvar,¹ A. Phan,¹ L. Czer,^{1,2} M. De Robertis,¹ J. Mirocha,¹ E. Schwarz,^{1,2} R.M. Kass,^{1,2} S. Simsir,^{1,2} A. Trento.^{1,2} ¹Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA; ²Cedars-Sinai Medical Center, Los Angeles, CA.
- 1:40 PM (21) Repetitive Episodes of Rejection Is Associated with Reduction of mRNA Expression of Myocardial Sarcoplasmic Reticulum Ca²⁺-ATPase and Ryanodine Receptor-2 in Transplanted Hearts;** T.S. Kato,¹ K. Hashimura,¹ Y. Sata,¹ H. Ueda,² T. Nakatani,³ T. Shishido,³ K. Komamura.⁴ ¹National Cardiovascular Center, Osaka, Japan; ²National Cardiovascular Center, Osaka, Japan; ³National Cardiovascular Center, Osaka, Japan; ⁴Takeda Pharmaceutical Company Limited, Osaka, Japan; ⁵National Cardiovascular Center, Osaka.
- 1:45 PM (22) Obesity Is Not a Risk Factor for Heart Transplantation;** B. Sareyyupoglu, T. Horai, P. Bonde, C.A. Bermudez, J.K. Bhamra, S. Tabata, N. Shigemura, R.N. Ramani, M.A. Simon, J.J. Teuteberg, M.A. Mathier, D.M. McNamara, R.L. Kormos, Y. Toyoda. Heart, Lung & Esophageal Surgery Institute, University of Pittsburgh Medical Center, Pittsburgh, PA.
- 1:50 PM (23) Orthotopic Heart Transplantation with Donor ≥ 60 Years-old: Single Centre Experience;** G. Bruschi, L. Botta, T. Colombo, G. Pedrazzini, A. Cannata, S. Trunfio, F. Macera, F. Oliva, F. Turazza, R. Paino, M. Frigerio, L. Martinelli. Niguarda Ca' Granda Hospital, Milan, Italy.
- 1:55 PM (24) Use of Ventricular Assist Device as a Bridge to Simultaneous Heart and Kidney Transplantation;** R. Yanagida,^{1,3} A. Ruzza,^{1,3} R. Vespignani,^{1,3} L. Czer,^{1,3}

E. Schwarz,^{1,3} S. Simsir,^{1,3} S. Jordan,^{2,3} J.L. Cohen,^{2,3} A. Trento.^{1,3} ¹Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA; ²Cedars-Sinai Medical Center, Los Angeles, CA; ³Cedars-Sinai Medical Center, Los Angeles, CA.

1:00 PM – 2:00 PM

MINI ORAL SESSION 3 (Waldorf)

CHAIRS: PETER JAKSCH, MD AND ALFRED E. WOOD, FRCSI

- 1:00 PM (25) Donor Specific Antibody (DSA) as a Time Dependent Predictor Shows a Significant Negative Impact on Survival in Lung Recipients (Recips) Regardless of Pretransplant (PreTx) Antibody (Ab) Status;** N.L. Reinsmoen,¹ D. Chen,² M. James,¹ S. Palmer,² A. Finlen-Copeland,² R.D. Davis.² ¹Cedars-Sinai Health System, LA, CA; ²Duke University, Durham, NC.
- 1:05 PM (26) Novalung Enables Protective Ventilation in Primary Graft Dysfunction;** C.P. Searl, T.A. Butt, A. Samuel, N. Wrightson, A.J. Fisher, J.H. Dark. Freeman Hospital, Newcastle upon Tyne, United Kingdom.
- 1:10 PM (27) Lung Transplantation as Treatment for Pulmonary Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Centre Experience;** C. Fegbeutel,¹ I. Kropivnit-skaya,¹ G. Warnecke,¹ J. Gottlieb,² S. Fischer,¹ M. Strueber,¹ A. Haverich,¹ A.R. Simon.¹ ¹Hannover Medical School, Hannover, Germany; ²Hannover Medical School, Hannover, Germany.
- 1:15 PM (28) Optimizing Renal Function through Minimizing Calcineurin Inhibitor Exposure – Long term Results from a Calcineurin Inhibitor-Everolimus Based Immunosuppression;** B. Zweytick, B. Ghanim, J. Sillipp, G. Boehmig, P. Jaksch, W. Klepetko. Medical University of Vienna, Vienna, Austria.
- 1:20 PM (29) Elevations in Troponin-I (Tn-I) Following Lung Transplantation Predict Survival;** R. Celis,² J.D. Estep,¹ C. Orrego,¹ L. Semones,¹ R. Kasevan,³ H. Seethamraju,³ G.P. Noon,³ M. Loebe,³ G. Torre.¹ ¹TMH, Houston, TX; ²UTMH, Galveston, TX; ³Baylor College of Medicine, Houston, TX.
- 1:25 PM (30) Enoxaparin for the Treatment of Venous Thromboembolism in Lung Transplant Recipients;** M.-Y. Huang,¹ C. Hui,¹ L.E. Leard,² R.F. Boettger,¹ J.P. Singer.² ¹University of California, San Francisco, San Francisco, CA; ²University of California, San Francisco, San Francisco, CA.
- 1:30 PM (31) Outcome of Lung Transplant Candidates on Mechanical Ventilation or Extracorporeal Support;** J. Gottlieb,¹ A.R. Simon,² J. Hadem,³ M. Dierich,¹ O. Wiesner,³ M. Strueber,² T. Welte.¹ ¹Hannover Medical School, Hannover, Germany; ²Hannover Medical School, Hannover, Germany; ³Hannover Medical School, Hannover, Germany.

- 1:35 PM (32) Role of ImmuKnow Assay Following Lung Transplantation;** M.R. Morrell, E.P. Trulock, R.R. Hachem. Washington University/Barnes-Jewish Hospital, St. Louis, MO.
- 1:40 PM (33) A Single-Centre Experience with the Use of Posaconazole for Invasive Fungal Infections in Lung and Heart-Lung Transplant Recipients;** B.J.H. Ng, P.M.A. Hopkins, F.D. Kermeen, D.C. Chambers. The Prince Charles Hospital, Chermside, QLD, Australia.
- 1:45 PM (34) Post Lung Transplant Peak Allograft Function Predictors. A Regression Model;** S.L.C. Reddy, R. Sharma, S.S. Lin, S.M. Palmer, D.W. Zaas, R.D. Davis. Duke University Medical Center, Durham, NC.
- 1:50 PM (35) The Australian Experience with Combined Heart-Lung-Liver Transplantation;** A. Fiene,¹ K.D. McNeil,¹ F.D. Kermeen,¹ D.C. Chambers,¹ K. Stuart,² J. Fawcett,³ R. Tam,⁴ G.J. Hart,¹ P.M.A. Hopkins.¹ ¹The Prince Charles Hospital, Brisbane, QLD, Australia; ²The Princess Alexandra Hospital, Brisbane, QLD, Australia; ³The Princess Alexandra Hospital, Brisbane, QLD, Australia; ⁴Townsville Base Hospital, Townsville, QLD, Australia.
- 1:55 PM (36) Efficacy of Oral Ribavirin in Lung Transplant Recipients with Paramyxoviral Infection;** T. Fuehner,¹ C. Duesberg,¹ C. DeWall,¹ A.R. Simon,² T. Welte,¹ J. Gottlieb.¹ ¹Hannover Medical School, Hannover, Germany; ²Hannover Medical School, Hannover, Germany.

1:00 PM – 2:00 PM

MINI ORAL SESSION 4 (Marquette)

CHAIRS: RICHARD D. WEISEL, MD AND
ANDREAS O. ZUCKERMANN, MD

- 1:00 PM (37) Recipient Cytokine Levels Are Associated with Early Allograft Dysfunction in Human Lung Transplantation;** J.G. Allen,¹ M.T. Lee,¹ G.J. Arnaoutakis,¹ C.A. Merlo,¹ Barbara Detrick, PhD, D(ABMLI),² A.S. Shah.¹ ¹Johns Hopkins Medical Institutions, Baltimore, MD; ²Immunology Laboratory/ Cytokine Laboratory Department of Pathology Johns Hopkins Medical Institutions, Baltimore, MD.
- 1:05 PM (38) Preservation Enhances Rat Cardiac Allograft Vasculopathy by Advancing Innate Immune and Dendritic Cell Activation, and Inducing IL-17 Production;** S.O. Syrjala, R. Krebs, R. Tuuminen, M.A. Keranen, A.I. Nykanen, K.B. Lemstrom. Haartman Institute, University of Helsinki, Helsinki, Finland.
- 1:10 PM (39) Functional Capacity of B-Cells in vitro and Relation to Tolerance after ABO-Incompatible Heart Transplantation;** L.A. Ryan, S. Urschel, L.J. West. University of Alberta, Edmonton, AB, Canada.

- 1:15 PM (40) Nanosystems in Transplantation: Neonatal Tolerance Induction by Blood Group Antigen-Expressing Implants;** M. Jeyakanthan,¹ P.J. Meloncelli,² V.A. Wright,³ X. Zhou,¹ K. Tao,¹ B. Daly,³ A. Cooper,³ Y. Coe,¹ T.L. Lowery,² J.M. Buriak,³ L.J. West.¹ ¹University of Alberta, Edmonton, AB, Canada; ²University of Alberta, Edmonton, AB, Canada; ³University of Alberta, Edmonton, AB, Canada.
- 1:20 PM (41) Results of a Randomized Phase 2 Trial of ALN-RSV01, an RNAi Therapeutic, Lung Transplant (LTX) Patients Infected with Respiratory Syncytial Virus (RSV);** M.R. Zamora,¹ M. Budev,² M. Rolfe,³ J. Gottlieb,⁴ J. DeVincenzo,⁵ J. Cehelsky,⁶ G. Albert,⁶ J. Gollob,⁶ S. Nochur,⁶ A. Vaishnav,⁶ A. Glanville,⁷ ¹University of Colorado Health Sciences Center, Aurora, CO; ²Cleveland Clinic, Cleveland, OH; ³Tampa General Hospital, Tampa, FL; ⁴Kliniken fur Pneumologie Medizinische Hochschule, Hannover, Germany; ⁵University of Tennessee Center for Health Sciences, Memphis, TN; ⁶Alnylam Pharmaceuticals, Cambridge, MA; ⁷St. Vincent's Hospital, Darlinghurst, NSW, Australia.
- 1:25 PM (42) Effect of MRSA Colonization on Clinical Outcomes Following Lung Transplantation;** A.M. Kapasi, R.G. Nador, K. Jackson, K. LaBranche, J.G. Weinkauff, D.C. Lien. University of Alberta, Edmonton, AB, Canada.
- 1:30 PM (43) Prognostic Value of Immune Cell Function Assay on Biopsy Results and Infection in Cardiac Transplant Patients;** R. Dancel, C. Wiesen, P. Chang. University of North Carolina, Chapel Hill, NC.
- 1:35 PM (44) Malignancies after Heart Transplantation: Incidence, Risk Factors, and Effects of Calcineurin Inhibitor Withdrawal;** A.O. Doesch,¹ S. Mueller,¹ S. Celik,¹ M. Konstandin,¹ P. Ehlermann,¹ A. Kristen,¹ F.-U. Sack,² H.A. Katus,¹ T.J. Dengler.¹ ¹University of Heidelberg, Heidelberg, Germany; ²University of Heidelberg, Heidelberg, Germany.
- 1:40 PM (45) Safety and Efficacy of the Novalung Interventional Lung Assist (iLA) Device as a Bridge to Lung Transplantation;** M. Cypel, S. Fischer, S. Reynolds, A. Pierre, M. de Perrot, J.C. Yeung, S. Azad, M. Hutcheon, C. Chaparro, C.-W. Chow, L.G. Singer, K. Yasufuku, S. Harwood, J. Granton, T.K. Waddell, S. Keshavjee. University of Toronto, Toronto, ON, Canada.
- 1:45 PM (46) Evolutionary Improvements in the Jarvik 2000 Heart Technology;** C. Selzman,¹ S. McConchie,² K. Gandhi,² D. Perry,² M. Blinder,² B. Griffith,³ R. Jarvik.² ¹University of Utah, Salt Lake City, UT; ²Jarvik Heart, Inc., New York, NY; ³University of Maryland Medical Center, Baltimore, MD.

- 1:50 PM (47) Mortality and Readmission Rates with Dobutamine and Milrinone in Pulmonary Hypertension and Right Ventricular Failure;** A. Rabinovitz,¹ R. Zolty.²
¹Jacobi Medical Center, Bronx, NY; ²Montefiore Medical Center, Bronx, NY.
- 1:55 PM (48) The Adverse Effects of Sirolimus in Heart Transplant Patients: Is It Worth It?;** M. Kittleson,² J. Patel,² J. Moriguchi,² A. Moradzadeh,² M. Kawano,² S. Davis,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.
- 2:00 PM (49) Pulmonary Artery Hypertension: Heart Failure and ACE Inhibition;** E.M. Bader,¹ R. Zolty.² ¹Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; ²Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

1:00 PM – 2:00 PM

MINI ORAL SESSION 5 (PDR-2)

CHAIRS: JOSE A. TALLAJ, MD AND DEBRA L. ISAAC, MD

- 1:00 PM (50) Everolimus (Certican) after Heart Transplantation: 2 Years' Single Center Follow-Up in Calcineurin Inhibitor-Free Immunosuppression;** M.A. Engelen,¹ H. Welp,² J.R. Sindermann,³ S. Amler,³ J. Stypmann,¹
¹University Hospital of Muenster, Muenster, Germany; ²University Hospital Muenster, Muenster, Germany; ³University Hospital Muenster, Muenster, Germany.
- 1:05 PM (51) Identifying PKC Epsilon as a Target Molecule To Control Intimal Hyperplasia;** T. Deuse,^{1,2} T. Koyanagi,³ H. Reichenspurner,¹ R.C. Robbins,² D. Mochly-Rosen,³ S. Schrepfer,^{1,2} ¹University Heart Center Hamburg, Hamburg, Germany; ²Stanford University School of Medicine, Stanford, CA; ³Stanford University School of Medicine, Stanford, CA.
- 1:10 PM (52) Sirolimus as Primary Immunosuppression Is Associated with Improved Renal Function and Survival Compared with Calcineurin Inhibitors in Stable Cardiac Transplant Recipients;** M.A. Al-Omari,
E. Raichlin, N.L. Pereira, B.S. Edwards, A.L. Clavell, R.J. Rodeheffer, R.P. Frantz, J.A. Schirger, S.S. Kushwaha. Mayo Clinic, Rochester, MN.
- 1:15 PM (53) Long Term Decline of Renal Function after Conversion to Proliferation Signal Inhibitors in Heart Transplant Recipients;** E. Gonzalez-Vilchez,
J. Vazquez de Prada, A. Canteli, C. Castrillo, M. Llano, R. Martin Duran. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain.
- 1:20 PM (54) Balancing Volume in Advanced Heart Failure before Heart Transplant: Mismatch between Right and Left Filling Pressures;** P. Campbell,¹ M.H. Drazner,² M. Kato,¹ N. Lakdawala,¹ A. Nohria,¹ L.W. Stevenson.¹ ¹Brigham and Women's Hospital, Boston, MA; ²University of Texas, Southwest Medical Center, Dallas, TX.

- 1:25 PM (55) Scintigraphic Heart Retention and Annular Plane Systolic Excursion Predict Outcome in Patients with Senile Systemic Amyloidosis;** A.V. Kristen,¹ S. Haufe,² P. Schnabel,³ C. Rocken,⁴ S. Hardt,¹ K. Altland,⁵ H.A. Katus,¹ T.J. Dengler.¹ ¹University of Heidelberg, Heidelberg, Germany; ²University of Heidelberg, Heidelberg, Germany; ³University of Heidelberg, Heidelberg, Germany; ⁴University of Kiel, Kiel, Germany; ⁵University of Giessen, Giessen, Germany.
- 1:30 PM (56) Characteristics of Patients Receiving Ventricular Assist Devices as a Bridge to Cardiac Transplant Candidacy;** S. Emami,¹ L.B. Louis,² A. Hasan,¹ C. Sai-Sudhakar,² B. Sun.² ¹The Ohio State University, Columbus, OH; ²The Ohio State University, Columbus, OH.
- 1:35 PM (57) Influence of Pulsatile and Non-Pulsatile Perfusion on Kidney Function;** H.A. Welp,¹ B. Nafz,² P.B. Persson,² S.R. Jurgen,¹ H.H. Scheld,¹ A. Hoffmeier.¹ ¹University Hospital Münster, Münster, NRW, Germany; ²Free University of Berlin, Berlin, Germany.
- 1:40 PM (58) Thyroid Deficiency Is Common in Advanced Heart Failure and Associated with Increased Operative Mortality after Assist Device Implantation;** N. Uriel,¹ S.-W. Pak,² P. Colombo,¹ R. Song,² D. Mancini,¹ Y. Naka,² U.P. Jorde.¹ ¹Columbia University, New York, NY; ²Columbia University, New York, NY.
- 1:45 PM (59) Nesiritide Worsens Renal Insufficiency in Patients with Right Ventricular Failure Due to Pulmonary Hypertension;** I. Kelesidis, P. Velankar, R. Chaudhari, R. Zolty. Albert Einstein College of Medicine, Bronx, NY.
- 1:50 PM (60) Impact of Pre-Transplant Pulmonary Hypertension on Post-Transplant Outcomes in IPF;** S.C. Mathai,¹ R.E. Girgis,¹ A. Shah,² P.M. Hassoun,¹ J.F. McDyer,¹ J.B. Orens,¹ C.A. Merlo.¹ ¹Johns Hopkins University School of Medicine, Baltimore, MD; ²Johns Hopkins University School of Medicine, Baltimore, MD.
- 1:55 PM (61) Correlation of Right Heart Catheterization (RHC) Parameters and Functional Tests after 16 Weeks of Bosentan-Based Therapy in Patients with Pulmonary Arterial Hypertension (PAH): The COMPASS-3 Study;** F. Torres,¹ S. Murali,² F.J. Soto,³ H. Gupta,⁴ M.H. Park,⁵ N. Frey,⁶ R.L. Benza.² ¹University of Texas Southwestern Medical Center, Dallas, TX; ²Allegheny General Hospital, PIttsburgh, PA; ³Prevea Health, Sheboygan, WI; ⁴University of Alabama at Birmingham, Birmingham, AL; ⁵University of Maryland School of Medicine, Baltimore, MD; ⁶Actelion Pharmaceuticals US, Inc., South San Francisco, CA.

2:30 PM – 4:45 PM

OPENING PLENARY SESSION

(International Ballroom)

CHAIRS: JAMES K. KIRKLIN, MD AND
HERMANN REICHENSPURNER, MD, PHD

2:30 PM *President's Welcome*, James K. Kirklin, MD,
University of Alabama at Birmingham, AL

2:35 PM *Program Chair's Report*, Hermann Reichenspurner,
MD, PhD, University Heart Centre Hamburg,
Germany

2:50 PM *ISHLT International Thoracic Registry Report*,
Marshall I. Hertz, MD, University of Minnesota,
Minneapolis, MN

3:20 PM *INTERMACS Report*, James K. Kirklin, MD,
University of Alabama at Birmingham, AL

3:30 PM **INVITED LECTURE**, *The Evolution of Lung Transplan-
tation*, Alec Patterson, Washington University School of
Medicine, St. Louis, MO

3:50 PM *In Memorium of Recently Deceased ISHLT Members*,
James K. Kirklin, MD, University of Alabama at
Birmingham, AL

3:55 PM *Margaret E. Billingham, MD Memoriam/Lifetime
Achievement Award Lecture*, Dr. John Billingham and
Bruce A. Reitz, MD, Stanford University, CA

4:20 PM *Presidential Address*, James K. Kirklin, MD,
University of Alabama at Birmingham, AL

4:45 PM – 5:15 PM

Coffee Break (Southeast Exhibit Hall)

5:15 PM – 6:45 PM

CONCURRENT SESSION 1:

Patients, Pumps and Outcomes (International Ballroom)

CHAIRS: KATHERINE LIETZ, MD, PHD AND
ALY EL BANAYOSY, MD

5:15 PM (62) *Strategies for LVAD Therapy in INTERMACS:
Intent Rate v. Event Rate*; J.J. Teuteberg,² G.C. Stewart,¹
M. Jessup,³ R.L. Kormos,² B. Sun,⁴ O.H. Frazier,⁵
D.C. Naftel,⁶ L.W. Stevenson.¹ ¹Brigham and Women's
Hospital, Boston, MA; ²University of Pittsburgh Medical
Center, Pittsburgh, PA; ³University of Pennsylvania,
Philadelphia, PA; ⁴Ohio State University Medical Center,
Columbus, OH; ⁵Texas Heart Institute, Houston,
TX; ⁶University of Alabama at Birmingham, Birmingham,
AL.

5:30 PM (63) *INTERMACS Profiles of Nutrition and Organ
Function in Relation to Outcomes*; M. Liszkowski,¹
J.J. Teuteberg,² S.L. Myers,³ J.G. Rogers,⁴ R. Starling,⁵
D.D. Ascheim,⁶ L.W. Stevenson.¹ ¹Brigham and
Women's Hospital, Boston, MA; ²University of Pitts-

burgh Medical Center, Pittsburgh, PA; ³University of
Alabama at Birmingham, Birmingham, AL; ⁴Duke
University Medical Center, Durham, NC; ⁵Cleveland
Clinic Foundation, Cleveland, OH; ⁶Mount Sinai
School of Medicine, New York, NY.

5:45 PM (64) *Rapidly Changing Characteristics of Patients
Receiving Mechanically Assisted Circulatory Support
in INTERMACS*; F.D. Pagani,¹ D.C. Naftel,² K.D.
Aaronson,¹ M.K. Parides,³ D.J. Farrar,⁴ S.V. Pam-
boukian,² J.K. Kirklin.² ¹University of Michigan, Ann
Arbor, MI; ²University of Alabama at Birmingham,
Birmingham, AL; ³Mount Sinai School of Medicine,
New York, NY; ⁴Thoratec Corporation, Pleasanton, CA.

6:00 PM (65) *Changing Patterns and Regional Differences in
the Use of Ventricular Assist Devices as a Bridge-to-
Transplant: An Analysis of UNOS Data*; S. Lee,¹
F. Kamdar,¹ R. John.² ¹University of Minnesota, Min-
neapolis, MN; ²University of Minnesota, Minneapolis,
MN.

6:15 PM (66) *Destination Therapy: Improving Outcomes with
Continuous Flow LVADs*; M.S. Slaughter,¹ J.G.
Rogers,² L. Blue,³ A.J. Lodge,⁴ A.J. Tatrooles,⁵ G. Bhat,⁶
M. Sobieski,⁷ C.A. Milano,⁸ ¹University of Louisville,
Louisville, KY; ²Duke University Medical Center,
Durham, NC; ³Duke University Medical Center,
Durham, NC; ⁴Duke University Medical Center,
Durham, NC; ⁵Advocate Christ Medical Center, Oak
Lawn, IL; ⁶Advocate Christ Medical Center, Oak Lawn,
IL; ⁷University of Louisville, Louisville, KY; ⁸Duke
University Medical Center, Durham, NC.

6:30 PM (67) *Comparing the Effects of Biventricular Support
with Left Ventricular Support Alone on Heart Trans-
plant Outcomes*; T.B. Reece, L.B. Weitzel, A.P. Can-
non, A. Brieke, J.C. Cleveland. University of Colorado,
Denver, Aurora, CO.

5:15 PM – 6:45 PM

CONCURRENT SESSION 2:

Heart Transplant Outcome; Does the Donor Matter?

(Continental A/B)

CHAIRS: ROBERTO FIOCCHI, MD, PHD AND
KEITH D. AARONSON, MD

5:15 PM (68) *Is History of Chronic Alcohol Abuse in a Donor
a Contraindication for Heart Transplant?*; P. Bonde,
J. Bhama, R. Kormos, C. Bermudez, B. Sareyyupoglu,
T. Horai, S. Tabata, N. Shigemura, D. McNamara, Y.
Toyoda. University of Pittsburgh Medical Center, Pitts-
burgh, PA.

5:30 PM (69) *Artificial Neural Networks – A Method for
Optimal Donor-Recipient Matching. Large Scale
Simulation of Survival after Heart Transplantation*;
J. Nilsson,¹ M. Ohlsson,² P. Hoglund,³ B. Ekmehag,⁴

B. Koul,¹ Clinical Science in Lund, Lund, Sweden; ²Theoretical Physics, Lund, Sweden; ³Clinical Science in Lund, Lund, Sweden; ⁴Clinical Science in Lund, Lund, Sweden.

5:45 PM (70) *De Novo Formed Donor-Specific Antibodies Adversely Affect Patient Survival after Cardiac Transplantation*; J.D. Smith,¹ N.R. Banner,² I.M. Hamour,² M. Ozawa,³ A. Goh,³ P. Terasaki,³ M.L. Rose.¹ ¹Harefield Hospital, Harefield, Middlesex, United Kingdom; ²Harefield Hospital, Harefield, Middlesex; ³Terasaki Foundation, Los Angeles, CA.

6:00 PM (71) *Are Donors Presenting with Cardiac Arrest but Successfully Resuscitated a Contraindication for Organ Donation in Heart Transplant?*; P. Bonde, C. Bermudez, R. Kormos, J. Bhama, B. Sareyyupoglu, T. Horai, S. Tabata, N. Shigemura, D. McNamara, Y. Toyoda. University of Pittsburgh Medical Center, Pittsburgh, PA.

6:15 PM (72) *Donor Cardiopulmonary Resuscitation Does Not Impact Overall Survival and Cardiac Allograft Function in Heart Transplant Recipients*; M. Pollet,¹ D.W. Markham,² M.H. Drazner,² J.M. Dimairo,¹ C.R. Ayers,² D.M. Meyer,¹ W.S. Ring,¹ B.T. Bethea.¹ ¹University of Texas Southwestern, Dallas, TX; ²University of Texas Southwestern, Dallas, TX.

6:30 PM (73) *Domino Heart Transplantation: Long Term Outcome of Recipients and Their Living Donors. Single Centre Experience*; G.M. Raffa, C. Pellegrini, A.M. D'Armini, M. Vigano'. San Matteo Hospital IRCCS, University of Pavia, Pavia, Italy.

5:15 PM – 6:45 PM

CONCURRENT SESSION 3:

Observations on Candidate Selection for Lung Transplant (Boulevard)

CHAIRS: GEERT M. VERLEDEN, MD, PHD AND FEDERICA MELONI, MD

5:15 PM (74) *A Clinical Prediction Rule for Selection of Mechanically Ventilated Lung Transplant Candidates*; J.S. Wilt, S.M. Arcasoy, F. D'Ovidio, M.D. Bacchetta, L. Whitley, L. Shah, J.R. Sonett, D.J. Lederer. Columbia University, New York, NY.

5:30 PM (75) *ECMO as a Bridge to Lung Transplantation: The Cleveland Clinic Experience*; J.J. Yun,¹ A.A. Mangi,¹ L.C. Benjamin,¹ S. Murthy,¹ M.M. Budev,² D.P. Mason,¹ G.B. Pettersson,¹ K.R. McCurry.¹ ¹Cleveland Clinic, Cleveland, OH; ²Cleveland Clinic, Cleveland, OH; ³Temple University, Philadelphia, PA.

5:45 PM (76) *Predictors of Outcome in Ventilated Lung Transplant Recipients*; C. Schreiber, G. Lang, S. Taghavi, C. Aigner, G. Marta, A. Scheed, L. Hatos, P. Jaksch, W. Klepetko. Vienna Medical University, Vienna, Austria.

6:00 PM (77) *The Impact of Recipient Body Mass Index on Outcomes Following Lung Transplantation*; J.G. Allen,¹ G.J. Arnaoutakis,¹ E.S. Weiss,¹ C.A. Merlo,² J.V. Conte,¹ A.S. Shah.¹ ¹Johns Hopkins Medical Institutions, Baltimore, MD; ²Johns Hopkins Medical Institutions, Baltimore, MD.

6:15 PM (78) WITHDRAWN

6:30 PM (79) *Insurance Status and Education Level Are Independent Predictors of Survival after Lung Transplantation*; J.G. Allen,¹ G.J. Arnaoutakis,¹ J.F. McDyer,² J.B. Orens,² A.S. Shah,¹ C.A. Merlo.^{2,3} ¹Johns Hopkins University School of Medicine, Baltimore, MD; ²Johns Hopkins University School of Medicine, Baltimore, MD; ³Johns Hopkins School of Public Health, Baltimore, MD.

5:15 PM – 6:45 PM

CONCURRENT SESSION 4:

Nursing Science: And Then We Were Done: Patient Experience Following Surgical Interventions for Heart and Lung Failure (Continental C)

CHAIRS: SHARON A. BEER, RN, MSC AND MICHAEL G. PETTY, PHD(C), RN, CCNS, CNS

5:15 PM (80) *Quality of Life and Predictors of Medication Adherence in Pediatric Heart Transplant Recipients*; K. Uzark,¹ M. Zamberlan,² P. Murphy,³ C. Nasman,⁴ R. Rodriguez,⁵ J. Dupuis,⁶ S. Rodgers,⁶ Y. Wang,¹ R. Ittenbach.¹ ¹Cincinnati Children's Hospital Medical Ctr, Cincinnati, OH; ²University of Michigan Medical Ctr, Ann Arbor, MI; ³St Louis Children's Hospital, St. Louis, MO; ⁴Cleveland Clinic Foundation, Cleveland, OH; ⁵Columbia University Medical Ctr, New York, NY; ⁶Children's Hospital of Michigan, Detroit, MI; ⁷Children's Memorial Hospital, Chicago, IL.

5:30 PM (81) *Timing of Transplant Following Mechanical Circulatory Support in 375 Patients: Lessons from a Single Center Experience*; K.J. Hoercher, N.G. Smedira, G. Gonzalez-Stawinski, D. Yoon, J. Rajeswaran, E.H. Blackstone. Cleveland Clinic, Cleveland, OH.

5:45 PM (82) *Patient-Reported Outcomes after the Minimally Invasive Approach to Lung Transplantation*; A. DeVito Dabbs,¹ M.A. Dew,² D. Zaldonis,³ J. Aubrecht,¹ M.M. Crespo,⁴ J.M. Pilewski,⁴ J.K. Bhama,³ S. Gilbert,³ C. Bermudez,³ Y. Toyoda.³ ¹University of Pittsburgh, Pittsburgh, PA; ²University of Pittsburgh, Pittsburgh, PA; ³University of Pittsburgh, Pittsburgh, PA; ⁴University of Pittsburgh, Pittsburgh, PA.

6:00 PM (83) *Transition of Pediatric Heart Transplant Patients to the Adult Heart Transplant Program: Are They Doomed To Be Rejected?*; C. Burch,¹ A. Amegatcher,¹ J. Patel,² M. Kittleson,² M. Kawano,² S. Davis,² Z. Goldstein,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

6:15 PM (84) Effect of High Frequency Chest Wall Oscillation Versus Chest Physiotherapy on Lung Function Post-Lung Transplant: A Pilot Study; T. Marcarian, M. Ilagan, A.J. Lee, A. Esguerra, J. Porter, B. Rodman, F. Villamor, C. Tamonang, K. Mayol-Ngo, A. Madsen, A. Parker, Z. Shameem, A. Richman, M. Mekpongsatorn, S. Madrona, C. Burchette, S. Sommer, P. Miller, P. Kehoe, S. Takayanagi, S. Lackey, J. Onga, S. Weigt, D. Ross, A. Gawlinski. UCLA Health System, Los Angeles.

6:30 PM (85) A High-Intensity Exercise Program Decreases Self-Reported Anxiety in Cardiac Transplant Recipients: A Randomized Study; S.B. Christensen,¹ C.H. Dall,² T. Hermann,¹ E. Prescott,² F. Gustafsson.¹ ¹Rigshospitalet, Copenhagen, Denmark; ²Bispebjerg Hospital, Copenhagen, Denmark.

5:15 PM – 6:45 PM

CONCURRENT SESSION 5:

Improving Donor and Recipient Selection in Pediatric Transplantation (Waldorf)

CHAIRS: LORI J. WEST, MD, DPHIL AND
ELFRIEDE PAHL SCHUETTE, MD

5:15 PM (86) Outcomes of Children Implanted with Ventricular Assist Device Therapy: Analysis of the Interagency Registry for Mechanical Circulatory Support (INTERMACS); E.D. Blume,¹ D.N. Rosenthal,² J.M. Chen,³ C.S.D. Almond,¹ P.D. Wearden,⁴ D.C. Naftel,⁵ J.K. Kirklin.⁵ ¹Children's Hospital, Boston, MA; ²Stanford University Medical Center, Palo Alto, CA; ³Morgan Stanley Children's Hospital of New York-Presbyterian, New York, NY; ⁴Children's Hospital of Pittsburgh, Pittsburgh, PA; ⁵University of Alabama at Birmingham, Birmingham, AL.

5:30 PM (87) Influence of the New Heart Allocation System on Pediatric Waitlist and Post-Transplant Survival; A. Iribarne,¹ M.J. Russo,¹ R.R. Davies,¹ H. Takayama,¹ J.M. Quaegebeur,¹ L.J. Addonizio,² J.M. Chen.¹ ¹Children's Hospital of New York-Presbyterian, New York, NY; ²Children's Hospital of New York-Presbyterian, New York, NY.

5:45 PM (88) Donor-to-Recipient Weight Ratio Effects on Post-Transplant Survival in Pediatric Heart Transplant Recipients: Analysis of the United Network for Organ Sharing (UNOS) Database; L. Tang, W. Du, T. L'Ecuyer, M. Zilberman. Children's Hospital of Michigan, Detroit, MI.

6:00 PM (89) A Novel Approach to Size-Matching for Pediatric Heart Transplantation. Can We Do Better?; W.A. Zuckerman,¹ M.E. Richmond,¹ R.K. Singh,¹ J.M. Chen,² K. Altmann,¹ L.J. Addonizio.¹ ¹New York Presbyterian Hospital/Columbia University Medical Center, New York, NY; ²New York Presbyterian Hospital/Columbia University Medical Center, New York, NY.

6:15 PM (90) Body Mass Index and Its Impact on Outcome in Children after Lung Transplantation: An Analysis of the ISHLT Pediatric Lung Transplant Registry; C. Benden,¹ D.A. Ridout,² S.C. Sweet,³ A. Boehler.¹ ¹University Hospital Zurich, Zurich, Switzerland; ²UCL Institute of Child Health, London, United Kingdom; ³Washington University School of Medicine, St. Louis, MO.

6:30 PM (91) Validation of a Risk Prediction Model for In-hospital Mortality Following Pediatric Heart Transplantation; C.S. Almond,¹ K. Gauvreau,¹ C. Canter,² G.E. Piercey,¹ T.P. Singh.¹ ¹Children's Hospital Boston, Boston, MA; ²St. Louis Children's Hospital, St. Louis, MO.

5:15 PM – 6:45 PM

CONCURRENT SESSION 6:

The AMR Story Continues (Marquette)

CHAIRS: MICHAEL C. FISHBEIN, MD AND
MARGARET M. BURKE, FRCPATH

5:15 PM (92) Detection of C4d Deposition in Cardiac Allografts: A Comparative Study of Immunofluorescence and Immunoperoxidase Methods; D.V. Miller,¹ A.C. Roden,² J.D. Gamez,² H.D. Tazelaar.³ ¹Utah Transplant Affiliated Hospitals (UTAH), Salt Lake City, UT; ²Mayo Clinic, Rochester, MN; ³Mayo Clinic, Scottsdale, AZ.

5:30 PM (93) Clinical Risk-Prediction of a Novel Thrombosis/Activation (TA) Score to Prognosticate Long-Term Cardiac Allograft Vasculopathy (CAV) in Heart Transplant Patients; C.A. Labarrere,¹ J.R. Woods,¹ J.W. Hardin,² G.L. Campana,¹ M.A. Ortiz,¹ B.R. Jaeger,³ B. Reichart,⁴ L.A. Baldrige,⁵ J.M. Bonnin,⁵ A. Currin,⁶ S.K. Cosgrove,⁶ P.C. Kirlin,⁶ J.A. O'Donnell,⁷ D.A. Hormuth,⁶ T.C. Wozniak.⁶ ¹Clarian Health Partners, Indianapolis, IN; ²University of South Carolina, Columbia, SC; ³Dr Stein und Kollegen, Monchengladbach, Germany; ⁴Ludwig-Maximilians-Universitat, Munchen, Germany; ⁵Indiana University School of Medicine, Indianapolis, IN; ⁶Clarian Health Partners, Indianapolis, IN; ⁷Krannert Institute of Cardiology, Indianapolis, IN.

5:45 PM (94) Phosphoproteomic Analysis of Cardiac Allograft Biopsies Reveals Novel Markers of Antibody Mediated Rejection; C. Lai,¹ J. Wei,¹ F. Li,¹ Q. Zhang,¹ D. Gjertson,¹ J.A. Kobashigawa,² M.C. Fishbein,¹ E.F. Reed.¹ ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

6:00 PM (95) C4d Methodology and Interpretation in Biopsy Diagnosis of Cardiac Antibody-Mediated Rejection: A European Survey from the Transplant Working Group of the Association for European Cardiovascular Pathology (AECVP); M. Burke,¹ C. Andersen,² M. Ashworth,³ F. Black,⁴ P. Bruneval,⁵ G. De Maglio,⁶ H.

Doran,⁷ M. Fedrigo,⁸ M. Goddard,⁹ M. Gonzalez-Cuesta,¹⁰ R. Gouveia,¹¹ S. Hoyer,¹² M. Kment,¹³ S. Lantuejoul,¹⁴ O. Leone,¹⁵ F. Lopez-Rubio,¹⁶ N. Monsef,¹⁷ D. Neil,¹⁸ F. Paraf,¹⁹ J. Pardo,²⁰ A. Raisen-Sokolowski,²¹ J. Ramirez,²² D. Rassl,⁹ F. Reinhold,²⁴ S. Rotman,²⁵ S. Stewart,⁹ B. Weynand,²⁷ F. Yilmaz,²⁸ G. Thiene,⁸ A. Angelini.⁸ ¹Harefield Hospital, London, United Kingdom; ²Rigshospitalet, Copenhagen, Denmark; ³Great Ormond Street Hospital for Children, London, United Kingdom; ⁴Freeman Hospital, Newcastle upon Tyne, United Kingdom; ⁵Hôpital Européen Georges Pompidou, Paris, France; ⁶S. M.della Misericordia, Udine, Italy; ⁷Wythenshawe Hospital, Manchester, United Kingdom; ⁸University of Padua, Padua, Italy; ⁹Papworth Hospital, Cambridge, United Kingdom; ¹⁰University Hospital, La Coruna, Spain; ¹¹Hospital de Santa Cruz, Lisbon, Portugal; ¹²University Hospital, Aarhus, Denmark; ¹³Institute for Clinical and Experimental Medicine, Prague, Czech Republic; ¹⁴University Hospital A Michallon, Grenoble, France; ¹⁵S.Orsola-Malpighi, Bologna, Italy; ¹⁶University Hospital Reine Sofia, Cordoba, Spain; ¹⁷Lund University Hospital, Lund, Sweden; ¹⁸Queen Elizabeth University Hospital, Birmingham, United Kingdom; ¹⁹Centre Hospitalier Universitaire Dupuytren, Limoges, France; ²⁰University of Navarra, Pamplona, Spain; ²¹Helsinki University Central Hospital, Helsinki, Finland; ²²Hospital Clinic, Barcelona, Spain; ²³Papworth Hospital, Cambridge, United Kingdom; ²⁴University Hospital, Oslo, Norway; ²⁵Institut Universitaire de Pathologie, Lausanne, Switzerland; ²⁶Papworth Hospital, Cambridge, United Kingdom; ²⁷Cliniques Universitaires St Luc, Brussels, Belgium; ²⁸University of Ege, Izmir, Turkey; ²⁹University of Padua, Padua, Italy; ³⁰University of Padua, Padua, Italy.

6:15 PM (96) *C4d in Heart Transplant Biopsies Does Not Appear to Represent Poor Outcome*; C. Lai,¹ J. Patel,² M. Fishbein,¹ M. Kittleston,² M. Share,² S. Davis,² M. Kawano,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

6:30 PM (97) *What Are the Best Antibody Predictors of AMR Resulting in Cardiac Death?*; M.E.H. Hammond, D.V. Miller, M.P. Revelo, J. Stehlik, G. Snow, M. Everitt, D. Budge, R. Alharethi, E.M. Gilbert, F. Bader, A.G. Kfoury, UTAH Cardiac Transplant Program, Salt Lake City, UT.

5:30 PM – 6:30 PM
PAST PRESIDENT'S COUNCIL MEETING (Joliet)

6:45 PM – 7:45 PM
EXHIBIT HALL OPENING RECEPTION
(Southeast Exhibit Hall)

VIEW POSTERS (Southwest Exhibit Hall)

Thursday, April 22, 2010

7:00 AM – 6:00 PM
Registration Desk Open (8th Street Registration)

7:00 AM – 7:00 PM
Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM
MECHANICAL CIRCULATORY SUPPORT SCIENTIFIC COUNCIL MEETING (Marquette)

PULMONARY ARTERIAL HYPERTENSION SCIENTIFIC COUNCIL MEETING (Joliet)

PATHOLOGY AND BASIC SCIENCE SCIENTIFIC COUNCIL MEETING (PDR-2)

INFECTIOUS DISEASE SCIENTIFIC COUNCIL MEETING (Waldorf)

8:30 AM – 10:15 AM
PLENARY SESSION
(International Ballroom)

CHAIRS: MANDEEP R. MEHRA, MD AND
JOHN WALLWORK, FRCS

8:30 AM INVITED LECTURE, *The 2010 ISHLT Post Heart Transplantation Guidelines*, Maria Rosa Costanzo, MD, FACC, FAHA, Midwest Heart Specialists, Naperville, IL

8:45 AM (98) FEATURED ABSTRACT *Comparison of Gene Expression Profiling and Endomyocardial Biopsy for Surveillance of Acute Cardiac Cellular Rejection: Results from the IMAGE Trial*; M.X. Pham,^{1,2} J.J. Teuteberg,⁴ A.G. Kfoury,⁵ R.C. Starling,⁶ M.C. Deng,³ T.P. Cappola,⁸ A. Kao,⁹ A.S. Anderson,⁷ W.G. Cotts,¹⁰ G.A. Ewald,¹³ D.A. Baran,¹² R.C. Bogaev,¹¹ H. Baron,¹⁴ J. Yee,¹⁴ H.A. Valantine.¹ ¹Stanford University Medical Center, Stanford; ²VA Palo Alto Health Care System, Palo Alto; ³Columbia University Medical Center, New York; ⁴University of Pittsburgh Medical Center, Pittsburgh; ⁵Intermountain Medical Center and Intermountain Healthcare, Salt Lake City, UT; ⁶Cleveland Clinic, Cleveland, OH; ⁷University of Chicago Medical Center, Chicago; ⁸Hospital of the University of Pennsylvania, Philadelphia; ⁹Mid America Heart Institute, Saint Luke's Hospital, Kansas City; ¹⁰Northwestern Medical Center, Chicago; ¹¹Texas Heart Institute, Houston; ¹²Newark Beth Israel Medical Center, Newark, NY; ¹³Washington University School of Medicine, St. Louis, MO; ¹⁴XDx Inc., Brisbane.

8:55 AM INVITED DISCUSSANT, Jayan Parameshwar, FRCP, Papworth Hospital, Cambridge, United Kingdom

9:00 AM (99) FEATURED ABSTRACT *Risk of Bronchiolitis Obliterans Syndrome Is Twice as High in Cyclosporine Treated Patients in Comparison to Tacrolimus 3 Years after Lung Transplantation: Results of a Prospective Randomized International Trial of 248 Patients;* H. Treede,¹ A. Glanville,² W. Klepetko,³ R. Lama,⁴ C. Bravo,⁵ M. Estenne,⁶ J.-D. Aubert,⁷ C. Aboyoun,² H. Reichenspurner.¹ ¹University Heart Center Hamburg, Hamburg, Germany; ²St. Vincent's Hospital, Sydney, NSW, Australia; ³University Hospital Vienna, Vienna, Austria; ⁴University Hospital Reina Sofia, Cordoba, Spain; ⁵Hospital Vall d'Hebron, Barcelona, Spain; ⁶Erasme University Hospital, Brussels, Belgium; ⁷University Hospital Lausanne, Lausanne, Switzerland.

9:10 AM INVITED DISCUSSANT, Paul A. Corris, MB FRCP, Freeman Hospital, Newcastle, United Kingdom

9:15 AM INVITED LECTURE, *Prospect of Xenotransplantation*, Bruno Reichart, MD, University of Munich/Grosshadern, Munich Germany

9:35 AM (100) FEATURED ABSTRACT *Impact of B-Cell Memory on Development of Donor-Specific Tolerance in ABO-Incompatible Heart Transplantation in Early Childhood;* S. Urschel, L.A. Ryan, M. Jeyakanthan, I.M. Larsen, L.J. West. University of Alberta, Edmonton, AB, Canada.

9:45 AM INVITED DISCUSSANT, Steven A. Webber, MB, ChB, Children's Hospital of Pittsburgh, Pittsburgh, PA

9:50 AM (101) FEATURED ABSTRACT *Are Recipients from Heart Donors Listed as Homeless at Increased Risk for Poor Outcome after Heart Transplantation?;* D. Lockhart,² L. Doering,¹ C. Burch,¹ S. Montgomery,² A. Velleca,² J. Patel,² M. Kittleson,² S. Davis,² M. Kawano,² Z. Goldstein,² A. Moradzadeh,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

10:00 AM INVITED DISCUSSANT, Duane Davis, MD, Duke University, Durham, NC

9:00 AM – 5:00 PM

Press Office Open (Continental Foyer Office 1)

10:00 AM – 4:30 PM

Exhibit Hall Open (Southeast Exhibit Hall)

Internet Café Open (Southeast Exhibit Hall)

Poster Viewing (Southwest Exhibit Hall)

10:15 AM – 10:45 AM

Coffee Break (Southeast Exhibit Hall)

10:45 AM – 12:15 PM

CONCURRENT SESSION 7:

Battle of the Sexes – PT Selection (International Ballroom)

CHAIRS: ROBERTA C. BOGAEV, MD, FACC AND ERIK A. M. VERSCHUUREN, MD, PHD

10:45 AM (102) Gender Differences in Long-term Mechanical Circulatory Supports; E.V. Potapov, A. Stepanenko, T. Krabatsch, J. Vierecke, Y. Weng, M. Pasic, M. Huebler, T. Drews, V. Regitz-Zagrosek, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

11:00 AM (103) Sex Differences in Usage of Mechanical Circulatory Support and Pre-Implant Baseline Characteristics Using the INTERMACS Database; K. O'Callaghan,¹ M. Camacho,² T. Martin,² K.L. Lockard,³ M.A. Miller,⁴ J.B. Young.⁵ ¹Food and Drug Administration, Silver Springs, MD; ²Newark Beth Israel Medical Center, Newark, NJ; ³University of Pittsburgh Medical Center, Pittsburgh, PA; ⁴National Heart Lung and Blood Institute, Bethesda, MD; ⁵Cleveland Clinic Foundation, Cleveland, OH.

11:15 AM (104) Survival after Implant of a Left Ventricular Assist Device: Is It the Device or Is It the Patient?; J.G. Rogers,¹ F.D. Pagani,² J.K. Kirklin,³ D.C. Naftel,³ R.J. Morris,⁴ W.P. Dembitsky,⁵ M.S. Blood,³ J.B. Young.⁶ ¹Duke University Medical Center, Durham, NC; ²University of Michigan Medical Center, Ann Arbor, MI; ³University of Alabama at Birmingham, Birmingham, AL; ⁴University of Pennsylvania, Philadelphia, PA; ⁵Sharp Memorial Hospital, San Diego, CA; ⁶Cleveland Clinic Foundation, Cleveland, OH.

11:30 AM (105) Decreased Survival after Bi-VAD Implant: Is It the Bi-VAD or the Patient?; J. Cleveland,¹ T.B. Reece,¹ D.C. Naftel,² J.F. Antaki,³ M.A. Murray,⁴ J.K. Kirklin,² R.L. Kormos.⁵ ¹University of Colorado at Denver, Aurora, CO; ²University of Alabama at Birmingham, Birmingham, AL; ³Carnegie Mellon University, Pittsburgh, PA; ⁴University of Wisconsin Hospital and Clinic, Madison, WI; ⁵University of Pittsburgh Medical Center, Pittsburgh, PA.

11:45 AM (106) Equivalent Outcomes of Ventricular Assist Device (VAD) Patients by Gender in the Modern Era of Mechanical Support; E.A. Genovese,¹ M.A. Dew,² J.J. Teuteberg,³ C.A. Bermudez,⁴ D.M. McNamara,³ S. Winowich,⁴ A. Weimer,⁴ R.L. Kormos.⁴ ¹University of Pittsburgh School of Medicine, Pittsburgh, PA; ²University of Pittsburgh School of Medicine, Pittsburgh, PA; ³University of Pittsburgh Medical Center, Pittsburgh, PA; ⁴University of Pittsburgh Medical Center, Pittsburgh, PA.

12:00 PM (107) Sex-Specific Differences in Outcome and Adverse Events with Primary Left Ventricular Assist Device Support Using the INTERMACS Database; E.M. Hsich,¹ D.C. Naftel,² S.L. Myers,² K.L. Grady,³ D. Schuml,¹ K.L. Ullisney,⁴ J.B. Young.¹ ¹Cleveland

Clinic Foundation, Cleveland, OH; ²University of Alabama at Birmingham, Birmingham, AL; ³Bluhm Cardiovascular Institute, Chicago, IL; ⁴National Heart, Lung and Blood Institute, Bethesda, MD.

10:45 AM – 12:15 PM

CONCURRENT SESSION 8:

Heart Transplantation Outcome (Continental A/B)

CHAIRS: GIUSEPPE FAGGIAN, MD AND RANDALL C. STARLING, MD, MPH

10:45 AM (108) Usefulness of INTERMACS Profiles To Predict Postoperative Outcomes in Critically Ill Patients Undergoing Urgent Heart Transplantation; E. Barge-Caballero, M.G. Crespo-Leiro, M.J. Paniagua-Martin, A. Perez-Perez, R. Estevez-Loureiro, J.A. Rodriguez-Fernandez, R. Campo-Perez, R. Marzoa-Rivas, X. Flores-Rios, M. Solla-Buceta, J.J. Cuenca-Castillo, A. Castro-Beiras. Hospital Universitario A Coruña, A Coruña, Spain.

11:00 AM (109) Improvement in Heart Transplant Survival Across Eras: Have All Racial Groups Benefited Equally? Race-Era Interaction in a Risk-Adjusted Model; T.P. Singh, C.S. Almond, G. Piercey, K. Gauvreau. Children's Hospital Boston, Boston, MA.

11:15 AM (110) Outcomes after Heart Transplantation for Chemotherapy-Induced Cardiomyopathy: Results from a Multi-Center Registry; B.W. Hardaway,¹ A.Y. Kucheryavaya,² L.B. Edwards,² J. Stehlik,³ D.O. Taylor.¹ ¹Cleveland Clinic, Cleveland, OH; ²United Network for Organ Sharing, Richmond, VA; ³University of Utah, Salt Lake City, UT.

11:30 AM (111) Safety and Outcomes with Newer Treatment Strategies for Cardiac Antibody-Mediated Rejection: Still in the Woods; D. Budge, F. Khan, M.E.H. Hammond, Z.D. Nilson, J. Stehlik, R. Alharethi, M.D. Everitt, E.M. Gilbert, F. Bader, D.V. Miller, P. Revelo, S.G. Drakos, A.G. Kfoury. UTAH Cardiac Transplant Program, Salt Lake City, UT.

11:45 AM (112) The Association between Metabolic Syndrome and Long-Term Survival in Patients Undergoing Orthotopic Heart Transplantation; F.H. Cheema,¹ S. Yaman,¹ V. Topkara,² T. Khawaja,¹ K.J. Schaeffle,¹ O. Siddiqui,¹ A. Chokshi,³ B. Worku,¹ M. Argenziano,¹ D.M. Mancini,³ Y. Naka,¹ P.C. Schulze.³ ¹Columbia University College of Physicians and Surgeons – New York Presbyterian Hospital, New York, NY; ²Washington University School of Medicine, St. Louis, MO; ³Columbia University College of Physicians and Surgeons – New York Presbyterian Hospital, New York, NY.

12:00 PM (113) Impact of 1 Year Creatinine on Long-Term Survival after Cardiac Transplantation; A.Z. Aliabadi, S.L. Mahr, D. Dunkler, M. Groemmer, F.A. Eskandary, D. Zimpfer, M. Grimm, G. Laufer, A.O. Zuckermann. Medical University of Vienna, Vienna, Austria.

10:45 AM – 12:15 PM

CONCURRENT SESSION 9:

Donor Influences on Outcomes After Lung Transplant (Boulevard)

CHAIRS: STEPHEN C. CLARK, MD AND DUANE DAVIS, MD

10:45 AM (114) The Role of Chronic Alcohol Abuse in the Development of Primary Graft Dysfunction (PGD) in Lung Transplant (LTx) Recipients; A. Pelaez,^{1,2} N. Shah,¹ S.D. Force,³ E.C. Lawrence,^{1,2} A.M. Ramirez,^{1,2} D.C. Neujahr,^{1,2} P.O. Mitchell,¹ D.M. Guidot.¹ ¹Emory University School of Medicine, Atlanta, GA; ²Emory University School of Medicine, Atlanta, GA; ³Emory University School of Medicine, Atlanta, GA.

11:00 AM (115) Successful Lung Transplant Outcomes with "High Risk Donors"; S. Novosad,¹ S.M. Palmer,¹ R.D. Davis,² S. Lin,² D.W. Zaas.¹ ¹Duke University, Durham, NC; ²Duke University, Durham, NC.

11:15 AM (116) Lung Transplantation with Lungs from Donors 55 Years or Older; T. Horai,¹ N. Shigemura,¹ P. Bonde,¹ B. Sareyyupoglu,¹ S. Tabata,¹ J. Pilewski,² M. Crespo,² B. Johnson,² P. George,² M. Morrell,² R.L. Kormos,¹ J.K. Bhamra,¹ S. Gilbert,¹ C.A. Bermudez,¹ Y. Toyoda.¹ ¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²University of Pittsburgh Medical Center, Pittsburgh, PA.

11:30 AM (117) Postoperative Results in Lung Transplantation with Donors 60 Years and Older; I. Lopez,¹ A. Jau-regui,¹ J. Sole,¹ M. Deu,¹ A. Ojanguren,¹ J. Rosado,¹ J. Teixidor,¹ L. Tenorio,³ V. Monforte,² M. Canela.¹ ¹Hospital Vall d'Hebron, Barcelona, Spain; ²Hospital Vall d' Hebron, Barcelona, Spain; ³Hospital Vall d' Hebron, Barcelona, Spain.

11:45 AM (118) Donation after Cardiac Death (DCD) Lung Allografts Have a Low Incidence of Primary Graft Dysfunction (PGD) after Transplantation (LTx); C.H. Wigfield,¹ J.W. Smith,¹ C.G. Alex,² A. D'Allesandro,³ R.B. Love.¹ ¹Loyola University Medical Center, Maywood, Chicago, IL; ²Loyola University Medical Center, Maywood, Chicago, IL; ³University of Wisconsin Hospitals and Clinics, Madison, WI.

12:00 PM (119) Long Term Pulmonary Graft Function in Pediatric Recipients after Living-Donor Lobar Lung Transplantation; M. Yamane, S. Toyooka, T. Oto, Y. Sano, S. Miyoshi. Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

10:45 AM – 12:15 PM

CONCURRENT SESSION 10:

Novel Genomic, Proteomic & Clinical Risk Markers in PAH (Continental C)

CHAIRS: JUERGEN BEHR, MD AND KEITH MCNEIL, FRACP

10:45 AM (120) Gene Expression Signature in the Explanted Lung Is a Better Predictor of Primary Graft Dysfunction after Lung Transplantation than Pulmonary Artery Pressures in Patients with Pulmonary Fibrosis; M. Mura,^{1,2} M. Anraku,^{1,2} Z. Yun,¹ C. Chaparro,² K. McRae,² M. Liu,¹ M. Hutcheon,² T.K. Waddell,^{1,2} L.G. Singer,² J.T. Granton,^{2,3} S. Keshavjee,^{1,2} M. de Perrot.^{1,2,3}
¹Latner Thoracic Surgery Research Laboratories, Toronto, ON, Canada; ²Toronto Lung Transplant Program, Toronto, ON, Canada; ³Pulmonary Hypertension Program, Toronto, ON, Canada.

11:00 AM (121) Soluble ST2 Is Associated with Right Heart Failure and Is Independently Predictive of Event Free Survival in Pulmonary Arterial Hypertension; J.E. Rame,¹ D. McGlothlin,² A.H.B. Wu,³ J.O. Hernandez,² E. Kobashigawa,² T. De Marco.² ¹University of Pennsylvania, Philadelphia, PA; ²University of California San Francisco, San Francisco, CA; ³University of California San Francisco, San Francisco, CA.

11:15 AM (122) Therapy-Related Shifts in NT-proBNP Correlate with Changes in 6MWD and cMRI Parameters in Bosentan-Treated Patients with PAH: The COM-PASS-3 Study; M.H. Park,¹ S. Murali,² F.J. Soto,³ F. Torres,⁴ H. Gupta,⁵ N. Frey,⁶ R.L. Benza.² ¹University of Maryland School of Medicine, Baltimore, MD; ²Allegheny General Hospital, Pittsburgh, PA; ³Prevea Health, Sheboygan, WI; ⁴University of Texas Southwestern Medical Center, Dallas, TX; ⁵University of Alabama at Birmingham, Birmingham, AL; ⁶Actelion Pharmaceuticals US, Inc., South San Francisco, CA.

11:30 AM (123) Association between Serial 6-Minute Walk Distance (6MWD) Assessments and the REVEAL Pulmonary Arterial Hypertension (PAH) Risk Score Calculator; R.L. Benza,¹ D.P. Miller,² R.P. Frantz,³ A.J. Foreman,² H.W. Farber,⁴ A.E. Frost,⁵ R.J. Barst,⁶ C.G. Elliott,^{7,8} M.D. McGoon.³ ¹Allegheny General Hospital, Pittsburgh, PA; ²ICON Clinical Research, San Francisco, CA; ³Mayo Clinic, Rochester, MN; ⁴Boston University Medical Center, Boston, MA; ⁵Baylor College of Medicine, Houston, TX; ⁶Columbia University College of Physicians and Surgeons, New York, NY; ⁷Intermountain Medical Center, Murray, UT; ⁸University of Utah, Salt Lake City, UT.

11:45 AM (124) Clinical, Echocardiographic, and Prognostic Significance of Pericardial Effusions in Patients with Pulmonary Arterial Hypertension: Outcomes with Pericardiocentesis; E.R. Fenstad,¹ R.J. Le,¹ L.J. Sinak,² H. Maradit-Kremers,² N.M. Ammash,² H.R. Villarraga,² J.K. Oh,² R.P. Frantz,² R.B. McCully,² M.D. McGoon,² G.C. Kane.² ¹Mayo Clinic, Rochester, MN; ²Mayo Clinic, Rochester, MN.

12:00 PM (125) RV Function Is Essential for Accurate Estimation of Right Ventricular Systolic Pressure by Transthoracic Doppler Echocardiography; A.J. Rieth, V. Mitrovic. Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.

10:45 AM – 12:15 PM

CONCURRENT SESSION 11:

Stem Cells: Basic and Translational Approaches (Waldorf)

CHAIRS: JOSEPH WOO, MD AND
TERRENCE M. YAU, MD, MSC

10:45 AM (126) Withdrawn

11:00 AM (127) Tolerance Induction with Stem and Progenitor Cells: Potential Role for Regulatory T Cells; L. Sun,^{1,3} K. Trapp,^{1,3} E. Inagaki,^{1,2,3} J. Domen,^{1,2,3} K. Gandy.^{1,2,3}
¹Children's Research Institute, Milwaukee, WI; ²Children's Hospital of Wisconsin (Herma Heart Center), Milwaukee, WI; ³Medical College of Wisconsin, Milwaukee, WI.

11:15 AM (128) Immunogenicity of Fetal Mesenchymal Stem Cells from the Umbilical Cord Line for Regenerative Therapies; K.R. Tang-Quan,^{1,2} M.V.V. Kolk,¹ T. Deuse,^{1,2} N. Philipp,³ M. Kay,³ R.C. Robbins,² H. Reichenspurner,¹ S. Schrepfer.^{1,2} ¹University Heart Center Hamburg, Hamburg, Germany; ²Stanford University School of Medicine, Stanford, CA; ³Stanford University, Stanford, CA.

11:30 AM (129) Autologous Bone Marrow Cell Implantation Attenuates Left Ventricular Remodeling and Improves Heart Function in Porcine Myocardial Infarction: An Echocardiographic, Six-Month Angiographic, and Molecular-Cellular Study; F.-Y. Lee,¹ H.-K. Yip,² C.-K. Sun,³ J.-J. Sheu,¹ L.-T. Chang,⁴ C.-M. Yuen,⁵ C.-H. Yen,⁶ C.-H. Chiang,⁷ S.-F. Ko,⁸ S.-N. Pei,⁹ S. Chua,² A.A. Youssef,¹⁰ C.-J. Wu.² ¹Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; ²Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; ³Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; ⁴Meiho Institute of Technology, Pingtung, Taiwan; ⁵Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; ⁶National Pingtung University of Science and Technology, Pingtung, Taiwan; ⁷National Pingtung University of Science and Technology, Pingtung, Taiwan; ⁸Chang Gung Memorial Hospital-Kaohsiung Medical, Kaohsiung, Taiwan; ⁹Chang Gung Memorial Hospital-Kaohsiung Medical, Kaohsiung, Taiwan; ¹⁰Suez Canal University Hospital, Ismailia, Egypt.

11:45 AM (130) Circulating Mesenchymal Stem Cells Are Associated with Cardiac Allograft Vasculopathy; S. Aharinejad,^{1,2} M. Salama,^{1,2} O. Andrukhova,² A. Thomas,² S. Rodler,¹ A. Zuckermann,¹ G. Laufer,¹ M. Grimm.¹ ¹Medical University of Vienna, Vienna, Austria; ²Medical University of Vienna, Vienna, Austria.

12:00 PM (131) Changes in Gene Expression and Improvement in Perioperative Outcomes after Orthotopic Cardiac Xenotransplantation; C.G.A. McGregor,^{1,2} M. Vlasin,¹ R.C. Walker,¹ H.D. Tazelaar,¹ K. Chandrasekaran,¹ B.A. Boilson,¹ G.W. Byrne.^{1,2} ¹Mayo Clinic, Rochester, MN; ²University College London, London, United Kingdom.

10:45 AM – 12:15 PM

CONCURRENT SESSION 12:

Immunosuppression After Heart Transplantation: Is Less More? (Marquette)

CHAIRS: BRUNO M. MEISER, MD AND ALLEN S. ANDERSON, MD, FACC

10:45 AM (132) Everolimus Introduction with CNI Minimization Significantly Improves Renal Function in Thoracic Transplant Recipients: A Scandinavian Multicenter, Randomized Study; L. Gullestad,¹ B. Rundqvist,² S.A. Mortensen,³ H. Eiskjaer,⁴ G.C. Riise,² L. Mared,⁵ O. Bjortuft,⁶ B. Ekmehag,⁵ K. Jansson,⁷ S. Simonsen,¹ E. Gude,¹ H. Fagertun,⁶ D. Solbu,⁶ M. Iversen.³ ¹Oslo University Hospital, Rikshospitalet, Oslo, Norway; ²Sahlgrenska University Hospital, Göteborg, Sweden; ³Rigshospitalet, Copenhagen, Denmark; ⁴Aarhus University Hospital, Aarhus, Denmark; ⁵University of Lund, Lund, Sweden; ⁶Oslo University Hospital, Rikshospitalet, Oslo, Norway; ⁷University Hospital Linköping, Linköping, Sweden.

11:00 AM (133) Tacrolimus in Combination, Tacrolimus Alone Compared: 5 Year Results of the TICTAC Trial; D.A. Baran,¹ M.J. Zucker,¹ M.E. Goldschmidt,¹ J. Prevost-Fernandez,¹ C. Carr,¹ S. Pardi,¹ V. Hou,¹ M. Binetti,¹ M.G. San Agustin,¹ J. Ebuenga,¹ A. Gass,² M. Camacho.¹ ¹Newark Beth Israel Medical Center, Newark, NJ; ²Westchester Medical Center, Westchester, NY.

11:15 AM (134) A Randomized Study Using Humanized Monoclonal Antibody Against Cd52 (Campath-1b) and Tacrolimus in Heart Transplant Recipients; S.M. Pham,¹ B.M. Bednar,¹ A. Panos,¹ E.J. Bauerlein,² F. Jimenez,² E. Rosenkrantz,¹ M. Ricci,¹ P. Rusconi,³ S. Chaparro,² M.A. Aycart,¹ R. Hershberger.² ¹University of Miami, Miami, FL; ²University of Miami, Miami, FL; ³University of Miami, Miami, FL.

11:30 AM (135) Experimental Transplantation: Novel Immunosuppression Using the JAK3-Inhibitor R348; T. Deuse,^{1,2} E. Masuda,³ V. Taylor,³ G. Park,³ D. Carroll,³ H. Reichenspurner,¹ J. Velotta,² R. Robbins,² S. Schrepfer.^{1,2} ¹University Heart Center Hamburg, Hamburg, Germany; ²Stanford University School of Medicine, Stanford, CA; ³Rigel, San Francisco, CA.

11:45 AM (136) Effect of Everolimus Introduction and Calcineurin Inhibitor Reduction on Graft Vasculopathy in Heart Transplant Recipients; S. Arora,¹ B. Wennerblom,² B. Rundqvist,² H. Eiskjaer,³ H.E. Botker,³

S.-A. Mortensen,⁴ K. Saunameki,⁴ B. Ekmehag,⁵ K. Jansson,⁶ S. Simonsen,¹ E. Gude,¹ K. Endresen,¹ D. Solbu,⁷ L. Gullestad.¹ ¹Oslo University Hospital, Oslo, Norway; ²Sahlgrenska University Hospital, Gothenburg, Sweden; ³Skeiby University Hospital, Aarhus, Denmark; ⁴Rigshospitalet, Copenhagen, Denmark; ⁵Lund Hospital, Lund, Sweden; ⁶Heart Center University Hospital, Linköping, Sweden; ⁷Novartis Norge AS, Oslo, Norway.

12:00 PM (137) Proteinuria after Conversion to Sirolimus-Based Immunosuppression in Cardiac Transplant Recipients: A Five Year Analysis; E. Raichlin,² M.A. Al-Omari,¹ B.S. Edwards,¹ R.C. Daly,¹ R.F.P. Frntz,¹ A.C.L. Clavell,¹ N.L. Pereira,¹ J.A. Schirger,¹ S.S. Kushwaha.¹ ¹Mayo Clinic, Rochester, MN; ²University of Nebraska Medical Center, Omaha, NE.

12:15 PM – 2:15 PM

Lunch Break

12:15 PM – 2:15 PM

JUNIOR FACULTY AND TRAINEE COUNCIL MENTOR LUNCH (PDR-2) (advance ticket purchase required)

12:30 PM – 2:00 PM

INTERNATIONAL PEDIATRIC LUNG TRANSPLANT COLLABORATIVE MEETING (Joliet)

2:30 PM – 4:00 PM

CONCURRENT SESSION 13:

Device Disasters: Can We Avoid Them? (International Ballroom)

CHAIRS: JAN F. GUMMERT, MD, PHD AND FINN GUSTAFSSON, MD, PHD

2:30 PM (138) Neurocognitive Evaluation of Destination Therapy Patients Receiving Continuous Flow Left Ventricular Assist Devices; R.J. Petrucci,¹ J.G. Rogers,²

L. Blue,² C.T. Gallagher,³ S.D. Russell,⁴ D. Dordunoo,⁴ B.E. Jaski,⁵ S. Chillcott,⁵ B.C. Sun,⁶ T.L. Yanssens,⁶ A.J. Tatrooles,³ L. Koundakjian,⁷ D.J. Farrar,⁷ M.S. Slaughter.⁸ ¹Drexel University College of Medicine, Philadelphia, PA; ²Duke University, Durham, NC; ³Advocate Christ Medical Center, Oak Lawn, IL; ⁴Johns Hopkins University Medical Center, Baltimore, MD; ⁵Sharp Memorial Hospital, San Diego, CA; ⁶Ohio State University, Columbus, OH; ⁷Thoratec Corporation, Inc., Pleasanton, CA; ⁸University of Louisville, Louisville, KY.

2:45 PM (139) Reducing Adverse Neurological Events in LVAD Patients: Pulsatile vs. Continuous Flow?; S.J. Park,¹

D.C. Naftel,² M.S. Slaughter,³ M.A. Sobieski,³ L.L. Staley,⁴ J.A. Tallaj,² J.T. Baldwin,² J.K. Kirklin.² ¹Mayo Clinic, Rochester, MN; ²University of Alabama at Birmingham, Birmingham, AL; ³University of Louisville, Louisville, KY; ⁴Mayo Clinic, Phoenix, AZ; ⁵National Heart, Lung and Blood Institute, Bethesda, MD.

3:00 PM (140) Standardized Psychosocial Evaluation Prior to LVAD May Predict Mortality and Length of Stay; P.M. Eckman,^{1,2} G.V. Gonzalez-Stawinski,¹ K. Kendall,¹ D. Racicki,¹ W. Tang,¹ R.C. Starling,¹ M.M. Mountis.¹
¹Cleveland Clinic Foundation, Cleveland, OH; ²University of Minnesota, Minneapolis, MN.

3:15 PM (141) Infection during Mechanical Circulatory Support: Can We Really Expect a Better Outlook with Continuous Flow Technology; C.A. Milano,¹ D.C. Naftel,² R.F. Padera,³ R.C. Starling,⁴ D.M. McNamara,⁵ S.V. Pamboukian,² S.L. Myers,² R.L. Kormos.⁵
¹Duke University Medical Center, Durham, NC; ²University of Alabama at Birmingham, Birmingham, AL; ³Brigham and Women's Hospital, Boston, MA; ⁴Cleveland Clinic, Cleveland, OH; ⁵University of Pittsburgh Medical, Pittsburgh, PA.

3:30 PM (142) Lead Fractures in Left Ventricular Assist Devices – A Multi-Institutional Experience; Y. Ravi,¹ R. John,² C. Salerno,³ Y. Tamara,¹ S. Wissman,¹ M. Firstenberg,¹ B. Sun,¹ L. Louis,¹ C.B. Sai Sudhakar.¹
¹The Ohio State University Medical Center, Columbus, OH; ²University of Minnesota, Minneapolis, MN; ³St. Vincent's Hospital, Indianapolis, OH.

3:45 PM (143) Pump Replacement for LVAD Failure Can Be Done Safely and Is Associated with Low Mortality; N. Moazami,¹ B. Sun,² C. Milano,³ R. John,⁴ J. Conte,⁵ R. Adamson,⁶ F. Pagani,⁷ O.H. Frazier,⁸ D. Farrar,⁹ M. Slaughter.¹⁰
¹Washington University School of Medicine, St. Louis, MO; ²Ohio State University, Columbus, OH; ³Duke University Medical Center, Durham, NC; ⁴University of Minnesota, Minneapolis, MN; ⁵Johns Hopkins University, Baltimore, MD; ⁶Sharp Memorial Hospital, San Diego, CA; ⁷University of Michigan, Ann Arbor, MI; ⁸Texas Heart Institute, Houston, TX; ⁹Thoratec Corporation, Pleasanton, CA; ¹⁰University of Louisville, Louisville, KY.

2:30 PM – 4:00 PM

CONCURRENT SESSION 14:

Heart Transplantation Post Op Dilemma (Continental A/B)

CHAIRS: BROOKS S. EDWARDS, MD AND DONALD S. ESMORE, MBBS, FRACS

2:30 PM (144) The Association between Cytomegalovirus Immune Globulin (CMVIG) Use and Long-Term Recipient and Graft Survival in Pediatric and Adult Heart Transplantation Recipients; D.R. Snyderman,¹ G.E. Bergman,² J. Vensak.²
¹Tufts University School of Medicine, Boston, MA; ²CSL Behring, King of Prussia, PA.

2:45 PM (145) Does a Normal Angiogram Further from Heart Transplantation Confer Less Chance To Develop CAV? Should We Still Do Annual Angiograms Late after Transplantation?; J. Patel,² M. Kittleson,² B. Azarbal,² A. Hage,² M. Kawano,² S. Davis,²

J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.²
¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

3:00 PM (146) High-Intensity Aerobic Exercise Improves Fore-arm Flow Mediated Dilatation and Blood Pressure Control Late after Cardiac Transplantation; T. Hermann,¹ C.H. Dall,² S. Christensen,¹ S. Boesgaard,¹ F. Gustafsson.¹
¹Rigshospitalet, Copenhagen, Denmark; ²Bispebjerg Hospital, Copenhagen, Denmark.

3:15 PM (147) Safety and Efficacy of High Dose vs. LDL-Driven Adjustments of Fluvastatin in Heart Transplant Recipients: A Randomized, IVUS-Based Study; L. Potena, F. Grigioni, F. Fabbri, G. Magnani, P. Ortolani, M. Masetti, F. Fallani, F. Coccolo, A. Russo, A. Branzi.
University of Bologna, Bologna, Italy.

3:30 PM (148) Are Circulating Antibodies Necessary To Make a Diagnosis of Antibody-Mediated Rejection?; J. Patel,² M. Kittleson,² Q. Zhang,¹ E. Reed,¹ M. Kawano,² S. Davis,² M. Cecka,¹ C. Burch,¹ A. Velleca,² E. Stimpson,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.²
¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

3:45 PM (149) Combinatorial Biomarkers of Cardiac Allograft Vasculopathy; D. Lin,¹ G. Cohen Freue,² Z. Hollander,¹ M. Sasaki,³ N. Opushneva,³ C. Imai,⁴ A. Ignaszewski,⁴ A. Mui,⁶ J. Wilson-McManus,³ R. Balshaw,² R.T. Ng,⁶ P.A. Keown,⁴ R. McMaster,⁵ B.M. McManus.¹
¹The University of British Columbia, Vancouver, BC, Canada; ²The University of British Columbia, Vancouver, BC, Canada; ³PROOF Centre of Excellence, Vancouver, BC, Canada; ⁴St. Paul's Hospital/The University of British Columbia, Vancouver, BC, Canada; ⁵The University of British Columbia, Vancouver, BC, Canada; ⁶The University of British Columbia, Vancouver, BC, Canada.

2:30 PM – 4:00 PM

CONCURRENT SESSION 15:

Clinical Investigation in Acute and Chronic Rejection After Lung Transplantation (Boulevard)

CHAIRS: SCOTT M. PALMER, MD, MHS AND JONATHAN B. ORENS, MD

2:30 PM (150) Flow Cytometric Parameters of CD8 Lavage Cells in Detection of Acute Cellular Rejection in Lung Transplant; D.C. Neujahr,¹ A. Mohammed,² O. Ulukpo,¹ A. Pelaez,¹ A. Ramirez,¹ E.C. Lawrence,¹ S.D. Force,³ A.A. Gal,⁴ C.P. Larsen,³ A.D. Kirk.³
¹Emory University School of Medicine, Atlanta, GA; ²Emory University School of Medicine, Atlanta, GA; ³Emory University School of Medicine, Atlanta, GA; ⁴Emory University School of Medicine, Atlanta, GA.

2:45 PM (151) SaLUTaRy: Survey of Lung Transplant Rejection; I.O. Gordon,¹ S. Bhorade,² W.T. Vigneswaran,³ P.J. McShane,² E.R. Garrity,² A.N. Husain.¹ ¹The University of Chicago, Chicago, IL; ²The University of Chicago, Chicago, IL; ³The University of Chicago, Chicago, IL.

3:00 PM (152) Humoral Immune Responses in Acute Phase of Living Double Lobar Lung Transplantation: Donor-Specific IgM Can Predict Onset of Acute Rejection; K. Miyoshi, Y. Sano, M. Yamane, S. Toyooka, T. Oto, S. Miyoshi. Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

3:15 PM (153) Achieving Therapeutic Levels of Cyclosporin C2 Early Post Transplant Has No Impact on Rejection Burden; S.C. Leong, D.C. Chambers, F.D. Kermeen, P.M.A. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia.

3:30 PM (154) Restrictive Allograft Syndrome (RAS): A Subset of Bronchiolitis Obliterans Syndrome (BOS) or a Distinct Entity?; M. Sato,^{1,2} D.M. Hwang,^{1,2} D. Wag-netz,^{1,2} G. Zehong,² L.G. Singer,¹ A. Haroon,¹ C. Chaparro,¹ C.-W. Chow,¹ T.K. Waddell,^{1,2} M. Hutcheon,¹ S. Keshavjee.^{1,2} ¹University Health Network, Toronto, ON, Canada; ²University Health Network, Toronto, ON, Canada.

3:45 PM (155) Immunological Correlates of Clinical Efficacy in BOS Patients Treated with Extracorporeal Photopheresis; F. Meloni,¹ C. Perotti,² T. Oggionni,¹ M. Morosini,¹ N. Solari,¹ F. Bini,¹ A. De Silvestri,³ C. Tinelli,³ A.M. Fiotta.¹ ¹University of Pavia & Foundation IRCCS San Matteo, Pavia, Italy; ²Foundation IRCCS San Matteo, Pavia, Italy; ³Foundation IRCCS San Matteo, Pavia, Italy.

2:30 PM – 4:00 PM

CONCURRENT SESSION 16:

Every Breath I Take is Now Better (Continental C)

CHAIRS: BRUCE A. REITZ, MD AND
THORSTEN WITTEW, MD, PHD, MA

2:30 PM (156) The Role of Extravascular Lung Water Measurement in the Potential Lung Donor; R.V. Venkateswaran,¹ V.B. Patchell,² J.H. Coote,² I.C. Wilson,¹ J.G. Mascaro,¹ R.D. Thompson,¹ R.S. Bonser.¹ ¹University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; ²University of Birmingham, Birmingham, United Kingdom.

2:45 PM (157) Low Potassium Dextran Is Superior to University of Wisconsin Solution in High Risk Lung Transplant Recipients; G.J. Arnaoutakis,¹ J.G. Allen,¹ C.A. Merlo,² J.V. Conte,¹ A.A. Shah.¹ ¹The Johns Hopkins Hospital, Baltimore, MD; ²The Johns Hopkins Hospital, Baltimore, MD.

3:00 PM (158) Prevention of Primary Graft Dysfunction in Lung Transplantation by N-Acetylcysteine after Prolonged Cold Ischemia; I. Inci, B. Erne, S. Arni, J. Wolfgang, S. Hillinger, B. Leskosek, W. Weder. University Hospital, Zurich, Switzerland.

3:15 PM (159) Transcriptional Signatures in Donor Lungs before and after Transplantation: A Functional Pathway Analysis of Donation after Cardiac Death (DCD) vs. Donation after Brain Death (DBD); C.H. Kang,¹ M. Anraku,² M. Cypel,² J. Yeung,² S. Gharib,³ A. Pierre,² M. de Perrot,² T. Waddell,² M. Liu,² S. Keshavjee.² ¹Seoul National University Hospital/University Health Network, Seoul, Republic of Korea; ²Toronto General Hospital, Toronto, ON, Canada; ³University of Washington, Seattle, WA.

3:30 PM (160) Evaluation of the Lung Allocation Score in High Urgent and Urgent Lung Transplant Candidates in Eurotransplant; J.M. Smits,¹ G.D. Nossent,² A.O. Rahmel,¹ G. Laufer,³ J. Gottlieb.⁴ ¹Eurotransplant, Leiden, Netherlands; ²UMCG, Groningen, Netherlands; ³University Hospital, Vienna, Austria; ⁴Hannover Medical School, Hannover, Germany.

3:45 PM (161) Initial Topical Cooling Followed by Backtable Celsior Flush Perfusion Provides Excellent Early Graft Function in Porcine Single Lung Transplantation after 24 Hours of Cold Ischemia; B. Gohrbandt,¹ M. Avsar,¹ G. Warnecke,¹ S.P. Sommer,² A. Haverich,¹ M. Strueber.¹ ¹Hannover Medical School, Hannover, Germany; ²University Hospital of Wuerzburg, Wuerzburg, Germany.

2:30 PM – 4:00 PM

CONCURRENT SESSION 17:

Quality of Life and Social Sciences: Have We Done the Right Thing?: Assessing Quality of Life Following Cardiothoracic Transplantation (Waldorf)

CHAIRS: BRONWYN J. LEVVEY, RN AND
CORBY L. D'AMICO, RN, MN

2:30 PM (162) The Obligation To Say Thank-You; J. Poole,¹ M. Shildrick,² P. McKeever,³ H. Ross,⁴ O. Mauthner,⁴ E. De Luca,⁵ S. Abbey.⁵ ¹Ryerson University, Toronto, ON, Canada; ²Queen's University Belfast, Belfast, Ireland; ³Bloorview Kids Rehab, Toronto, ON, Canada; ⁴University Health Network-Toronto General Hospital, Toronto, ON, Canada; ⁵University Health Network-Toronto General Hospital, Toronto, ON, Canada.

2:45 PM (163) Predictors and Outcomes Associated with Quality of Life (QOL) in Family Caregivers to Cardiothoracic Transplant Recipients; M.A. Dew,¹ L. Myaskovsky,² A.J. DeVito Dabbs,³ A.F. DiMartini,⁴ Y. Toyoda,⁵ R. Zomak,⁶ R.L. Kormos.⁵ ¹University of Pittsburgh School of Medicine, Pittsburgh, PA; ²University of Pittsburgh School of Medicine, Pittsburgh, PA; ³University of Pittsburgh School of Nursing, Pittsburgh,

PA; ⁴University of Pittsburgh School of Medicine, Pittsburgh, PA; ⁵University of Pittsburgh Medical Center, Pittsburgh, PA; ⁶University of Pittsburgh Medical Center, Pittsburgh, PA.

3:00 PM (164) *The Relationships among Satisfaction with Heart Transplant on Quality of Life (QOL) Outcomes 5 to 10 Years after Heart Transplantation (HT)*; C. White-Williams,¹ K.L. Grady,² E. Wang,³ D.C. Naftel,⁴ J.K. Kirklin,⁵ S. Myers,⁶ B. Rybarczyk,⁷ J.B. Young,⁸ J. Czerny,⁹ D. Pelegrin,¹⁰ J. Kobashigawa,¹¹ J. Chait,¹² A. Heroux,¹³ R. Higgins.¹⁴ ¹University of Alabama at Birmingham, Birmingham, AL; ²Northwestern Memorial Hospital, Chicago, IL; ³Northwestern Memorial Hospital, Chicago, IL; ⁴University of Alabama at Birmingham, Birmingham, AL; ⁵University of Alabama at Birmingham, Birmingham, AL; ⁶University of Alabama at Birmingham, Birmingham, AL; ⁷Virginia Commonwealth University, Richmond, VA; ⁸The Cleveland Clinic, Cleveland, OH; ⁹The Cleveland Clinic, Cleveland, OH; ¹⁰The Cleveland Clinic, Cleveland, OH; ¹¹Cedars-Sinai Heart Institute, Los Angeles, CA; ¹²UCLA Medical Center, Los Angeles, CA; ¹³Loyola University Medical Center, Maywood, IL; ¹⁴Rush University Medical Center, Chicago, IL.

3:15 PM (165) *Pre-Transplant Smoking in Heart Transplant Patients: A Marker for Long Term Outcome?*; E. Moreno,¹ A. Velleca,² C. Burch,¹ J. Patel,² M. Kittleson,² M. Kawano,² S. Davis,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

3:30 PM (166) *Evaluation of Exercise Limitations as Measured by Cardiopulmonary Exercise Testing in Patients after Lung Transplantation*; M.N. Bartels, R.E. Gerardo. Columbia University, New York, NY.

3:45 PM (167) *Pregnancy and Delivery after Heart Transplantation. A Single Center Experience*; F. Macera, G. Foti, G. Masciocco, M. Frigerio, G. Pedrazzini. Niguarda-Ca' Granda Hospital, Milan, Italy.

2:30 PM – 4:00 PM

CONCURRENT SESSION 18:

Tissue Gene Regulation and Protection From Injury (Marquette)

CHAIRS: STEPHAN M. ENSMINGER, MD, PHD AND MICHAEL P. FISCHBEIN, MD

2:30 PM (168) *A Novel Model for the Focused Study of Functional and Genomic Recovery from Decompensated Heart Failure*; N.M. Andersen,¹ R. Tang,¹ W.E. Stansfield,¹ M. Rojas,¹ C.H. Selzman.² ¹University of North Carolina, Chapel Hill, NC; ²University of Utah, Salt Lake City, UT.

2:45 PM (169) *Connective Tissue Growth Factor Gene Expression in the Failing Human Heart*; N. Patel,¹ T. Kim,³ A. McElligott,³ K.K. Henderson,³ B. Pavlovic-Surjanec,² A.L. Heroux,² A.M. Samarel.³ ¹Loyola University Medical Center, Maywood, IL; ²Loyola University Medical Center, Maywood, IL; ³Loyola University Chicago, Maywood, IL.

3:00 PM (170) *Hypoxia Inducible Factor-1 Preconditioning Protects Transplanted Hearts Against Ischemia-Reperfusion Injury through Effects on Remote Tissues*; M.A.I. Keranen,¹ R. Tuuminen,¹ R. Krebs,¹ L.A. Flippen,² M. Arend,² A.I. Nykanen,¹ K.B. Lemstrom.^{1,3} ¹University of Helsinki, Helsinki, Finland; ²FibroGen Inc., San Francisco, CA; ³Helsinki University Central Hospital, Helsinki, Finland.

3:15 PM (171) *Nebulized Nitrite Protects Rat Lung Grafts from Ischemia/Reperfusion Injury*; T. Okamoto,¹ X. Tang,¹ S.C. Erzurum,¹ C. Farver,³ M.T. Gladwin,⁴ K.R. McCurry.^{1,2} ¹Lerner Research Institute Cleveland Clinic, Cleveland, OH; ²Cleveland Clinic, Cleveland, OH; ³Cleveland Clinic, Cleveland, OH; ⁴University of Pittsburgh, Pittsburgh, PA.

3:30 PM (172) *CCSP+ Progenitor Cells Respond to Lung Injury and Transplantation*; S.E. Gilpin, M. Cypel, N. Kherani, S. Keshavjee, T.K. Waddell. University Health Network, Toronto, ON, Canada.

3:45 PM (173) *Carbon Monoxide (CO) Prolongs Survival of Pulmonary Allografts in MHC-Inbred CLAWN Miniature Swine*; H. Sahara, K. Setoyama, H. Nishimura, W. Oriyhanan, A. Shimizu, K. Yamada. Frontier Science Research Center, Kagoshima University, Kagoshima, Japan.

4:00 PM – 4:30 PM

Coffee Break (Southeast Exhibit Hall)

4:30 PM – 6:00 PM

CONCURRENT SESSION 19:

Clinical Heart Transplantation and Immunology (International Ballroom)

CHAIRS: ADRIAN B. VAN BAKEL, MD, PHD AND MAURO RINALDI, MD

4:30 PM (174) *The Use of Gene Expression Profiling Post Heart Transplant in the Real World: The Mid America Experience*; A. Kao,¹ K. St Clair,¹ S.L. Lawhorn,¹ A. Magalski,¹ T.L. Stevens,¹ A.M. Borkon.² ¹Mid America Heart Institute, Kansas City, MO; ²Mid America Heart Institute, Kansas City, MO.

4:45 PM (175) *Highly Sensitized LVAD Patients Can Be Safely Transplanted with Non-Crossmatched Hearts Using Plasmapheresis and Alemtuzumab: A Contemporaneous Case-Control Series*; S.D. Lick, K.K. Kislingsbury, A.C. Kollar, N.A. Barbagelata, M.M. Koerner, V.G. Valentine. University of Texas, Medical Branch, Galveston, TX.

5:00 PM (176) Accommodation after Heart Transplantation: Does It Exist?; M. Kittleson,² J. Patel,² E. Reed,¹ D. Gjertson,¹ M. Kawano,² S. Davis,² C. Burch,¹ A. Velleca,² E. Stimpson,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

5:15 PM (177) Normalization of Heart Failure Genomic Markers after Transplantation; Z. Hollander,¹ D. Lin,¹ R. Ng,² J. Wilson-McManus,² A. Ignaszewski,³ R. Balshaw,⁴ R. McMaster,⁵ P. Keown,³ B. McManus.¹ ¹The University of British Columbia, Vancouver, BC, Canada; ²PROOF Centre of Excellence, Vancouver, BC, Canada; ³The University of British Columbia, Vancouver, BC, Canada; ⁴The University of British Columbia, Vancouver, BC, Canada; ⁵The University of British Columbia, Vancouver, BC, Canada.

5:30 PM (178) Frequency of Gene Expression Profiling Use in Lieu of Endomyocardial Biopsy Post Heart Transplant Increases with Familiarity: The Mid America Experience; A. Kao,¹ K. St Clair,¹ S.L. Lawhorn,¹ A. Magalski,¹ T.L. Stevens,¹ A.M. Borkon.² ¹Mid America Heart Institute, Kansas City, MO; ²Mid America Heart Institute, Kansas City, MO.

5:45 PM (179) Interplay between Graft-Function and Intravascular Deposition of C4d in Heart Transplant Recipients; F. Fabbri,¹ T. Ionico,¹ L. Potena,¹ P. Prestinenzi,¹ G. Magnani,¹ M. Masetti,¹ O. Leone,² F. Fallani,¹ F. Cocco, ¹F. Grigioni,¹ A. Branzi.¹ ¹Cardiovascular Department, University of Bologna, Bologna, Italy; ²Pathology Department, University of Bologna, Bologna, Italy.

4:30 PM – 6:00 PM

CONCURRENT SESSION 20:

Getting Back to the Basics: MCSD and the Myocyte
(Continental A/B)

CHAIRS: PAUL W. M. FEDAK, MD, PHD, FRCSC AND PASCAL LEPRINCE, MD, PHD

4:30 PM (180) The Time-Course of Unloading-Induced Cardiac Improvement in Patients with Chronic Non-Ischemic Cardiomyopathy Predicts the Outcome after Weaning from Ventricular Assist Devices; M. Dandel, Y. Weng, H. Siniawski, T. Krabatsch, H.B. Lehmkühl, E. Potapov, C. Knosalla, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

4:45 PM (181) Plasma Galectin 3 Is Increased in Terminal Heart Failure Patients and Is Elevated in Patients Not Surviving Mechanical Circulatory Support; G. Erkiilet,¹ S. Schulte-Eistrup,² M. Morshuis,² B. Bohms,¹ D. Roefe,² J. Gummert,² H. Milting.¹ ¹Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; ²Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany.

5:00 PM (182) Regulation of Collagen and Prolyl-4-Hydroxylase during Ventricular Assist Device (VAD) Support: Collagen Regulation during VAD-Support Depends on the Degree of Remodeling at the Time of VAD-Implantation; A. Gaertner,¹ A. Kassner,¹ S. Schulte-Eistrup,² M. Morshuis,² A. El-Banayosy,³ J. Gummert,² H. Milting,¹ ¹Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; ²Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; ³Penn State Milton S. Hershey Medical Center, Hershey, PA.

5:15 PM (183) The Role of Cathepsin K in Extra Cellular Matrix Remodeling in Patients with End Stage Heart Failure; P. van der Weide,¹ A.H. Bruggink,¹ D.F. van Wichen,¹ J. van Kuik,¹ N. de Jonge,² J.R. Lahpor,² M.E.I. Schipper,¹ R.A. de Weger.¹ ¹University Medical Center, Utrecht, Netherlands; ²University Medical Center, Utrecht, Netherlands.

5:30 PM (184) Myocardial Recovery Is Associated with Low Levels of Circulating MMP8 at LVAD Implantation; J. Beale,¹ R.S. George,^{1,2} J. Smith,¹ A. Khaghani,² M.H. Yacoub,¹ E.J. Birks,^{1,2} P. Barton.¹ ¹Imperial College, Harefield, Middlesex, United Kingdom; ²Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom.

5:45 PM (185) Myocardial Recovery from Advanced Heart Failure Using the Heartmate II LVAD Combined with Drug Therapy: Results from a Prospective Study; E.J. Birks,^{1,2} R.S. George,^{1,2} M. Hedger,¹ A. Firouzi,¹ T. Bahrami,¹ M. Amrani,¹ M.H. Yacoub,² G. Dreyfus,¹ A. Khaghani.¹ ¹Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; ²Imperial College, Harefield, Middlesex, United Kingdom.

4:30 PM – 6:00 PM

CONCURRENT SESSION 21:

From Bench to Bedside Update in Transplant Infections
(Boulevard)

CHAIRS: MARGARET M. HANNAN, MD AND MARTHA L. MOONEY, MD

4:30 PM (186) CD8+ pp65-Specific T Cell Responses and T-Bet Levels Predict Relapsing Viremia Following Primary CMV Infection in Lung Transplant Recipients; M.R. Pipeling, E.R. John, N. Lechtzin, J.F. McDyer. Johns Hopkins University School of Medicine, Baltimore, MD.

4:45 PM (187) CMV Reactivation within the Lung Allograft Is Associated with Bronchiolitis Obliterans Syndrome Following Lung Transplantation; M.A. Paraskeva,¹ B. Levvey,¹ A. Griffiths,¹ M. Bailey,² T.C. Kotsimbo,¹ G.I. Snell,¹ G.P. Westall.¹ ¹Alfred Hospital, Melbourne, Vic, Australia; ²School Public Health & Preventive Medicine, Monash University Alfred, Melbourne, Vic, Australia.

5:00 PM (188) Development of Cytomegalovirus (CMV) Infection during Ongoing Valganciclovir Therapy; J. Patel,² M. Kittleson,² B. Kubak,¹ M. Kawano,² S. Davis,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.²
¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

5:15 PM (189) Subtherapeutic Ganciclovir Levels Result in Resistant CMV in Lung Transplantation Patients; J.P. Gagermeier,¹ C.G. Alex,¹ D.F. Dilling,¹ J. Rusinak,¹ P. O' Keefe,¹ N.S. Lurain,³ C.H. Wigfield,² R.B. Love.²
¹Loyola University Medical Center, Maywood, IL; ²Loyola University Medical Center, Maywood, IL; ³Rush University, Chicago, IL.

5:30 PM (190) RSV and Human Metapneumovirus Are Not Associated with Obliterative Bronchiolitis or Inferior Survival Post Lung Transplantation; P.M.A. Hopkins, F.D. Kermeen, H. Seale, T.M. Leisfield, S.T. Yerkovich, D.C. Chambers. The Prince Charles Hospital, Brisbane, QLD, Australia.

5:45 PM (191) Importance of VAD Insertion Site Colonisation; D. Wearmouth,¹ L. Reed,¹ G. MacGowan,² T. Pillay,² S. Schueler,² N. Wrightson,² K. Gould.¹ ¹Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Freeman, Newcastle upon Tyne, United Kingdom.

4:30 PM – 6:00 PM

CONCURRENT SESSION 22:

Immunosuppression After Lung Transplantation: From Mouse to Man (Continental C)

CHAIRS: CYNTHIA J. GRIES, MD, MSC AND CLEMENS AIGNER, MD

4:30 PM (192) Mechanisms behind Local Immunosuppression Using Inhaled Tacrolimus in Preclinical Models of Lung Transplantation; T. Deuse,^{1,2} R. Sista,³ D. Weill,³ H. Reichenspurner,¹ R.C. Robbins,² S. Schrepfer.^{1,2}
¹University Heart Center Hamburg, Hamburg, Germany; ²Stanford University School of Medicine; ³Stanford University School of Medicine, Stanford, CA.

4:45 PM (193) Lung Deposition of a Liposomal Cyclosporine A Inhalation Solution in Patients after Lung Transplantation; J. Behr,¹ G. Zimmermann,¹ R. Baumgartner,¹ H. Leuchte,¹ C. Neurohr,¹ P. Brand,³ C. Herpich,³ K. Sommerer,² J. Seitz,² M. Keller.² ¹Ludwig-Maximilians-University, Munich, Germany; ²Pari-Pharma GmbH, Munich, Germany; ³Inamed Research GmbH, Gauting, Germany.

5:00 PM (194) Inhaled Cyclosporine Is Well Tolerated in the CYCLIST Clinical Trial; B.A. Johnson,¹ M. Rolfe,² C. Johnson,³ W. Verret,³ T. Breen,³ J. Golden.⁴ ¹University of Pittsburgh, Pittsburgh, PA; ²Tampa General Hospital, Tampa, FL; ³APT Pharmaceuticals, Burlingame, CA; ⁴University of California San Francisco, San Francisco, CA.

5:15 PM (195) Omental Stromal Cells (OSC) Abrogate Acute Lung Injury Associated with Allogenic Transplant in Absence of Immunosuppression; R.K. Braun,¹ A.A. Martin,¹ P. Sethupathi,¹ M.G. Medina,¹ W. Jungraithmayr,² C.H. Wigfield,¹ M. Iwishima,³ R.B. Love.¹
¹Loyola University Medical Center, Maywood, IL; ²University Hospital Zurich, Zurich, Switzerland; ³Loyola University Medical Center, Maywood, IL.

5:30 PM (196) Identifying the Potassium Channel KCa3.1 as a New Therapeutic Target To Prevent Chronic Airway Allograft Rejection; X. Hua,¹ D. Meyberg,¹ T. Deuse,^{1,2} H. Wulff,³ R. Kohler,⁴ H. Reichenspurner,¹ S. Schrepfer.^{1,2} ¹University Heart Center Hamburg, Hamburg, Germany; ²Stanford University School of Medicine, Stanford, CA; ³University of California, Davis, Davis; ⁴Centrum for Internal Medicine, Marburg, Germany.

5:45 PM (197) Side Effects in a Calcineurin Inhibitor-Everolimus Based Immunosuppressive Regime in Lung Transplanted Recipients; B. Zweytick, B. Ghanim, J. Sillip, M. Winter, P. Jaksch, W. Klepetko. Medical University of Vienna, Vienna, Austria.

4:30 PM – 6:00 PM

CONCURRENT SESSION 23:

Pediatric Transplantation in Unique Patient Populations (Waldorf)

CHAIRS: STUART C. SWEET, MD, PHD AND MATTHEW J. FENTON, MRCPCH

4:30 PM (198) White, Black and Hispanic Children Have Benefited Equally from Improvement in Early Post-Transplant Survival in Pediatric Heart Transplantation; T.P. Singh, C.S. Almond, K. Gauvreau. Children's Hospital Boston, Boston, MA.

4:45 PM (199) Use of Induction Agents and Incidence of Infection and Malignancy Following Pediatric Heart Transplantation; R.J. Gajarski,¹ E.D. Blume,³ K. Schechtman,⁶ J. Zheng,⁶ L.J. West,⁵ S. Urschel,⁵ S. Miyamoto,⁴ L. Altamirano,⁵ D. Nafel,⁷ J.K. Kirklind,⁷ M.C. Zamberlan,¹ C. Canter.² ¹C.S. Mott Children's Hospital, University of Michigan Health System, Ann Arbor, MI; ²St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, MO; ³Boston Children's Hospital, Harvard Medical School, Boston, MA; ⁴Denver Children's Hospital, University of Colorado Health System, Aurora, CO; ⁵Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada; ⁶Washington University School of Medicine, St. Louis, MO; ⁷University of Alabama, Birmingham, AL.

5:00 PM (200) Center-Specific Outcomes for Pediatric Heart Transplantation: Do Past Outcomes Predict Future Performance?; W.T. Mahle, K.R. Kanter, R.N. Vincent. Children's Healthcare of Atlanta, Atlanta, GA.

5:15 PM (201) Lung Transplantation in Children after Hematopoietic Stem-Cell Transplantation; S. Yousef,¹ C. Benden,³ T. Frischer,⁸ G. Westall,¹ S. Goldfarb,⁴ M. Ballman,³ P. Aurora,⁶ G. Doherty,⁶ D. Boyer,⁷ G. Visner,⁷ M. Woo,¹² M.G. Michaels,⁹ S.C. Sweet,¹⁰ M.G. Schecter,² G.B. Mallory,² O. Elidemir.² ¹University of Miami, Miami, FL; ²Baylor College of Medicine, Houston, TX; ³University Hospital Zurich, Zurich, Switzerland; ⁴Children's Hospital of Philadelphia, Philadelphia, PA; ⁵Hannover Medical School, Hannover, Germany; ⁶Great Ormond Street Hospital, London, United Kingdom; ⁷Harvard University, Boston, MA; ⁸University of Vienna, Vienna, Austria; ⁹Children's Hospital of Pittsburgh, Pittsburgh, PA; ¹⁰Washington University, St. Louis, MO; ¹¹Alfred Hospital and Monash University, Melbourne, Vic, Australia.

5:30 PM (202) Outcomes of Heart Transplantation for Patients with Systemic Muscular Disorders; N. Cain,¹ J. Teuteberg,² B. Feingold,¹ S. Miller,¹ E. Quivers,¹ V. Morell,¹ P. Wearden,¹ R. Kormos,² Y. Toyoda,² D. McNamara,² C. Chrysostomou,¹ V. Gerard,¹ S. Webber.¹ ¹Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ²UPMC Presbyterian, Pittsburgh, PA.

5:45 PM (203) Comparison of Risk Factors and Outcomes for Pediatric Patients Listed for Heart Transplantation after Bidirectional Glenn and after Fontan: A Multi-Institutional Study; J.R. Kovach,¹ E.D. Blume,⁶ D.C. Naftel,² F.B. Pearce,³ M.T. Foushee,² E.R. Edens,⁴ J.H. Shuhaiber,⁵ F. Fynn-Thompson,⁶ J.K. Kirklin,² S.D. Zangwill.¹ ¹Medical College of Wisconsin, Milwaukee, WI; ²University of Alabama at Birmingham, Birmingham, AL; ³University of Alabama at Birmingham, Birmingham, AL; ⁴University of Iowa Children's Hospital, Iowa City, IA; ⁵Cincinnati Children's Hospital, Cincinnati, OH; ⁶Children's Hospital Boston, Boston, MA.

4:30 PM – 6:00 PM

CONCURRENT SESSION 24:

Heart Failure: Prognostication and Outcomes (Marquette)

CHAIRS: TUVIA BEN GAL, MD AND DONNA M. MANCINI, MD

4:30 PM (204) Does Access to Device Therapies Affect Transplant Outcomes for Adults with Congenital Heart Disease? Analysis of the United Network for Organ Sharing (UNOS) Database; M.D. Everitt,^{1,2} A.T. Yetman,^{1,2} A.E. Donaldson,² J. Stehlik,² A.K. Kaza,^{1,2} D. Budge,³ R. Alharethi,³ E.A. Bullock,¹ M. Cardon,¹ L.T. Tani,^{1,2} A.G. Kfoury.³ ¹Primary Children's Medical Center, Salt Lake City, UT; ²University of Utah, Salt Lake City, UT; ³Intermountain Medical Center, Salt Lake City, UT.

4:45 PM (205) Cardiac Resynchronization Therapy (CRT) Induced Cellular Reverse Cardiac Remodeling Similar to Left Ventricular Assist Devices; C.M. Orrego, J. Florez, K. Youker, G. Torre-Amione. The Methodist Hospital, Houston, TX.

5:00 PM (206) Sildenafil Is More Selective Pulmonary Vasodilator than PGE1 in Patients with Severe Pulmonary Hypertension Secondary to Heart Failure; H. Al-Hiti, V. Melenovskiy, J. Kettner, J. Kautzner. IKEM, Prague, Czech Republic.

5:15 PM (207) Electrocardiogram QRS Duration Predicts Recovery of Left Ventricular Ejection Fraction after Renal Transplant; P.S.D. Yeo,¹ R. Fatica,² W.W.H. Tang.¹ ¹Cleveland Clinic, Cleveland, OH; ²Cleveland Clinic, Cleveland, OH.

5:30 PM (208) Gamma-Glutamyltransferase (GGT) Rather than Bilirubin Is of Prognostic Significance in Chronic Heart Failure; M. Ess,¹ C. Mussner-Seeber,¹ H. Ulmer,² M. Frick,¹ G. Poelzl.¹ ¹University Hospital, Innsbruck, Austria; ²Innsbruck Medical University, Innsbruck, Austria.

5:45 PM (209) Hemodynamic and Echocardiographic Correlations of Peak VO₂; M. Guglin, F. Matar, H. Khan. University of South Florida, Tampa, FL.

6:00 PM – 7:00 PM

PULMONARY TRANSPLANTATION COUNCIL QUALITY OF LIFE WORKFORCE MEETING (Joliet)

JUNIOR FACULTY AND TRAINEE COUNCIL MEETING (PDR-2)

6:00 PM – 7:00 PM

MINI ORAL SESSION 6 (Boulevard)

CHAIRS: ANGELIKA COSTARD-JAECKLE, MD AND SEAN P. PINNEY, MD

6:00 PM (210) Review of 12,703 Endomyocardial Biopsies: The Truth of Quilty Lesions in the Cyclosporine and Tacrolimus Era; M. Kawano,² M. Kittleston,² M. Fishbein,¹ C. Lai,¹ J. Patel,² S. Davis,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

6:05 PM (211) The Importance of Anti-HLA DQ Antibodies as a Risk Factor for the Development of Transplant Coronary Artery Disease (TCAD) after Heart Transplantation; J. Patel,² M. Kittleston,² E. Reed,¹ G. Aguas,¹ M. Kawano,² S. Davis,² C. Burch,¹ A. Velleca,² E. Stimpson,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

6:10 PM (212) Heart Transplantation Is Associated with Impaired Peripheral Artery Function and Chronic Endothelial Dysfunction; M.M. Colvin-Adams, N. Harcourt, Y. Sonbol, G. Raveendran, M. Pritzker, D. Duprez. University of Minnesota, Minneapolis, MN.

6:15 PM (213) Cardiac Allograft Vasculopathy after Heart Transplantation: 25-year Single-Center Experience; M. Pozzi, M.L. Aiello, C. Pellegrini, C. Goggi, A.M. D'Armini, M. Viganò. IRCCS Policlinico "S. Matteo" Foundation – University of Pavia, Pavia, Italy.

6:20 PM (214) Analysis of Impact of Post Transplant Neoplastic Disease on Long-Term Follow up Following Heart Transplant; P. Totaro,¹ M. Savasta,¹ S. Nicolardi,¹ N. Ippoliti,¹ C. Pellegrini,¹ C. Goggi,¹ A.M. D'Armini,² M. Viganò.² IRCCS Foundation S. Matteo, Pavia, Italy; ²University School of Medicine, Pavia, Italy.

6:25 PM (215) Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) Level Correlates with Kidney Dysfunction in Heart Allograft Recipients; P. Przybyłowski,¹ J.M. Malyszko,² J. Malyszko.² Collegium Medicum, Jagiellonian University, Krakow, Poland; ²Medical University Białystok, Białystok, Poland.

6:30 PM (216) Extra-Corporeal Membrane Oxygenation for Primary Graft Failure after Cardiac Transplantation. Six-Year Single Center Experience; C. D'Alessandro,¹ J.L. Golmard,³ S. Aubert,¹ A. Julien,² E. Barreda,¹ P. Leprince,¹ G. Iradj,¹ P. Alain.¹ ¹La Pitie Hospital, Paris, France; ²La Pitie Hospital, Paris, France; ³La Pitie Hospital, Paris, France.

6:35 PM (217) A High-Intensity Exercise Program Improves Peak VO₂ and Reduces Markers of Systemic Inflammation in Cardiac Transplant Recipients: A Randomized Study; C.H. Dall,¹ S.B. Christensen,¹ T. Hermann,¹ E. Prescott,² F. Gustafsson.¹ ¹Rigshospitalet, Copenhagen, Denmark; ²Bispebjerg Hospital, Copenhagen, Denmark.

6:40 PM (218) The Use of Neurohormonal Antagonists Is Not Associated with Vasoplegia in Post-Orthotopic Heart Transplant Patients; M.M. Patarroyo,¹ C.A. Simbaqueba,² R. Wong,³ D.O. Taylor,³ W.H.W. Tang,³ K. Shrestha.³ ¹Cleveland Clinic Foundation, Cleveland, OH; ²Cleveland Clinic Foundation, Cleveland, OH; ³Cleveland Clinic Foundation, Cleveland, OH.

6:45 PM (219) Conversion to Everolimus in Heart Transplant Patients with Calcineurin Inhibitor (CNI)-Associated Myopathy; S. Meyer,¹ M. Adam,¹ A. v. Stritzky,¹ F.M. Wagner,² T. Deuse,² H. Reichenspurner,² A. Costard-Jaeckle.¹ ¹University Heart Center, Hamburg, Germany; ²University Heart Center, Hamburg, Germany.

6:50 PM (220) A Web-Based Pilot Study of Inter-Pathologist Reproducibility Using the ISHLT 2004 Classification System for Biopsy Diagnosis of Acute Cardiac Allograft Rejection: The European Experience on Behalf of the Transplant Working Group of the Association for European Cardiovascular Pathology; A. Angelini,¹ C. Andersen,² G. Bartoloni,³ F. Black,⁴ P. Bishop,⁵ H. Doran,⁶ M. Fedrigo,⁷ J. Fries,⁸ M. Goddard,⁹ H. Goebel,¹⁰ D. Neil,¹¹ O. Leone,¹² A. Marzullo,¹³ M. Ortmann,¹⁴ F. Paraf,¹⁵ S. Rotman,¹⁶ N. Turhan,¹⁷ A.C. Frigo,¹⁸ F. Grigoletto,¹⁹ A. Gasparetto,²⁰ R. Mencarelli,²¹

G. Thiene,²² M. Burke.²³ ¹Pathological Anatomy-Cardiovascular Pathology, Padua, Italy; ²Frederik V's vej 11, Copenhagen, Denmark; ³Settorato Int. 'via Palermo, 47, P.O. Garibaldi Nesima, Catania, Italy; ⁴Freeman Cardiothoracic Centre, Newcastle upon Tyne NHS Hospitals Trust, Royal Victoria Infirmary, Queen Victoria Road, Newcastle, United Kingdom; ⁵Wythenshawe Hospital, UHSM, Southmoor Road, Manchester, United Kingdom; ⁶Wythenshawe Hospital, Manchester, United Kingdom; ⁷Pathological Anatomy-Cardiovascular Pathology, Padua, Italy; ⁸Kerpener Strasse 62, Cologne, Germany; ⁹Papworth Everard, Cambridge, United Kingdom; ¹⁰Kerpener Strasse 62, Cologne, Germany; ¹¹University Hospital Birmingham, Medical School, Edgbaston, Birmingham, United Kingdom; ¹²S.Orsola-Malpighi Hospital, Bologna, Italy; ¹³University of Bari, Policlinico p.za G. Cesare 11, Bari, Italy; ¹⁴Kerpener Strasse 62, Cologne, Germany; ¹⁵Centre Hosp Univ Dupuytren, Limoges, France; ¹⁶Insitut Universitaire de Pathologie de Lausanne, Lausanne, Switzerland; ¹⁷Yüksek İhtisas Hospital, Ankara, Turkey; ¹⁸University of Padua, Padua, Italy; ¹⁹University of Padua, Padua, Italy; ²⁰Azienda ULSS 18, Rovigo, Italy; ²¹Azienda ULSS 18, Rovigo, Italy; ²²Pathological Anatomy-Cardiovascular Pathology, Padua, Italy; ²³Harefield, Middx, Harefield, United Kingdom.

6:55 PM (221) Patterns and Predictors of Stress and Coping from 5 to 10 Years after Heart Transplantation; K.L. Grady,¹ E. Wang,² C. White-Williams,⁹ D. Naftel,⁸ S. Myers,⁸ J.K. Kirklin,⁸ J.B. Young,³ D. Pelegrin,³ J. Czerny,³ J. Kobashigawa,⁴ J. Chait,⁴ B. Rybarczyk,⁵ A. Heroux,⁶ R. Higgins.⁷ ¹Northwestern Memorial Hospital, Chicago, IL; ²Northwestern Memorial Hospital, Chicago, IL; ³The Cleveland Clinic, Cleveland, OH; ⁴David Geffen School of Medicine at UCLA/Cedars-Sinai Heart Institute, Los Angeles, CA; ⁵Virginia Commonwealth University, Richmond, VA; ⁶Loyola University Medical Center, Maywood, IL; ⁷Rush University Medical Center, Chicago, IL; ⁸University of Alabama at Birmingham, Birmingham, AL; ⁹University of Alabama at Birmingham, Birmingham, AL.

6:00 PM – 7:00 PM

MINI ORAL SESSION 7 (Continental C)

CHAIRS: MICHEL E. ERASMUS, MD, PHD AND HENDRIK TREEDE, MD

6:00 PM (222) Underutilized Donor Pool for Lung Transplantation: Drowning Victims; F. Zafar,¹ J.S. Heine,¹ G.B. Mallory,² M.G. Schecter,² O. Elidemir,² D.L.S. Morales.¹ ¹Baylor College of Medicine, Houston, TX; ²Baylor College of Medicine, Houston, TX.

6:05 PM (223) Cadaveric Lobar Lung Transplantation Is a Viable Option To Cut Donor Waiting Time in Small Cystic Fibrosis Patients; D.E.M. Van Raemdonck,¹ G.M. Verleden,² L. Dupont,² W. Coosemans,¹ H. De-

caluwe,¹ G. Decker,¹ P. De Leyn,¹ P. Naftoux,¹ T. Lerut.¹
¹University Hospitals Leuven, Leuven, Belgium;
²University Hospitals Leuven, Leuven, Belgium.

- 6:10 PM (224) Should We Perform Single Lung Transplantation When the Contra-Lateral Donor Lung Is Injured?;** M. Cypel, T.K. Waddell, M. de Perrot, J.C. Yeung, F. Chen, W. Karolak, M. Hutcheon, C. Chaparro, C.-W. Chow, K. Yasufuku, A. Pierre, L.G. Singer, S. Keshavjee. University of Toronto, Toronto, ON, Canada.
- 6:15 PM (225) Survival and Status Transition of Patients Initially Listed UNOS Status 2: The Effect of Physician Decisions;** T.F. Dardas,¹ K.D. Aaronson,¹ F.D. Pagani.² ¹Department of Internal Medicine, Division of Cardiology, Ann Arbor, MI; ²University of Michigan Health System, Ann Arbor, MI.
- 6:20 PM (226) A Decision Analysis Comparing the Societal Impact of Bilateral Versus Single Lung Transplantation for Chronic Obstructive Pulmonary Disease;** J.C. Munson, J.D. Christie, R.M. Kotloff, S.D. Halpern. University of Pennsylvania, Philadelphia, PA.
- 6:25 PM (227) Novel Observations of Differences in Lung Inflammatory Gene Expression Profiles between Donation after Cardiac Death vs. Donation after Brain Death: Inflammation-Specific Microarray Study;** C.-H. Kang,^{1,2} M. Anraku,¹ M. Cypel,¹ J.C. Yeung,¹ A.F. Pierre,¹ M. de Perrot,¹ T.K. Waddell,¹ M. Liu,¹ S. Keshavjee.¹ ¹Toronto General Hospital, University of Toronto, Toronto, ON, Canada; ²Seoul National University Hospital, Seoul National University, Seoul, Korea.
- 6:30 PM (228) Closed or Open Circuit during Ex-Vivo Lung Perfusion for Reconditioning of Damaged Donor-Lungs – Which Shall We Use?;** S. Wipper, Y. Rittberg, J. Lindner, E. Joubert-Hubner, J. Schirmer, H. Reichenspurner, F.M. Wagner. University Heart Center Hamburg, Hamburg, Germany.
- 6:35 PM (229) Activated Omental Stromal Cells Ameliorate Bleomycin Induced Acute Lung Injury;** A.A. Martin,¹ B.K. Braun,¹ M.G. Medina,¹ S. Shah,² P. Sethupathi,¹ C. Wigfield,¹ R.B. Love.¹ ¹Loyola University Medical Center, Maywood, IL; ²Loyola University Medical Center, Maywood, IL.
- 6:40 PM (230) Size Reduced Lung Transplantation –9 Years of Experience by a Single Centre;** M.A. Hoda, B.D. Ghanim, M. Winter, P. Jaksch, A. Scheed, C. Aigner, S. Taghavi, G. Lang, K. Walter. Medical University Vienna, Vienna, Austria.
- 6:45 PM (231) High Incidence of Acute Rejection in Lung Transplant Recipients with Cystic Fibrosis and Bronchiectasies;** F. Calabrese, F. Lunardi, E. Bazzan, M. Loy, G. Marulli, U. Fantoni, E. Balestro, F. Calabrese, F. Rea. University of Padua, Padua, Italy.

6:50 PM (232) Postoperative Dialysis Is a Highly Fatal Complication after Lung Transplantation; S.A. Hennessy, T. Hranjec, B.D. Kozower, D.R. Jones, C.L. Lau. University of Virginia, Charlottesville, VA.

6:00 PM – 7:00 PM

MINI ORAL SESSION 8 (Waldorf)

CHAIRS: ROBERT P. FRANTZ, MD AND
TOBIAS DEUSE, MD, PHD

- 6:00 PM (233) Impact-DCM: A Randomized, Controlled, Multi-Center Phase II Trial Utilizing Expanded Autologous Bone Marrow As Sole Therapy for Dilated Cardiomyopathy;** B.A. Bruckner,¹ D. Bull,⁴ B. Hammond,³ G. Ali,¹ B. Elmar,² L. Matthias,¹ R.J. Michael,¹ L. Perryman,¹ N. Smedira,⁵ O. Lattouf,⁶ R.R. Bunge,¹ A. Patel.⁴ ¹The Methodist Hospital DeBakey Heart and Vascular Center, Houston, TX; ²Aastrom Biosciences, Inc., Ann Arbor, MI; ³Baylor University Medical Center, Dallas, Tx; ⁴The University of Utah School of Medicine, Salt Lake City, UT; ⁵Cleveland Clinic Heart and Vascular Institute, Cleveland, OH; ⁶Emory University Hospital Midtown, Atlanta, GA.
- 6:05 PM (234) WITHDRAWN**
- 6:10 PM (235) Strategies for Cardiac Xenotransplantation Provide Technologies for Improved Calcium Resistant Bioprosthetic Heart Valves;** C.G.A. McGregor,^{1,2} N. Lila,³ M. Vlasin,¹ B.S. Wiseman,¹ J.S. Logan,¹ G.W. Byrne.^{1,2} ¹Mayo Clinic, Rochester, MN; ²University College London, London, United Kingdom; ³University of Paris, Paris, France.
- 6:15 PM (236) Immunosuppressive Agents Differently Suppress T Cell Subpopulations;** X. Hua,¹ T. Deuse,^{1,2} H. Reichenspurner,¹ R.C. Robbins,² S. Schrepfer.^{1,2} ¹University Heart Center Hamburg, Hamburg, Germany; ²Stanford University School of Medicine, Stanford, CA.
- 6:20 PM (237) HGF or VEGF Gene Transfer Maximizes Mesenchymal Stem Cell-Based Myocardial Salvage after Acute Myocardial Infarction;** T. Deuse,^{1,2} P. Fedak,³ R.C. Robbins,² H. Reichenspurner,¹ S. Schrepfer.^{1,2} ¹University Heart Center Hamburg, Hamburg, Germany; ²Stanford University School of Medicine, Stanford, CA; ³University Calgary, Calgary, Canada.
- 6:25 PM (238) Imaging of Transplanted Bone Marrow Derived Stem Cells for Therapy of Ischemic Cardiomyopathy;** B. Bruckner,¹ A. Ghodsizad,² C. Piechaczek,² A. Ruhparwar,² M. Karck,² M. Loebe,¹ G. Noon,¹ M. Reardon,¹ R. Basel,¹ W. Jones,¹ L. Morales,¹ M. Donovan,¹ R. Bunge,¹ L. Perryman.¹ ¹The Methodist Hospital DeBakey Heart and Vascular Center, Houston, TX; ²University of Heidelberg, Heidelberg, Germany.
- 6:30 PM (239) CD14 and CD36 Restrain Inducible T reg Generation and Prevent Costimulatory Blockade Ex-**

tion of Allograft Survival; H. Shen, D. Goldstein. Yale University School of Medicine, New Haven, CT.

- 6:35 PM (240) Everolimus (ERL) Drug-Drug Interaction (DDI) Management with Azole Antifungals (AF) in Lung Transplant Patients**; R. Guillemain,¹ M. Berge,² L. Sandrine,² C. Amrein,¹ V. Boussaud,¹ E.M. Billaud.²
¹APHP, Hôpital Eur G Pompidou, Paris, France; ²APHP, Hôpital Eur G Pompidou, Université Paris Descartes, Paris, France.
- 6:40 PM (241) Risk Factors for Nontuberculous Mycobacterial (NTM) Infections in Heart and Lung Transplant Recipients**; S.A. Longworth,¹ C. Vinnard,¹ I. Lee,¹ T. Barton,¹ K. Sims,¹ M. Synnestevedt,² E. Blumberg.¹
¹Hospital of the University of Pennsylvania, Philadelphia, PA; ²University of Pennsylvania School of Medicine, Philadelphia, PA.
- 6:45 PM (242) Pre-B-Cell Colony Enhancing Factor (PBEF) Is a Novel target in Hypoxia-Induced Murine Pulmonary Hypertension**; R.F. Machado,¹ L. Moreno-Vinasco,¹ R. Zaidi,¹ S. Sammani,¹ J.G.N. Garcia.¹
¹University of Chicago, Chicago, IL; ², Chicago, IL.
- 6:50 PM (243) Impact of Mechanical Unloading on Myocardial Endothelium and Microvasculature**; S. Drakos,^{1,2,3,4} E. Hammond,^{2,3} S. Clayson,^{1,3} M.P. Revelo,^{2,3} S. Stoker,^{1,3} A. McCormick,^{1,3} H. Smith,^{1,3} C. Selzman,^{2,3} D.R. Verma,^{1,2,3} D. Budge,^{1,3} J. Stehlik,^{2,3} D. Li,² A. Kfoury.^{1,2,3}
¹Utah Artificial Heart Program, Intermountain Medical Center, Salt Lake City, UT; ²University of Utah, Salt Lake City, UT; ³UTAH Cardiac Transplant Program, Salt Lake City, UT; ⁴3rd Cardiology Department, University of Athens, Athens, Greece.
- 6:55 PM (244) Effect of Mechanical Unloading on Fibrosis and Hypertrophy during Cardiac Remodeling in Humans**; S. Drakos,^{1,2,3} E. Hammond,^{2,3} B. Reid,^{1,2,3} S. Stoker,^{1,3} M.P. Revelo,^{2,3} B. Rasmusson,^{1,3} C. Selzman,^{2,3} R. Alharethi,^{1,3} A. McCormick,^{1,2} E. Gilbert,^{2,3} D. Miller,³ D. Li,² A. Kfoury.^{1,2,3}
¹Utah Artificial Heart Program, Salt Lake City, UT; ²University of Utah, Salt Lake City, UT; ³UTAH Cardiac Transplant Program, Salt Lake City, UT.
- 6:00 PM – 7:00 PM**
MINI ORAL SESSION 9 (Marquette)
- CHAIRS: CHRISTIAN BENDEN, MD AND KRISTINE GULESERIAN, MD
- 6:00 PM (245) Allomap Use in Cardiac Transplantation: Single Center Experience**; I. Dumitru,¹ S. Radio,² D. Tayama.³
¹UNMC, Omaha, NE; ²UNMC, Omaha, NE; ³XDX, Brisbane, CA.
- 6:05 PM (246) Switch to Sirolimus and Dose Reduced Calcineurin-Inhibitor after Cardiac Transplantation**

Is Safe and Results in Renal Stability over the Ensuing Three Years; S. Khandhar,¹ H. Shah,¹ M. Shullo,² C. Newman,³ M. Rebel,³ C. Yost,³ R. Zomak,³ D. McNamara,¹ R. Kormos,³ Y. Toyoda,³ J. Teuteberg.¹
¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²University of Pittsburgh Medical Center, Pittsburgh, PA; ³University of Pittsburgh Medical Center, Pittsburgh, PA.

- 6:10 PM (247) Relationship between Microvascular and Macrovascular Disease in Heart Transplant Recipients**; M.S. Abu-Qaoud,¹ D. Chen,² J. Kerstetter,³ L.N. Stoletniy,² R.G. Pai.²
¹Loma Linda University Medical Center, Loma Linda, CA; ²Loma Linda University Medical Center, Loma Linda, CA; ³Loma Linda University Medical Center, Loma Linda, CA.
- 6:15 PM (248) The Important Role of Immune Responses to Self-Antigens in Pathogenesis of Coronary Artery Vasculopathy Following Human Cardiac Transplantation**; D.S. Nath, H. Ilias Basha, D. Saini, S. Ramachandran, G.A. Ewald, N. Moazami, T. Mohanakumar. Washington University, Saint Louis.
- 6:20 PM (249) A Randomized, Open-Label Study To Compare the Safety and Efficacy of Conversion From a Calcineurin Inhibitor (CNI) to Sirolimus Versus Continued Use of a CNI in Cardiac Transplant Recipients with Mild to Moderate Renal Insufficiency**; A. Zuckerman,¹ A. Keogh,² M.G. Crespo-Leiro,³ D. Mancini,⁴ F. Gonzalez-Vilchez,⁵ L. Almenar,⁶ S. Brozna,⁷ H. Eisen,⁸ S. See Tai,⁹ S. Kushwaha.¹⁰
¹AKH Wien, Vienna, Austria; ²St. Vincent's Hospital, Darlinghurst, NSW, Australia; ³Complejo Hospitalario Universitario A Coruña, Coruña, Spain; ⁴Columbia University Medical Center, New York, NY; ⁵Hospital Marques de Valdecilla, Santander, Cantabria, Spain; ⁶Hospital La Fe, Valencia, Spain; ⁷University of Pennsylvania, Philadelphia, PA; ⁸Drexel University College of Medicine, Philadelphia, PA; ⁹Wyeth Pharmaceuticals, Collegeville, PA; ¹⁰Mayo Clinic Rochester, Rochester, MN.
- 6:25 PM (250) Conversion to Everolimus in Persistent Cytomegalovirus or Herpes simplex Viremia Following Thoracic Organ Transplantation**; S. Meyer,¹ M. Adam,¹ A. v Stritzky,¹ F.M. Wagner,² T. Deuse,² H. Reichenspurner,² A. Costard-Jaeckle.¹
¹University Heart Center, Hamburg, Germany; ²University Heart Center, Hamburg, Germany.
- 6:30 PM (251) Surveillance HLA Antibody Screening Post Cardiac Transplant – A Single Center Pediatric Experience**; S. Zangwill,¹ G. Stendahl,¹ K. Tillman,¹ S. Berger,¹ T. Ellis,² K. Gandy,³ M. Mitchell,³ J. Tweddell.³
¹Medical College of Wisconsin, Milwaukee, WI; ²Blood Center of Wisconsin, Milwaukee, WI; ³Medical College of Wisconsin, Milwaukee, WI.


6:35 PM (252) *The Successful Use of Oral Sildenafil in Right Ventricular Dysfunction and High Pulmonary Vascular Resistance after Pediatric Heart Transplantation;* R.K. Singh,¹ M. Richmond,¹ T.B. Giblin,¹ R. Rodriguez,¹ J.M. Chen,² L.J. Addonizio.¹ ¹Columbia University Medical Center, New York, NY; ²Columbia University Medical Center, New York, NY.

6:40 PM (253) *Black Race Is Not an Independent Risk Factor for Mortality in Pediatric Patients Listed for Heart Transplant: A Single Center Experience;* W.R. Morrow, E.A. Frazier, J.M. Gossett, M. Imamura, X. Garcia, J.C. Bryant, K. Knecht, R.D.B. Jaquiss. Arkansas Childrens Hospital, Little Rock, AR.

6:45 PM (254) *Lung Transplantation for Childhood Interstitial Lung Disease;* M.G. Schechter,¹ J.A. Rama,¹ E.D. McKenzie,² J.S. Heinle,² D.L. Morales,² G.B. Mallory,¹ O. Elidemir.¹ ¹Baylor College of Medicine, Houston, TX; ²Baylor College of Medicine, Houston, TX.

6:50 PM (255) *Rapid Reduction in Donor Specific Antibodies with Bortezomib in Pediatric Heart Transplant Recipients with Positive Crossmatch and Antibody Mediated Rejection;* W.R. Morrow,¹ E.A. Frazier,¹ W.T. Mahle,² H.O. Terry,¹ S.E. Pye,¹ R.L. Saylor,¹ X. Garcia,¹ R.D.B. Jaquiss.¹ ¹Arkansas Children's Hospital, Little Rock, AR; ²Sibley Heart Center, Atlanta, GA.

6:55 PM (256) *Risk Factors for Renal Dysfunction in Pediatric Heart Transplantation: A Multi-Institutional Study;* B. Feingold,¹ J. Zheng,² Y. Law,³ W.R. Morrow,⁴ T.M. Hoffman,⁵ K.B. Schechtman,² C. Canter.⁶ ¹Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ²Washington University, St. Louis, MO; ³Seattle Children's Hospital, Seattle, WA; ⁴Arkansas Children's Hospital, Little Rock, AR; ⁵Nationwide Children's Hospital, Columbus, OH; ⁶Washington University, St. Louis, MO.



Friday, April 23, 2010

7:00 AM – 6:00 PM

Registration Desk Open (8th Street Registration)

7:00 AM – 6:00 PM

Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM

PULMONARY TRANSPLANTATION SCIENTIFIC COUNCIL MEETING (Waldorf)

HEART FAILURE AND TRANSPLANT MEDICINE SCIENTIFIC COUNCIL MEETING (Marquette)

PEDIATRIC TRANSPLANTATION SCIENTIFIC COUNCIL MEETING (Joliet)

NURSING, HEALTH SCIENCE, AND ALLIED HEALTH SCIENTIFIC COUNCIL MEETING (PDR-2)

BASIC SCIENCE SCIENTIFIC COUNCIL MEETING (tentative) (PDR-4)

8:15 AM – 10:15 AM

PLENARY SESSION

(International Ballroom)

CHAIRS: JON KOBASHIGAWA, MD AND
STUART JAMIESON, MD

8:15 AM INVITED LECTURE, *Co-Stimulation Blockade: Lessons of Kidney Transplantation, Implications For Thoracic Transplantation*, Christian P. Larsen, MD, Emory University, Atlanta, GA

8:35 AM (257) FEATURED ABSTRACT *Determinants of Survival in Patients Bridged to Heart Transplantation with Continuous-Flow Versus Pulsatile-Flow Ventricular Assist Devices*; J.N. Nativi,¹ A.Y. Kucheryavaya,² L.B. Edwards,² D. Taylor,³ M.I. Hertz,⁴ J. Stehlik.¹ ¹University of Utah, Salt Lake City, UT; ²United Network for Organ Sharing (UNOS), Richmond, VA; ³Cleveland Clinic Foundation, Cleveland, OH; ⁴University of Minnesota, Minneapolis, MN.

8:45 AM INVITED DISCUSSANT, O. Howard Frazier, MD, Texas Heart Institute, Houston, TX

8:50 AM (258) FEATURED ABSTRACT *Ex Vivo Lung Perfusion in Clinical Lung Transplantation – The “HELP” Trial*; M. Cypel, J.C. Yeung, M. de Perrot, W. Karolak, F. Chen, M. Sato, S. Azad, M. Madonik, M. Hutcheon, C. Chaparro, C.-W. Chow, K. Yasufuku, A. Pierre, L.G. Singer, T.K. Waddell, S. Keshavjee. University of Toronto, Toronto, ON, Canada.

9:00 AM INVITED LECTURE, *Organ Resuscitation of the Heart, Lung, and Liver*, Shaf Keshavjee, MD, Toronto General Hospital, Toronto, Ontario, Canada

9:20 AM (259) FEATURED ABSTRACT *Effect of Donor Associated Characteristics on Primary Graft Dysfunction and Outcome after Cardiac Transplantation*; A.Z. Aliabadi,¹

S.L. Mahr,¹ D. Dunkler,¹ F.A. Eskandary,¹ M. Groemmer,¹ D. Zimpfer,¹ M. Grimm,¹ G. Laufer,¹ A.O. Zuckermann.¹ ¹Medical University of Vienna, Vienna, Austria.

9:30 AM INVITED DISCUSSANT, Bruce Rosengard, MD, Boston, MA

9:35 AM (260) FEATURED ABSTRACT *Changes in the Causes of Heart Transplant Mortality over Two Decades: Successes, Failures and Opportunities*; D.O. Taylor,¹ J.K. Kirklin,² D.C. Naftel,² R.N. Brown,² M.H. Drazner,³ T. Stevens,⁴ J.M. Herre,⁵ J. Stehlik,⁶ D.C. McGiffin.² ¹Cleveland Clinic, Cleveland, OH; ²University of Alabama at Birmingham, Birmingham, AL; ³University of Texas Southwestern Medical Center, Dallas, TX; ⁴Mid-America Heart Institute, Kansas City, MO; ⁵Sentara Cardiovascular Research Institute, Norfolk, VA; ⁶University of Utah, Salt Lake City, UT.

9:45 AM INVITED DISCUSSANT, Sharon A. Hunt, MD, Stanford University, Palo Alto, CA

9:50 AM INVITED LECTURE, *Preventing Heart Graft Rejection and Ischemia Reperfusion Injury Using siRNA*, Weiping Min, MD, PhD, University of Western Ontario, London, Ontario, Canada

9:00 AM – 5:00 PM

Press Office Open (Continental Foyer Office 1)

10:00 AM – 4:30 PM

Exhibit Hall Open (Southeast Exhibit Hall)

Internet Café Open (Southeast Exhibit Hall)

Poster Viewing (Southwest Exhibit Hall)

10:15 AM – 10:45 AM

ANNUAL BUSINESS MEETING (International Ballroom)
ISHLT Members Only

10:15 AM – 10:45 AM

Coffee Break (Southeast Exhibit Hall)

10:45 AM – 12:15 PM

CONCURRENT SESSION 25:

Cost Effectiveness and Long-Term Outcomes
(International Ballroom)

CHAIRS: CARMELO A. MILANO, MD AND
ROBERT E. PADERA, MD, PHD

10:45 AM (261) *The Ventricular Assist Device (VAD) Driveline: What Is the Price of Living with This Technology?*; R.L. Kormos, P. Bonde, C.A. Bermudez, K.L. Lockard, G.A. Elizabeth, J.J. Teuteberg, J.K. Bhamra, M.A. Simon, T. Yoshiya, H. Tetsuya, D.M. McNamara, University of Pittsburgh, Pittsburgh, PA.

11:00 AM (262) *Changing Costs of Mechanical Circulatory Support: Impact of Era and Device*; M.S. Slaughter,¹ R. Bostic,² J.G. Rogers,³ M.J. Russo,⁴ L.W. Miller.⁵

¹University of Louisville, Louisville, KY; ²Thoratec Corporation, CA; ³Duke University Medical Center, Durham, NC; ⁴Columbia University, New York, NY; ⁵Georgetown University, Washington, DC.

11:15 AM (263) Outpatients on Mechanical Circulatory Support: Risk or Chance?; T.N.H. Drews, T. Krabatsch, E. Potapov, A. Stepanenko, M. Hubler, M. Pasic, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

11:30 AM (264) Home Discharge with CardioWest-t Total Artificial Heart – Single Center Experience; A. Stepanenko, E.V. Potapov, T. Drews, H.B. Lehmkühl, Y. Weng, M. Pasic, T. Krabatsch, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

11:45 AM (265) Quality of Life in Patients Supported 2 Years with a Continuous Flow Left Ventricular Assist Device as Destination Therapy; L.A. Coyle,¹ C.T. Gallagher,¹ G. Bhat,¹ P.S. Pappas,¹ M.S. Slaughter,² A.J. Tatoes.¹ ¹Advocate Christ Medical Center, Oak Lawn, IL; ²University of Louisville, Louisville, KY.

12:00 PM (266) The Type of Ventricular Assist Device Implanted Does Not Affect Post-Heart Transplant Renal Function; A.C. Alba,¹ V. Rao,¹ H.J. Ross,¹ D.H. Delgado,¹ F. Gustafsson,² A.S. Jensen,² K. Sander.² ¹University Health Network, Toronto, ON, Canada; ²Rigshospitalet, Copenhagen, Denmark.

10:45 AM – 12:15 PM

CONCURRENT SESSION 26:

Assessing the Risk of Heart Transplantation (Continental A/B)

CHAIRS: JOHN V. CONTE, MD AND PAUL J. MOHACSI, MD

10:45 AM (267) Minimizing Infection and Rejection Death: Clues Acquired from 19 Years of Multi-institutional Cardiac Transplantation Data; J.F. George,¹ D.O. Taylor,² E.D. Blume,³ J.K. Kirklin,¹ D.C. Naftel,¹ R.N. Brown,¹ A.I. Dipchand,⁴ J.A. Tallaj,¹ ¹University of Alabama at Birmingham, Birmingham, AL; ²Cleveland Clinic, Cleveland, OH; ³Children's Hospital, Boston, MA; ⁴Hospital for Sick Children, Toronto, ON, Canada.

11:00 AM (268) Has the Risk Abated in the Current Era? A 15 Year Multi-institutional Analysis; R.S.D. Higgins,¹ P.P. Chang,² R.C. Starling,³ G.A. Ewald,⁴ J.A. Tallaj,⁵ R.N. Brown,⁵ N.M. Kirklin.⁵ ¹Rush University Medical Center, Chicago, IL; ²University of North Carolina at Chapel Hill, Chapel Hill, NC; ³Cleveland Clinic Foundation, Cleveland, OH; ⁴Washington University School of Medicine, St. Louis, MO; ⁵University of Alabama at Birmingham, Birmingham, AL.

11:15 AM (269) Heart Transplant Rejection with Cardiogenic Shock Supported with Extracorporeal Membrane Oxygenation (ECMO): Outcome from a Single Center Experience; M. Kittleson,² J. Patel,² J. Moriguchi,² M. Kawano,² K. Patel,¹ S. Davis,² A. Hage,² M. Hamilton,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of

Medicine at UCLA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

11:30 AM (270) BMI Is an Independent Risk Factor for Surgical Wound Complication in de-novo Heart Transplant Recipients (HTxR) Regardless of the Immunosuppressive Therapy; M.J. Barten,¹ J.M. Arizon,² G. Dong,³ H. Eisen,⁴ J. Kobashigawa,⁵ H. Lehmkühl,⁶ H. Ross,⁷ M. Vigano,⁸ S.-S. Wang,⁹ A. Zuckermann.¹⁰ ¹University of Leipzig, Heart Center, Leipzig, Germany; ²Reina Sofia University Hospital, Cordoba, Spain; ³Novartis Pharmaceuticals Corporation, East Hanover; ⁴Drexel University College of Medicine, Philadelphia, PA; ⁵Cedars-Sinai Heart Institute, Los Angeles, CA; ⁶Deutsches Herzzentrum Berlin, Berlin, Germany; ⁷University Health Network, Toronto General Hospital, Toronto, ON, Canada; ⁸Università degli Studi di Pavia, Pavia, Italy; ⁹National Taiwan University, Taipei, Taiwan; ¹⁰University of Vienna, Vienna, Austria.

11:45 AM (271) QTc-Interval and Molecular Gene Expression Profiling Test Score in Cardiac Allograft Dysfunction after Heart Transplantation; K. Shahzad,¹ J. He,¹ Q.A. Aziz,¹ M. Cadeiras,¹ F. Latif,¹ A. Sinha,¹ S. Auerbach,² S. Mital,⁴ S. Restaino,¹ C.C. Marboe,³ L.J. Addonizio,² M.C. Deng.¹ ¹Columbia University Medical Center, New York, NY; ²Columbia University Medical Center, New York, NY; ³Columbia University Medical Center, New York, NY; ⁴University of Toronto, Calgary, Canada.

12:00 PM (272) Persistent Pulmonary Hypertension in Heart Transplant Patients: Is This a Recipe for Long-Term Failure?; J. Patel,² M. Kittleson,² M. Share,² M. Kawano,² S. Davis,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

10:45 AM – 12:15 PM

CONCURRENT SESSION 27:

Bronchiolitis Obliterans Syndrome (BOS): Risk Factors and Prevention (Boulevard Room)

CHAIRS: ANNETTE BOEHLER, MD AND ALLAN R. GLANVILLE, MD, FRACP

10:45 AM (273) The Impact of Air Pollution on Bronchiolitis Obliterans Syndrome and Mortality after Lung Transplantation; B. Vanaudenaerde,^{1,2} T. Nawrot,^{2,3} R. Vos,^{1,2} S. Verleden,^{1,2} L. Jacobs,² C. Faes,³ P. Hoet,² D. Van Raemdonck,^{1,2} L. Dupont,^{1,2} B. Nemery,² G. Verleden.^{1,2} ¹Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; ²Katholieke Universiteit Leuven, Leuven, Belgium; ³University Hasselt, Hasselt, Belgium.

11:00 AM (274) Molecular Typing of Pseudomonas Aeruginosa Isolated from CF Lung Transplant Recipients: Implications for BOS Risk; A. Nicholson,¹ J.D. Perry,¹ S. Peart,¹ A. Fisher,² K.F. Gould.¹ ¹Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; ²Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.

11:15 AM (275) *The Impact of Viral Infections on the Occurrence of Bronchiolitis Obliterans Syndrome and Its Influence on BOS Stage*; E. Balestro, M. Loy, M. Damin, F. Braccioni, M. Schiavon, F. Lunardi, A. De Filippis, F. Calabrese, F. Rea. University of Medical School of Padova, Padova, Italy.

11:30 AM (276) *Epstein Barr Virus Reactivation in the Lung Allograft Is Inversely Associated with Histopathological Acute Rejection in the Current Era of Routine Antiviral Prophylaxis*; D.T. Keating,¹ A. Michaelides,² G.P. Westall,^{1,3} G.I. Snell,^{1,3} T. Kotsimbos.^{1,3} ¹The Alfred Hospital, Melbourne, Vic, Australia; ²The Alfred Hospital, Melbourne, Vic, Australia; ³Monash University, Melbourne, Vic, Australia.

11:45 AM (277) *Azithromycin for Bronchiolitis Obliterans Syndrome after Lung Transplantation*; R. Vos, B.M. Vanaudenaerde, A. Schoonis, D.E. Van Raemdonck, L.J. Dupont, G.M. Verleden. University Hospitals Leuven, Leuven, Belgium.

12:00 PM (278) *1-Year Results of the CeMyLungs Study, a 3-Year Randomised, Open Label, Multi-Centre Investigator Driven Study Comparing De Novo Enteric Coated Mycophenolate Sodium with Delayed Onset Everolimus, Both Arms in Combination with Cyclosporin (Using C2 Monitoring) and Corticosteroids for the Prevention of the Bronchiolitis Obliterans Syndrome in Heart-Lung, Bilateral Lung and Single Lung Transplant Recipients*; A.R. Glanville,¹ C.L. Aboyou,¹ W. Klepetko,² H. Reichenspurner,³ H. Treede,³ E.A. Verschuuren,⁴ A. Boehler,⁵ C. Bendin,⁵ P. Hopkins,⁶ P.A. Corris.⁷ ¹St.Vincent's Hospital, Sydney, NSW, Australia; ²University of Vienna, Vienna, Austria; ³University Heart Center, Hamburg, Germany; ⁴University Medical Centre, Groningen, Netherlands; ⁵University Hospital, Zurich, Switzerland; ⁶The Prince Charles Hospital, Brisbane, Australia; ⁷Newcastle University, Newcastle, United Kingdom.

10:45 AM – 12:15 PM

CONCURRENT SESSION 28:

Making a Better Breath (Continental C)

CHAIRS: ABBAS ARDEHALI, MD AND FLORIAN M. WAGNER, MD

10:45 AM (279) *The Effect of Ex-Vivo Perfusion on the Microbiological Profile of the Donor Lung*; D.M. Karamanou,^{1,2} J. Perry,² H.R. Walden,¹ A.J. Simpson,³ P. Corris,^{1,2} K. Gould,² A.J. Fisher,^{1,2} J.H. Dark.^{1,2} ¹Newcastle University, Newcastle upon Tyne, United Kingdom; ²Freeman Hospital, Newcastle upon Tyne, United Kingdom; ³University of Edinburgh, Edinburgh, Scotland, United Kingdom.

11:00 AM (280) *Post-Mortem and Ex-Vivo Carbon Monoxide (CO) Ventilation Reduces Ischemia-Reperfusion Injury (IRI) in Rat Lungs Transplanted from Non-*

Heart-Beating Donors (NHBDs); B. Dong, T. Egan. School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.

11:15 AM (281) *Ex Vivo Adenoviral Vector Gene Delivery Results in Decreased Vector-Associated Inflammation Pre- and Post- Lung Transplantation*; J.C. Yeung, D. Wagnetz, T. Koike, M. Rubacha, M. Cypel, Y. Matsuda, D.M. Hwang, M. Liu, T.K. Waddell, S. Keshavjee. University of Toronto, Toronto, ON, Canada.

11:30 AM (282) *Ex Vivo Donor Lung Evaluation Using Multi-Detector Row Computed Tomography*; W.R. Lynch,¹ S.K. Alford,² A.J. Schmidt,³ A.F. Halaweish,² E.A. Hoffmann.² ¹University of Iowa, Iowa City, IA; ²University of Iowa, Iowa City, IA; ³University of Iowa, Iowa City, IA.

11:45 AM (283) *Lactate Production during Acellular Normothermic Ex Vivo Pig and Human Lung Perfusion*; T. Koike, J.C. Yeung, M. Cypel, M. Rubacha, Y. Matsuda, M. Liu, T.K. Waddell, S. Keshavjee. University of Toronto, Toronto, ON, Canada.

12:00 PM (284) *Ex-Vivo Repair of Donor Lungs – Is Cell-Free Solution Superior to Blood Perfusion?* S. Wipperf, ¹ Y. Rittberg, ¹ A. Dupree, ¹ E. Youbert-Hubner, ¹ B. Reiter, ¹ A. Koops, ² H. Reichenspurner, ¹ F.M. Wagner. ¹University Heart Center Hamburg, Hamburg, Germany; ²University Hospital Hamburg-Eppendorf, Hamburg, Germany.

10:45 AM – 12:15 PM

CONCURRENT SESSION 29:

Pulmonary Hypertension; Innovative Therapy (Waldorf)

CHAIRS: REDA GIRGIS, MD, BCH AND PATRICIA A. UBER, PHARMD

10:45 AM (285) *Waitlist Mortality among Young Patients with Idiopathic or Familial Pulmonary Hypertension Awaiting Lung Transplantation in the United States*; M.P. Mullen,^{1,4} R.R. Thiagarajan,^{1,4} D. Boyer,^{2,4} T. Kulik,^{1,4} F. Fynn Thompson,^{3,4} G. Visner,^{2,4} K. Gauvreau,^{1,3} G. Piercey,¹ C.S. Almond.^{1,4} ¹Children's Hospital, Boston, MA; ²Children's Hospital, Boston, MA; ³Children's Hospital, Boston, MA; ⁴Harvard Medical School, Boston, MA.

11:00 AM (286) *Effect of 16 Weeks of Bosentan-Based Therapy on Cardiac MRI (cMRI) Derived Ventricular Function, 6-Minute Walk Test Distance (6MWD) and Borg Dyspnea Index (BDI) in Patients with Pulmonary Arterial Hypertension (PAH): Results from the COMPASS-3 Study*; S. Murali,¹ S.G. Lloyd,² H. Gupta,² F.J. Soto,³ M.H. Park,⁴ F. Torres,⁵ N. Frey,⁶ R.L. Benza.¹ ¹Allegheny General Hospital, Pittsburgh, PA; ²University of Alabama at Birmingham, Birmingham, AL; ³Prevea Health, Sheboygan, WI; ⁴University of Maryland School of Medicine, Baltimore, MD; ⁵University of Texas Southwestern Medical Center,

Dallas, TX; ⁶Actelion Pharmaceuticals US, Inc., South San Francisco, CA.

11:15 AM (287) *Endothelin Receptor Antagonists Are a Effective Long Term Treatment Option in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease with or without Trisomy 21*; F. Kermeen,¹ C. Franks,¹ K. O'Brien,¹ H. Seale,¹ K. Hall,¹ K. McNeil,¹ D. Radford.² ¹The Prince Charles Hospital, Brisbane, QLD, Australia; ²The Prince Charles Hospital, Brisbane, QLD, Australia.

11:30 AM (288) *Aldosterone Antagonism in Pulmonary Hypertension and Right Heart Failure*; J.A. Mazurek,² A. Rabinovitz,² R. Zolty.¹ ¹Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; ²Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY.

11:45 AM (289) *Comparison of Aprotinin and Tranexamic Acid in Pulmonary Thromboendarterectomy Surgery – Review of 161 Consecutive Patients*; M. Berman,¹ D. Cardone,² K. Goldsmith,³ A. Vuylsteke,² A. Klein,² C. Gerrard,² J. Dunning,¹ S. Tsui,¹ D. Jenkins.¹ ¹Papworth Hospital, Cambridge, United Kingdom; ²Papworth Hospital, Cambridge, United Kingdom; ³Papworth Hospital, Cambridge, United Kingdom.

12:00 PM (290) *Impact of Aggressive Management on Outcome in Patients with idiopathic Pulmonary Arterial Hypertension Listed for Lung Transplantation*; M. de Perrot, J. Granton, A.F. Pierre, K. McRae, T.K. Waddell, K. Yasufuku, C. Whytehead, M. Hutcheon, C. Chaparro, L.G. Singer, S. Keshavjee. Toronto General Hospital, Toronto, ON, Canada.

10:45 AM – 12:15 PM

CONCURRENT SESSION 30:

Clinical Case Dilemmas in Thoracic Transplantation
(Marquette)

CHAIRS: LORRIANA E. LEARD, MD AND
DANIEL F. DILLING, MD

10:45 AM *Introduction*, Lorriana E. Leard, MD,
University of California, San Francisco, CA

10:50 AM *Challenges in Lung Transplantation*

CASE PRESENTER: Basar Sareyyupoglu, MD,
University of Pittsburgh Medical Center, Pittsburgh, PA

MODERATOR: Daniel F. Dilling, MD, Loyola
University Medical Center, Maywood, IL

PANELISTS: Robert B. Love, MD, Loyola University
Medical Center, Maywood, IL and Geert M. Verleden,
MD, PhD, University Hospital Gasthuisberg, Leuven,
Belgium

11:05 AM *Challenges in Heart Transplantation*

CASE PRESENTER: Oscar Kolsrud, MD, Sahlgrenska
University Hospital, Gothenburg, Switzerland

MODERATOR: David W. Markham, MD, University
of Texas Southwestern Medical Center, Dallas, TX

PANELISTS: Stuart D. Russell, MD, Johns Hopkins
Hospital, Baltimore, MD and Leslie W. Miller, MD,
Washington Hospital Center & Georgetown University
Hospital, Washington, DC

11:20 AM *Infectious Disease Challenges in Thoracic Transplantation*

CASE PRESENTER: Sonia Vishin, MD, University of
Alabama at Birmingham, AL

MODERATOR: Cynthia J. Gries, MD, MSc, University
of Washington, Seattle, WA

PANELISTS: Aimee Zaas, MD, MHS, Duke University
Medical Center, Durham, NC and Kate Gould, FRC-
Path, Freeman Hospital, Newcastle Upon Tyne, United
Kingdom

11:35 AM *Challenges in Pulmonary Hypertension*

CASE PRESENTER: Kathleen Tong, MD, University of
California at San Francisco, CA

MODERATOR: Pali D. Shah, MD, Vanderbilt
University Medical Center, Nashville, TN

PANELISTS: Teresa De Marco, MD, FACC, University
of California, San Francisco, CA and Raymond L. Benza,
MD, Allegheny General Hospital, Pittsburgh, PA

11:50 AM *Challenges in Pediatric Thoracic Transplantation*

CASE PRESENTER: Joseph W. Rossano, MD, Baylor
College of Medicine, Houston, TX

MODERATOR: Lorriana E. Leard, MD, University of
California, San Francisco, CA

PANELISTS: Cynthia S. Herrington, MD, Children's
Hospital Los Angeles, CA and Lori J. West, MD,
D.Phil, University of Alberta, Edmonton, Alberta,
Canada

12:15 PM – 2:15 PM

Lunch Break

12:30 PM – 2:00 PM

JHLT EDITORIAL BOARD LUNCHEON MEETING (Joliet)

SCIENTIFIC COUNCIL CHAIRS LUNCHEON MEETING
(PDR-4)

1:15 PM – 2:15 PM

2011 PROGRAM COMMITTEE MEETING (Lake Erie Room)

2:30 PM – 4:00 PM

CONCURRENT SESSION 31:

The Menu: Which Device When? (Continental A/B)

CHAIRS: STEVEN S. L. TSUI, MD, FRCS AND
EMMA BIRKS, MRCP

2:30 PM (291) Evaluation of the Minimally Invasive HeartWare® Ventricular Assist System as a Long Term Support Device; M. Strueber,¹ P. Jansz,² G. Wieselthaler,³ G. O'Driscoll,⁴ M. Morshuis,⁵ A. Khaghani,⁶ S. Schueler,⁷ R. Hetzer,⁸ A. Hoffmeier,⁹ D. Duveau.¹⁰ ¹Hannover Medical School, Hannover, Germany; ²St Vincenz Hospital, Sydney, Australia; ³Medical University Vienna, Vienna, Austria; ⁴Royal Perth Hospital, Perth, Australia; ⁵Heart Center NRW, Bad Oeyenhausen, Germany; ⁶Harefield Hospital, Harefield, United Kingdom; ⁷Freeman Hospital, Newcastle, United Kingdom; ⁸German Heart Center, Berlin, Germany; ⁹University Hospital Münster, Münster, Germany; ¹⁰Hopital Guillaume, Nantes, France.

2:45 PM (292) Concept of a Catheterization-Lab Implanted Long-Term Circulatory Assist Device: Acute Animal Study Hemodynamic Data; R. Delgado, F. Raissi Shabari, Texas Heart Institute, Houston, TX.

3:00 PM (293) Differential Impact on Post-transplant Outcomes between HeartMate XVE and HeartMate II Left Ventricular Assist Devices; P.A. Ventura, B.B. Reid, B.D. Horne, N.O. Mason, S. Stoker, R. Alharethi, D. Budge, B. Rasmusson, J. Doty, S.E. Clayson, A.G. Kfoury, Intermountain Medical Center, Salt Lake City, UT.

3:15 PM (294) Design and Feasibility Testing of a Miniaturized Transapical Mechanical Circulatory Support Device: MVAD; M.S. Slaughter,¹ G.A. Giridharan,² S. Aggarwal,³ M. Sobieski,⁴ D. Tamez,⁵ J. LaRose,⁶ L. Sherwood,⁷ S.C. Koenig.⁸ ¹University of Louisville, Louisville, KY; ²University of Louisville, Louisville, Ky; ³University of Louisville, Louisville, KY; ⁴University of Louisville, Louisville, KY; ⁵HeartWare International, Inc., Framingham, MA; ⁶HeartWare International, Inc., Framingham, MA; ⁷University of Louisville, Louisville, KY; ⁸University of Louisville, Louisville, KY.

3:30 PM (295) A Single Center Experience with the Dura-Heart™ Mag-Lev Centrifugal Left Ventricular Assist System; M.J. Morshuis, L. Arusoglu, M. Schonbrodt, J. Boergermann, J. Gummert, Heart and Diabetic Center North Rhine Westfalia, Bad Oeyenhausen, NRW, Germany.

3:45 PM (296) Versatility and Patient Outcomes with the Levitronix CentriMag Temporary Ventricular Assist Device; A.J. McCormick, B.B. Reid, D. Budge, S.E. Clayson, J.R. Revenaugh, S. Stoker, A.L. Raymond, H.K. Smith, J.R. Doty, W.T. Caine, R. Alharethi, A.G. Kfoury, Intermountain Medical Center, Salt Lake City, UT.

2:30 PM – 4:00 PM

CONCURRENT SESSION 32:

Mechanisms of Inflammation and Repair in the Lung Allograft Airway (Boulevard)

CHAIRS: MARC ESTENNE, MD AND
GREGORY I. SNELL, FRACP, MBB

2:30 PM (297) IL-17 Producing T-Lymphocytes in Acute and Chronic Lung Allograft Rejection; S.E. Verleden, E.K. Verbeken, B.M. Vanaudenaerde, R. Vos, S.I. De Vleeschauwer, A. Willems-Widyastuti, L.J. Dupont, G.M. Verleden, D.E. Van Raemdonck, UZ Gasthuisberg, Leuven, Belgium.

2:45 PM (298) Acute Rejection and Lymphocytic Bronchiolitis after Lung Transplantation: IL-17 Revisited; R. Vos, S.E. Verleden, B.M. Vanaudenaerde, S.I. De Vleeschauwer, A. Willems-Widyastuti, D.E. Van Raemdonck, E.K. Verbeken, L.J. Dupont, G.M. Verleden, University Hospital Gasthuisberg, Leuven, Belgium.

3:00 PM (299) Central Bronchial Biopsies: An Additional Value in the Assessment of Lymphocytic Airway Inflammation after Lung Transplantation?; R. Vos, B.M. Vanaudenaerde, S.E. Verleden, S.I. De Vleeschauwer, A. Willems-Widyastuti, D.E. Van Raemdonck, L.J. Dupont, G.M. Verleden, Lung Transplant Unit, Leuven, Belgium.

3:15 PM (300) Lymphocytic Bronchiolitis Is Associated with Inadequate Suppression of Blood T-Cell Granzyme B, IFN γ and TNF α ; C.-L. Liew,^{1,3} G. Hodge,¹ S. Hodge,¹ D. Chambers,² P. Hopkins,² P.N. Reynolds,¹ M.D. Holmes.^{1,3} ¹Royal Adelaide Hospital, Adelaide, Australia; ²The Prince Charles Hospital, Brisbane, Australia; ³SA Lung Transplant Service, Adelaide, Australia.

3:30 PM (301) A Novel Approach to the Assessment of Lymphocytic Bronchiolitis – The ‘B Score’; D.C. Chambers,¹ S. Hodge,² G. Hodge,² F. Kermeen,¹ P. Reynolds,² M. Holmes,² P. Hopkins.¹ ¹The Prince Charles Hospital, Brisbane, QLD, Australia; ²Hanson Institute, Adelaide, South Australia, Australia.

3:45 PM (302) Lung Resident Mesenchymal Stem Cells Are Involved in Bronchiolitis Obliterans; S. Aharinejad,^{1,2} M. Salama,^{1,2} O. Andrukhova,² S. Taghavi,¹ W. Klepetko,¹ P. Jaksch.¹ ¹Medical University of Vienna, Vienna, Austria; ²Medical University of Vienna, Vienna, Austria.

2:30 PM – 4:00 PM

CONCURRENT SESSION 33:

Heart Transplantation; Immunosuppression Controversies (Continental C)

CHAIRS: JOSEF STEHLIK, MD, MPH AND
ARI L. J. HARJULA, MD

2:30 PM (303) Gender Mismatch in Non-induction/Triple-Drug Regimens: Poor 10-Year Outcomes; R. Shemin,¹ J. Patel,² A. Ardehali,¹ M. Kittleson,² M. Kawano,² S. Davis,² J. Moriguchi,² J. Kobashigawa.² ¹David Geffen

School of Medicine at UCLA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

2:45 PM (304) Alemtuzumab Induction Facilitates Steroid-Free Immunosuppression in Human Cardiac Transplantation: Two Year Outcomes; M.A. Shullo,¹ R. Zomak,² J.K. Bhama,² C. Bermudez,² D.M. McNamara,³ M. Navoney,² R.L. Kormos,² Y. Toyoda,² J. Teuteberg.³
¹University of Pittsburgh, Pittsburgh, PA; ²University of Pittsburgh, Pittsburgh, PA; ³University of Pittsburgh, Pittsburgh, PA.

3:00 PM (305) Mid-Term Results of Campath Induction and Steroid-free Maintenance Immunosuppression in Cardiac Transplantation; S. Aggarwal,¹ K. Luftman,¹ R. Bowles,¹ K. McCants,² S. Prabhu,² R.D. Dowling,¹ M.S. Slaughter.¹ ¹University of Louisville School of Medicine, Louisville, KY; ²University of Louisville School of Medicine, Louisville, KY.

3:15 PM (306) Steroid Minimization Is Associated with Improved Survival in Patients with Diabetes after Heart Transplant; P. Zymek,¹ J.J. Teuteberg,¹ M.A. Shullo,² C. Bermudez,³ R.L. Kormos,³ J.K. Bhama,³ Y. Toyoda,³ D.M. McNamara.¹ ¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²University of Pittsburgh, Pittsburgh, PA; ³University of Pittsburgh Medical Center, Pittsburgh, PA.

3:30 PM (307) The Effectiveness of a Standardized Desensitization Protocol in Reducing Calculated Panel Reactive Antibodies (cPRA) in Sensitized Heart Transplant Candidates: Does It Make Sense To Desensitize?; J. Patel,² M. Kittleson,² E. Reed,¹ Q. Zhang,¹ R. Rajalingam,¹ A. Velleca,² E. Stimpson,² C. Burch,¹ M. Kawano,² S. Davis,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

3:45 PM (308) Lower Incidence of New Onset Diabetes after Cardiac Transplant with Alemtuzumab Induction; R. Jones,¹ M.A. Shullo,² R. Zomak,² C. Newman,² M. Rebel,² C. Yost,² M. Navoney,² D.M. McNamara,² Y. Toyoda,² R.L. Kormos,² J. Teuteberg.² ¹University of Pittsburgh Medical School, Pittsburgh, PA; ²University of Pittsburgh, Pittsburgh, PA.

2:30 PM – 4:00 PM

CONCURRENT SESSION 34:

Healing My Broken Heart (Waldorf)

CHAIRS: GABOR B. SZABO, MD, PHD AND VALLUVAN JEEVANANDAM, MD

2:30 PM (309) Extended Myocardial Preservation by Polypharmaceutical Supplementation of Celsior; A.J. Watson,^{1,2} L. Gao,¹ J. Tsun,¹ L. Sun,¹ A. Jabbour,^{1,2} M. Hicks,³ P.S. Macdonald.^{1,2} ¹Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; ²St Vincent's

Hospital, Sydney, NSW, Australia; ³St Vincent's Hospital, Sydney, NSW, Australia.

2:45 PM (310) Direct Microvascular Endothelial Stabilization by Donor Simvastatin Treatment Prevents Endothelial-to-Mesenchymal Transition and Vasculopathy of Cardiac Allografts; R. Tuuminen,¹ A.I. Nykanen,¹ S. Syrjala,¹ R. Krebs,¹ K. Koli,² K. Lemstrom.¹ ¹Haartman Institute, University of Helsinki, Helsinki, Finland; ²Biomedicum, University of Helsinki, Helsinki, Finland.

3:00 PM (311) Post-Mortem Tissue-Type Plasminogen Activator Preserves Graft Function of Hearts Harvested from Non-Pretreated Non-Heart-Beating Donors; M. Hirota,^{1,2} I. Kozo,² T. Tedoriya,¹ S. Sano.² ¹Showa University Medical School, Tokyo, Japan; ²Okayama University School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

3:15 PM (312) Extended Donor Criteria in Heart Transplantation with Pharmacological Stress Echocardiography; G. Arpesella,¹ S. Martin-Suarez,¹ P.M. Mikus,¹ S. Gherardi,² M. Macherini,³ O. Leone,⁴ E. Picano,⁴ T. Bombardini.⁴ ¹S.Orsola-Malpighi Hospital, Bologna, Italy; ²Cesena Hospital, Cesena, Italy; ³Santa Maria Alle Scotte Hospital, Siena, Italy; ⁴National Research Center, Pisa, Italy.

3:30 PM (313) Exogenous T3 Causes Acute Pulmonary Hypertension in a Porcine Model of Brain Death; A.J. Watson,^{1,2} L. Gao,¹ L. Sun,¹ S. Faddy,³ M. Hicks,^{1,4} P.C. Jansz,^{1,2} P.S. Macdonald.^{1,2} ¹Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; ²St Vincent's Hospital, Sydney, NSW, Australia; ³St Vincent's Hospital, Sydney, NSW, Australia; ⁴St Vincent's Hospital, Sydney, NSW, Australia.

3:45 PM (314) Myocardial Protection in Heart Transplantation Using Blood Cardioplegia: 12 Years Outcome of a Prospective Randomized Trial; A. Forni, G. Faggian, G.B. Luciani, B. Chiominto, F. Patelli, V. Giambruno, A. Mazzucco. University Hospital of Verona, Verona, Italy.

2:30 PM – 4:00 PM

CONCURRENT SESSION 35:

New Approaches to the Evaluation and Treatment of Rejection in the Pediatric Transplant (Marquette)

CHAIRS: OKAN ELIDEMIR, MD AND OLAF REINHARTZ, MD

2:30 PM (315) The Impact of HLA-G Polymorphism on Acute Rejection in Pediatric Heart Transplant Recipients; A. Zeevi,¹ M. Brooks,¹ D. Girnita,¹ R. Ferrell,¹ R. Chinnock,² C. Canter,³ L. Addonizio,⁴ D. Bernstein,⁵ J. Kirklin,⁶ D. Naftel,⁶ S. Webber.¹ ¹University of Pittsburgh, Pittsburgh, PA; ²Loma Linda University, Loma Linda, CA; ³Washington University, St. Louis, MO; ⁴Columbia University, New York, NY; ⁵Stanford

University, Palo Alto, CA; ⁶University of Alabama Birmingham, Birmingham, AL.

2:45 PM (316) Minimal (A1) Acute Rejection Episodes are Independent Risk Factors for the Development of Bronchiolitis Obliterans Syndrome in Pediatric Lung Transplant Recipients; O. Elidemir,¹ N.P. Varghese,¹ E.O. Smith,¹ G.B. Mallory,¹ E.D. McKenzie,² J.S. Heinle,² D.L. Morales,² M.G. Schecter.¹ ¹Baylor College of Medicine, Houston, TX; ²Baylor College of Medicine, Houston, TX.

3:00 PM (317) Cell Bound Complement Activation Products as Biomarkers of Humoral Rejection in Pediatric Heart Transplantation; B. Feingold,¹ J.S. Navratil,² B. Paul,² J.M. Ahearn,² C. Galambos,³ A. Zeevi,⁴ S.A. Webber.¹ ¹Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ²University of Pittsburgh School of Medicine, Pittsburgh, PA; ³Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA; ⁴University of Pittsburgh School of Medicine, Pittsburgh, PA.

3:15 PM (318) Comparison of De Novo Everolimus, AZA and MMF in Cyclosporine Based Immunosuppressive Protocol in Pediatric Heart Transplant Patients; S. Schubert,¹ H.B. Lehmkuhl,² M. Huebler,² R. Hetzer,² F. Berger.¹ ¹Deutsches Herzzentrum, Berlin, Germany; ²Deutsches Herzzentrum, Berlin, Germany.

3:30 PM (319) Antibody Mediated Rejection (AMR) Predicted by New C1q Assay; C. Chin,¹ G. Chen,² S. Siehr,¹ D. Rosenthal,¹ O. Reinartz,¹ D. Bernstein,¹ F. Sequeira,² D. Tyan.² ¹Stanford University, Palo Alto, CA; ²Stanford University, Palo Alto, CA.

3:45 PM (320) Donor-Specific Antibodies (DSA) Patterns after Pediatric Heart Transplantation with A + and – Crossmatch; C. Reddy,¹ E. Riddle,¹ P. Checchia,¹ C. Huddleston,² S. Gandhi,² D. Phelan,³ C. Canter.¹ ¹Washington University School of Medicine, Saint Louis, MO; ²Washington University School of Medicine, Saint Louis, MO; ³Washington University School of Medicine, Saint Louis, MO.

2:30 PM – 4:00 PM

CONCURRENT SESSION 36:

Autoimmunity, Tolerance and Inflammation (PDR-2)

CHAIRS: MARLENE ROSE, PHD AND
E. RENE RODRIGUEZ, MD

2:30 PM (321) WITHDRAWN

2:45 PM (322) IL-17F Induces a Distinct Form of Anti-MHC Class I Induced Autoimmunity and Playing a Role in Chronic Rejection Post-Lung Transplantation; H. Ilias Basha,¹ V. Tiriveedhi,¹ M. Takenaka,¹ S. Ramachandran,¹ G.A. Patterson,² T. Mohanakumar.^{1,3} ¹Washington University School of Medicine, St. Louis, MO;

²Washington University School of Medicine, St. Louis, MO; ³Washington University School of Medicine, St. Louis, MO.

3:00 PM (323) Alloimmune Responses to Mismatched MHC Class I Antigens Induces Immune Responses to Self Antigens Leading to Chronic Rejection; V. Tiriveedhi,¹ D.H. Brand,² D. Saini,¹ S. Ramachandran,¹ R. Hachem,³ E.P. Trulock,³ G.A. Patterson,⁴ T. Mohanakumar.^{1,5} ¹Washington University School of Medicine, St. Louis, MO; ²University of Tennessee, Memphis, TN; ³Washington University School of Medicine, St. Louis, MO; ⁴Washington University School of Medicine, St. Louis, MO; ⁵Washington University School of Medicine, St. Louis, MO.

3:15 PM (324) De Novo Formation of Lymphoid Tissue in the Lung Evolves Post Transplant Obliterative Airway Disease; D. Wagnetz,¹ M. Sato,¹ J. Yeung,¹ S. Hirayama,¹ T. Waddell,¹ M. Liu,² S. Keshavjee.¹ ¹Toronto General Hospital, Toronto, ON, Canada; ²Latner Thoracic Research Laboratories, Toronto, ON, Canada.

3:30 PM (325) cKit and MHC Class-I Expression in the Tolerizing Inoculum Dictates Donor-specific Tolerance vs Third-Party Cardiac Allograft Acceptance in a Neonatal Tolerance Model; M. Jeyakanthan, K. Tao, L.J. West. University of Alberta, Edmonton, AB, Canada.

3:45 PM (326) Allogeneic CD4+CD25+ T Cells Regulate Rejection of Bronchus Transplants in Porcinized Mice; A.-K. Knoefel, N. Madrahimov, G. Warnecke, M. Avsar, K. Dreckmann, M. Strueber, A. Haverich. Hannover Medical School, Hannover, Germany.

4:00 PM – 4:30 PM

Coffee Break (Southeast Exhibit Hall)

4:30 PM – 11:59 PM

Exhibit Hall/Poster Hall Strike (Southeast/Southwest Exhibit Halls)

4:30 PM – 6:00 PM

CONCURRENT SESSION 37:

Heart Transplantation Clinical Challenges (Continental A/B)

CHAIRS: RAY E. HERSHBERGER, MD AND
GONZALO V. GONZALEZ-STAWINSKI, MD

4:30 PM (327) Gender Does Matter – Gender Specific Outcome Analysis of 1000 Heart Transplants at a Single Centre; I. Kaczmarek, S. Eifert, S. Kofler, B. Meiser, B. Reichart. Grosshadern University Hospital, Munich, Germany.

4:45 PM (328) Increased LV Mass and Concentricity as Assessed by Cardiac MRI Are Associated with Increased Mortality in Cardiac Transplant Recipients; P.C. Patel,¹ S.C. Reimold,¹ F.G. Araj,¹ P.A. Kaiser,¹ R.M. Peshock,¹ C.W. Yancy,² W.S. Ring,³ S. Gupta,¹ J.D. Mishkin,¹ P.P.A. Mammen,¹ D.W. Markham,¹ M.H. Drazner.¹ ¹University of Texas Southwestern Medical

Center, Dallas, TX; ²Baylor University Medical Center, Dallas, TX; ³University of Texas Southwestern Medical Center, Dallas, TX.

- 5:00 PM (329) Primary Graft Dysfunction Does Not Lead to Increased Cardiac Allograft Vasculopathy in Surviving Patients;** S. Wong,¹ J. Moriguchi,² M. Kawano,² J. Kobashigawa,² R. Shemin,¹ M. Kwon.¹ ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.
- 5:15 PM (330) Blood Product Requirements during Heart Transplantation Are Significantly Higher in Patients Bridged with Continuous Flow Devices Compared to Pulsatile Flow Devices;** N. Uriel,¹ S.-W. Pak,² E.M. Sutton,² Y. Naka,² U.P. Jorde,¹ D. Mancini.¹ ¹Columbia University, New York, NY; ²Columbia University, New York, NY.
- 5:30 PM (331) Cardiac Index, Peak Exercise Oxygen Consumption, and Listing Priority for Cardiac Transplantation;** A.B. Methvin, V.V. Georgiopoulou, A.P. Kalogeropoulos, A. Malik, P. Anarado, M. Chowdhury, I. Hussain, W.M. Book, S.R. Laskar, J.D. Vega, A.L. Smith, J. Butler. Emory University Hospital, Atlanta, GA.
- 5:45 PM (332) The Slope of Renal Function in De Novo HTxR. Can We Improve?;** J. Kobashigawa,¹ J. Arizon,² G. Dong,³ H.J. Eisen,⁴ G. Junge,⁵ H. Schwende,⁵ A. Zuckermann,⁶ H.B. Lehmkuhl.⁷ ¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²Hospital Universitario, Cordoba, Spain; ³Novartis Pharmaceuticals Corporation, East Hanover; ⁴Temple University, Philadelphia; ⁵Novartis Pharma, Basel, Switzerland; ⁶Medical University of Vienna, Vienna, Austria; ⁷Deutsches Herzzentrum Berlin, Berlin, Germany.

4:30 PM – 6:00 PM

CONCURRENT SESSION 38:

Lung Transplant for Interstitial Lung Disease (Boulevard)

CHAIRS: VINCENT G. VALENTINE, MD AND CHRISTOPHE PISON, MSC, MD, PHD

4:30 PM (333) WITHDRAWN

- 4:45 PM (334) Does Bilateral Versus Single Lung Transplantation Improve Long Term Survival for Patients with Pulmonary Fibrosis?;** S.D. Force,¹ A. Pelaez,² D.C. Neujahr,² P.D. Kilgo,³ A.M. Ramirez,² D.L. Miller,¹ A. Pickens,¹ F.G. Fernandez,¹ C. Lawrence.² ¹Emory University, Atlanta, GA; ²Emory University, Atlanta, GA; ³Emory University, Atlanta, GA.

- 5:00 PM (335) Impact of the UNOS Lung Allocation Scoring System on Lung Transplantation for Interstitial Lung Disease;** S. Osaki,¹ J. Maloney,¹ R.D. Cornwell,² K.C. Meyer,² N.M. Edwards,¹ N.C. De Oliveira.¹ ¹University of Wisconsin, Madison, WI; ²University of Wisconsin, Madison, WI.

- 5:15 PM (336) Pre-Obese and Obese Patients with Idiopathic Pulmonary Fibrosis Are at High Risk for Early Mor-**

ality after Double Transplantation; C.J. Gries,¹ J.D. Edelman,¹ C.H. Goss,¹ G. Raghu,¹ M.S. Mulligan.² ¹University of Washington, Seattle, WA; ²University of Washington, Seattle, WA.

- 5:30 PM (337) Lung Transplantation in Patients with Scleroderma: A Single Center Experience;** M.M. Crespo,¹ D. Zaldonis,² M.P. George,¹ Y. Toyoda,² B. Johnson,¹ C. Bermudez,² S.S. Haider,¹ J.K. Bhama,² M.R. Morell,¹ J.M. Pilewski.¹ ¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²University of Pittsburgh Medical Center, Pittsburgh, PA.

- 5:45 PM (338) End Stage Idiopathic Pulmonary Fibrosis: Which Patients Are at Higher Risk of Mortality Awaiting Lung Transplantation?;** G. Marulli,¹ M. Loy,¹ F. Di Chiara,¹ E. Balestro,² F. Calabrese,³ E. Perissinotto,⁴ F. Lunardi,³ S. Nicotra,¹ A. Zuin,¹ F. Rea.¹ ¹Thoracic Surgery, Padova, Italy; ²Pneumology, Padova, Italy; ³Pathology, Padova, Italy; ⁴Biostatistic, Padova, Italy.

4:30 PM – 6:00 PM

CONCURRENT SESSION 39:

Molecular Mechanisms of Organ Rejection (Continental C)

CHAIRS: JAMES F. GEORGE, PHD AND SONJA SCHREPPER, MD

- 4:30 PM (339) Anti-Apoptotic Role of IL-16 Associated with Attenuation of Acute and Chronic Cardiac Rejection;** N. Kimura,¹ S. Ito,¹ J.B. Vellota,¹ O.P. Palmer,¹ H. Kotsuge,² S. Nakae,³ H. Kornfeld,⁴ R.C. Robbins,¹ M.P. Fischbein.¹ ¹Stanford University, School of Medicine, Palo Alto, CA; ²Stanford University, School of Medicine, Palo Alto, CA; ³The University of Tokyo, The Institute of Medical Science, Tokyo, Japan; ⁴University of Massachusetts, Medical School, Worcester, MA.

- 4:45 PM (340) IL-6 Plays a Crucial Role in the Induction of Autoimmunity and Development of Chronic Rejection;** S. Ramachandran,¹ N. Fukami,¹ N. Benschoff,¹ T. Mohanakumar.^{1,2} ¹Washington University in St Louis, St. Louis, MO; ²Washington University in St Louis, St. Louis, MO.

- 5:00 PM (341) Explaining the Bronchiolitis Obliterans Syndrome (BOS) Phenotype – Epithelial-Mesenchymal Transition (EMT) Occurs More Readily in Small Airway Epithelium;** B. Banerjee,^{1,2} A. Kicic,^{1,3,4} M.M. Musk,² S.M. Stick,^{1,3,4} D.C. Chambers.⁵ ¹University of Western Australia, Crawley, Western Australia, Australia; ²Western Australia Lung Transplant Unit, Royal Perth Hospital, Perth, Western Australia, Australia; ³Telethon Institute of Child Health Research, Subiaco, Western Australia, Australia; ⁴Princess Margaret Hospital for Children, Subiaco, Western Australia, Australia; ⁵Queensland Centre for Pulmonary Transplantation Vascular Disease, Brisbane, QLD, Australia.

- 5:15 PM (342) Obliterative Airway Disease (OAD) Induced by Antibodies to MHC- Class I Is B Cell Dependent: An Obligatory Role for Antibodies to Self Antigens in the**

Pathogenesis of OAD; S. Ramachandran,¹ N. Fukami,¹ D. Saini,¹ T. Mohanakumar,² ¹Washington University in St. Louis, St. Louis, MO; ²Washington University in St. Louis, St. Louis, MO.

5:30 PM (343) *Combination of Clopidogrel and Everolimus Dramatically Reduced the Development of Transplant Arteriosclerosis*; S. Eckl, C. Heim, S. Abele-Ohl, J. Hoffmann, M. Ramsperger-Gleixner, M. Weyand, S.M. Ensminger. Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.

5:45 PM (344) *A Novel Approach To Generate Regulatory T Cells Using CD103 Depletion*; S.D. Moffatt-Bruce, N. Zikri, E. Schumer, D. Bobek, G. Hadley. The Ohio State University, Columbus, OH.

4:30 PM – 6:00 PM

CONCURRENT SESSION 40:

Expert Consensus Definitions in Cardiothoracic Transplantation and Mechanical Circulatory Support Infections (Waldorf)

CHAIRS: STEPHAN SCHUELER, MD, PHD AND JOSE G. MONTOYA, MD

This session will present a summary of the completed consensus document on infections in cardiac transplantation and mechanical circulatory support, which will form the basis for a set of international standardized variables for entry of infection data into the ISHLT Registry and for future research.

4:30 PM *Definitions of Infection in Mechanical Circulatory Support*, Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

5:00 PM *Definitions of Infection in Heart and Lung Transplantation*, Martha L. Mooney, MD, Sentara Norfolk Transplant Center/EVMS, Norfolk, VA

5:30 PM *Panel Discussion with Taskforce Members*: Shahid Husain, MD, MS, Toronto General Hospital, Toronto, Canada, Frauke Mattner, MD, Hannover Medical Center, Germany, Lara Danziger-Isakov, MD, MPH, Cleveland Clinic Foundation, Cleveland, OH, John V. Conte, MD, Johns Hopkins Hospital, Baltimore, MD, Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle, United Kingdom, Robert F. Padera, MD, PhD, Brigham and Women's Hospital, Boston, MA

4:30 PM – 6:00 PM

CONCURRENT SESSION 41:

Philip K. Caves Award Candidate Presentations (Marquette)

CHAIRS: STUART D. RUSSELL, MD AND LUCIANO POTENA, MD

4:30 PM (345) *Blocking VEGF Receptors 1 and 2 Prevents Inflammatory Response and Experimental Obliterative Airway Disease*; R. Krebs,¹ J.M. Tikkanen,¹ M. Hollmen,¹ Y. Wu,² D.J. Hicklin,² P.K. Koskinen,¹ K.B. Lemstrom.¹ ¹University of Helsinki, Helsinki, Finland; ²ImClone Systems Incorporated, New York, NY.

4:45 PM (346) *Constantly Stable Hypoxia Inducible Factor-1 in Myeloid Cells Prevents Acute Rejection in Mouse Cardiac Allografts*; M.A.I. Keranen,¹ R. Krebs,¹ R.S. Johnson,² A.I. Nykanen,¹ K.B. Lemstrom.^{1,3} ¹University of Helsinki, Helsinki, Finland; ²University of California, San Diego, CA; ³University Central Hospital, Helsinki, Finland.

5:00 PM (347) *Generation of Genetically Engineered Low-Antigenicity MHC I Knock-Down Human Embryonic Stem Cells To Prevent Immune Rejection*; T. Deuse,^{1,2} M. Seifert,³ A. Fire,⁴ N. Phillips,⁵ M. Kay,⁵ H. Reichen-spurner,² R.C. Robbins,¹ S. Schrepfer.^{1,2} ¹Stanford University School of Medicine, Stanford, CA; ²University Heart Center, Hamburg, Germany; ³Charite Berlin, Berlin, Germany; ⁴Stanford University, Stanford, CA; ⁵Stanford University, Stanford, CA.

5:15 PM (348) *Splenocyte Infusion and Low Dose Irradiation Induce Peripheral Tolerance in Porcine Lung Transplantation – Modifications of the Protocol for Improved Clinical Feasibility*; M. Avsar, G. Warnecke, K. Dreckmann, A.-K. Knoefel, N. Madrahimov, S. Thissen, B. Kruse, P. Ziehme, W. Sommer, J. Gottlieb, A.R. Simon, J.-H. Karstens, A. Haverich, M. Strueber. Hannover Medical School, Hannover, Germany.

5:30 PM (349) *Lentivirus-Mediated Long-Term Gene Transduction in the Lung Attenuates Allograft Airway Obliteration after Mouse Intra-Pulmonary Trachea Transplantation*; S. Hirayama,¹ M. Sato,¹ G. Zehong,¹ M. Liu,¹ T.K. Waddell,¹ J.A. Medin,² S. Keshavjee.¹ ¹University of Toronto, Toronto, ON, Canada; ²Ontario Cancer Institute and the Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.

5:45 PM (350) *Osteopontin mRNA as a Biomarker for Heart Failure after Left Ventricular Assist Device Support and Heart Transplantation*; M.E.I. Schipper,¹ M.R. Scheenstra,¹ J. van Kuik,¹ D.F. van Wichen,¹ P. van der Weide,¹ N. de Jonge,² R.A. de Weger.¹ ¹University Medical Center, Utrecht, Netherlands; ²University Medical Center, Utrecht, Netherlands.

6:00 PM – 7:00 PM

NEW ISHLT BOARD MEMBER ORIENTATION MEETING (PDR-4)

8:00 PM – 10:00 PM

GALA ANNIVERSARY RECEPTION (Grand Ballroom)

Saturday, April 24, 2010

7:00 AM – 10:30 AM

Registration Desk Open (8th Street Registration)

7:00 AM – 9:00 PM

Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 6:

Linking Outcomes and Quality of Life After Lung Transplant (Boulevard)

CHAIRS: SELIM M. ARCASOY, MD AND
MARTIN P. IVERSEN, MD, MPH

There has been a major focus on survival and physical outcomes after lung transplant. This has, however, under-estimated the importance of quality of life assessment of outcomes. It is important that the wider lung transplant community recognize the value of quality of life assessment and its impact on outcomes after lung transplant. This session will investigate the associations between patient quality of life and outcomes after lung transplant.

7:00 AM Interventions to Improve Adherence After Thoracic Organ Transplantation, Fabienne Dobbels, MSc, PhD, University Hospital Leuven, Belgium

7:15 AM Integrated Survival and Quality of Life Outcomes in Lung Transplantation, Roger D. Yusen, MD, MPH, Washington University School of Medicine, St. Louis, MO

7:30 AM Patient-Reported Outcomes in Lung Transplantation, Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Ontario, Canada

7:45 AM Integrating Palliative Care in Lung Transplantation, Annette J. DeVito Dabbs, RN, PhD, University of Pittsburgh School of Nursing, Pittsburgh, PA

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 7:

Crossing the Lines (Continental C)

CHAIRS: REYNOLDS M. DELGADO, MD AND
MARGARET M. HANNAN, MD

7:00 AM Central Lines Infections In Cardiothoracic Transplantation, Jose G. Montoya, MD, Stanford University School of Medicine, Stanford, CA

7:20 AM VAD Infections – Going Into the Future and Learning From the Past, Aly El Banayosy, MD, Penn State Hershey Medical Center, Hershey, PA

7:40 AM Definitions of VAD Infections, Drive-Line Infections, Pocket Infections, and Device Infections, and their Application into Databases for Future Research, William L Holman, MD, University of Alabama at Birmingham, AL

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 8:

Disasters Early After Lung Transplant (Waldorf)

CHAIRS: THOMAS M. EGAN, MD, MSC AND
JOHN DARK, MB FRCS

Unexpected events and early disasters continue to challenge all centres, with a range of possible responses. A range of acute surgical and medical problems and specific solutions to these problems will be discussed.

7:00 AM Unexpected PGD 1 Hyperacute Rejection, Duane Davis, MD, Duke University Medical Center, Durham, NC

7:10 AM Unexpected PGD 2 Left Heart Failure, David C. McGiffin, MD, University of Alabama at Birmingham, AL

7:20 AM Kinked PA/PV, Joshua Sonett, MD, Columbia Presbyterian Medical Center, New York, NY

7:30 AM Unexpected Donor Anatomy, Martin Strueber, MD, Hannover Medical School, Hannover, Germany

7:40 AM Technical Aspects of ECMO, Clemens Aigner, MD, Medical University of Vienna, Austria

7:00 AM – 8:00 AM

SUNRISE SYMPOSIUM 9:

Tough Cases in the Management of the Sensitized Patient Case Presentations (Marquette)

CHAIRS: JACQUELINE LAMOUR, MD AND
ELAINE F. REED, PHD

This symposium will address a practice gap in the diagnosis and management of the patient who has evidence of anti-HLA antibodies undergoing transplantation. There is a significant amount of controversy in surrounding the appropriate management of the highly sensitized patient and this symposium will allow participants to understand the state-of-the-art thinking in the field. This symposium will use a practical case-based approach to highlight the issues raised in the transplantation of the highly sensitized patient undergoing heart or lung transplantation.

INVITED DISCUSSANTS, Linda J. Addonizio, MD, Columbia Presbyterian Medical Center, New York, NY and
Stephan M. Ensminger, MD, PhD, University of Erlangen-Numberg, Germany

7:00 AM Treatment of the Sensitized Lung Transplant Patient, Susan D. Moffatt-Bruce, MD, PhD, Ohio State University Medical Center, Columbus, OH

7:15 AM Discussion

7:20 AM Rising Donor Specific Antibodies after Transplant despite Excellent Graft Function: To Treat or Not to Treat, Jeffrey G. Gossett, MD, Children's Memorial Hospital, Chicago, IL

7:35 AM Discussion

7:40 AM *Cardiac Transplantation in a Highly Sensitized Pediatric Patient with Congenital Heart Disease*, Chesney D. Castleberry, MD, Medical College of Wisconsin, Wauwatosa, WI

7:55 AM *Discussion*

8:00 AM – 10:15 AM
PLENARY SESSION

(Continental A/B)

CHAIRS: JOHN DARK, MB FRCS AND
RICHARD N. PIERSON, III, MD

8:00 AM **INVITED LECTURE**, *New Therapies for Sensitized Renal Allograft Recipients*, Patrick G. Dean, MD, Mayo Clinic Transplant Center, Rochester, MN

8:20 AM **(351) FEATURED ABSTRACT** *Are DCD Lungs Superior? Excellent Intermediate Results from a Donation after Cardiac Death Lung Transplant National Collaborative*; B. Levvey,¹ M. Harkess,² D. Chambers,³ E. Granger,² I. Ahmed,² P. Hopkins,³ A. Glanville,² G. Snell.¹ ¹The Alfred Hospital, Melbourne, Vic, Australia; ²St. Vincent's Hospital, Sydney, NSW, Australia; ³Prince Charles Hospital, Brisbane, QLD, Australia.

8:30 AM **INVITED DISCUSSANT**, Andres Varela, MD, Hospital Universita Puerta de Hierro

8:35 AM **(352) FEATURED ABSTRACT** *Cardiac Resuscitation Following Circulatory Arrest in the Organ Donor Is Associated with Excellent Functional and Metabolic Recovery: Implications for Clinical Heart Transplantation*; A.A. Ali,¹ B. Xiang,² P. White,¹ S. Tsui,¹ E. Ashley,³ S.R. Large,¹ T.W. Lee,² R. Arora,² G. Tian,² D.H. Freed.² ¹Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom; ²University of Manitoba, Winnipeg, MB, Canada; ³Stanford University Medical Center, Palo Alto, CA.

8:45 AM **INVITED DISCUSSANT**, Carmelo A. Milano, MD, Duke University Medical Center, Durham, NC

8:50 AM **INVITED LECTURE**, *Stem Cell Tissue Engineering*, Prof. Dr. Thomas Eschenhagen, University Hospital Hamburg-Eppendorf, Hamburg, Germany

9:10 AM **(353) FEATURED ABSTRACT** *United States Lung Allocation Score Predicts Hospital Charges Post-Transplant*; G.J. Arnaoutakis,¹ J.G. Allen,¹ C.A. Merlo,² W.A. Baumgartner,¹ J.V. Conte,¹ A.S. Shah.¹ ¹The Johns Hopkins Hospital, Baltimore, MD; ²The Johns Hopkins Hospital, Baltimore, MD.

9:20 AM **INVITED DISCUSSANT**, Edward R. Garrity, Jr., MD, University of Chicago Medical Center, Chicago, IL

9:25 AM **(354) FEATURED ABSTRACT** *Serum IgA Deficiency Is Common in Lung Transplantation and Is Independently Associated with Bronchiolitis Obliterans Syndrome (BOS)*; D.C. Chambers, B. Davies, S. Yerkovich, P.M. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia.

9:35 AM **INVITED DISCUSSANT**, Andrew J. Fisher, MD, Institute of Cellular Medicine, Newcastle Upon Tyne, United Kingdom

9:40 AM **AWARDS PRESENTATIONS**

9:55 AM **DEBATE: Mechanical Circulatory Support is IN, Heart Transplantation is OUT**

PRO: O. Howard, Frazier, MD, Texas Heart Institute, Houston, TX

CON: Mandeep R. Mehra, MD, University of Maryland School of Medicine, Baltimore, MD

9:00 AM – 12:00 Noon

Press Office Open (Continental Foyer Office 1)

10:15 AM – 10:30 AM

Coffee Break (Registration Area)

10:30 AM – 12:00 PM

CONCURRENT SESSION 42:
Blood, Clots and Antibodies (Continental A/B)

CHAIRS: DARREN H. FREED, MD, PHD, FRCSC AND
ROLAND HETZER, MD, PHD

10:30 AM **(355) Morbidity and Mortality Due to Thrombotic and Haemorrhagic Complications in Children Receiving Mechanical Cardiac Support Using the Berlin Heart Device**; T. Biss,¹ J. Cassidy,² A. Hasan,² P. Kesteven.¹ ¹Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Trust, Newcastle, Tyne and Wear; ²Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Trust, Newcastle, Tyne and Wear.

10:45 AM **(356) Patients in Critical Status Due to High Risk of Thromboembolism under Mechanical Circulatory Support Benefit More from Urgent Heart Transplantation than Other Candidates**; T. Komoda, T. Drews, H.B. Lehmkuhl, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

11:00 AM **(357) Acquired Von Willebrand Disease Frequently Occurs in Continuous Flow Left Ventricular Assist Devices**; N. Uriel,¹ S.-W. Pak,² U.P. Jorde,¹ S.A. Cappelman,² Y. Naka,² D. Mancini.¹ ¹Columbia University, New York, NY; ²Columbia University, New York, NY.

11:15 AM **(358) Desensitization Therapies Are Ineffective and May Increase Infection Rates in VAD Patients**; E. Feller,¹ E. Sorensen,² B. Griffith.³ ¹University of Maryland, Baltimore, MD; ²University of Maryland, Baltimore, MD; ³University of Maryland, Baltimore, MD.

11:30 AM (359) Highly Sensitized Patients on VAD Support Awaiting Heart Transplant on a Ventricular Assist Device (VAD) Appear To Have a Less Robust Immune Response Compared to Non-VAD Patients; M. Kittleson,² J. Moriguchi,² M. Kwon,¹ E. Reed,¹ S. Davis,² M. Kawano,² C. Burch,¹ A. Velleca,² E. Stimpson,² J. Patel,² A. Ardehali,¹ J. Kobashigaw,² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

11:45 AM (360) In Vivo Assessment of Thrombogenicity of the Penn State Pediatric Ventricular Assist Device; W.J. Weiss, E.L. Carney, J.B. Clark, T. Cooper, R. Peterson, T.P. Nifong, C. Siedlecli, B. Lukic, G. Rosenberg. Penn State Milton S. Hershey Medical Center, Hershey, PA.

10:30 AM – 12:00 PM

CONCURRENT SESSION 43:

Lung Transplantation Complications (Boulevard)

CHAIRS: MARC A. STERN, MD AND
PETER M. HOPKINS, FRACF

10:30 AM (361) Retinoid Therapy Is Ineffective in Preventing Cutaneous Malignancy Complicating Lung Transplantation; T. Tse, D.C. Chambers, P.M.A. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia.

10:45 AM (362) PTLD after Lung Transplantation – Influence of CMV Prophylaxis on Incidence – Multicentre Centre Analysis and Review of the Literature; P. Jaksch,¹ J. Gottlieb,⁴ C. Geltner,² A. Simon,³ J. Ankersmit,¹ W. Klepetko.¹ ¹Medical University Vienna, Vienna, Austria; ²LKH Natter, Innsbruck, Austria; ³Medical University Hannover, Hannover, Germany; ⁴Medical University Hannover, Hannover, Germany.

11:00 AM (363) Tacrolimus Neurotoxicity in Lung Transplant Recipients; L.J. Stuckey,¹ R. Florn,² C. Bartos,² H. McCullough,² M.K. Han,² K.R. Flaherty,² V.N. Lama,² S. Gay,² T. Ojo,² F.J. Martinez,² A.C. Chang,³ R. Mahidhara,³ J. Lin,³ K.M. Chan.² ¹University of Michigan Health Systems, Ann Arbor, MI; ²University of Michigan Health Systems, Ann Arbor, MI; ³University of Michigan Health Systems, Ann Arbor, MI.

11:15 AM (364) Posterior Reversible Encephalopathy Syndrome after Lung Transplantation; L. Hatos-Agyi,¹ A. Scheed,¹ M. Keplinger,² P. Jaksch,¹ W. Klepetko.¹ ¹Medical University of Vienna, Vienna, Austria; ²Medical University of Vienna, Vienna, Austria.

11:30 AM (365) Ambulatory Muscle Strength Recovery Is Significantly Delayed When Compared to Improvements in Lung Function and Six Minute Walk Distance after Lung Transplantation; J.R. Walsh,¹ D.C. Chambers,¹ R.J. Davis,¹ H.E. Seale,¹ N.R. Morris,² F.D. Kermeen,¹ P.M.A. Hopkins.¹ ¹The Prince Charles Hospital, Brisbane, QLD, Australia; ²Griffith University, Gold Coast, QLD, Australia.

11:45 AM (366) Lung Transplantation following Hematopoietic Stem Cell Transplantation: An International Review; S.M. Chernenko, J. Lipton, J. Dorosz, D. Zogalo, T. Waddell, M. de Perrot, S. Keshavjee, L.G. Singer. Toronto General Hospital, Toronto, ON, Canada.

10:30 AM – 12:00 PM

CONCURRENT SESSION 44:

Late Complications Post Heart Transplantation (Continental C)

CHAIRS: MARIAN ZEMBALA, MD, PHD, FESC AND
DANIEL J. GOLDSTEIN, MD

10:30 AM (367) Lung Cancer after Heart Transplantation: Incidence and Prognosis. Data from the Spanish Post-Heart-Transplant Tumour Registry; M.G. Crespo-Leiro,¹ N. Manito,² G. Rabago,³ L. Almenar-Bonet,⁴ L.A. Alonso-Pulpon,⁵ S. Mirabet,⁶ J. Fernandez-Yanez,⁷ B. Diaz-Molina,⁸ F. Gonzalez-Vilchez,⁹ N. Romero,¹⁰ J.M. Arizon,¹ J.F. Delgado,¹² E. Roig,¹³ T. Blasco,¹⁴ D.A. Pascual-Figal,¹⁵ L. de la Fuente-Galan,¹⁶ J. Muniz.¹⁷ ¹Hospital Universitario A Coruña, A Coruña, Spain; ²Hospital Universitario de Bellvitge, Barcelona, Spain; ³Clinica Universitaria de Navarra, Pamplona, Spain; ⁴Hospital Universitario La Fe, Valencia, Spain; ⁵Hospital Puerta de Hierro, Madrid, Spain; ⁶Hospital Santa Creu i Sant Pau, Barcelona, Spain; ⁷Hospital General Universitario Gregorio Marañón, Madrid, Spain; ⁸Hospital Universitario Central de Asturias, Oviedo, Spain; ⁹Hospital Universitario Marques de Valdecilla, Santander, Spain; ¹⁰Hospital Virgen del Rocío, Sevilla, Spain; ¹¹Hospital Universitario Reina Sofia, Cordoba, Spain; ¹²Hospital Universitario ¹² de Octubre, Madrid, Spain; ¹³Hospital Clinic i Provincial, Barcelona, Spain; ¹⁴Hospital Universitario Miguel Servet, Zaragoza, Spain; ¹⁵Hospital Virgen de la Arrixaca, Murcia, Spain; ¹⁶Hospital Clinico de Valladolid, Valladolid, Spain; ¹⁷Instituto de Ciencias de la Salud, A Coruña, Spain.

10:45 AM (368) Outcomes after Chemotherapy for Post Transplant Lymphoproliferative Disorder in Pediatric Heart Transplant Recipients; M.E. Spotnitz,¹ M.E. Richmond,² J.D. Dayton,² M.A. Orjuela,³ J.M. Chen,⁴ L.J. Addonizio.² ¹Columbia University College of Physicians and Surgeons, New York, NY; ²Columbia University Medical Center, Children's Hospital of New York-Presbyterian, New York, NY; ³Columbia University Medical Center, Children's Hospital of New York-Presbyterian, New York, NY; ⁴Columbia University Medical Center, Children's Hospital of New York-Presbyterian, New York, NY.

11:00 AM (369) Non-Invasive Assessment of Coronary Flow Reserve Is Associated to the Severity of Newly Defined ISHLT Classification of Cardiac Allograft Vasculopathy; A. Iacovoni, R. Fiocchi, R. Sebastiani, A. Fontana, E. Radavelli, A. Gamba. Ospedali Riuniti, Bergamo, Italy.

11:15 AM (370) The Incidence and Outcome of Sensitization in Patients Awaiting Re-do Heart Transplantation; M. Kawano,² J. Patel,² M. Kittleson,² E. Reed,¹ D. Gjertson,¹ M. Cecka,¹ A. Velleca,² E. Stimpson,² C. Burch,¹ S. Davis,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

11:30 AM (371) First Angioplasty Does Not Appear To Alter Outcome in Heart Transplant Patients with Newly Diagnosed Transplant Coronary Artery Disease; M. Kittleson,² J. Patel,² B. Azarbal,² J. Moriguchi,² M. Kawano,² S. Davis,² A. Hage,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

11:45 AM (372) Asymptomatic Positive CMV Serology Is Associated with Increased Risk for the Development of Transplant Coronary Artery Disease (TCAD): Who Needs Symptoms?; J. Patel,² M. Kittleson,² B. Kubak,¹ M. Kawano,² S. Davis,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

10:30 AM – 12:00 PM

CONCURRENT SESSION 45:

Transplantation for Pediatric Cardiomyopathies (Waldorf)

CHAIRS: KIMBERLY L. GANDY, MD, PHD AND CHARLES E. CANTER, MD

This symposium will provide important information about the specific outcomes of heart transplantation in children with different classes of cardiomyopathies. This information will be used to provide clinicians with a better understanding of the risks and benefits of transplantation in children with pediatric cardiomyopathies. This symposium will review the indications and outcomes of transplantation in patients with all forms of cardiomyopathy

10:30 AM Classification of Cardiomyopathies and Impact of Genetic Diagnosis on Prognosis, Jeffrey A. Towbin, MD, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

10:45 AM Indications and Outcomes of Listing for Transplantation in Pediatric Cardiomyopathies, Daphne Hsu, MD, Children's Hospital at Montefiore, Bronx, NY

11:00 AM Which Patients, What Device, and When to Use Mechanical Assist Support in Pediatric Cardiomyopathies? Robert D. B. Jaquiss, MD, Arkansas Children's Hospital, Little Rock, AR

11:15 AM Outcomes of Transplantation in Patients With Dilated Cardiomyopathy, Richard Kirk, MA FRCP FRCPCH, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

11:30 AM Outcomes of Transplantation in Patients With Restrictive Cardiomyopathy, Steven D. Zangwill, MD, Children's Hospital of Wisconsin, Milwaukee, WI

11:45 AM Outcomes of Transplantation in Patients With Hypertrophic Cardiomyopathy, Robert J. Gajarski, MD, CS Mott Children's Hospital, Ann Arbor, MI

10:30 AM – 12:00 PM

CONCURRENT SESSION 46:

What's Hot! Best Abstracts from Mechanical Circulatory Support, Heart Transplantation, Lung Transplantation (Marquette)

CHAIRS: RICHARD N. PIERSON, III, MD AND HERMANN REICHENSPURNER, MD, PHD

This session provides summaries of the best, most compelling abstracts presented earlier in the week during the ISHLT 2010 Annual Meeting.

10:30 AM What's Hot, What's Cool in Clinical Thoracic Transplantation and Cardiopulmonary Support, Bartley P. Griffith, MD, University of Maryland, Baltimore, MD

11:00 AM What's Hot! Best Abstracts from Stem Cell Transplantation and Tissue Engineering, Sonja Schrepfer, MD, PhD, University Heart Centre Hamburg, Germany

11:30 AM What's Hot! Best Abstracts from Experimental Solid Organ Transplantation, Paul Fedak, MD, PhD, FRCS, Foothills Medical Center, Calgary, Canada

12:15 PM – 1:15 PM

COUNCIL REPORTS TO THE MEMBERSHIP AND BOARD (Continental C)

1:30 PM – 5:30 PM

ISHLT BOARD OF DIRECTORS MEETING (Lake Erie Room)

Wednesday • Thursday • Friday
April 21 – 23, 2010

SOUTHWEST EXHIBIT HALL

(373) Does Race Mismatch Have an Impact on Outcome after Heart Transplantation?; S. Montgomery,² M. Kawano,² D. Lockhart,² A. Velleca,² C. Burch,¹ J. Patel,² S. Davis,² M. Kittleson,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

(374) The Threat of Medication Miscommunication in Non-English Speaking Heart Transplant Recipients; A. Velleca,² C. Burch,¹ S. Montgomery,² D. Lockhart,² J. Patel,² M. Kittleson,² M. Kawano,² S. Davis,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

(375) Impact of Ventricular Assist Device (VAD) Implantation on Clinical and Economic Outcomes of Heart Transplantation (HT) in the United States (US) from 2001-2006; H.K. Song,¹ B. Diggs,¹ F. Mcneil,¹ K. Caddell,¹ M. Slater,¹ F. Tibayan,¹ S. Guyton,¹ E. Adler,² A. Kim.² ¹Oregon Health and Science University, Portland, OR; ²Oregon Health and Science University, Portland, OR.

(376) Trends in the Functional Outcomes and Quality of Life of Cystic Fibrosis Patients following Lung Transplant; M. Loadman, J. Holman, K. Jackson, J. Weinkauf, N. Roland, A. Kapasi, D. Lien. University of Alberta, Edmonton, AB, Canada.

(377) Children's Conceptions of Their Parent's Lung Transplant; T.M. Leisfield,¹ K. Wiggins,¹ P. Fullbrook.² ¹The Prince Charles Hospital, Brisbane, QLD, Australia; ²The Prince Charles Hospital, Brisbane, QLD, Australia.

(378) Factors Modifying Immunosuppression-Related Symptom Experiences in Heart Transplant Recipients; C. Kugler, P. Stiefel, D. Malehsa, M. Strueber, A. Simon, U. Tegtbur, A. Haverich, C. Bara. Hannover Medical School, Hannover, Germany; Hannover Medical School, Hannover, Germany.

(379) Improved Bloodcompatibility of a Poly-4-Methyl-1-Pentene Gas Exchange Membrane by Endothelialization; B. Wiegmann,¹ C. Hess,² A. Hilfiker,² A. Haverich,¹ S. Fischer.¹ ¹Hannover Medical School, Hannover, Germany; ²Leibniz Research Laboratories for Biotechnology and Artificial Organs, Hannover, Germany.

(380) Non-Volume-Loaded Heart Provides a More Relevant Heterotopic Transplantation Model; K.R. Tang-Quan,^{1,2} J. Bartos,² T. Deuse,^{1,2} R.C. Robbins,² H. Reichenspurner,¹ S. Schrepfer.^{1,2} ¹University Heart Center Hamburg, Hamburg, Germany; ²Stanford University School of Medicine, Stanford, CA.

(381) The Effect of Gastro-Duodenal Contents on Tracheal Mucosa: There Is More to It than Acid; V. Mertens,¹ R. Farre,¹ K. Blondeau,¹ A. Pauwels,¹ D. Sifrim,^{1,2} L. Dupont.^{3,4} ¹University Hospital Gasthuisberg, Leuven, Belgium; ²Barts and The London School of Medicine and Dentistry, University of London, London, United Kingdom; ³Katholieke Universiteit Leuven, Leuven, Belgium; ⁴University Hospital Gasthuisberg, Leuven, Belgium.

(382) Reduced Transplant Arteriosclerosis after Treatment with MMF and MMF in Combination with Ganciclovir in a Mouse Aortic Transplant Model; J. Hoffmann, M. Bohm, S. Abele-Ohl, M. Weyand, S.M. Ensminger, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany.

(383) MyD88-Independent Signaling Pathway Is Involved with Lung Ischemic Preconditioning; A. Shimamoto, Y. Yajima, S. Shomura, M. Takao, H. Shimpō, Mie University Graduate School of Medicine, Tsu, Japan.

(384) Egr1 Prevents Coronary Endothelial ICAM-1 Expression in Response to Calcineurin Inhibition; M.V. Badiwala, L.C. Tumiati, A. Ghashghai, J.M. Joseph, V. Rao. Toronto General Hospital, Toronto, ON, Canada.

(385) Expression of a Stabilized Hypoxia Inducible Factor-1 α Reduces Cardiomyocyte Apoptosis and Prevents Cardiac Allograft Vasculopathy; M.A.I. Keranen,¹ A.I. Nykanen,¹ R. Krebs,¹ K. Pajusola,² K. Alitalo,² K.B. Lemstrom.^{1,3} ¹University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; ²Biomedicum Helsinki, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; ³University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

(386) Contribution of Pre-Existing Vascular Disease to Allograft Vasculopathy in Mice; A. Zaki, J. Jordan, G. Hirsch, B. Ross, T. Lee. Dalhousie University, Halifax, NS, Canada.

(387) The Role of Plaque Haemorrhage in Progression of Coronary Allograft Vasculopathy; C. Castellani,¹ A. Angelini,¹ O. de Boer,² C. van der Loos,² M. Fedrigo,¹ A. Gambino,³ G. Gerosa,³ G. Thiene,¹ A.C. van der Wal.² ¹University of Padua, Padua, Italy; ²Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands; ³University of Padua, Padua, Italy.

(388) Electroporation-Mediated Delivery of Functional Genes – A Promising Approach for Non-Viral-Based Gene Therapy for the Failing Heart; S. Eigeldinger-Berthou, P. Buntschuh, M. Fluck, M.-N. Fluck-Giraud, T. Carrel, H. Tevearai, A. Kadner. University Hospital Berne, University Berne, Berne, Switzerland.

(389) The Indirect Alloimmune Response Causes Endothelial Dysfunction without Endothelial Replacement after Cardiac Transplantation; Y. Xu, A. McCormack, A. Chester, B. Hariri, P. Sarathchandra, M.L. Rose, Imperial College London, London, United Kingdom.

(390) Impact of Topically-Applied Preservation Solutions on Mucociliary Clearance and Tracheal Ischemic Injury in Rats; A.E. de Azevedo-Pereira,¹ K.A. Oliveira,¹ R. Pazetti,¹ J. Saka,¹ M. Canzian,² P.M. Pego-Fernandes,¹ F.B. Jatene.¹ ¹Heart Institute, University of São Paulo Medical School, São Paulo, Brazil; ²Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.

(391) T-Bet Deficiency Alters Murine Obliterative Airway Disease Immunopathology and Is Associated with Both Type 1 and Type 17 Effector T Cell Responses; E.A. Lendermon,¹ E.R. John,¹ H. Miller,¹ P.D. Shah,¹ J.B. Orens,¹ A.C. Myers,² J.F. McDyer.¹ ¹Johns Hopkins, Baltimore, MD; ²Johns Hopkins, Baltimore, MD.

(392) Interaction between α -1-Antitrypsin (AAT) and A-Defensins in Regulating Immune Responses Leading to Chronic Rejection Following Human Lung Transplantation; D. Saini,¹ S. Ramachandran,¹ N. Steward,¹ A. Aloush,¹ R. Hachem,¹ E. Trulock,¹ A. Patterson,¹ T. Mohanakumar.^{1,2} ¹Washington University in St Louis, St. Louis, MO; ²Washington University in St Louis, St. Louis, MO.

(393) The Gender Divide: Does Donor Gender Matter for Mesenchymal Stem Cell Transplantation?; C. Pahrman,¹ K.R. Tang-Quan,^{1,2} M. Yamada,² T. Deuse,^{1,2} R. Robbins,² H. Reichenspurner,¹ S. Schrepfer.^{1,2} ¹University Heart Center Hamburg, Hamburg, Germany; ²Stanford University School of Medicine, Stanford, Germany.

(394) The Role of CCR4 during the Pathogenesis of Murine Obliterative Bronchiolitis Post-Transplantation; V. Palchevskiy,¹ Y.Y. Xue,¹ R. Kern,¹ S.S. Weigt,¹ S. Hu,¹ A. Derhovanessian,¹ S.X. Song,² A. Gregson,¹ R. Elashoff,¹ J.P. Lynch,¹ J.A. Belperio.¹ ¹University of California, Los Angeles, Los Angeles, CA; ²University of California, Los Angeles, Los Angeles, CA; ³University of California, Los Angeles, Los Angeles, CA.

(395) Assessment of a Liposomal Ciclosporin Inhalation Formulation to Better Understand Drug Delivery, Drug Distribution and Biopharmaceutical Properties; M. Keller, O. Denk, F. Gruber, A. Bucholski, S. Prante, J. Schierholz. PARI Pharma GmbH, Munich, Germany.

(396) Coronary Intervention in Lung Transplant Candidates – Does It Impact Survival?; C. Chaparro,² W. Karolak,¹ C. Volling,² L. Daniel,⁵ D. Delgado,⁵ F. Chen,¹ M. Cypel,¹ C. Guitierrez,² C. Whytehead,¹ L.G. Singer,² M. Hutcheon,² C.-W. Chow,² K. McRae,⁴ V. Rao,³ R.J. Cusimano,³ M. de Perrot,¹ T. Waddell,¹ A. Pierre,¹ K. Yasufuku,¹ S. Keshavjee.¹ ¹Toronto General Hospital, University of Toronto, Toronto, ON, Canada; ²Toronto General Hospital, University of Toronto, Toronto, ON, Canada; ³Toronto General Hospital, University of Toronto, Toronto, ON, Canada; ⁴Toronto General Hospital, University of Toronto, Toronto, ON, Canada; ⁵Toronto General Hospital, Toronto, ON, Canada.

(397) Post Lung Transplant Cardiovascular Complications – Role of Cardiovascular MRI; H. Seethamraju,¹ D. Shah,² R. Kesavan,¹ S. Bollineni,¹ J. Estep,² M. Loebe,¹ G.P. Noon,¹ A. Shah,² S. Scheinin,¹ S. Jyothula,¹ G. Torre.² ¹Baylor College of Medicine, Houston, TX; ²Methodist DeBakey Heart and Vascular Center, Houston, TX.

(398) Reduction in Venous Thromboembolism Following Prophylaxis Modification in Lung Transplantation Patients; J.P. Gagermeier,¹ C.G. Alex,¹ D.F. Dilling,¹ T. Patel,¹ C.H. Wigfield,² R.B. Love.² ¹Loyola University Medical Center, Maywood, IL; ²Loyola University Medical Center, Maywood, IL.

(399) Early Surgical Complications Affect Outcome after Lung and Heart-Lung Transplantations; O. Mercier, E. Fadel, F. Leroy Ladurie, J. Cerrina, S. Mussot, D. Fabre, P.G. Darteville. Marie Lannelongue Hospital, Le Plessis Robinson, France.

(400) Aggressive Skin Cancers Associated with Prolonged Voriconazole Therapy in 3 Lung Transplant Patients; S. Quetant,¹ C. Saint-Raymond,¹ A. Hugon,⁴ P. Bedouch,⁴ O. Epaulard,³ C. Pison,¹ M.-T. Leccia.² ¹Grenoble University Hospital, Grenoble, France; ²Grenoble University Hospital, Grenoble, France; ³Grenoble University Hospital, Grenoble, France; ⁴Grenoble University Hospital, Grenoble, France.

(401) Post Transplant Neoplastic Disease Following Lung Transplant: 17-Years Single Centre Experience; P. Totaro,¹ C. Pellegrini,¹ M. Savasta,¹ S. Nicolardi,¹ T. Oggionni,² G. Orlandoni,³ A.M. D'Armini,⁴ M. Viganò.⁴ ¹IRCCS Foundation S Matteo, Pavia, Italy; ²IRCCS Foundation S Matteo, Pavia, Italy; ³IRCCS Foundation S Matteo, Pavia, Italy; ⁴University School of Medicine, Pavia, Italy.

(402) Multidisciplinary Diagnostic Approach Identifies Gastroesophageal Reflux Disease-Related Lung Aspiration Associated with High Risk of Chronic Rejection; M. Loy, F. Calabrese, F. Lunardi, F. Di Chiara, E. Balestro, M. Costantini, L. Zanatta, F. Rea. University of Padua Medical School, Padua, Italy.

(403) The Incidence of Oropharyngeal Dysphagia and Associated Risk Factors Following Double Lung Transplantation: A Retrospective Study; S.A. Skoretz,^{1,2} M. Graham,² G. Kamitomo,² R. Martino.^{1,3} ¹University of Toronto, Toronto, ON, Canada; ²University of Alberta Hospital, Edmonton, AB, Canada; ³Toronto Western Research Institute, Toronto, ON, Canada.

(404) Comparative Outcome of Transplantation for Eisenmenger Syndrome and Other Pulmonary Arterial Hypertension Indications; E. Fadel, O. Mercier, S. Mussot, D. Fabre, P. Darteville. Hopital Marie Lannelongue, Le Plessis Robinson, France.

(405) Peri-Operative Hyperglycemia and Acute Cellular Rejection 12 Months after Lung Transplantation; S. Indacochea,¹ A. DePorre,³ D.F. Dilling,¹ N.V. Emanuele,¹ J.P. Gagermeier,¹ C.H. Wigfield,² C.G. Alex,¹ R.B. Love,² M.A. Emanuele.¹ ¹Loyola University Medical Center, Maywood, IL; ²Loyola University Medical Center, Maywood, IL; ³Loyola University Stritch School of Medicine, Maywood, IL.

(406) The Clinical Relevance of Mannose-Binding Lectin (MBL) in Long Term Survival of Lung Transplant Recipients; J.M. Kwakkel-van Erp,¹ E.A. van de Graaf,¹ A.W.M. Paantjens,² D.A. van Kessel,³ J.M.M. van den Bosch,³ J.C. Grutters,³ H. Otten.² ¹University Medical Center Utrecht, Utrecht, Netherlands; ²University Medical Center Utrecht, Utrecht, Netherlands; ³Antonius Hospital, Nieuwegein, Netherlands.

(407) Comparison of Outcome Following Heart/Lung Transplantation for Chronic Thromboembolic Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension; R.V. Venkateswaran, D. Jenkins, J. Dunning, S. Tsui, J. Wallwork, J. Parmar. Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.

(408) Benefits of a Structured Lung Transplant Curriculum in Pulmonary/Critical Care Fellowship; D. Hayes, Jr., R. Berger,² E. Diaz-Guzman,² T.W. Mullett,³ S.S. Kraman.² ¹University of Kentucky College of Medicine, Lexington, KY; ²University of Kentucky College of Medicine, Lexington, KY; ³University of Kentucky College of Medicine, Lexington, KY.

(409) Minimizing Post Operative Ventilation Times in Lung Transplant Recipients; J.D. Maloney,¹ S. Osaki,¹ H. Thomas,¹ R.D. Cornwell,² K.C. Meyer,² N.C. De Oliveira.¹ ¹University of Wisconsin, Madison, WI; ²University of Wisconsin, Madison, WI.

(410) Outcome of Lung Graft Volume Reduction for Oversized Donors during Pulmonary Transplantation; S. Shanmuganathan, B. Tanveer, S. Clark. The Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom.

(411) 25 Years of Heart & Lung Transplantation: Past, Present & Future; D.G. Healy, J. Dunning, J. Parmar, L. Sharples, J. Parameshwar, J. Wallwork, S. Tsui. Papworth Hospital, Cambridge, United Kingdom.

(412) Antibiotic Desensitization in Cystic Fibrosis Patients with a History of Hypersensitivity Undergoing Lung Transplantation Is Not Mandatory; T. Tse,¹ P.M.A. Hopkins,¹ M.W. France,² P.J. Masel,² S.C. Bell,² F.D. Kermeen,¹ D.C. Chambers.¹ ¹The Prince Charles Hospital, Brisbane, QLD, Australia; ²The Prince Charles Hospital, Brisbane, QLD, Australia.

(413) Impact of the UNOS Lung Allocation Score on Lung Transplantation for Chronic Obstructive Pulmonary Disease; S. Osaki,¹ J.D. Maloney,¹ R.D. Cornwell,² K.C. Meyer,² N.M. Edwards,¹ N.C. De Oliveira.¹ ¹University of Wisconsin, Madison, WI; ²University of Wisconsin, Madison, WI.

(414) Lung Transplantation in Lithuania: Two Years Experience; K. Malakauskas,¹ L. Jankauskiene,² E. Gasiuniene,¹ A. Vitkauskiene,³ V. Sarauskas,⁴ N. Vaguliene,¹ E. Sirvinskas,⁵ R. Bolys,² R. Benetis,² R. Sakalauskas.¹ ¹Kaunas University of Medicine, Kaunas, Eiveniu 2, Lithuania; ²Kaunas University of Medicine, Kaunas, Eiveniu 2, Lithuania; ³Kaunas University of Medicine, Kaunas, Eiveniu 2, Lithuania; ⁴Kaunas University of Medicine, Kaunas, Eiveniu 2, Lithuania; ⁵Kaunas University of Medicine, Kaunas, Eiveniu 2, Lithuania.

(415) Pre-Transplant Allosensitization Is a Barrier to Lung Transplantation; J.T. Weber,¹ B.F. Meyers,² A. Patterson,² E.P. Trulock,¹ R.R. Hachem.¹ ¹Washington University School of Medicine, Saint Louis, MO; ²Washington University School of Medicine, Saint Louis, MO.

(416) The Preoperative Levels of Panel Reactive Antibody Is Associated with Poor Outcome of Lung Transplant; A. Khani-Hanjani, D. Lien, J. Mullen, S. Meyer, J. Weinkauff, P. Campbell, K. Jackson, K. LaBranche, C. Norris, A. Oreopolus, P. Lo. University of Alberta, Edmonton, AB, Canada.

(417) Analysis of Nontuberculous Mycobacteria Infections in Lung Transplant Recipients; R.R. Pillai,¹ V.G. Valentine,¹ S.D. Lick,¹ G.A. Lombard,² S.G. LaPlace,² K.J. McAnally,² L. Seoane.² ¹University of Texas, Medical Branch, Galveston, TX; ²Ochsner Medical Center, New Orleans, LA.

(418) Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation in Severe End Stage Pulmonary Disease; P. Hammainen,¹ H. Schersten,² K. Lemstrom,¹ G.C. Riise,³ S. Kukkonen,³ K. Sward,⁴ J. Sipponen,¹ M. Silverborn,² G. Dellgren,³ ¹Helsinki University Hospital, Helsinki, Finland; ²Sahlgrenska University Hospital, Göteborg, Sweden; ³Sahlgrenska University Hospital, Göteborg, Sweden; ⁴Sahlgrenska University Hospital, Göteborg, Sweden; ⁵Helsinki University Hospital, Helsinki, Finland.

(419) Significant Side Effect Burden of Voriconazole Curtails Clinical Utility in Lung Transplantation; C.A. Beck, D.C. Chambers, F.D. Kermeen, T. Tse, P.M.A. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia.

(420) The Impact of Repeat HLA Mismatch on Pulmonary Retransplantation; A. Zeevi,¹ D. Zaldonis,¹ K. Spichty,¹ A. Girnita,² J. Howe,¹ L. Jelinek,¹ J. Lomago,¹ M. Crespo,¹ J. Pilewski,¹ C. Bermudez,¹ Y. Toyoda.¹ ¹University of Pittsburgh, Pittsburgh, PA; ²University of Cincinnati Academic Health Center, Cincinnati, OH.

(421) Should Patients with Coronary Artery Disease Undergo Lung Transplantation?; W. Sherman, D. Rabkin, D. Ross, R. Saggari, J.P. Lynch, D. Gjertson, M. Hamilton, A. Ardehali. David Geffen School of Medicine at UCLA, Los Angeles, CA.

(422) First Year Body Mass Index Trajectory Predicts Subsequent Survival in Lung Transplant Recipients; J.L. McMillan, P.M.A. Hopkins, S.T. Yerkovich, K.M. Herd, D.C. Chambers. The Prince Charles Hospital, Brisbane, QLD, Australia.

(423) Avoiding Mechanical Ventilation during Extracorporeal Membrane Oxygenation before Lung Transplantation Decreases Postoperative Mortality; W. Sommer, G. Warnecke, K. Olsson, J. Hadem, M.M. Hoepfer, J. Gottlieb, C. Fegbeutel, T. Welte, M. Strueber, A. Haverich, A.R. Simon. Hannover Medical School, Hannover, Germany.

(424) Impact of Pharmacokinetics on the Anticipated Duration of Calcineurin Inhibition after Inhalation of Cyclosporine Solution; R.W. Niven,¹ T.E. Corcoran.² ¹APT Pharmaceuticals, Burlingame, CA; ²University of Pittsburgh Medical Center, Pittsburgh, PA.

(425) Impact of Body Mass Index on Survival Following Lung Transplantation; J.K. Bhamra,¹ D. Zaldonis,¹ N. Shigemura,¹ T. Horai,¹ S. Tabata,¹ P. Bonde,¹ B. Sareyyupoglu,¹ J.M. Pilewski,² M. Crespo,² B.A. Johnson,² P. George,² S. Gilbert,¹ C.A. Bermudez,¹ M.A. Zenati,¹ Y. Toyoda.¹ ¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²University of Pittsburgh Medical Center, Pittsburgh, PA.

(426) The Combined Australian Experience with Human Swine Influenza H1N1 in Lung Transplant Recipients; B.J.H. Ng,¹ A.R. Glanville,² J. D'Costa,² G. Snell,³ M. Musk,⁴ M. Holmes,⁵ D.C. Chambers,¹ P.M.A. Hopkins.¹ ¹The Prince Charles Hospital, Chermside, QLD, Australia; ²St Vincent's Hospital, Darlinghurst, NSW, Australia; ³The Alfred Hospital, Melbourne, Vic, Australia; ⁴Royal Perth Hospital, Perth, Western Australia, Australia; ⁵Royal Adelaide Hospital, Adelaide, South Australia, Australia.

(427) Reduced Survival in Lung Transplant Recipients with Bile Acids Aspiration Despite Azithromycin Therapy; V. Mertens,¹ K. Blondeau,¹ B. Vanaudenaerde,² R. Vos,² A. Pauwels,¹ G. Verleden,^{2,3} D.E. Van Raemdonck,³ D. Sifrim,^{1,4} L.J. Dupont.^{2,3} ¹University Hospital Gasthuisberg, Leuven, Belgium; ²Katholieke Universiteit Leuven, Leuven, Belgium; ³University Hospital Gasthuisberg, Leuven, Belgium; ⁴Barts and The London School of Medicine and Dentistry, University of London, London, United Kingdom.

(428) Initial Experience with Concomitant Surgery of Lung Transplantation and Tricuspid Valve Repair for Patients with Severe Pulmonary Hypertension; N. Shigemura,¹ B. Sareyupoglu,¹ S. Tabata,¹ T. Horai,¹ P. Bonde,¹ M. Crespo,² B. Johnson,² J. Pilewski,² J. Bhama,¹ S. Gilbert,¹ C. Bermudez,¹ Y. Toyoda.¹ ¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²University of Pittsburgh Medical Center, Pittsburgh, PA.

(429) Long Term Outcome of Lung Transplantation in Previous Intravenous Drug Users with Tale Lung Granulomatosis; J.G. Weinkauf,¹ R. Nador,¹ A. Kapasi,¹ K. Jackson,² K. LaBranche,² L. Puttagunta,³ K.C. Stewart,⁴ J. Mullen,⁴ D.L. Modry,⁴ D.C. Lien.¹ ¹University of Alberta, Edmonton, AB, Canada; ²University of Alberta, Edmonton, AB, Canada; ³University of Alberta, Edmonton, AB, Canada; ⁴University of Alberta, Edmonton, AB, Canada.

(430) Novel Surgical Training System of Lung Transplantation in Continuous Pulmonary Perfusion and Ventilation Using Pig Heart-Lung Blocks; T. Okamoto, T. Yamada, H. Morikawa, E. Nakayama, N. Satoda, J. Zhang, A. Takahashi, X. Zhao, F. Chen, T. Fujinaga, T. Shoji, H. Sakai, T. Bando, H. Date. Graduate School of Medicine, Kyoto University, Kyoto, Japan.

(431) Outcomes of Lung Transplant in Elderly Patients; C. Whytehead, S. Azad, M.A. Hutcheon, C.-W. Chow, C. Chaparro, T. Waddell, A. Pierre, K. Yasufuku, M. de Perrot, S. Keshavjee, L.G. Singer. Toronto General Hospital, Toronto, ON, Canada.

(432) Near-Infrared Spectroscopy in Lung Transplant Patients: Correlation with Invasive Hemodynamic Measurements; A.N. Ibrahimiye,¹ G. Singh,¹ H. Kim,¹ A. Iribarne,¹ R. Sladen,² J. Sonett,¹ M. Bacchetta.¹

¹Columbia University College of Physicians and Surgeons, New York, NY; ²Columbia University College of Physicians and Surgeons, New York, NY.

(433) Single Lung Transplantation in the Setting of Aborted Double Lung Transplantation; V. Puri, T. Guthrie, M. Scavuzzo, A.S. Krupnick, D. Kreisel, G.A. Patterson, B.F. Meyers. Washington University School of Medicine, St. Louis, MO.

(434) Statin Therapy Is Associated with Reduced Pulmonary Artery Pressures in Lung Transplant Candidates with COPD; R.M. Reed, R. Girgis. Johns Hopkins University School of Medicine, Baltimore, MD.

(435) Pulmonary Artery Hypertension: Endothelial Dysfunction and Statin Treatment; E.M. Bader,¹ R. Zolty.² ¹Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; ²Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

(436) Mortality and Readmission Rates in Hypoatremic Patients with Pulmonary Hypertension and Right Ventricular Failure; A. Rabinovitz,¹ R. Zolty.² ¹Jacobi Medical Center, Bronx, NY; ²Montefiore Medical Center, Bronx, NY.

(437) CMR Late Gadolinium Enhancement of the Right Ventricular Insertion Point in Pulmonary Arterial Hypertension; B.H. Freed, M. Gombert-Maitland, S. Chandra, S. Rich, E.B. Jamison, S.L. Archer, A.R. Patel. University of Chicago Medical Center, Chicago, IL.

(438) Determinants of Quality of Life and Patient Responses to Living with Pulmonary Arterial Hypertension; M.H. Park, M.A. Chesney, T.O. Aje, M. Gottlieb, G. Ramani, S.J. Synowski, J. Frederick, W.J. Kop. University of Maryland, Baltimore, MD.

(439) Does Diastolic Dysfunction Contribute to Pulmonary Hypertension in Patients with Advanced COPD Awaiting Lung Transplantation?; N. Selimovic, B. Andersson, M. Lomsky, G.C. Risse, B. Rundqvist. Sahlgrenska University Hospital, Gothenburg, Sweden.

(440) Secondary Pulmonary Hypertension Does Not Affect Survival but Impacts Short and Long Term Outcome Measures Following Lung Transplantation; J.G. Weinkauf,¹ R.G. Nador,¹ K.B. Jackson,² A.M. Kapasi,¹ K. LaBranche,² S.R. Meyer,³ D.L. Modry,³ J.C. Mullen,³ D.C. Lien.¹ ¹University of Alberta, Edmonton, AB, Canada; ²University of Alberta Hospital, Edmonton, AB, Canada; ³University of Alberta, Edmonton, AB, Canada.

(441) Predictors of Right Ventricular Function in Lung Transplant Candidates; N. Selimovic, B. Andersson, M. Lomsky, G.C. Riise, B. Rundqvist. Sahlgrenska University Hospital, Gothenburg, Sweden.

(442) Lower Weight Related to Elevated Liver Enzymes in Pulmonary Hypertension Patients Treated with Bosentan; E.A. Kobashigawa,¹ J.B. Schwartz,¹ W.-C. Hsueh,¹ N. Bendjilali,¹ A. Wu,² T. De Marco.¹ ¹University of California San Francisco, San Francisco, CA; ²San Francisco General Hospital, San Francisco, CA.

(443) WITHDRAWN

(444) Severe Hypoxia in Eisenmenger Syndrome Does Not Preclude Safe Performance of the Six Minute Walk Test; R.J. Davis,¹ K. Hall,¹ J.R. Walsh,¹ H.E. Seale,¹ J.E. Harris,¹ D.J. Radford,² F.D. Kermeen.¹ ¹The Prince Charles Hospital, Brisbane, QLD, Australia; ²The Prince Charles Hospital, Brisbane, QLD, Australia.

(445) Lack of Sensitivity of Morphological Features for the Detection of Antibody-Mediated Rejection on Monitoring Endomyocardial Biopsies; M. Fedrigo,¹ A. Gambino,² E. Benazzi,³ F. Poli,³ F. Tona,² A. Caforio,² C. Castellani,¹ M. Valente,¹ G. Gerosa,² G. Thiene,¹ A. Angelini.¹ ¹University of Padua, Padua, Italy; ²University of Padua, Padua, Italy; ³IRCCS Fondazione OMP MARE, Milano, Italy.

(446) Quantitative Analysis of Nerve Density across Airway Anastomosis in Lung Transplant Recipients; A.G. Duarte,¹ G.A. Campbell,¹ V.G. Valentine,¹ A.C. Myers.² ¹University of Texas Medical Branch, Galveston, TX; ²Johns Hopkins University, Baltimore, MD.

(447) Quilty Is a Risk Factor for Microvasculopathy in Biopsy Following Heart Transplantation – Evidence from a Prospective Clinical Study; N.E. Hiemann,¹ E. Wellnhofer,² H.B. Lehmkuhl,¹ C. Knosalla,¹ R. Hetzer,¹ R. Meyer.¹ ¹Deutsches Herzzentrum Berlin, Berlin, Germany; ²Deutsches Herzzentrum Berlin, Berlin, Germany.

(448) Tissue Plasminogen Activator Is the Most Important Component of a Novel Thrombosis/Activation (TA) Score for Predicting Cardiac Allograft Vasculopathy Following Heart Transplantation; C.A. Labarrere,¹ J.R. Woods,¹ J.W. Hardin,² G.L. Campana,¹ M.A. Ortiz,¹ B.R. Jaeger,³ B. Reichart,⁴ L.A. Baldrige,⁵ J.M. Bonnin,⁵ A. Currin,⁶ S.K. Cosgrove,⁶ P.C. Kirlin,⁶ J.A. O'Donnell,⁷ D.A. Hormuth,⁶ T.C. Wozniak.⁶ ¹Methodist Research Institute, Clarian Health Partners, Indianapolis, IN; ²University of South Carolina, Columbia, SC; ³Dr Stein und Kollegen, Monchengladbach, Germany; ⁴Ludwig-Maximilians-Universität, München, Germany; ⁵Indiana University School of Medicine, Indianapolis, IN; ⁶Clarian Health Partners, Indianapolis, IN; ⁷Krannert Institute of Cardiology, Indianapolis, IN.

(449) Relating Microarray Results from 105 Heart Allograft Biopsies to Pathology and Function: Molecular Phenotypes of Myocardial Inflammation and Injury Correlate with Impaired Function and Histological Signs of Microcirculation Injury; M. Mengel,¹

J. Chang,¹ D. Kim,² B. Sis,¹ J. Burton,² W. Tymchak,² P. Halloran.¹ ¹University of Alberta, Edmonton, Canada; ²University of Alberta, Edmonton, Canada.

(450) Characterization of IgM and Complement within CAV Lesions; E.L. Moseley,¹ M.J. Goddard,¹ J. Wallwork,³ C. Atkinson.² ¹Papworth Hospital NHS Trust, Cambridge, United Kingdom; ²Medical University of South Carolina, Charleston; ³Papworth Hospital NHS Trust, Cambridge, United Kingdom.

(451) Longitudinal Evaluation of Microvessel Density in Survivors Versus Non-Survivors of Cardiac Antibody-Mediated Rejection; M.P. Revelo, D.V. Miller, A.G. Kfoury, J. Stehlik, M. Everitt, D. Budge, R. Alharethi, E.M. Gilbert, F. Bader, M.E.H. Hammond. UTAH Cardiac Transplant Program, Salt Lake City, UT.

(452) Differential Leukocyte Gene Expression in Cardiac Transplant Recipients Receiving Tacrolimus Compared to Cyclosporine; J. Patel,¹ A.J. Hicks,¹ T. Rowe,² S.R. Hankins,¹ H.J. Eisen.¹ ¹Drexel University College of Medicine, Philadelphia, PA; ²Hahnemann University Hospital, Philadelphia, PA.

(453) Does a Difference in Molecular Diagnostic Test Results Exist between Proliferation Signal Inhibitors and Mycophenolic Acid in Cardiac Allograft Recipients?; J. Patel,¹ G. Mwanda,¹ T. Rowe,² S.R. Hankins,¹ H.J. Eisen.¹ ¹Drexel University College of Medicine, Philadelphia, PA; ²Hahnemann University Hospital, Philadelphia, PA.

(454) Lack of Association between Pre-Transplant MICA Antibodies and Cardiac Allograft Dysfunction; M.A. McDonald,¹ J. Braga,¹ P. Billia,¹ S. Tapiawala,² H.J. Ross,¹ K.J. Tinckam.² ¹University Health Network, Toronto, ON, Canada; ²University Health Network, Toronto, ON, Canada; ³Edmonton, AB.

(455) Applications of a Uniform Strategy of Virtual Cross Match in Heart Transplantation; P. Bonde, A. Zeevi, Y. Toyoda, R. Kormos, J. Bhama, R. McNamara, J. Teuteberg, B. Sareyyupoglu, T. Horai, M. Shullo, C. Bermudez. University of Pittsburgh Medical Center, Pittsburgh, PA.

(456) Heart Transplant Therapy in United States Veterans: 16-year Experience at A Single Center; D.R. Murray,¹ S. Osaki,² P. Jewel-Ripp,¹ M.R. Johnson,¹ L. Lozonschi,² N.M. Edwards,² T. Kohmoto.² ¹University of Wisconsin School of Medicine and Public Health, and William S. Middleton Memorial Veterans Hospital, Madison, WI; ²University of Wisconsin School of Medicine and Public Health, and William S. Middleton Memorial Veterans Hospital, Madison, WI.

(457) Does Listing Status Affect Cost of Heart Transplantation?; W. Sherman,¹ J. Kobashigawa,² M. Hamilton,² D. Gjertson,¹ J. Gomez Abraham,¹ H. Laks,¹ A.

Ardehali.¹ ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²David Geffen School of Medicine at UCLA/Cedars-Sinai Heart Institute, Los Angeles, CA.

(458) Positive Flow Crossmatches Associated with Poorer Survival; V. Kasirajan, M. Flattery, P. Kimball. Medical College of Virginia Hospitals, Richmond, VA.

(459) Positive Flow Cytometry Crossmatches and HLA Antibodies May Not Be Contraindications to Heart Transplantation; R.H. Kerman,¹ R. Radovancevic,² P.A. Allison,² E. McKissick,¹ R. Bogaev,² A.W. Bracey,² S. Allison,² I. Gregoric,² O.H. Frazier.² ¹University of Texas Health Science Center—Houston, Houston, TX; ²St. Luke's Episcopal Hospital, Houston, TX.

(460) Long-Term Follow-Up (>20 Years) after Orthotopic Heart Transplantation: Our Experience; S. Mastrobuoni,¹ A.M. Dell'Aquila,¹ P.M. Azcarate,² G. Bastarrika,³ G. Rabago,¹ J. Herreros.¹ ¹Clinica Universidad de Navarra, Pamplona, Navarra, Spain; ²Clinica Universidad de Navarra, Pamplona, Navarra, Spain; ³Clinica Universidad de Navarra, Pamplona, Navarra, Spain.

(461) Prediction of Survival in Patients on the Waiting List for Heart Transplantation: Prognostic Value of QRS Duration and Right Ventricular Dilatation; S. Buiz, N. Qedra, B. Tutkun, H. Lehmkuhl, C. Knosalla, M. Hubler, M. Pasic, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

(462) Does MFI Quantitation of Circulating Antibodies Correlate with Positive Cytotoxicity?; M. Kitleson,² J. Patel,² E. Reed,¹ Q. Zhang,¹ M. Cecka, E. Stimpson,² A. Velleca,² C. Burch,¹ M. Kawano,² S. Davis,² J. Moriguchi,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

(463) RVSWI Is an Independent Predictor of Need for MCS and/or HT in Stable Outpatients with NYHA Class III HF; G.R. Stevens,¹ J. Peacock,¹ A. Levin,¹ P. Pak,² N. Uriel,¹ P.C. Schulze,¹ P. Colombo,¹ U. Jorde,¹ Y. Naka,² D. Mancini,¹ M. Farr.¹ ¹Columbia University Medical Center, New York, NY; ²Columbia University Medical Center, New York, NY.

(464) The Impact of Virtual Crossmatch on Cardiac Allograft Vasculopathy in Heart Transplant Recipients; J.K. Rhee, E. McGee, Jr., H. Subacius, K.L. Grady, G. Ferguson, J.L. O'Leary, E. Schupbach, E. Shao, P. Kansal, A.R. Tambur, L. Klein, W.G. Cotts. Northwestern University, Chicago, IL.

(465) Should Aprotinin Be Used in Heart and Lung Transplantation?; M.I. Mydin,¹ M. Hawari,¹ R. Venkateswaran,¹ J. Parmar,¹ C. Sudarshan,¹ A. Vuylsteke,² D. Jenkins,¹ J. Dunning,¹ S. Tsui.¹ ¹Papworth Hospital, Papworth Everard, Cambridge, United Kingdom; ²Papworth Hospital, Papworth Everard, Cambridge, United Kingdom.

(466) Posttraumatic Stress Disorder and Major Depression in Heart Transplantation Recipients: The Relationship with Outcome and Medical Compliance; A. Favaro,¹ C. d'Agostino,² D. Zarnieri,¹ S. Boscolo,¹ M. Moz,² A. Gambino,² B. Volpe,¹ P. Santonastaso,¹ G. Gerosa.² ¹University of Padova, Padova, Italy; ²University of Padova, Padova, Italy.

(467) Low Immune Cell Function Assay Value Predicts Increased Risk for Cytomegaloviral, But Not Other Opportunistic Infections in Heart Transplant Patients: A Mid America Experience; T.M. Khumri,¹ K. St Clair,¹ S.L. Lawhorn,¹ A. Magalski,¹ T.L. Stevens,¹ A.M. Borkon,² A. Kao.¹ ¹Mid America Heart Institute, Kansas City, MO; ²Mid America Heart Institute, Kansas City, MO.

(468) High Plasma N-Terminal Brain Natriuretic Peptide Levels Are a Strong Predictor of Death in Patients after Orthotopic Heart Transplantation; T. Zielinski, M. Piotrowska, M. Sobieszczanska-Malek, K. Komuda, J. Korewicki. Institute of Cardiology, Warsaw, Poland.

(469) Diabetes Mellitus Following Heart Transplantation; L. Nikolaidis, S. Shah, F. McGonagle, J. Wong. Temple University, Philadelphia, PA.

(470) Discordance between Morphological and Functional Alterations during Cardiac Allograft Rejection: Diagnostic Value of Myocardial Wall Motion and Deformation Imaging; M. Dandel, H.B. Lehmkuhl, H. Siniawski, C. Knosalla, D. Kemper, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

(471) Combined Heart Kidney Re transplant Has Lower Survival than De Novo Transplant; V. Cotarlan, N. Uriel, G. Stevens, P.C. Colombo, M. Farr, S. Restaino, M.C. Deng, F. Latif, R. Bijou, Y. Naka, U. Jorde, D. Mancini. Columbia Presbyterian Med Ctr, New York, NY.

(472) Are There Differences in Gene Expression as Reflected by Molecular Diagnostic Testing between African-American and Non-African American Cardiac Transplant Recipients?; A.J. Hicks,¹ T. Rowe,² J. Patel,¹ G. Mwandia,¹ S.R. Hankins,¹ H.J. Eisen.¹ ¹Drexel University College of Medicine, Philadelphia, PA; ²Hahnemann University Hospital, Philadelphia, PA.

(473) CD4+ CD25+ Regulatory T-cell Levels Are Associated with Cardiac Allograft Vasculopathy; S. Aharinejad,^{1,2} M. Gmeiner,² S. Rodler,¹ A. Thomas,² T. Lucas,² G. Laufer,¹ A. Zuckermann,¹ M. Grimm.¹ ¹Medical University of Vienna, Vienna, Austria; ²Medical University of Vienna, Vienna, Austria.

(474) Interaction of CMV Prophylaxis and Pre-Emptive Strategies with Immunosuppressive Therapy: Potential Antiviral Effect of Everolimus; L. Potena,¹ C. d'Agostino,² D. Abate,⁴ G. Magnani,¹ F. Baccolini,³ T. Ionico,¹ F. Grigioni,¹ A. Gambino,² D. Sgarabotto,⁵ G. Toscano,² A. Branzi,¹ G. Gerosa.² ¹University of Bologna, Bologna, Italy; ²University of Padua, Padua, Italy; ³University of Bologna, Bologna, Italy; ⁴University of Padua, Padua, Italy; ⁵University of Padua, Padua, Italy.

(475) Graftvasculopathy: Have We Learned Something after All These Years?; S.L. Mahr, A.Z. Aliabadi, D. Dunkler, F. Eskandary, M. Grommer, D. Zimpfer, G. Laufer, A.O. Zuckermann. Medical University of Vienna, Vienna, Austria.

(476) Acute Kidney Injury in Heart Transplant Patients Assessed by RIFLE, AKIN, and Delta-Creatinine: Implications on Outcome; A. Schiferer,¹ D. Hutschala,¹ D. Dunkler,² M. Hiesmayr,¹ A. Zuckermann,³ E. Tschernko.¹ ¹Medical University of Vienna, Vienna, Austria; ²Medical University of Vienna, Vienna, Austria; ³Medical University of Vienna, Vienna, Austria.

(477) Levosimendan for Primary Graft Failure after Heart Transplantation: A Three-Year Follow up; A. Beiras-Fernandez,¹ F. Weis,² I. Kaczmarek,¹ M. Weis,² P. Uberfuhr,¹ F. Kur,¹ B. Reichart.¹ ¹LM-University, Munich, Germany; ²LM-University, Munich, Germany.

(478) Late Gadolinium Enhancement Patterns on Cardiac Magnetic Resonance Images in Heart Transplant Patients; C. Vittori,¹ M. Cipriani,¹ P. Pedrotti,¹ S. Dellegrottaglie,² S. Pedretti,¹ G. Bruschi,¹ A. Roghi,¹ M. Frigerio.¹ ¹'Niguarda Ca' Granda Hospital, Milano, Italy; ²Federico II University, Napoli, Italy.

(479) Incidence of Bradyarrhythmias Requiring Permanent Pacemakers Immediately Following Heart Transplantation and during Subsequent Follow-Up; A. Rodriguez-Vilela, M.G. Crespo-Leiro, M.J. Paniagua-Martin, L. Perez-Alvarez, E. Barge-Caballero, Z. Grille, A. Perez-Perez, R. Estevez-Loureiro, J. Perez-Lopez, F. Estevez-Cid, I. Mosquera-Perez, E. Ricoy-Martinez, J.J. Cuenca-Castillo, A. Castro-Beiras. Hospital Universitario A Coruña, A Coruña, Spain.

(480) Feasibility of Aliskiren for Treatment of Refractory Arterial Hypertension in Heart Transplant Recipients; M. Adam,¹ S. Meyer,¹ F.M. Wagner,² T. Deuse,² H. Reichenspurner,² A. Costard-Jaeckle.¹ ¹University Heart Center, Hamburg, Germany; ²University Heart Center, Hamburg, Germany.

(481) Use of Peripheral Gene Expression Testing in the Detection of Coronary Allograft Vasculopathy with Intravascular Ultrasound; R.L. Scott, D.L. Kasper, C. Bachtel, F.D. Fortuin, J.P. Sweeney, R.W. Lee, D.E. Steidley, F.A. Arabia, R.S. Gopalan, A.V. Kalya. Mayo Clinic Arizona, Phoenix, AZ.

(482) Prevalence of Kidney Function in Heart Transplant Recipients Using New CKD-EPI Formula; P. Przybylowski,¹ J.M. Malyszko,² J. Malyszko.² ¹Collegium Medicum, Jagiellonian University, Krakow, Poland; ²Medical University Bialystok, Bialystok, Poland.

(483) Significance of Pre Transplant Donor Specific HLA Antibodies and Post Transplant Cardiac Allograft Vasculopathy; M.J. Gandhi,¹ S.R. De Goeij,¹ N. Periera,² S. Kushwaha,² B. Edwards,² S. Park,² A. Clavell,² J. Schirger,² R. Rodeheffer,² R. Frantz,² R.C. Daly.² ¹Mayo Clinic, Rochester, MN; ²Mayo Clinic, Rochester, MN.

(484) New Development of Diabetes in Tacrolimus Treated Patients. Does It Really Matter?; G. Seebacher, A.Z. Aliabadi, S. Mahr, D. Dunkler, A. Fiala, A. Zuckermann. Medical University Vienna, Vienna, Austria.

(485) Inadequate Blood Pressure Control in Orthotopic Heart Transplant Recipients (OHT); P. Przybylowski,¹ J. Malyszko,² J.M. Malyszko.² ¹Collegium Medicum, Jagiellonian University, Krakow, Poland; ²Medical University Bialystok, Bialystok, Poland.

(486) The Influence of VAD Bridging in Different Gender on Outcome Following Heart Transplantation; S. Klotz, H. Welp, J.R. Sindermann, H.H. Scheld. University Hospital Muenster, Muenster, Germany.

(487) Alemtuzumab, a Promising Tool in the Rescue Armamentarium for Refractory Allograft Dysfunction with Cardiogenic Shock: Experience from a Single-Institution; K.K. Kisingbury, A.C. Kollar, M.M. Koerner, N.A. Barbagelata, V.G. Valentine, S.D. Lick. University of Texas, Medical Branch, Galveston, TX.

(488) The Etiology of Allograft Vasculopathy; M.H. Hart-Matyas,¹ S. Nejat,¹ B.M. Ross,² G.M. Hirsch,² T.D.G. Lee.^{1,2,3} ¹Dalhousie University, Halifax, NS, Canada; ²Dalhousie University, Halifax, NS, Canada; ³Dalhousie University, Halifax, NS, Canada.

(489) Cilostazol as an Adjunct to Cyclosporine Prevents Neointimal Hyperplasia after Vascular Injury; M.V. Badiwala, L.C. Tumiati, D.H. Delgado, H.J. Ross, V. Rao. Toronto General Hospital, Toronto, ON, Canada.

(490) Adding a Hydrogen-Producing Magnesium Stick to the Drinking Water Protects Cardiac Allografts and Reduces Allograft Vasculopathy in Rats; A. Nakao, S. Lee, C.-S. Huang, Z. Wang, N. Shigemura, Y. Toyoda. University of Pittsburgh, Pittsburgh, PA.

(491) Everolimus for the Prevention of Microvasculopathy in Biopsy in Cardiac Transplant Recipients: Preliminary Results from Re-Evaluation of the RAD B253 Trial; N.E. Hiemann,¹ C. Bara,² J. Segovia,³ S. Simonsen,⁴ M. Crespo-Leiro,⁵ H. Eiskjaer,⁶ J. Vanhaceck,⁷ A. Poncelet,⁸ P. Przybylowski,⁹ M. Frigerio,¹⁰

H.B. Lehmkuhl,¹ R. Meyer.¹ ¹Deutsches Herzzentrum Berlin, Berlin, Germany; ²Medizinische Hochschule Hannover, Hannover, Germany; ³Hospital Puerta de Hierro Majadahonda, Madrid, Spain; ⁴Oslo University Hospital, Rikshospitalet, Oslo, Norway; ⁵Hospital Universitario Juan Canalejo, La Coruna, Spain; ⁶Aarhus University Hospital, Skejby, Denmark; ⁷University Hospital Gasthuisberg, Leuven, Belgium; ⁸Cliniques Universitaires Saint-Luc, Brussels, Belgium; ⁹Jagiellonian University, John Paul II Hospital, Krakow, Poland; ¹⁰Az. Ospedaliera Ospedale Niguarda-Ca' Granda, Milan, Italy.

(492) Incidence of Tacrolimus-Associated Hyperammonemia in a Cohort of Lung Transplant Recipients; J. Rusinak,¹ E. Greenhalgh,¹ D.F. Dilling,² C.H. Wigfield,³ J.P. Gagermeier,² R.B. Love,³ C.G. Alex.² ¹Loyola University Medical Center, Maywood, IL; ²Loyola University Medical Center, Maywood, IL; ³Loyola University Medical Center, Maywood, IL.

(493) Reduced Dose-Adapted MMF Exposure under Proton Pump Inhibitor Co-Medication in Stable Heart Transplant Recipients; A.O. Doesch,¹ S. Mueller,¹ S. Celik,¹ M. Konstandin,¹ A. Kristen,¹ L. Frankenstein,¹ P. Ehlermann,¹ F.-U. Sack,² H.A. Katus,¹ T.J. Dengler.¹ ¹University of Heidelberg, Heidelberg, Germany; ²University of Heidelberg, Heidelberg, Germany.

(494) Anti-Thymocyte Globulin Preserves Renal Function in Heart Transplantation; A.B. Cochrane,¹ M.C. Chu,² S.E. Fedson.² ¹Univ of Chicago, Chicago, IL; ²Univ of Chicago, Chicago, IL.

(495) Everolimus Prevents Endomyocardial Remodeling after Heart Transplantation; N.E. Hiemann,¹ H.B. Lehmkuhl,¹ E. Wellnhofer,² C. Knosalla,¹ R. Hetzer,¹ R. Meyer.¹ ¹Deutsches Herzzentrum Berlin, Berlin, Germany; ²Deutsches Herzzentrum Berlin, Berlin, Germany.

(496) Tacrolimus Versus Cyclosporine in Pediatric Lung Transplantation; O. Elidemir,¹ S.M. Moonnukamal,¹ E.D. McKenzie,² J.S. Heinle,² D.L. Morales,² J.A. Rama,¹ E.O. Smith,¹ G.B. Mallory,¹ M.G. Schecter.¹ ¹Baylor College of Medicine, Houston, TX; ²Baylor College of Medicine, Houston, TX.

(497) Cardiac MRI in the Assessment and Management of Heart Failure; D. Arumugam, R. Slaughter, M. Brown, G. Javorsky, D. Platts. The Prince Charles Hospital, Brisbane, QLD, Australia.

(498) WITHDRAWN

(499) Impact of Baseline RV Structural and Functional Abnormalities on the Presence of Cardiac Dyssynchrony: Insight from the Evaluation of Resynchronization Therapy for Heart Failure (EARTH) TRIAL; H. Prylutska,¹ B. Thibault,¹ F. Harel,¹ M. White,¹ A. Fortier,² P.G. Guerra,¹ A. Ducharme.¹ ¹Montreal Heart Institute, Montreal, QC, Canada; ²Montreal Heart Institute Coordinating Center, Montreal, QC, Canada.

(500) The Impact of Baseline Cardiac Structural and Functional Abnormalities on Exercise Capacity: Insight from the Evaluation of Resynchronization Therapy for Heart Failure (EARTH) Trial; A. Ducharme,¹ M. White,¹ H. Prylutska,¹ J. Graham,¹ F. Harel,¹ A. Fortier,² P.G. Guerra,¹ B. Thibault.¹ ¹Montreal Heart Institute, Montreal, QC, Canada; ²Montreal Heart Institute Coordinating Center (MHICC), Montreal, QC, Canada.

(501) Efficacy of Immunoabsorption as Bridge-to-Transplant Therapy in Patients with Idiopathic Dilated Cardiomyopathy and Evidence of Beta-1 Adrenoceptor Autoantibodies; M. Dandel,¹ G. Wallukat,² A. Englert,¹ H.B. Lehmkuhl,¹ R. Hetzer.¹ ¹Deutsches Herzzentrum Berlin, Berlin, Germany; ²Max Delbrück Centrum für Molekulare Medizin, Berlin, Germany.

(502) Geographic Changes in Waitlist Survival after Initiation of New Heart Allocation Policy; A. Iribarne,¹ M.J. Russo,¹ H. Takayama,¹ M. Williams,¹ A.S. Stewart,¹ M. Argenziano,¹ D.M. Mancini,² Y. Naka.¹ ¹Columbia University Medical Center, New York, NY; ²Columbia University Medical Center, New York, NY.

(503) Does the Ex-Vivo Lung Evaluation System Affect Post-Transplant Graft Function in Swine Donation after Cardiac Death (DCD) Lung Transplantation?; S. Otani, T. Oto, K. Miyoshi, S. Yamamoto, T. Kakishita, M. Okazaki, O. Yoshida, N. Waki, S. Hori, S. Sugimoto, J. Soh, M. Yamane, S. Toyooka, Y. Sano, S. Miyoshi. Okayama University Graduate School of Medicine, Okayama, Japan.

(504) The Effect of Ex-Vivo Perfusion on the Inflammatory Profile of the Donor Lung; D.M. Karamanou,^{1,2} H.R. Walden,¹ S. Bean,² M. Prabhu,² S. Clark,² A.J. Simpson,³ P. Corris,^{1,2} J.H. Dark,^{1,2} A.J. Fisher.^{1,2} ¹Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom; ²Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; ³University of Edinburgh, Edinburgh, Scotland, United Kingdom.

(505) Retrograde Flush Is More Effective Than Heparinization in the Uncontrolled Non-Heart-Beating Donor; C. Van De Wauwer,¹ A. Neyrinck,¹ F. Rega,¹ G.M. Verleden,² T. Lerut,³ D. Van Raemdonck.^{1,3} ¹KU Leuven, Leuven, Belgium; ²KU Leuven, Leuven, Belgium; ³UZ Leuven, Leuven, Belgium.

(506) Effect of N-Acetylcysteine on Acute Allograft Rejection after Lung Transplantation; B.V. Erne, W. Jungraithmayr, S. Arni, W. Weder, I. Inci. University Hospital Zurich, Zurich, Switzerland.

(507) Evidence of Progressive Inflammatory and Cardiac Stress Responses Following Brain Death; V.B. Dronavalli,¹ A. Normandale,² P. Gosling,² C.A. Rogers,^{3,6} H. Thomas,⁴ N.R. Banner,^{3,6} R.S. Bonser.^{1,6}
¹Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; ²University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; ³Bristol Heart Institute, University of Bristol, Bristol, United Kingdom; ⁴NHS Blood and Transplant, Bristol, United Kingdom; ⁵Harefield Hospital, Royal Brompton and Harefield Hospital NHS Trust, Harefield, Middlesex, United Kingdom; ⁶On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, United Kingdom.

(508) A Porcine Model of Acute Lung Injury by Gastric Aspiration To Study Ex Vivo Lung Resuscitation; C.M.F. Meers,¹ W. De Wever,² E. Verbeken,³ S. Wauters,¹ V. Mertens,⁴ S.I. De Vleeschauwer,⁵ R. Vos,⁵ B.M. Vanaudenaerde,⁵ G.M. Verleden,⁵ T.E. Lerut,⁶ D.E.M. Van Raemdonck.^{1,6}
¹KU Leuven, Leuven, Belgium; ²UZ Leuven, Leuven, Belgium; ³UZ Leuven, Leuven, Belgium; ⁴KU Leuven, Leuven, Belgium; ⁵KU Leuven, Leuven, Belgium; ⁶UZ Leuven, Leuven, Belgium.

(509) Injury of Donor Lungs from Donation after Cardiac Death in Various Settings; Investigation by RT-PCR and Pathology; T. Yamada, F. Chen, J. Sakamoto, D. Nakajima, N. Satoda, A. Takahashi, T. Fujinaga, T. Shoji, H. Sakai, T. Bando, H. Date. Kyoto University, Kyoto, Japan.

(510) Heparin and Thrombosis in Donor Lungs after Cardiac Death; H.B. Keshava,¹ D.P. Mason,¹ J.J. Yun,¹ S.C. Murthy,¹ N. Vakil,¹ G.B. Pettersson,¹ C.F. Farver.²
¹Cleveland Clinic, Cleveland, OH; ²Cleveland Clinic, Cleveland, OH.

(511) Impact of High Dose Inotropic Donor Support on Early Myocardial Necrosis and Outcome in Cardiac Transplantation; J.L. Nixon,¹ K. Brunisholz,¹ B. Horne,¹ C. Myrick,^{1,2} D. Budge,¹ A.G. Kfoury,¹ M. Everitt,¹ J. Stehlik,¹ T.C. Schmidt,^{1,2} E.M. Gilbert,¹ F. Bader,¹ R. Alharethi.¹
¹UTAH Cardiac Transplant Program, Salt Lake City, UT; ²Intermountain Donor Services, Salt Lake City, UT.

(512) Increasing the Donor Pool by the Use of a Lung Donor Quality Score; J.M. Smits,¹ W. van der Bij,² D. Van Raemdonck,³ A.O. Rahmel.¹
¹Eurotransplant, Leiden, Netherlands; ²UMCG, Groningen, Netherlands; ³Gasthuisberg, Leuven, Belgium.

(513) Tachycardia but Not T Wave Inversion or QTc Duration Is Associated with Donor Heart Injury; V.B. Dronavalli,¹ J.N. Townend,¹ C.A. Rogers,^{3,5} H. Thomas,⁴ N.R. Banner,^{2,5} R.S. Bonser.^{1,5}
¹Queen Eliza-

beth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; ²Royal Brompton and Harefield Hospital NHS Trust, Harefield, Middlesex, United Kingdom; ³Bristol Heart Institute, University of Bristol, Bristol, United Kingdom; ⁴NHS Blood and Transplant, Bristol, United Kingdom; ⁵On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, United Kingdom.

(514) The Effect of Direct Hemoperfusion with a Polymyxin B-Immobilized Fiber Column (DHP-PMX therapy) on Pulmonary Ischemia-Reperfusion Injury in a Canine Model; K. Oshima,¹ T. Akao,² K. Kobayashi,² K. Matsumoto,³ I. Takeyoshi.²
¹Gunma University Hospital, Maebashi, Gunma, Japan; ²Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan; ³CML Pathological Laboratory, Ebina, Kanagawa, Japan.

(515) Mitochondrial Behavior in Warm Pulmonary-Ischemia Reperfusion Injury; S.-P. Sommer,¹ S. Sommer,¹ V. Lange,¹ I. Aleksic,¹ B. Sinha,² C. Schimmer,¹ R.G. Leyh.¹
¹University Hospital Würzburg, Würzburg, Germany; ²University Hospital Würzburg, Würzburg, Germany.

(516) Custodiol-N, A Novel Organ Protection Solution Protects Against Myocardial and Endothelial Reperfusion Injury after Orthotopic Heart Transplantation; G. Szabo, G. Veres, T. Radovits, M. Karck. University of Heidelberg, Heidelberg, Germany.

(517) Dextrane Free Preservation Improves Early Graft Function in Porcine Single Lung Transplantation after 24 Hours of Cold Ischemia; B. Gohrbandt,¹ M. Avsar,¹ G. Warnecke,¹ S.P. Sommer,² A. Haverich,¹ M. Strueber.¹
¹Hannover Medical School, Hannover, Germany; ²University Hospital of Wuerzburg, Wuerzburg, Germany.

(518) Respiratory Morbidity Associated with the Berlin Heart in Children; A. Hosenie, A. Hasan, C. O'Brien, M. Griselli, R. Kirk, J.H. Smith, S.R. Haynes, J.V. Cassidy, Freeman Hospital, Newcastle upon Tyne, United Kingdom.

(519) Predictors of Complications after Heart Transplantation in Pediatric Patients with Restrictive Cardiomyopathy; T. Shindo, J.C. Alejos, N. Halnon. David Geffen School of Medicine and Mattel Children's Hospital, UCLA, Los Angeles, CA.

(520) Sudden Cardiac Death (SCD) in Pediatric Patients with Transplant Coronary Artery Disease (TCAD): Does Intravascular Ultrasound have a Role in Early Diagnosis of TCAD and Prevention of SCD in These Patients?; D.P. Bhat,² C. Nasman,¹ S. Worley,¹ G.J. Boyle.¹
¹Cleveland Clinic Children's Hospital, Cleveland, OH; ²Metrohealth Medical Center, Cleveland, OH.

(521) Evaluation of Safety and Efficacy of Exercise Stress Echocardiography To Screen for Coronary Allograft Vasculopathy in Pediatric Heart Transplant Recipients; M.H. Chen,¹ F.I. Lunze,² T.P. Singh,³ L. Bergersen,⁴ L. Smoot,⁵ C.S. Almond,⁶ K. Gauvreau,⁷ T. Geva,⁸ S.D. Colan,⁹ K.E. Hall,¹⁰ E.D. Blume.¹¹ ¹Children's Hospital Boston, Boston, MA; ²Children's Hospital Boston, Boston, MA; ³Children's Hospital Boston, Boston, MA; ⁴Children's Hospital Boston, Boston, MA; ⁵Children's Hospital Boston, Boston, MA; ⁶Children's Hospital Boston, Boston, MA; ⁷Children's Hospital Boston, Boston, MA; ⁸Children's Hospital Boston, Boston, MA; ⁹Children's Hospital Boston, Boston, MA; ¹⁰Children's Hospital Boston, Boston, MA; ¹¹Children's Hospital Boston, Boston, MA.

(522) Pediatric Heart Transplant Recipients with Transplant Coronary Artery Disease Show a Show Increase in Filling Pressures over Time; C. Tissot, B.A. Pietra, D.D. Ivy, M.B. Mitchell, D.N. Campbell, D.J. Gilbert, S.D. Miyamoto. The Children's Hospital, Aurora, CO.

(523) Diagnosis, Treatment and Outcome of Hodgkin Like Post-Transplant Lymphoproliferative Disease after Pediatric Heart Transplantation: A Single Center Experience; K. Behnke-Hall,¹ H.-J. Wagner,² J. Bauer,¹ J. Thul,¹ M. Horn,¹ A. Reiter,² D. Schranz.¹ ¹Children's University Hospital, Giessen, Germany; ²Children's University Hospital, Giessen, Germany.

(524) The Use of Rituximab for Antibody Mediated Rejection after Pediatric Heart Transplantation; M.E. Richmond,¹ R.K. Singh,¹ L.A. Gilmore,¹ K. Beddows,¹ J.M. Chen,² L.J. Addonizio.¹ ¹Columbia University, College of Physicians & Surgeons, New York, NY; ²Columbia University, College of Physicians & Surgeons, New York, NY.

(525) Pre-Emptive Treatment for CMV in Paediatric Heart Transplantation- The Newcastle (UK) Experience; J.R. Samuel, K. Gould. Freeman Hospital, Newcastle upon Tyne, United Kingdom.

(526) Asymptomatic Rejection Diagnosed by Surveillance Endomyocardial Biopsy in Pediatric Heart Transplant Recipients: Do We Need To Treat?; C. Tissot, B.A. Pietra, D.D. Ivy, D.N. Campbell, M.B. Mitchell, B.A. Diamond, S.D. Miyamoto. The Children's Hospital, Aurora, CO.

(527) Daclizumab Is an Efficacious Induction Agent for Highly Sensitized Pediatric Heart Transplant Recipients; S.R. Auerbach, D.N. Rosenthal, D. Bernstein, C. Chin. Stanford University, Palo Alto, CA.

(528) The Doppler Derived Myocardial Performance Index (MPI) May Detect Patients with Coronary Allograft Vasculopathy (CAV) in Pediatric Heart Transplant Recipients; S. Schubert,¹ H.B. Lehmkühl,²

M. Yegitbasi,¹ M. Huebler,² N. Hiemann,² R. Hetzer,² F. Berger.¹ ¹Deutsches Herzzentrum, Berlin, Germany; ²Deutsches Herzzentrum, Berlin, Germany.

(529) A Non-Invasive Assessment of Cardiac Output in Pediatric Heart Transplant Patients; M.L. Likes, J.C. Alejos. Mattel Children's Hospital UCLA, Los Angeles, CA.

(530) Postoperative Extracorporeal Membrane Oxygenation (ECMO) As a Bridge to Recovery in Infants Immediately after Heart Transplantation (HTX) 1999-2009; R. Nubani,¹ S. Kaushal,² J.G. Gossett,¹ K.L. Matthews,¹ C.L. Backer,² D. Wang,³ E. Pahl.¹ ¹Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago; ²Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago; ³Children's Memorial Research Center, Chicago.

(531) Lobar Versus Conventional Whole Lung Transplantation for Children with Advanced Lung Disease; K. Moneghetti,¹ D.T. Keating,¹ S. Marasco,¹ J.H. Burton,¹ M. Buckland,¹ B. Levvey,¹ C. Robertson,² T.J. Williams,¹ G.I. Snell,¹ G.P. Westall.¹ ¹Alfred Hospital, Melbourne, Vic, Australia; ²Royal Children's Hospital, Melbourne, Vic, Australia.

(532) Bilateral Bronchial Anastomosis Versus Tracheal Anastomosis with Bronchial Revascularization in Pediatric Lung Transplantation; M.G. Schecter,¹ S. Das,¹ E.D. McKenzie,² J.S. Heinle,² D.L. Morales,² G.B. Mallory,¹ O. Elidemir.¹ ¹Baylor College of Medicine, Houston, TX; ²Baylor College of Medicine, Houston, TX.

(533) Recovery of Right Heart Function with Temporary Extracorporeal Membrane Oxygenation in Patients with Severe Biventricular Failure; S. Saito, G. Matsumiya, T. Sakaguchi, S. Miyagawa, Y. Yoshikawa, T. Yamauchi, T. Kuratani, Y. Sawa. Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

(534) Major Neurological Events after Ventricular Assist Device (VAD) Implantation Are Device Specific but Are Also Related to Pre-Implant Factors; T. Horai,¹ N.C. Ku,¹ E.A. Genovese,¹ C.A. Bermudez,¹ J.K. Bahma,¹ J.J. Teuteberg,² S. Winowich,¹ A. Weimer,¹ G.C. O'Shea,¹ Y. Toyoda,¹ D.M. McNamara,² R.L. Kormos.¹ ¹University of Pittsburgh, Pittsburgh, PA; ²University of Pittsburgh, Pittsburgh, PA.

(535) Cerebrovascular Bleeding during Ventricular Assist Device Support Is Highly Associated with Pre-Existing Right Heart Failure and Systemic Infection; T.S. Kato,¹ K. Komamura,² T. Shishido,⁴ K. Hashimura,¹ T. Nakatani,³ M. Yanase,³ K. Toda,³ T. Funatsu,⁷ T. Fujita,³ K. Niwaya,⁶ N. Oda,⁵ I. Nakajima,¹ A. Takahashi.¹ ¹National Cardiovascular Center, Osaka, Japan; ²Takeda Pharmaceutical Company Limited, Osaka,

Japan; ³National Cardiovascular Center, Osaka, Japan; ⁴National Cardiovascular Center, Osaka, Japan; ⁵Hiroshima University School of Medicine, Hiroshima, Japan; ⁶Garatia Hospital, Osaka, Japan; ⁷Osaka Rosai Hospital, Osaka, Japan.

(536) Continuous Flow Ventricular Assist Devices Do Not Reverse the Gene Expression Program Typical of Heart Failure; A. Nair,¹ A. Anyanwu,¹ C. Nwasike,¹ S. Pinney,¹ E. Adler.² ¹Mount Sinai Heart, New York City, NY; ²Oregon Health School of Medicine, New York City, NY.

(537) Creating a Safe and Effective Method for First Responders To Identify Mechanical Circulatory Support Patients in the Community Setting; D. Rivard, T. Elliott, C. Hanny Gilbert, A. Wolfe, T. Van de Bussche. Johns Hopkins Hospital, Baltimore; INOVA Fairfax, Fairfax; Washington Hospital Center, Washington, DC.

(538) Delayed Sternal Closure Following Left Ventricule Assist Device Implantation; Z.A. Hashmi,¹ G.B. Pelz,¹ R.J. Moraca,¹ S. Murali,² R.L. Benza,² G.G. Sokos,² A. Hopwood,¹ S. Stutz,¹ G.J. Magovern, Jr.,¹ S.H. Bailey,¹ D.A. Dean.¹ ¹Allegheny General Hospital, Pittsburgh, PA; ²Allegheny General Hospital, Pittsburgh, PA.

(539) Characterization of Gastrointestinal Bleeding in HeartMate II Left Ventricular Assist Device Patients; N.O. Mason, B.B. Reid, G. Harmstan, J. Jones, S. Stoker, D. Budge, R. Alharethi, G. Thomsen, S.E. Clayson, W. Caine, A.G. Kfoury. Intermountain Medical Center, Salt Lake City, UT.

(540) Preoperative Risk Factors for Left Ventricular Assist Device Related Infection; S. Pauwaa, C. Blair, P. Avula, P. Mehta, A.J. Tatoes, G. Bhat. Advocate Christ Medical Center, Oak Lawn, IL.

(541) Cardiac Performance in Patients without Early Native Aortic Valve Opening; O.H. Frazier, S.M. Parnis, R. Stainback, X. Quan, Z.T. Demirozu, W.E. Cohn, I. Gregoric. Texas Heart Institute, Houston, TX.

(542) Effect of Fibrosis at Implantation on Clinical Outcome in Patients with HeartMate II Ventricular Support; A.M. Segura, L.M. Buja, M.A. Elayda, S. Wang, O.H. Frazier. Texas Heart Institute, Houston.

(543) Long Term Outcome of Bridge to Recovery Versus Bridge to Transplantation; E.J. Birks,¹ R.S. George,¹ M. Noor,¹ T. Bahrami,¹ M. Amrani,¹ J. Pepper,¹ G. Dreyfus,¹ M. Petrou,¹ M.H. Yacoub,² A. Khaghani.¹ ¹Harefield Hospital, Harefield, Middlesex, United Kingdom; ²Harefield Hospital, Harefield, Middlesex, United Kingdom.

(544) Is Bridge to Recovery More Likely with Pulsatile LVADs than with Non-Pulsatile-Flow Systems?; T. Krabatsch, M. Dandel, A. Stepanenko, T. Drews, Y. Weng, E.V. Potapov, R. Hetzer. Deutsches Herzzentrum Berlin, Berlin, Germany.

(545) Continuous Flow-Type VADs Induce Lower Levels of Unloading but Exert Similar Effects on Cellular Remodeling Compared to Pulsatile-Type VADs; L.J. Garcia, A.R. Trevino, K.A. Youker, B.A. Bruckner, M. Loebe, J.E. Estep, C. Orrego, G. Torre-Amione. The Methodist Hospital, Houston, TX.

(546) Localization and Distribution of Micro-RNAs in the Myocardium of Heart Failure Patients before and after LVAD Support; J. Van Kuik,¹ S. Lok,² M.E.I. Schipper,¹ H. Dullens,¹ L. De Windt,³ P.A. Da Costa Martins,³ N. De Jonge,² R.A. de Weger.¹ ¹University Medical Center Utrecht, Utrecht, Netherlands; ²University Medical Center Utrecht, Utrecht, Netherlands; ³Cardiovascular Research Institute Maastricht, Maastricht, Netherlands.

(547) Impact of Acute Renal Failure on Survival after HM II LVAD Implantation; J.A. Morgan,¹ R.J. Brewer,¹ H.W. Neme, S.E. Henry,¹ J. Borgi,¹ B. Czerska,² C.T. Williams,² D.E. Lanfear,² C. Tita,² C. Drost,¹ C. Smith,¹ J. Chernich,¹ H.N. Sabbah,² G. Paone.¹ ¹Henry Ford Health System, Detroit, MI; ²Henry Ford Health System, Detroit, MI.

(548) Ventricular Assist Devices Rescue Patients in Cardiogenic Shock without Adversely Impacting the Complexity of Subsequent Heart Transplantation; P. Aduri,¹ J.L. Howard,¹ E.D. Kozin,¹ B.W. Ullery,¹ W. Hiesinger,¹ J.R. Fitzpatrick,¹ M. Jessup,² M.A. Acker,¹ R.J. Morris,¹ Y.J. Woo.¹ ¹University of Pennsylvania, Philadelphia, PA; ²University of Pennsylvania, Philadelphia, PA.

(549) Additional Procedure to Aortic Valve at LVAD Placement; A. Goda,¹ H. Takayama,² S.-W. Pak,² U. Jorde,¹ D. Mancini,¹ Y. Naka.² ¹Columbia University, New York, NY; ²Columbia University, New York, NY.

(550) Early Severe Post Operative Liver Dysfunction after Heartmate II® LVAD Placement: Incidence, Risk Factors, and Outcomes; E.A. Ziemba,³ J.M. Aho,⁴ K. Liao,¹ M.A. Kuskowski,⁵ M.M. Colvin-Adams,² P. Echman,² M.R. Pritzker,² R. John.¹ ¹University of Minnesota, Minneapolis, MN; ²University of Minnesota, Minneapolis, MN; ³University of Minnesota, Minneapolis, MN; ⁴Chicago Medical School, Chicago, IL; ⁵VA Medical Center, Minneapolis, MN.

(551) Percutaneous LVAD Support in Refractory Cardiogenic Shock Rapidly and Disparately Modulates Serum Biomarkers of Apoptosis, Neurohormonal Activation, Inflammation, and Extracellular Matrix Remodeling; N.R. Shah,¹ M.C. Bieniarz,¹ P. Loyalka,² D.L. Mann,³ B. Kar.^{1,2} ¹Baylor College of Medicine, Houston, TX; ²Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX; ³Washington University School of Medicine, St. Louis, MO.

(552) Use of Extracorporeal Membrane Oxygenation (ECMO) in Patients with Chronic Cardiomyopathy: A Word of Caution; C. Bermudez,¹ Y. Toyoda,¹ F. Avila,¹ S. Mulukutla,² O. Marroquin,² J. Teuteberg,² R. Kormos.¹ ¹University of Pittsburgh Medical Center, Pittsburgh; ²University of Pittsburgh Medical Center, Pittsburgh.

(553) LVAD Support Results in a Significant Improvement in the Myocardial Sympathetic Nervous System, as Assessed by 123I-Metaiodobenzylguanidine (123I-MIBG), Independent of Ventricular Function; R.S. George,^{1,2} M.H. Yacoub,² A. Cheetham,³ A. Kelion,³ E.J. Birks.^{1,2} ¹Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; ²Imperial College, Harefield, Middlesex, United Kingdom; ³Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom.

(554) A Safe and a Cost-Effective Approach for Managing Patients with Levitronix CentriMag® Short Term Devices; A. Firouzi,¹ R.S. George,¹ K. Absalom,¹ S.M. Panther,¹ H. Doyle,¹ A. Bashford,² C. Bindoff,³ A. Khaghani,¹ E.J. Birks.¹ ¹Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom; ²Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom; ³Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.

(555) DNA-Methylation of the Human b1-Adrenergic Receptor Core Promoter Pre and Post VAD-Support and Its Putative Role for Gene Silencing in the Terminal Failing Myocardium; A. Kassner,¹ B. Bohms,¹ M. Morshuis,² S. Schulte-Eistrup,² J. Gummert,² H. Milting.¹ ¹Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; ²Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany.

(556) The SWAT Team Approach for Treating the Unstable Patient in Acute Cardiopulmonary Shock; D. Jaroszewski,¹ C. Pierce,¹ R. Scott,² E. Steidley,² R. Gopalan,² P. DeValeria,¹ L. Lanza,¹ F. Arabia.¹ ¹Mayo Clinic, Phoenix, AZ; ²Mayo Clinic, Phoenix, AZ.

(557) Improved Right Heart Function Secondary to Favorable Loading Conditions after Axial Flow Left Ventricular Assist Device Implantation; R. Rasalingam,¹ K.R. Bilhorn,³ S.N. Johnson,³ C.B. Kapadia,¹ M. Mekan,¹ J.E. Perez,¹ N. Moazami.² ¹Washington University in St Louis, St. Louis, MO; ²Washington University in St Louis, St. Louis, MO; ³Barnes Jewish Hospital, St. Louis, MO.

(558) The Effect of Continuous, Nonpulsatile Flow on Renal Function in Patients Supported by the HeartMate II Left Ventricular Assist Device; Z.T. Demirozu, R. Radovancevic, O.H. Frazier. Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, TX.

(559) Feasibility of BiVAD Support with Membrane Oxygenation; J.A. Yang, H. Takayama, H. Kim, S.A. Cohen, Y. Naka. Columbia University Medical Center, New York, NY.

(560) Longitudinal Fibre Shortening Velocity Measured by Tissue Doppler Imaging Reflects Exercise-Induced Increase in Cardiac Output during LVAD Support; M. Andersen,¹ F. Gustafsson,¹ A.S. Jensen,¹ P.L. Madsen,¹ C. Hassager,¹ N.H. Secher,² J.E. Moller.¹ ¹Rigshospitalet, Copenhagen, Denmark; ²Rigshospitalet, Denmark.

(561) The Effects of Clenbuterol on the Left Ventricular Wall Thickness and Function in Patients Recovered on Left Ventricular Assist Device (LVAD); R.S. George,^{1,2} M.H. Yacoub,² H. Lister,⁴ C. Webb,³ A. Khaghani,¹ E.J. Birks.^{1,2} ¹Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; ²Imperial College, Harefield, Middlesex, United Kingdom; ³Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; ⁴Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom.

(562) Peripheral Transcriptomes after Continuous Flow LVAD Support: Improved Inflammatory Signature after One Month; J. Teuteberg,¹ K. Lockard,² K. Hanley-Yanez,¹ K. Janosko,¹ C. Bermudez,² J.K. Bhama,² R. Ramani,¹ M. Simon,¹ R.L. Kormos,² C. McTiernan,¹ D.M. McNamara.¹ ¹University of Pittsburgh, Pittsburgh, PA; ²University of Pittsburgh, Pittsburgh, PA.

(563) Lack of Sensitization in Patients Awaiting Heart Transplantation on Heartmate II Axial Flow Assist Devices; M. Kwon,¹ J. Moriguchi,² M. Kittleson,² J. Patel,² M. Kawano,² S. Davis,² E. Reed,¹ C. Burch,¹ A. Velleca,² E. Stimpson,² A. Ardehali,¹ J. Kobashigawa.² ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

(564) Trends in Body Mass Index Following Long Term Mechanical Circulatory Support; Y. Ravi, A. Knapkie, S. Wissman, T. Yanssens, B. Sun, L. Louis, M. Firstenberg, B. Needleman, A. Hasan, C.B. Sai Sudhakar. The Ohio State University Medical Center, Columbus, OH.

(565) Less Invasive Surgery with Circulite® Synergy® Pocket Micro-Pump Reduces Adverse Events Verses Traditional VADs; B. Meyns,¹ F. Rega,¹ A. Simon,² S. Klotz,³ C. Schlensak,⁴ T. Wittwer,⁵ D. Burkhoff.^{6,7} ¹Gasthuisberg University Hospital, Leuven, Belgium; ²Hannover Medical School, Hannover, Germany; ³University Hospital, Muenster, Germany; ⁴University Medical Center, Freiburg, Germany; ⁵University Hospital of Cologne, Cologne, Germany; ⁶Columbia University, New York, NY; ⁷CircuLite, Inc., Saddle Brook, NJ.

(566) Improved Outcomes after Ventricular Assist Device Implantation in Patients Requiring Intra-Aortic Balloon Pump; S. Osaki,¹ N.M. Edwards,¹ M.R. Johnson,² M.A. Murray,¹ A.K. Proebstle,¹ L. Lozonschi,¹ T. Kohmoto.¹ ¹University of Wisconsin School of Medicine and Public Health, Madison, WI; ²University of Wisconsin School of Medicine and Public Health, Madison, WI.

(567) Single-Center Experience Using the Heartmate II Left Ventricular Assist Device as a Bridge to Decision; M. Toma,¹ G.V. Gonzalez-Stawinski,² D. Schmuhl,¹ N.G. Smedira,² R.C. Starling,¹ M.M. Mountis.¹ ¹The Cleveland Clinic Foundation, Cleveland, OH; ²The Cleveland Clinic Foundation, Cleveland, OH.

(568) Liberal Use of Tricuspid Valve Annuloplasty during Left Ventricular Assist Device Implantation Does Not Increase Perioperative Risk; K. Krishan, S. Pinney, V. Ramjee, D. Adams, A. Anyanwu. Mount Sinai Medical Center, New York, NY.

(569) Effects of Piperacillin -Tazobactam Perioperative Pneumonia Prophylaxis on Outcomes in the First 30 days Post Lung Transplantation; N. Marks, L. Singer, C. Chaparro, C. Chow, M. Hutcheon, T. Waddell, K. Yasufuku, A. Pierre, M. de Perrot, D. Munyal, J. Wang, S. Keshavjee, S. Husain. UHN, Toronto, ON, Canada.

(570) Safety of EBV-DNA-Load Guided Pre-Emptive Reduction of Immunosuppression To Prevent PTLTD; E.A. Verschuuren,¹ M.E. Erasmus,² B.L. Rottier,³ G.D. Nossent,¹ W. van der Bij.¹ ¹University Medical Centre Groningen, Groningen, Netherlands; ²University Medical Centre Groningen, Groningen, Netherlands; ³University Medical Centre Groningen, Groningen, Netherlands.

(571) Activity of Colistin Against Filamentous Fungi Isolated from Lung Transplant Recipients; G. Short,¹ C. Rennison,¹ K. Gould,¹ A. Fisher.² ¹Freeman Hospital, Newcastle upon Tyne, United Kingdom; ²Freeman Hospital, Newcastle upon Tyne, United Kingdom.

(572) Predictors of Subtherapeutic Serum Posaconazole Levels in Heart/Lung Transplant Recipients; R.K. Shields, A.A. Vadnerkar, C.J. Clancy, E.J. Kwak, F. Silveira, M. Crespo, J.M. Pilewski, Y. Toyoda, M.H. Nguyen. University of Pittsburgh Medical Center, Pittsburgh, PA.

(573) Is Targeted Antifungal Prophylaxis Effective in Lung Transplants?; S.M. Hosseini,¹ L. Singer,² C. Chapparo,² M. Hutcheon,² C. Rotstein,¹ S. Keshavjee,² S. Husain.¹ ¹University Health Network, Toronto, ON, Canada; ²University Health Network, Toronto, ON, Canada.

(574) Risks of Invasive Hemodynamics in UNOS IA Patients; E.C. DePasquale, D.L. Jacoby, F.A. Lee. Yale University School of Medicine/Yale-New Haven Hospital, New Haven, CT.

(575) Hyponatremia on Admission Predicts Longer Length of Stay in Patients with Pulmonary Hypertension and Right Ventricular Failure; A. Rabinovitz,¹ R. Zolty.² ¹Jacobi Medical Center, Bronx, NY; ²Montefiore Medical Center, Bronx, NY.

(576) Clinical Outcomes in Pediatric Heart Transplant Patients with Hepatitis C Virus Infection; T.B. Giblin, K. Beddows, R. Rodriguez, L. Gilmore, R. Singh, M. Richmond, L.J. Addonizio. Columbia University Medical Center, New York, NY.



(577) Th17 Cells and Their Role in Acute Rejection in Heart Transplant Patients; C.C. Baan,¹ A.H.M.M. Balk,² A.M.A. Peeters,¹ E. Dijke,¹ A.P.W.M. Maat,³ K. Caliskan,² W. Weimar.¹ ¹Erasmus MC, Rotterdam, Netherlands; ²Erasmus MC, Rotterdam, Netherlands; ³Erasmus MC, Rotterdam, Netherlands.

(578) Cysteinyl Leukotrienes/Prostaglandin E2 Balance Following Lung Transplantation; S. Ptaszynski,¹ E. O'Carroll,¹ S. Al-Mot,¹ A. Al-Rabea,¹ C. Poirier,² C. Bergeron.¹ ¹Centre de Recherche CHUM- Hotel-Dieu, Montreal, QC, Canada; ²CHUM- Notre-Dame, Montreal, QC, Canada.

(579) IL35 Is Released by T Cells of Lung Transplant Recipients; F. Meloni,¹ N. Solari,¹ M. Morosini,¹ P. Draghi,¹ A. Grasso,¹ S. Giuliano,² V. Conio,¹ A.M. Fietta.¹ ¹University of Pavia & Foundation IRCCS San Matteo, Pavia, Italy; ²University of Pavia, Pavia, Italy.

(580) Poly I:C Abrogates Murine Airway Allograft Tolerance Induced by CD154 Costimulation Blockade and Enhances Allospecific CD8+ T Cell Effector Responses; P.D. Shah,² E.A. Lendermon,¹ E. John,¹ A.B. Whitlock,¹ J.B. Orens,¹ J.F. McDyer.¹ ¹Johns Hopkins University School of Medicine, Baltimore, MD; ²Vanderbilt University Medical Center, Nashville, TN.

POSTER HALL



SOUTHWEST HALL









EXHIBIT HALL FLOORPLAN

SOUTHEAST HALL



160

161



EXHIBITING COMPANIES

ALPHABETICAL LIST OF EXHIBITORS	BOOTH NUMBERS	ALPHABETICAL LIST OF EXHIBITORS	BOOTH NUMBERS
Abiomed Inc.	523	Lippincott, Williams & Wilkins	322
Actelion Pharmaceuticals US, Inc.	316	Miller Pharmacal Group, Inc.	602
Argon Medical Devices, Inc.	218	Novartis Pharma AG	310
Astellas Pharma US	512	One Lambda, Inc.	612
Avalon Laboratories, LLC	317	Pulmonary Hypertension Association	222
Berlin Heart GmbH	304 & 306	Quality Assured Services, Inc.	305
CardiacAssist, Inc.	421	Scanlan International, Inc.	606
Circulite, Inc.	610	Scholten Surgical Instruments, Inc.	221
CSL Behring	604	SynCardia Systems, Inc.	405
Cylex Inc.	215	Terumo Heart, Inc.	204
Elsevier, Inc.	205	The Apothecary Shops	216
Essential Pharmaceuticals	323	Thoratec Corporation	407
Evaheart Medical	423	United Network for Organ Sharing	223
Genentech	313	United Therapeutics/Lung Rx	212
Gilead Sciences	404	Vital Engineering	206
Heartware, Inc.	219	World Heart Corporation	321
ISHLT	613	XDx	502
ISHLT Registry	520	XVIVO Perfusion AB	307
Jarvik Heart, Inc.	319		
Levitronix, LLC	522		

EXHIBITORS AND PRODUCT DESCRIPTIONS

Abiomed, Inc.

22 Cherry Hill Drive
Danvers, Massachusetts 01923
www.abiomed.com

Booth Number: 523

Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. Abiomed's product portfolio stands from the surgical suite to the catheterization lab including the Impella® platform, Impella® 2.5, Impella® 5.0 and Impella® LD, AB5000™, BVS®5000 and the Abiocor, the world's first completely self-contained replacement heart.

Actelion Pharmaceuticals US, Inc.

5000 Shoreline Court, Suite 200
So. San Francisco, California 94080
www.actelionus.com

Booth Number: 316

Actelion Pharmaceuticals is a biopharmaceutical company focusing on the discovery, development and commercialization of innovative treatments to serve unmet medical needs. Actelion is committed to research in cardiopulmonary disease, sleep disorders and immunology.

Argon Medical Devices, Inc. (USA)

1445 Flat Creek Road
Athens, Texas 75782
www.argonmedical.com

Booth Number: 218

Argon Medical Devices, Inc. manufacturer of Jawz™ Endomyocardial Biopsy Forceps and a full line of vascular access products including introducers, guide wires, thermolulution catheters and many kits specific to needs of cardiac transplantation centers. Ask about Argon's line of Micro-Introducer kits for Biopsy IJ/Femoral access.

Astellas Pharma US, Inc.

Three Parkway North
Deerfield, Illinois 60015
www.us.astellas.com

Booth Number: 512

Astellas Pharma US, Inc., a U.S. affiliate of Tokyo-based Astellas Pharma Inc., is a pharmaceutical company dedicated to *changing tomorrow* by improving the health of people around the world through innovative and reliable pharmaceutical products. In the US, Astellas has an intense focus on six key therapeutic areas – Cardiology, Dermatology, Infectious Disease, Neuroscience, Transplant and Urology. At all levels throughout the company our people are committed to the opportunity to positively affect and improve patient lives while remaining socially responsible to our community and those with whom we work and collaborate. For more information about Astellas Pharma US, Inc., please visit our web site at www.us.astellas.com

Avalon Laboratories, LLC

301 Michigan St. NE, Ste. 500
Grand Rapids, Michigan 49503
www.avalonlabs.com

Booth Number: 317

Avalon Laboratories is a leading manufacturer of wire-reinforced cardiopulmonary vascular cannula. Avalon Elite® is the company's premium line of proprietary catheters providing new and unique solutions for patients receiving extracorporeal support. The Avalon Elite Bi-Caval Dual Lumen Catheter (DLC) is indicated for use as a single catheter for simultaneous venous drainage and reinfusion of blood via the internal jugular vein. With a wide range of sizes, the DLC is the world's first wire-reinforced, veno-venous catheter available for both pediatrics and adults. The Avalon Elite line also features the high performing Multi-Port Venous Femoral Catheter and a Vascular Access Kit.

Berlin Heart

Wiesenweg 10
Berlin, Germany 12247
www.berlinheart.com

Booth Number: 304 & 306

Berlin Heart is the only company worldwide that develops, manufactures and distributes implantable and paracorporeal ventricular assist devices for patients for every age and body size.

EXCOR® is a paracorporeal pulsatile VAD for uni- or biventricular support in newborns, children, adolescents and adults. EXCOR® Pediatric is leading the worldwide market of pediatric VADs.

INCOR® is an implantable axial-flow LVAD for adults.

INCOR® is the only 3rd generation axial flow pump with CE-mark Approval.

INCOR® is not FDA approved. EXCOR® is approved for clinical investigation in pediatric patients in USA.

CardiacAssist, Inc.

240 Alpha Dr.
Pittsburgh, Pennsylvania 15238
www.tandemheart.com

Booth Number: 421

The TandemHeart® System delivers extracorporeal circulatory support in *minutes*, not hours! Utilized by both Cardiologists and Cardiac Surgeons in the Cardiac Cath Lab or OR, the TandemHeart is leading the way in short-term extracorporeal circulatory support. The TandemHeart System can provide *up to 5.0 lpm of support when used percutaneously and up to 8.0 lpm of support if utilized with a direct surgical cannulation method.*

CircuLite, Inc.

250 Pehle Ave, Suite 403
Park 80 West
Saddle Brook, New Jersey 07663
www.circulite.net

Booth Number: 610

CircuLite is a cardiovascular device company that is transforming heart failure treatment with the development of minimally-invasive devices for long-term partial circulatory support (PCS). By enabling a proactive and lower-risk

treatment approach by supplementing a patient's native pumping capacity, CircuLite has the potential to improve the quality of life for millions of chronic heart failure patients and their families. CircuLite's pipeline of PCS devices is led by the Synergy® Pocket Micro-Pump, the world's smallest implantable blood pump, currently in a CE Mark clinical trial. Next-generation Synergy micro-pumps include an endovascular system, a fully-implantable system and a pediatric system.

CSL Behring

1020 First Ave.
King of Prussia, Pennsylvania 19406
www.cslbehring-us.com

Booth Number: 604

CSL Behring is a global leader in the plasma protein biotherapeutics industry. CSL Behring manufacture and markets a range of safe and effective plasma-derived and recombinant products and related services.

The company's products are used for organ transplantation, inherited emphysema, in the prevention of hemolytic diseases in the newborn, in cardiac surgery and in the treatment of burns and shock. Additional therapies are used in the treatment of hemophilia, von Willebrand disease, other bleeding disorders and immune deficiency disorders.

CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit www.cslbehring-us.com.

Cylex, Inc.

8980 I Old Annapolis Road
Columbia, Maryland 21045
www.cylex.net

Booth Number: 215

Cylex is a global life sciences company focused on the development, manufacture and commercialization of In Vitro diagnostic products intended to illuminate immunity in the area of transplant medicine. The company has developed patented technology that provides an innovative platform to simply and reproducibly assess immune cell function, thus providing crucial insight for individualized transplant patient management. ImmuKnow®, the Company's first FDA-cleared product, is used to effectively manage and optimize immunosuppression in organ transplant patients.

Elsevier, Inc.

1600 JFK Blvd.
Suite 1800
Philadelphia, Pennsylvania 19103
www.elsevierhealth.com

Booth Number: 205

Elsevier is proud to publish *The Journal of Heart and Lung Transplantation*, the official journal of the International Society for Heart and Lung Transplantation. Please stop by our booth to view the latest issue of the journal and browse our other books and journals in the field of heart and lung transplantation.

Essential Pharmaceuticals

770 Newtown Yardley Road, Suite 212
Newtown, Pennsylvania 18940
www.essentialpharma.com
www.custodiol.coml

Booth Number: 323

Essential Pharmaceuticals, LLC. is a specialty pharmaceutical company devoted solely to the development and sales of exclusive branded pharmaceutical products including Custodiol® HTK organ preservation solution. Custodiol® HTK, with its easy handling characteristics, water like viscosity and no need for additives or filters make it a preferred solution for many transplant centers

Evaheart Medical USA, Inc.

880 William Pitt Way
Pittsburgh, Pennsylvania 15238
Web address: www.evaheart-usa.com

Booth Number: 423

The EVAHEART Left Ventricular Assist System (LVAS) is an implantable centrifugal Blood Pump designed to generate flow and pressure in cardiac transplant candidates with advanced heart failure and compromised left ventricular function. The Blood Pump contains a unique impeller fixed to a rotating shaft within a journal bearing and a mechanical seal, and a recirculating flushing system to reduce friction and extend the life of the pump. The current average duration of patient support in the Japanese trial is over 805 days. The EVAHEART LVAS is embarking on a bridge-to-transplant clinical trial in the United States.

Genentech

1 DNA Way
South San Francisco California, 94080
www.gene.com

Booth Number: 313

Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a wholly owned member of the Roche Group, has headquarters in South San Francisco, California.

For additional information about the company, please visit <http://www.gene.com>.

Please visit our exhibit to learn more about CellCept, Valcyte and our ongoing commitment to transplantation.

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, California 94404
www.gilead.com

Booth Number: 404

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Heartware, Inc.

205 Newbury St.
Framingham, Massachusetts 07701
www.heartwareinc.com

Booth Number: 219

HeartWare, Inc. is developing a family of implantable mechanical circulatory support systems for the treatment of advanced heart failure. Through a cadence of progressively smaller devices implanted using less invasive techniques, HeartWare expects to treat an increasing proportion of heart failure patients and to access them at an earlier stage of their disease progression. HeartWare's lead device, the HeartWare® Ventricular Assist System, incorporates state-of-the-art peripherals and features the only full-output pump designed to be implanted less invasively in the pericardial space. The HeartWare® System has CE-Mark approval and is currently the subject of a 150-patient US IDE clinical trial.

ISHLT Thoracic Transplant Registry

700 North 4th Street
Richmond, Virginia 23219
Website: www.help@ishlt.org

Booth Number: 520

The ISHLT International Registry for Heart and Lung Transplantation was created to collect on-going, current information on the worldwide thoracic organ transplantation experience. Our registry is the only one of its kind. The data we maintain is utilized for scientific study and contributes to the body of knowledge regarding thoracic transplantation. Our goal is to identify overall and best practices for improving cardiothoracic patient care.

This year the exhibit will make center-specific information available for review by ISHLT clients. In addition, clients can view data screens and receive guidance on participation in our registry, submission of data and special data request services.

Jarvik Heart, Inc.

333 West 52nd Street
New York, New York 10019-6238
www.jarvikheart.com

Booth Number: 319

Jarvik Heart, Inc. is a privately held, New York based company that develops and manufactures miniaturized heart assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available for the long-term treatment of Heart Failure.

Levitronix

45 1st Avenue
Waltham, Massachusetts 02451
www.levitronix.com

Booth Number: 522

Levitronix designed, developed and produces the CentriMag, PediMag and PediVAS circulatory support devices. In the United States, the CentriMag pump is approved for up to 30 days of use for patients requiring right ventricular support, and is undergoing clinical trials to treat patients in cardiogenic shock as a bridge to decision. The PediVAS is optimized to provide circulatory support for neonatal and pediatric patients, and is currently only available outside the United States. The PediMag pump is available in the United States for use in a cardiopulmonary circuit for up

to 6 hours. CentriMag and PediVAS systems are both CE Mark approved for use for up to 30 days for use as a VAD or for ECMO.

Lippincott, Williams & Wilkins

1578 Fordham St.
Bolingbrook, Illinois 60490
www.lww.com

Booth Number: 322

Lippincott, Williams & Wilkins will have on display the latest textbooks, electronic media and journal publications in the fields of transplantation as well as general surgery.

Miller Pharmacal Group, Inc

350 Randy Road, Ste #2
Carol Stream, Illinois 60188
www.mgplusprotein.com

Booth Number: 602

“MG Plus Protein” is used at many transplant programs for the treatment and prevention of the hypomagnesemia caused by immunosuppressants, without causing the GI disturbances common with magnesium oxide. “MG Plus Protein” is: Well-tolerated, effective and inexpensive.

Novartis Pharma AG

Postfach
Basel, CH-4002
Switzerland
www.novartis.com

Booth Number: 310

Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit <http://www.novartis.com>.

One Lambda, Inc.

21001 Kittridge Street
Canoga Park, California 91303
www.onelambda.com

Booth Number: 612

One Lambda representatives will be on hand to discuss our single antigen products – ideal for post-transplant antibody screening and monitoring. Using Luminex® xMap® technology, flow cytometry or ELISA, our single antigen assays are the best way to detect de novo donor-specific antibodies post transplantation.

In addition to our comprehensive line of antibody detection products, we also manufacture and distribute several lines of histocompatibility (HLA) typing tests utilizing both serological and molecular technology, as well as laboratory instrumentation and computer software that are used to simplify and automate testing procedures and final test evaluations.

Pulmonary Hypertension Association

801 Roeder Road
Silver Spring, Maryland 20910
www.PHAssociation.org
www.PHAOnlineUniv.org

Booth Number: 222

Pulmonary Hypertension (PH) is an underdiagnosed illness that affects people of all ages and backgrounds. PHA is the voice of the medical community, patients and family members united against this illness. Visit PHA's booth for complimentary information on PH, including PHA's medical journal, *Advances in Pulmonary Hypertension* and a variety of educational tools like our Diagnosis CD-ROM and Cases DVD.

Quality Assured Services, Inc.

30 Keller Road
Ste. 100B
Orlando, Florida 32810
www.qualityassuredservices.com

Booth Number: 305

QAS is the only company in the US providing services to outpatients in both equipment and dressing supplies for a ventricular assist device and for patient self-testing of INR.

Scanlan International, Inc.

One Scanlan Plaza
Saint Paul, Minnesota 55107
www.scanlaninternational.com

Booth Number: 606

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, full line of VATS/MICS Thoracoscopic instruments including the Chitwood Clamp and Knot Pusher, D'Amico and Wolf Suction instruments, D'Amico and Harkin Clamps; SCANLAN® Super Cut™ Scissors and Rendina needle holder. Single-use products include: VASCU-STAT™ bulldog clamps, SCANLAN® Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument design modifications to meet your individual needs.

Scholten Surgical Instruments, Inc.

170 Commerce St, #101
Lodi, California 95240
www.bioptome.com

Booth Number: 221

Scholten Surgical Instruments is excited to be exhibiting here in Chicago at this year's 30th Annual ISHLT meeting, debuting for the first time in the U.S. our new Novatome™ single-use endomyocardial biopsy forcep. In the tradition of the Scholten Bioptome trusted for its uncompromising quality and reliability the single-use Novatome™ is specially designed to acquire maximum sample size with the same precise feel, ease of placement and superior cutting force, expected from Scholten Products. Our biopsy forceps have been proven by over 30 years of successful clinical experience, and we are excited to continue setting the standard worldwide.

SynCardia Systems, Inc.

1992 E Silverlake Road
Tucson Arizona 85713
www.syncardia.com

Booth Number: 405

The SynCardia temporary Total Artificial Heart (TAH-t) is the only FDA, Health Canada and CE approved device that provides circulatory restoration in morbidly ill patients with irreversible bi-ventricular failure, providing a life-saving bridge until a donor human heart becomes available. In 2006, the EXCOR® TAH-t mobile driver was granted a CE mark, enabling European hospitals to discharge stable TAH-t patients to return home while they are awaiting a transplant. Visit our booth for updates on upcoming clinical studies for the Freedom™ driver, the 50cc TAH-t and the pediatric VAD.

Terumo Heart Inc.

6190 Jackson Road
Ann Arbor, Michigan 48103
www.terumoheart.com

Booth Number: 204

Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the development of the DuraHeart™ Left Ventricular Assist System (LVAS) designed to provide long-term circulatory support and address the shortage of donor hearts for cardiac transplantation. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products. DuraHeart™ LVAS is limited to investigational use only in the United States, and is CE marked in Europe.

The Apothecary Shops

23620 N. 20th Dr., Ste 12
Phoenix, Arizona 85085
www.theapothecaryshop.com

Booth Number: 216

Years of experience in the field of transplant pharmacy, coupled with a caring and compassionate staff make The Apothecary Shops your best referral source. All transplant medications, including compounded medications and hard-to-find ones are stocked. We accept insurance, complete prior authorizations and offer free shipping. Ask about our New Patient Transplant Kit!

Thoratec Corporation

6035 Stoneridge Dr.
Pleasanton, California 94588
www.thoratec.com

Booth Number: 407

With more than 14,000 patient implants and three decades of experience, Thoratec® Corporation offers the broadest portfolio of mechanical circulatory support devices. Thoratec's product line includes the CentriMag® Acute Circulatory Support Device, HeartMate® LVAS, Thoratec PVAD™ and IVAD.™ Now the HeartMate II® is FDA approved for both Bridge to Transplantation and Destination Therapy.

United Network for Organ Sharing (UNOS)

700 N 4th Street
Richmond, Virginia 23219
www.unos.org

Booth Number: 223

UNOS is a 501(c) 3 not-for-profit, scientific, educational and charitable Richmond-based Virginia membership corporation that manages the national Organ Procurement and Transplantation Network. Its mission is to advance organ availability and transplantation by uniting and supporting its communities for the benefit of patients through education, technology and policy development. UNOS also plays a major role in the ongoing development and operation of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS). Through Its subsidiary, Tii Informatix Group specializes in the design and operation of clinical registries in transplantation, Mechanical Circulatory Support and immunosuppressive therapies. Tii developed and has operated the ISHLT Thoracic Registry since 2001.

United Therapeutics and LungRx

1040 Spring Street
Silver Spring, Maryland 20910
www.unither.com

Booth Number: 212

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. Lung Rx LLC, a wholly-owned subsidiary of United Therapeutics Corporation, is a biotechnology company focused on unmet medical needs in pulmonary medicine and pulmonary delivery of innovative therapeutic products.

Vital Engineering

330 Scaife Hall, 200 Lothrop St
Pittsburgh, Pennsylvania 15213-2582
www.vitalengineering.com

Booth Number: 206

Vital Engineering provides training and educational programs for physicians and other health care providers as well as on-site training and technical support prior to, during and following device implantation. Vital Engineering has the knowledge and resources to improve patient care from surgery through discharge planning and outpatient care. Our clinical experience equips the artificial organ industry with the ultimate product quality improvement from emerging to experienced companies. Vital Engineering offers many partnership benefits to patients, clinicians, hospitals and industry.

World Heart Corp

4750 Wiley Post Way, Suite 120
Salt Lake City, Utah 84116
www.worldheart.com

Booth Number: 321

WorldHeart's focus is to develop the innovative rotary Levacor™ VAD based on proprietary maglev technology. The IDE application for the Levacor VAD to start a pivotal BTT trial in the USA was unconditionally approved by the FDA in January 2010, and two implants followed shortly thereafter.

The Levacor VAD builds on a quarter-century of support provided by the long-term implantable pulsatile Novacor® LVAS to more than 1,800 patients worldwide with life-threatening heart failure. Utilizing its maglev technology platform, WorldHeart is also developing a miniaturized, partial-support MiVAD™ for less-sick heart failure adults, and a PediaFlow™ VAD for neonates and infants.

XDx

3260 Bayshore Blvd.
Brisbane, California 94005
www.allomap.com

Booth Number: 502

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to aid in the management of heart transplant patients.

XVIVO Perfusion AB

Box 9080
SE – 400 92 Göteborg
Sweden
www.xvivo-perfusion.com

Booth Number: 307

XVIVO Perfusion AB (Part of the Vitrolife Group) manufactures and markets solutions and equipment for transplantation and thoracic surgery, designed to preserve organs and tissues prior to transplantation. Our main two solutions are Perfadex® for hypothermic flushing and transportation of transplant lungs and STEEN Solution™ for normothermic ex vivo evaluation (approved in US for research purposes only).

XVIVO aims to:

- minimize ischemic reperfusion injuries by improving the solutions used for extra corporeal preservation of organs and tissues.
- extend the safe extra corporeal preservation time for organs and tissues prior to transplantation.
- increase the organ availability and transplantation success rates by introduction of new transplantation concepts and techniques.



Chicago River • Alfred
vell Lily Pool Garden
ns • Taste of Chicago

MAKE PLANS TO ATTEND!

2011

**31ST ISHLT ANNUAL MEETING
AND SCIENTIFIC SESSIONS**

Hilton San Diego Bayfront

San Diego

CALIFORNIA, USA

April 13-16

2012

**32ND ISHLT ANNUAL MEETING
AND SCIENTIFIC SESSIONS**

Convention Center

Prague

CZECH REPUBLIC

April 18-21

